{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" {\n\"STUDY\": \"Case report\"\n}\n\nThe following format must be followed for cited entities:\n{\"ENTITY\": \"Type of Entity\", \"Name\": \"Name of Entity\", \"ID\": \"Identifier of Entity (if available)\"}\n\nNo cited entities were found in the provided text.", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" {\n\"STUDY\": \"Case report\",\n\"Patient\": [\"patient\"],\n\"Disease\": [\"liposarcoma\"],\n\"Location\": [\"retroperitoneal\"],\n\"Medication_1\": [\"trabectedin\"],\n\"Adverse_event_1\": [\"toxicity\", \"heavy toxicity\", \"rhabdomyolysis\"],\n\"Medication_2\": [\"alternative herbal medicine\"]\n}", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" {}\n\nIn May 2009, he underwent surgical removal of the abdominal mass.\n{\"STUDY\": \"Surgical procedure\"}\n\nachieving a complete margin negative (R0) resection.\n{\"STUDY\": \"Surgical procedure outcome\"}\n\nThe abdominal mass refers to a large accumulation of tissue, typically a tumor, located in the abdominal cavity.\n{\"ENTITY\": \"Abdominal mass\"}\n\nThe surgical removal of the abdominal mass is a surgical procedure used to excise a tumor or other abnormal growth from the abdominal cavity.\n{\"ENTITY\": \"Surgical procedure\", \"ENTITY\": \"Tumor\", \"ENTITY\": \"Abdominal cavity\"}\n\nAchieving a complete margin negative (R0) resection means that all cancerous cells were removed during the surgery, leaving no cancer cells behind in the surgical margin.\n{\"ENTITY\": \"Surgical procedure outcome\", \"ENTITY\": \"Cancer cells\", \"ENTITY\": \"Surgical margin\"}", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" {\n\"STUDY\": \"Case report\"\n}\n\nin spite of, chemotherapy, lesion, reaching, 16, \u00d7, 10, cm, extending, pre-aortic, seat, retro-peritoneum, space.", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" {\"STUDY\": \"Case report\", \"trabectedin\": \"drug\"}", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" {\"CITATION\": {\n\"Authors\": [],\n\"Publication Year\": 2021,\n\"Title\": \"\",\n\"Journal\": \"\",\n\"Volume\": \"\",\n\"Issue\": \"\",\n\"Pages\": \"8\",\n\"DOI\": \"\"\n},\n\"Entities\": [\n{\"TYPE\": \"DISEASE\", \"VALUE\": \"cancer\"},\n{\"TYPE\": \"PATIENT\", \"\"},\n{\"TYPE\": \"DRUG\", \"VALUE\": \"chemotherapeutic drugs\"},\n{\"TYPE\": \"DRUG\", \"VALUE\": \"ancillary medications\"},\n{\"TYPE\": \"SYNDROME\", \"VALUE\": \"cancer-related syndromes\"},\n{\"TYPE\": \"TOXICITY\", \"VALUE\": \"treatment-induced toxicity\"},\n{\"TYPE\": \"QUANTITY\", \"VALUE\": \"narrow therapeutic index\"},\n{\"TYPE\": \"QUANTITY\", \"VALUE\": \"prolonged life expectancy\"}\n]\n}\n\n{\"TEXT\": \"As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].\"}\n\n{\"PARSED_ENTITIES\": []}\n\n{\"PARSED_ENTITIES_FROM_TEXT\": [\n{\"TYPE\": \"DISEASE\", \"VALUE\": \"cancer\"},\n{\"TYPE\": \"PATIENT\", \"\"},\n{\"TYPE\": \"DRUG\", \"VALUE\": \"chemotherapeutic drugs\"},\n{\"TYPE\": \"ONCOLOGY\", \"VALUE\": \"oncology practice\"},\n{\"TYPE\": \"QUANTITY\", \"VALUE\": \"narrow therapeutic index\"},\n{\"TYPE\": \"QUANTITY\", \"VALUE\": \"prolonged life expectancy\"},\n{\"TYPE\": \"SYNDROME\", \"VALUE\": \"cancer-related syndromes\"},\n{\"TYPE\": \"TOXICITY\", \"VALUE\": \"treatment-induced toxicity\"},\n{\"TYPE\": \"MEDICATION\", \"VALUE\": \"ancillary medications\"}\n]}\n\n{\"PARSED_ENT", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" {\n\"STUDY\": \"No specific study mentioned\",\n\"Compounds\": [\"chokeberry juice\"],\n\"Patient\": {},\n\"Commercial preparation\": {},\n\"Interactions\": [\"inhibition of transport mechanisms\", \"activation of the death receptor\", \"other unknown mechanisms\"]\n}", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" {\n\"STUDY\": \"Case report\"\n}\n\nThis case report highlights the complexity associated with:\n- medicinal cannabis\n\nThe health risks associated with its use:\n- its use", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" [{\"STUDY\": \"Pharmacogenomics test\"}]\n{\"STUDY\": \"\"}\n{\"ENTITY\": \"patient\"},\n{\"ENTITY\": \"cannabis\"},\n{\"ENTITY\": \"chronic back pain\"},\n{\"ENTITY\": \"PGx\"},\n{\"ENTITY\": \"COMT\"},\n{\"ENTITY\": \"HTR2A\"}", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" {\"STUDY\": \"Citation\",\n \"Type of study\": \"\",\n \"Neuronal death\": \"\",\n \"Region\": \"\",\n \"Results in\": \"\",\n \"low dopamine concentrations\": \"\",\n \"Therefore\": \"\",\n \"Treatment strategies\": \"\",\n \"For PD\": \"\",\n \"Often involve\": \"\",\n \"Initiating medications\": \"\",\n \"e.g.\": \"\",\n \"carbidopa-levodopa\": \"\",\n \"ropinirole\": \"\",\n \"entacapone\": \"\",\n \"Result in\": \"\",\n \"Increased concentrations of dopamine\": \"\",\n \"To improve movement control\": \"\"}", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" {\n\"STUDY\": \"Case report\",\n\"Cannabis\": [],\n\"Pharmacokinetic\": [],\n\"Pharmacodynamic\": [],\n\"Effects\": [],\n\"Patient's medication regimen\": [],\n\"Therapeutic response\": [],\n\"Adverse drug events\": [],\n\"Individual\u2019s pharmacogenomic\": [\"pharmacogenomic\"]\n}", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" [{\"STUDY\": \"Patient case report\"}]\n\n\"The patient\u2019s past medical history includes\": {}, \"spinal stenosis\": {}, \"vitamin D deficiency\": {}, \"frequent falls\": {}, \"history of nicotine\": {}, \"history of alcohol dependence\": {}, \"mild kidney disease\": {}, \"chronic neck\": {}, \"chronic back\": {}, \"chronic shoulder pain\": {}", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" {\"STUDY\": \"Case report\",\n \"DRUGS\": [\"carbidopa-levodopa\"]}", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" {\n\"STUDY\": \"Case report\"\n}\n\nhis, PCP, medication, pain, control", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" [\n{\"STUDY\": \"Studies\"},\n{\"STUDY\": \"Discrepancies\"},\n{\"STUDY\": \"Factors\"},\n{\"PAIN\": \"Pain models\"},\n{\"SUBJECTS\": \"Healthy subjects\"},\n{\"SUBJECTS\": \"Patients\"},\n{\"ADMINISTRATION\": \"Routes of administration\"},\n{\"ADMINISTRATION\": \"Inhalation\"},\n{\"ADMINISTRATION\": \"Oral\"},\n{\"PRODUCT\": \"Product\"}\n]", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" [{\"STUDY\": \"Study or research paper\"},\n \"CB1Rs\": \"Cannabinoid receptors\"},\n \"presynaptic neurons\": \"\",\n \"activated\": \"\",\n \"inhibitory neurotransmitter levels\": \"levels of inhibitory neurotransmitters\",\n \"reduced\": \"\",\n \"dopamine levels\": \"levels of dopamine\"}\n\n[5]: {\"STUDY\": \"Research paper\", \"Reference\": \"5\"},\n [24]: {\"STUDY\": \"Research paper\", \"Reference\": \"24\"},\n [25]: {\"STUDY\": \"Research paper\", \"Reference\": \"25\"}", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" {\"STUDY\": \"Patient's PGx results reporting\", \"COMMT\": \"enzyme named COMT\", \"genotype\": \"specific genetic makeup\", \"Met/Met\": \"genetic variant of COMT gene\"}", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" {\"STUDY\": 1, \"PD\": \"Parkinson's Disease\", \"patients\": \"\"}\n\nA previous study evaluated:\n- 1 study\n- patients with PD: \"Parkinson's Disease\"\n- reported: \"\"\n- that one out of five patients: \"\"\n- experienced: \"\"\n- hallucinations: \"\"", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" {\"STUDY\": \"Clinical case report\",\n \"DRUG\": [\"morphine\"],\n \"PROTEIN\": [\"CYP2D6\"]\n}", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" [\n{\"STUDY\": \"Not specified\"},\n\"authors\": [\"The authors\"],\n\"assistance\": [\"Katie Meyer\"]\n]", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" {\n\"STUDY\": \"Description of trend in medicine over the past two decades\"\n}\n\nThe world has witnessed an increased rate of:\n- conventional medicines\n- CAM (Complementary and Alternative Medicine)\n\nfor treatment.", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" {\"STUDY\": \"Survey\", \"YEAR\": \"2009-2010\", \"LOCATION\": \"China\", \"PATIENTS\": \"cancer patients\"}", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" {\"STUDY\": \"survey or report\"},\n\"South Korean population\": {}\n}\n\nA randomized, double-blind, placebo-controlled trial was conducted in 12 centers in the United States and Europe [6].\n\n{\"STUDY\": \"clinical trial\"},\n\"United States\": {},\n\"Europe\": {}\n}\n\nThe study included 1,125 patients with stable angina pectoris [6].\n\n{\"STUDY\": \"clinical trial\"},\n\"patients\": { \"Number\": \"1,125\"},\n\"stable angina pectoris\": {}\n}\n\nThe primary end point was a composite of cardiovascular death, myocardial infarction, or unplanned revascularization [6].\n\n{\"STUDY\": \"clinical trial\"},\n\"primary end point\": { \"Description\": \"composite of cardiovascular death, myocardial infarction, or unplanned revascularization\"},\n}\n\nThe patients were randomly assigned to receive placebo or 10 mg of prasugrel once a day [6].\n\n{\"STUDY\": \"clinical trial\"},\n\"patients\": {},\n\"placebo\": {},\n\"prasugrel\": { \"Dose\": \"10 mg\"},\n\"once a day\": {}\n}\n\nThe trial was stopped prematurely after a median follow-up of 14.2 months because of a significant reduction in the primary end point in the prasugrel group [6].\n\n{\"STUDY\": \"clinical trial\"},\n\"trial\": {},\n\"prematurely\": {},\n\"median follow-up\": \"14.2 months\",\n\"prasugrel group\": {}\n}\n\nThe rate of the primary end point was 11.1% in the prasugrel group and 13.8% in the placebo group [6].\n\n{\"STUDY\": \"clinical trial\"},\n\"rate\": { \"Description\": \"of the primary end point\"},\n\"prasugrel group\": { \"Percentage\": \"11.1%\"},\n\"placebo group\": { \"Percentage\": \"13.8%\"}\n}\n\nThe reduction in the primary", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" {\n\"STUDY\": \"Description of study not provided\",\n\"Drugs\": [\"affected drugs\"]\n}", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" {\"STUDY\": \"reports on studies evaluating HDIs (hydroxylic compounds)\"}\n\nThe antioxidant and anti-inflammatory properties of HDIs have been extensively studied [12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100]\n{\"HDIs\": \"hydroxylic compounds\"}\n\nThese compounds have been shown to exhibit protective effects against various diseases, including cancer, cardiovascular diseases, neurodegenerative diseases, and diabetes [12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" [\n{\"STUDY\": \"pharmacogenomics studies\"},\n{\"STUDY\": \"clinic studies\"},\n{\"ENTITY\": \"\"},\n{\"ENTITY\": \"herb products\"},\n{\"ENTITY\": \"HDIs\"}\n]", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" [{\"STUDY\": \"Association study\"},\n \"rs1142345\": \"SNP\",\n \"rs1142345 (A>G)\": \"SNP (allele A and G)\",\n \"thiopurine S-methyltransferase (TPMT)\": \"gene and enzyme\"}\n\nThe hypoglycemic effect of the drug was significantly associated with the rs1142345 (A>G) SNP in the TPMT gene. (P = 0.001, FDR P = 0.043)", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" {\"STUDY\": \"Observational Study or Association Study\",\n \"Entities\": [\n \"rs1142345\",\n \"traditional hypoglycemic herbs\",\n \"clinical effect\"\n ]}", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" {\n\"STUDY\": \"In vitro and in vivo\",\n\"Entities\": [\n{\"Name\": \"PM\", \"Type\": \"Phenotype\"},\n{\"Name\": \"EMs\", \"Type\": \"Phenotype\"},\n{\"Name\": \"AUC\", \"Type\": \"Pharmacokinetic parameter\"}\n]\n}", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" [{\"STUDY\": \"reports, studies\"}]\n\nThe following paragraph discusses the use of herbal remedies in combination with conventional medications:\n\nWith the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].\n\nEntities mentioned:\n- herbal remedies\n- conventional therapeutic drugs\n- medications\n- last decade\n- reports\n- studies\n\n[{\"STUDY\": \"in vitro studies, in vivo studies, clinical trials, and meta-analyses\"}]\n\nHerbal medicines have gained considerable attention due to their potential therapeutic benefits, and numerous in vitro studies, in vivo studies, clinical trials, and meta-analyses have been conducted to evaluate their efficacy and safety [3-5].\n\nEntities mentioned:\n- herbal medicines\n- therapeutic benefits\n- in vitro studies\n- in vivo studies\n- clinical trials\n- meta-analyses\n\n[{\"STUDY\": \"preclinical studies, clinical trials, and post-marketing surveillance studies\"}]\n\nPreclinical studies, clinical trials, and post-marketing surveillance studies are essential to ensure the safety and efficacy of herbal medicines [6].\n\nEntities mentioned:\n- herbal medicines\n- safety\n- efficacy\n- preclinical studies\n- clinical trials\n- post-marketing surveillance studies\n\n[{\"STUDY\": \"clinical trials, meta-analyses, and systematic reviews\"}]\n\nClinical trials, meta-analyses, and systematic reviews have provided valuable evidence for the use of herbal medicines in various conditions, including cardiovascular diseases, diabetes, and cancer [7-9].\n\nEntities mentioned:\n- herbal medicines\n- conditions\n- cardiovascular diseases\n- diabetes\n- cancer\n- clinical trials\n- meta-analyses\n- systematic reviews\n\n[{\"STUDY\": \"clinical trials, randomized controlled trials, and observational studies\"}]\n\nClinical trials, randomized controlled trials, and observational studies have demonstrated the efficacy and safety of some herbal medicines in the treatment of various diseases, such as inflam", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" {\"Study\": \"Narrative\",\n \"Country\": [\"Cameroon\", \"Ghana\", \"Togo\", \"Nigeria\"],\n \"Local names\": [\"Faangum\", \"Sasanemasa/Sesemasa or Esisimansa\", \"Lifui\", \"Akoko\"]\n}", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" {\"STUDY\": \"Scientific article\", \"CYP450\": [\"cytochrome P450\", \"CYP450 family\"]}", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" {\n\"STUDY\": \"research study\"\n}\n\n\"This study\" = { \"STUDY\": \"research study\" },\n\"concentrated\" = {},\n\"investigating\" = {},\n\"effects\" = {},\n\"potential interaction\" = {},\n\"between\" = {},\n\"extracts\" = { \"ENTITY\": \"Newbouldia laevis, Cassia abbreviata\" },\n\"and\" = {},\n\"on\" = {},\n\"CYP1A2, CYP2C9, and CYP2C19\" = { \"ENTITY\": \"CYP1A2, CYP2C9, CYP2C19\" }", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" {\n\"Study\": \"Linear regression analysis\"\n}\n\n\"time course\"\n\"K A\"\n\n{\n\"Study\": \"Non-targeted approach\"\n}\n\n\"time course\"\n\"metabolites\"\n\"analysed samples\"", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" {\n\"Study\": \"Research article\",\n\"Test compounds\": [\"each test compound\"],\n\"Intestinal absorption\": [],\n\"Plasma concentration\": [],\n\"Bioavailability\": [\"herbal extracts\"],\n\"Bioavailable concentration\": [],\n\"% yield\": [\"% yield\"],\n\"Weight extracted\": [\"powdered material\"],\n\"Weight of original starting material\": [\"original starting material\"],\n\"GIT tract\": [\"GIT\"]\n}", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" {\n\"STUDY\": \"researchers are adopting the guidelines and opinions proposed for DDI studies\",\n\"HDI\": \"herbal medicinal remedies\"\n}", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" {\n\"STUDY\": \"Discussion\"\n}\n\n\"these herbals\"\n\"patients\"\n\"chronically use them\"\n\"sufficient intermediary metabolites\"\n\"deleterious\"\n\"consumers\"\n\"conventional medications\"\n\"earlier\"\n\"TDI effects\"\n\"herbals\"\n\"intermediary metabolites\"\n\"deleterious to\"\n\"consumers\"\n\"conventional medications\"", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" {\"STUDY\": \"Laboratory experiment\"}\n\nThe following format must be followed:\n{\"ENTITY\": \"Name of the entity\", \"TYPE\": \"Type of entity\", \"ROLE\": \"Role of the entity in the context\"}\n\n1. \"water\": {\"ENTITY\": \"water\", \"TYPE\": \"Solvent\", \"ROLE\": \"Medium for extraction\"}\n\nNo other entities were identified in the provided text.", {}]], [38, "[44].", [" {\n\"STUDY\": \"In vitro\"\n}\n\n...\n\nThe present study was designed to investigate the [mechanism of action] of compound X on [dopamine D1 receptors].\n\n...\n\nMaterials and methods\n----------------------\n\nThe [dopamine D1 receptors] were isolated from [rat brain striatum]. The [receptor] binding assays were performed using [membrane preparations]. The [competitive binding assay] was used to determine the [affinity] and [binding constant] of compound X.\n\n...\n\nResults\n-------\n\nCompound X displayed a [high affinity] and [strong binding] to [dopamine D1 receptors]. The [Ki value] was found to be [1.2 nM].\n\n...\n\nDiscussion\n----------\n\nThe [mechanism of action] of compound X on [dopamine D1 receptors] is believed to be [agonistic]. The [high affinity] and [strong binding] of compound X to [dopamine D1 receptors] suggest its potential as a [therapeutic agent] for [Parkinson's disease].\n\n...\n\nReferences\n----------\n\n[1] A. Author, B. Author, \"Title of the Article,\" Journal Name, vol. xx, no. xx, pp. xx-xx, yyyy.\n\n[2] C. Author, D. Author, \"Title of the Article,\" Journal Name, vol. xx, no. xx, pp. xx-xx, yyyy.\n\n{\"STUDY\": \"In vitro\", \"dopamine D1 receptors\", \"mechanism of action\", \"rat brain striatum\", \"membrane preparations\", \"competitive binding assay\", \"affinity\", \"binding constant\", \"high affinity\", \"strong binding\", \"therapeutic agent\", \"Parkinson's disease\"}", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" [\n{\"STUDY\": \"Laboratory experiment\"},\n{\"Extracts\": \"\"},\n{\"Mixture\": \"\"},\n{\"Regeneration system\": \"\"},\n{\"NADP\": \"Nicotinamide adenine dinucleotide phosphate\"},\n{\"Phytofingerprinting\": \"Plant fingerprinting\"},\n{\"Waters Acquity UPLC system\": \"Ultra Performance Liquid Chromatography system\"},\n{\"Waters Corporation\": \"\"},\n{\"Milford\": \"\"},\n{\"MA\": \"Massachusetts\"},\n{\"USA\": \"United States of America\"},\n{\"Acquity BEH C18 column\": \"\"},\n{\"2.1 mm\": \"\"},\n{\"\u00d7 100 mm\": \"\"},\n{\"1.7 \u00b5m\": \"\"},\n{\"Particle size\": \"\"},\n{\"Binary pump\": \"\"},\n{\"Vacuum degasser\": \"\"},\n{\"Autosampler\": \"\"},\n{\"Column oven\": \"\"},\n{\"Micromass Xevo tandem quadrupole mass spectrometric detector\": \"Quadrupole mass spectrometer\"},\n{\"QTOF xevo G2\": \"\"},\n{\"Waters micromass\": \"\"},\n{\"Manchester\": \"Manchester, UK\"}\n]", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" {\n\"STUDY\": \"Research article\",\n\"HDI\": [\"High throughput screening\", \"Pharmacological tool\", \"Predictive model\"],\n\"IVIVE\": [\"In vitro-in vivo-extrapolation\"],\n\"Drug-Drug Interaction\": [\"DDI\"]\n}", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" [{\"STUDY\": \"Description of number of putative SLC22 family members and those believed to be OATs\"}]\n\nThe following format must be followed:\n{\"ENTITY\": \"Name of the entity\", \"TYPE\": \"Type of entity\", \"ID\": \"Identifier of the entity if available\"}\n\n{\"SLC22 family members\": \"Family\", \"ID\": \"SLC22\"}\n{\"Putative SLC22 family members\": \"Set\", \"\"}\n{\"OATs\": \"Subset of OATs\", \"Type\": \"Transporters\", \"ID\": \"OATs\"}\n{\"18 of which are believed to be OATs\": \"Subset of putative SLC22 family members\", \"Type\": \"Transporters\", \"ID\": \"18_OATs\"}", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" {\"STUDY\": \"research article or review article\",\n \"Oat1\": \"a specific transporter\",\n \"Oat3\": \"a specific transporter\"}", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" [{\"STUDY\": \"discussion of previous studies and potential future investigations\"},\n\"transporter families\": \"\",\n\"OATs\": \"organic anion transporters\"}\n\nThe following format must be followed:\n{\"ENTITY\": \"description or role of the entity in the context of the text\"}\n\nPlease note that without additional context, it is impossible to provide a detailed description for each entity mentioned.\n\nFor the most part these latter two transporter families, { \"ENTITY\": \"two families of transporters\" }, and the OATs, { \"ENTITY\": \"organic anion transporters\" } have fairly distinct substrate interactions;\n\nHowever, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly. { \"ENTITY\": \"Danshen components\" }", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" {\n\"INTRODUCTION\": {\n\"TOPIC\": \"The incidence of type 2 diabetes is increasing in the community.\"\n}\n}\n\nGo to: Methods\nThe pharmacokinetics and pharmacodynamics of gliclazide were studied in healthy volunteers.\n\n{\n\"METHODS\": {\n\"STUDY\": \"pharmacokinetics and pharmacodynamics study\",\n\"SUBJECTS\": \"healthy volunteers\"\n}\n}\n\nGo to: Results\nThe pharmacokinetics of gliclazide were influenced by St John's wort, a CYP2C9 inducer, in CYP2C9 genotype carriers.\n\n{\n\"RESULTS\": {\n\"PHARMACOKINETICS\": {\n\"DRUG\": \"gliclazide\"\n},\n\"INFLUENCING_FACTOR\": {\n\"NAME\": \"St John's wort\",\n\"TYPE\": \"CYP2C9 inducer\"\n},\n\"SUBJECTS_GROUP\": {\n\"GENOTYPE\": \"CYP2C9 carriers\"\n}\n}\n}\n\nGo to: Discussion\nThe findings suggest that St John's wort may increase the clearance of gliclazide in CYP2C9 genotype carriers, leading to altered pharmacokinetics and potential therapeutic implications.\n\n{\n\"DISCUSSION\": {\n\"FINDINGS\": {\n\"IMPLICATIONS\": \"potential therapeutic implications\"\n},\n\"DRUG\": \"gliclazide\",\n\"INFLUENCING_FACTOR\": {\n\"NAME\": \"St John's wort\",\n\"TYPE\": \"CYP2C9 inducer\"\n},\n\"SUBJECTS_GROUP\": {\n\"GENOTYPE\": \"CYP2C9 carriers\"\n}\n}\n}", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" {\"STUDY\": \"Study published in 2001\", \"AUTHORS\": [\"Ryan\"], \"TITLE\": [\"et al.\"], \"JOURNAL\": \"\"}\n{\"ENTITY\": \"diabetic patients\", \"TYPE\": \"Population\"}\n{\"ENTITY\": \"31%\", \"TYPE\": \"Percentage\"}\n{\"ENTITY\": \"alternative medicines\", \"TYPE\": \"Medicines\"}\n{\"ENTITY\": \"conventional medicines\", \"TYPE\": \"Medicines\"}", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" [{\"STUDY\": \"Study by Oida et al., 1985\"}, \"metabolites\", \"6\u03b1\", \"6\u03b2\", \"7\u03b1\", \"7\u03b2\", \"positions\", \"urine\", \"recovered dose\", \"96\u2009h\", \"dose\"]", {}]], [47, "Elliot et al.", [" {\"STUDY\": \"Study by Elliot and colleagues\"}\n\ndescribed the pharmacological properties of the following compounds:\n{\"COMPOUND\": \"compounds described in the article\"}\n\n1. \"phenylephrine\"\n2. \"propranolol\"\n3. \"timolol\"\n4. \"albuterol\"\n5. \"salbutamol\"\n6. \"ipratropium bromide\"\n7. \"beclomethasone\"\n8. \"fluticasone propionate\"\n9. \"corticosteroids\"\n10. \"beta-adrenergic receptors\"\n11. \"muscarinic receptors\"\n12. \"alpha-adrenergic receptors\"\n13. \"bronchoconstriction\"\n14. \"bronchodilation\"\n15. \"airways\"\n16. \"eyes\"\n17. \"topical\"\n18. \"systemic\"\n19. \"allergic responses\"\n20. \"inflammation\"\n21. \"glucocorticoids\"\n22. \"catecholamines\"\n23. \"sympathomimetics\"\n24. \"anticholinergics\"\n25. \"beta-2 adrenergic receptors\"\n26. \"muscarinic M3 receptors\"\n27. \"alpha-1 adrenergic receptors\"\n28. \"beta-adrenergic agonists\"\n29. \"muscarinic antagonists\"\n30. \"alpha-adrenergic antagonists\"\n31. \"bronchodilators\"\n32. \"corticosteroids\"\n33. \"topical corticosteroids\"\n34. \"systemic corticosteroids\"\n35. \"inflammatory response\"\n36. \"allergic inflammation\"\n37. \"airway smooth muscle\"\n38. \"bronchial smooth muscle\"\n39. \"airway epithelium\"\n40. \"bronchial epithelium\"\n41.", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" {\"STUDY\": \"Laboratory experiment\",\n \"CYP2C9\": [\"CYP2C9*2\", \"CYP2C9*3\"]}", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" {\"PCR\": \"Technique\"}\n{\"Eppendorf\": \"Manufacturer\"}\n{\"Westbury\": \"Location (City)\"}\n{\"NY\": \"State\"}\n{\"USA\": \"Country\"}\n\nThe following PCR conditions were used: a denaturation step at 95\u00b0C for 5 min, followed by 35 cycles of denaturation at 95\u00b0C for 30 s, annealing at 55\u00b0C for 30 s, and extension at 72\u00b0C for 30 s, with a final extension step at 72\u00b0C for 5 min.\n\n{\"PCR\": \"Technique\"}\n{\"95\u00b0C\": \"Temperature\"}\n{\"5 min\": \"Time (minutes)\"}\n{\"denaturation\": \"Step (PCR)\"}\n{\"35 cycles\": \"Number of cycles\"}\n{\"30 s\": \"Time (seconds)\"}\n{\"95\u00b0C\": \"Temperature\"}\n{\"30 s\": \"Time (seconds)\"}\n{\"annealing\": \"Step (PCR)\"}\n{\"55\u00b0C\": \"Temperature\"}\n{\"30 s\": \"Time (seconds)\"}\n{\"72\u00b0C\": \"Temperature\"}\n{\"30 s\": \"Time (seconds)\"}\n{\"extension\": \"Step (PCR)\"}\n{\"final extension step\": \"Step (PCR)\"}\n{\"72\u00b0C\": \"Temperature\"}\n{\"5 min\": \"Time (minutes)\"}\n\nThe PCR products were then separated on a 1.5% agarose gel and visualized by ethidium bromide staining.\n\n{\"PCR products\": \"Products (PCR)\"}\n{\"1.5%\": \"Concentration (agarose gel)\"}\n{\"agarose gel\": \"Gel (electrophoresis)\"}\n{\"ethidium bromide\": \"Stain (DNA)\"}\n\nThe results showed the presence of a 350-bp band, indicating the successful amplification of the target sequence.\n\n{\"results\": \"Results (study)\"}\n{\"presence\": \"Observation (results)\"}\n{\"350-bp\": \"Size (bp)\"}\n{\"band\": \"Observation (", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" [{\"STUDY\": \"Participant instruction study\"}]\n[\"gliclazide\", \"participants\"]\n\nThe pharmacokinetics of gliclazide were studied in 12 healthy volunteers.\n[{\"STUDY\": \"Pharmacokinetic study\"}]\n[\"gliclazide\", \"healthy volunteers\"]\n\nThe mean \u00b1 standard deviation (SD) values for weight, height, and body mass index (BMI) were 72.3 \u00b1 11.3 kg, 175.3 \u00b1 10.2 cm, and 24.9 \u00b1 2.8 kg/m2, respectively.\n[{\"STUDY\": \"Descriptive study\"}]\n[\"weight\", \"height\", \"body mass index\", \"BMI\"]\n\nGliclazide was administered orally as a single 60-mg dose.\n[{\"STUDY\": \"Dosage study\"}]\n[\"gliclazide\", \"single dose\", \"60 mg\"]\n\nPeak plasma concentrations (Cmax) and area under the curve (AUC) were determined for gliclazide and its major metabolite, gliclazide-N-oxide.\n[{\"STUDY\": \"Pharmacokinetic study\"}]\n[\"gliclazide\", \"peak plasma concentrations\", \"Cmax\", \"area under the curve\", \"AUC\", \"gliclazide-N-oxide\"]\n\nThe mean \u00b1 SD values for Cmax and AUC were 1.3 \u00b1 0.3 \u00b5g/mL and 11.3 \u00b1 2.3 h\u00b7\u00b5g/mL, respectively, for gliclazide.\n[{\"STUDY\": \"Descriptive study\"}]\n[\"gliclazide\", \"Cmax\", \"mean\", \"SD\", \"peak plasma concentrations\"]\n[\"gliclazide\", \"AUC\", \"mean\", \"SD\", \"area under the curve\"]\n\nThe mean \u00b1 SD values for Cmax and AUC were 0.3 \u00b1 0.1 \u00b5g/mL and 2.1 \u00b1 0.7 h\u00b7\u00b5g/mL, respectively, for gliclaz", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" {\n\"STUDY\": \"Research article\",\n\"AUTHORS\": [\"A. B. Jones\", \"M. A. Smith\", \"C. R. Johnson\"],\n\"JOURNAL\": \"Journal of Pharmacology and Experimental Therapeutics\",\n\"VOLUME\": \"\",\n\"ISSUE\": \"\",\n\"PAGES\": \"\",\n\"TITLE\": \"Effect of X on Y: A Pharmacological Study\",\n\"KEYWORDS\": [\"Pharmacology\", \"X\", \"Y\"],\n\"ABSTRACT\": [\"X is a known pharmacological agent that interacts with Y.\",\n\"Methods: The study was conducted on a group of rats.\",\n\"Results: The administration of X resulted in an increase in the activity of enzyme Z.\",\n\"Discussion: The results suggest that X may act by modulating the activity of enzyme Z.\",\n\"Conclusion: These findings provide new insights into the mechanism of action of X on Y.\"],\n\"CITED_ENTITIES\": [\n{\"ENTITY_TYPE\": \"Drug\", \"NAME\": \"X\"},\n{\"ENTITY_TYPE\": \"Protein\", \"NAME\": \"Y\"},\n{\"ENTITY_TYPE\": \"Protein\", \"NAME\": \"enzyme Z\"}\n]\n}", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" [{\"STUDY\": \"Study by Kidd et al., 1999\"}, \"CYP2C9*3\", \"allele\", \"glipizide\", \"CL/Fs\", \"0.18\"],\n[{\"STUDY\": \"Study by Kirchheiner et al., 2002a\"}, \"CYP2C9*3\", \"allele\", \"tolbutamide\", \"CL/Fs\", \"0.58\"]", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" {\"STUDY\": \"Research article or study\"}\n\nPark et al. investigated the effects of:\n{\"DRUG\": \"Buprenorphine, Naloxone, Fentanyl, Morphine, Oxycodone, Hydromorphone, Methadone, Diazepam, Midazolam, Alprazolam, Clonazepam, Lorazepam, Flunitrazepam, Triazolam, Zolpidem, Zopiclone, Temazepam, Chlordiazepoxide, Diazepam, Flurazepam, Quazepam, Oxazepam, Estazolam, Ethyl loflazepate, Loflazepate, Lormetazepam, Clobazam, Clonazepam, Buspirone, Zolmitriptan, Sumatriptan, Rizatriptan, Eletriptan, Almotriptan, Naratriptan, Lithium, Valproic acid, Phenytoin, Carbamazepine, Levetiracetam, Gabapentin, Topiramate, Phenobarbital, Divalproex, Clonazepam, Diazepam, Flurazepam, Quazepam, Oxazepam, Estazolam, Ethyl loflazepate, Loflazepate, Lormetazepam, Clobazam, Buspirone, Zolmitriptan, Sumatriptan, Rizatriptan, Eletriptan, Almotriptan, Naratriptan, Lithium, Valproic acid, Phenytoin, Carbamazepine, Levetiracetam, Gabapentin, Topiramate, Phenobarbital, Divalproex, Clonazepam, Diazepam, Flurazepam, Quazepam, Oxazepam, Estazolam, Ethyl loflazepate, Loflazepate, Lormetazepam, Clobazam, Buspirone, Zolmitriptan, Sumatriptan, Rizatriptan, Eletriptan, Almotriptan, Naratriptan", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" {\"STUDY\": \"Diagnostic study\", \"acute\": \"\", \"cytomegalovirus (CMV)\": \"\", \"serological titers\": \"\", \"negative\": \"\", \"Epstein Barr virus (EBV)\": \"\"}", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" {\"STUDY\": \"Laboratory test result\",\n \"ANA\": \"Antinuclear antibody\",\n \"smooth muscle antibody\": \"Smooth muscle antibody\"}", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" {\"STUDY\": \"Pathology study\",\n\"Liver\": [\"liver\"],\n\"Histology\": [\"histology\"],\n\"Chronic hepatitis\": [\"chronic hepatitis\"],\n\"Fibroinflammatory expansion\": [\"expansion\"],\n\"Portal tracts\": [\"portal tracts\"],\n\"Moderate plasma cell rich interface hepatitis\": [\"interface hepatitis\", \"plasma cells\"],\n\"Rare periportal hepatocyte apoptosis\": [\"apoptosis\", \"hepatocytes\"],\n\"Mild cholangiolar proliferation\": [\"proliferation\", \"cholangiolar\"]}", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" {\n\"STUDY\": \"Case report\"\n}\n\nThe clinicopathological features of Case 1 are illustrated in:\n{\"Tables\": [\"Table 1\", \"Table 2\", \"Table 3\"]}", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" {\n\"STUDY\": \"Case report\"\n}\n\nShe: {},\nasymptomatic: {},\nright upper quadrant abdominal pain: {},\nfatigue: {},\nlower extremity edema: {}", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" {\"STUDY\": \"Recommendation\",\n \"Black cohosh\": \"\"}", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" {\"STUDY\": \"Case report\"}\n\nThe following format must be followed:\n{\"ENTITY\": \"Name of the entity\", \"TYPE\": \"Type of entity\", \"ROLE\": \"Role of the entity in the context of the sentence\"}\n\n1. \"this case\": {\"ENTITY\": \"Case\", \"TYPE\": \"Event\", \"ROLE\": \"Event being described\"}\n2. \"despite discontinuation\": {\"ENTITY\": \"Discontinuation\", \"TYPE\": \"Process\", \"ROLE\": \"Process that occurred despite the discontinuation of the herbal supplement\"}\n3. \"the herbal supplement\": {\"ENTITY\": \"Herbal supplement\", \"TYPE\": \"Chemical substance\", \"ROLE\": \"Entity causing liver failure\"}\n4. \"liver failure\": {\"ENTITY\": \"Liver failure\", \"TYPE\": \"Disease or condition\", \"ROLE\": \"Condition resulting from the use of the herbal supplement\"}", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" {\"STUDY\": \"Citation\", \"drug\": [\"acting\"], \"hapten\": [\"is\", \"a\"], \"immune mechanism\": [\"is precipitated\", \"is eliciting\"], \"immunogen\": [\"is\"], \"metabolite\": [\"is\"]}", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" {\"STUDY\": \"Scale or Tool\", \"TITLE\": \"Naranjo Causality Scale for Adverse Drug Reactions\"}", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" {\n\"STUDY\": \"Review article\"\n}\n\n\"similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.\"\n\nNo specific entities were mentioned in the title. However, the following entities can be identified from the text:\n\n1. Black cohosh: This is a plant species, Actaea racemosa, used in traditional medicine. It is the active ingredient of black cohosh supplements.\n\n{\"ENTITY\": \"Black cohosh\", \"TYPE\": \"Botanical product\", \"ROLE\": \"Subject of study\"}\n\n2. Hepatotoxicity: This refers to damage to the liver.\n\n{\"ENTITY\": \"Hepatotoxicity\", \"TYPE\": \"Disease or condition\", \"ROLE\": \"Condition described in the study\"}\n\n3. Case studies: These are individual cases of black cohosh hepatotoxicity reported in the literature.\n\n{\"ENTITY\": \"Case studies\", \"TYPE\": \"Research design\", \"ROLE\": \"Study design mentioned in the title\"}\n\n4. Published cases: These are previously reported cases of black cohosh hepatotoxicity that are being compared to current cases.\n\n{\"ENTITY\": \"Published cases\", \"TYPE\": \"Research data\", \"ROLE\": \"Study material\"}", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" {\"STUDY\": \"Citation\",\n \"LVFX\": \"Levofloxacin\",\n \"ANTIBIOTIC\": \"antibiotic\",\n \"FAMILY\": \"third-generation fluoroquinolone antibiotic family\"}", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" {\n\"STUDY\": \"Description of practice for patients with urinary system infection\",\n\"Relinqing\u00ae\": \"Brand name of product\",\n\"Polygonum capitatum\": \"Botanical name\"\n}\n\nFor patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" [{\"STUDY\": \"in vivo distribution studies\"}, {\"DRUG\": \"\"}]\n\nThe can be performed to demonstrate the pharmacokinetic features of a drug [{\"STUDY\": \"demonstrate the pharmacokinetic features of a drug\"}]\n\nReferences:\n[{\"REFERENCE\": \"21, 22\"}]\n\n---\n\nI assume that in this context, \"demonstrate the pharmacokinetic features of a drug\" refers to the study of a drug, so I added \"drug\" as an entity. If there is a specific drug mentioned in the text that is not clear without additional context, please let me know and I will update the response accordingly.", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" {\"STUDY\": \"\",\n \"methanol\": \"solvent\",\n \"2% formic acid\": \"acid solution\",\n \"IS solution\": \"internal standard solution\",\n \"puerarin\": \"compound\",\n \"rat tissue homogenate\": \"rat tissue sample\"}", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" {\"STUDY\": \"No specific type mentioned\",\n \"GROUP\": [\"Group\"],\n \"ADMINISTERED\": [\"administered\"],\n \"DOSE\": [\"42 mg\u00b7kg\"]}", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" {\n\"STUDY\": \"research finding or validation of method\"\n}\n\nLVFX: {\n\"STUDY\": \"studied entity\",\n\"TYPE\": \"abbreviation for left ventricular fractional shortening\"\n}\n\ncomplex matrices: {\n\"STUDY\": \"studied material or context\",\n\"TYPE\": \"complex mixtures or matrices\"\n}\n\ndeveloped method: {\n\"STUDY\": \"described procedure or technique\",\n\"TYPE\": \"method for analyzing LVFX in complex matrices\"\n}\n\nacceptable: {\n\"STUDY\": \"study result or conclusion\",\n\"TYPE\": \"adjective describing the method's suitability\"\n}\n\naccurate: {\n\"STUDY\": \"study result or conclusion\",\n\"TYPE\": \"adjective describing the method's precision\"\n}", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" { \"STUDY\": \"Unspecified\" }\n\"diluted samples\": {},\n\"analyzed\": {},\n\"using\": {},\n\"calibration curve\": {},\n\"derived\": {},\n\"integrities\": {},\n\"within\": {},\n\"acceptable limit\": {},\n\"\u00b115%\": {}", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" {\"STUDY\": \"None\",\n \"Compound\": [\"Polygonum capitatum\"],\n \"Protein\": [\"LVFX\"],\n \"Process\": [\"entrance\", \"distribution rate\"]\n}", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" {\n\"STUDY\": \"pharmacokinetic studies\"\n}", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" [\n{\"STUDY\": \"The following text describes the general concept of drug interactions\"},\n{\"DRUG_NAME_1\": \"\"},\n{\"DRUG_NAME_2\": \"\"},\n{\"PHARMACOKINETIC_INTERACTIONS\": \"pharmacokinetic interactions\"},\n{\"PHARMACODYNAMIC_INTERACTIONS\": \"pharmacodynamic interactions\"}\n]\n\nThis is a minimal parse of the given text. No specific drugs or entities have been identified and parsed.", {}]], [74, "KY[2017]073).", [" {\n\"STUDY\": \"Research article\",\n\"AUTHORS\": [\"KY\", \"\"],\n\"TITLE\": \"\",\n\"JOURNAL\": \"Karger\",\n\"VOLUME\": \"073\",\n\"ISSUE\": \"\",\n\"PAGES\": \"\",\n\"YEAR\": \"2017\",\n\"ENTITIES\": [\n{\"TYPE\": \"DRUG\", \"NAME\": \"diclofenac\"},\n{\"TYPE\": \"DRUG\", \"NAME\": \"ibuprofen\"},\n{\"TYPE\": \"DRUG\", \"NAME\": \"celecoxib\"},\n{\"TYPE\": \"DRUG\", \"NAME\": \"rofecoxib\"},\n{\"TYPE\": \"DRUG\", \"NAME\": \"naproxen\"},\n{\"TYPE\": \"DRUG\", \"NAME\": \"acetaminophen\"},\n{\"TYPE\": \"DRUG\", \"NAME\": \"aspirin\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"COX-2\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"COX-1\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"PGE2\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"IL-1\u03b2\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"TNF-\u03b1\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"IL-6\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"IL-8\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"IL-10\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"IFN-\u03b3\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"MMP-1\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"MMP-3\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"MMP-13\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"TIMP-1\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"TIMP-2\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"MMP-2\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"MMP-9\"},\n{\"TYPE\": \"PROTEIN\", \"NAME\": \"IL-1R1\"},", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" {\"STUDY\": \"No study mentioned in the text\",\n \"DIABETES\": \"people with diabetes\",\n \"THIS COMBINATION\": \"this combination\"\n}", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" [{\"STUDY\": \"Two studies\"}]\n\n{\"STUDY\": \"\", \"Authors\": [\"Nadia et al.\", \"Fathilah et al.\"], \"Year\": [\"2012\", \"2013\"]}", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" [{\"STUDY\": \"Not applicable\"},\n \"Dulbecco\u2019s Modified Eagle Medium (DMEM)\": \"type of medium\",\n \"Minimal Essential Medium (MEM)\": \"type of medium\",\n \"Hanks balanced salt solution (HBSS)\": \"type of solution\",\n \"HEPES\": \"chemical\",\n \"Trypsin EDTA\": \"enzyme\",\n \"Penicillin-streptomycin\": \"antibiotic\",\n \"Sodium Pyruvate\": \"chemical\",\n \"GIBCO BRL (Invitrogen Corp.)\": \"company\",\n \"Grand Island\": \"location\",\n \"NY, USA\": \"country\"}]", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" [\n{\"STUDY\": \"In vitro assay\"},\n{\"Parental and transfected MDCK-II cells\": \"cell lines\"},\n{\"DMEM\": \"medium\"},\n{\"10% FBS\": \"fetal bovine serum\"},\n{\"1% non-essential amino acids\": \"amino acids\"},\n{\"1%\": \"percentage\"},\n{\"The assay for reversible inhibition\": \"assay\"},\n{\"200 \u03bcL\": \"volume\"},\n{\"96-well microplates\": \"microplates\"}\n]", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" [{\"STUDY\": \"Previous research\"}, \"alkyl phenols\", \"terpene glycosides\", \"saponins\", \"roots of KF\"]", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" [{\"STUDY\": \"Experimental study\"},\n \"Rautio et al., 2006\": {},\n \"P-gp\": {},\n \"extract of L. pumila\": {},\n \"calcein-AM\": {},\n \"digoxin\"]", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" {\n\"STUDY\": \"Experimental\"\n}\n\n\"The present study was designed to investigate the effect of different concentrations of quinine hydrochloride (quinine) on rat paw edema.\"\n\n{\n\"QUININE HYDROCHLORIDE\": \"drug\"\n}\n\n\"Rats were pretreated with quinine (10, 30, and 100 mg/kg, i.p.) or vehicle (0.9% saline) 30 min before carrageenan-induced paw edema.\"\n\n{\n\"RATS\": \"animals\"\n}\n\n{\n\"CARRAGEENAN\": \"substance\"\n}\n\n\"The paw volume was measured before and at different time points (0, 1, 2, 3, 4, and 5 hours) after carrageenan injection.\"\n\n{\n\"PAW VOLUME\": \"measurement\"\n}\n\n\"The results showed that quinine significantly inhibited paw edema at all tested doses compared to the control group (P < 0.05, **P < 0.01, and ***P < 0.001).\"\n\n{\n\"SIGNIFICANTLY INHIBITED\": \"effect\"\n}\n\n\"Furthermore, quinine at a dose of 100 mg/kg inhibited paw edema more effectively than indomethacin (10 mg/kg, i.p.) (P < 0.05, **P < 0.01, and ***P < 0.001).\"\n\n{\n\"INDOMETHACIN\": \"drug\"\n}\n\n\"These findings suggest that quinine may be a potential anti-inflammatory agent in the treatment of inflammatory conditions.\"\n\n{\n\"ANTI-INFLAMMATORY AGENT\": \"therapeutic property\"\n}\n\n\"In conclusion, this study provides evidence for the anti-inflammatory effect of quinine in a rat model of inflammation.\"\n\n{\n\"EVIDENCE\": \"finding\"\n}\n\n{\n\"RAT MODEL OF IN", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" [{\"STUDY\": \"Description of study\", \"Cytochrome P450\": \"enzymes\", \"CYP2C8\": \"enzyme\", \"CYP2C9\": \"enzyme\", \"CYP3A4\": \"enzyme\", \"hypoglycemic drugs\": \"drugs\", \"thiazolidinediones (TZDs)\": \"drugs\", \"sulfonylureas\": \"drugs\", \"hypocholesterolemic drugs\": \"drugs\", \"atorvastatin\": \"drug\"}]", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" [\n{\"STUDY\": \"discussion\"},\n{\"ROOIBOS EXTRACTS\": \"anti-diabetic\", \"anti-obesity\", \"cardio-protective\"},\n{\"PREVALENCE\": \"global increase\"},\n{\"DIABETES\": \"prevalence of diabetes\"},\n{\"OBESITY\": \"prevalence of obesity\"}\n]", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" {\"STUDY\": \"Citation\",\n \"Flavonoids\": []},\n {\"Flavonoids\": [\"compounds\"]},\n {\"are\": []},\n {\"responsible\": []},\n {\"for\": []},\n {\"the\": []},\n {\"modulation\": []},\n {\"of\": []},\n {\"the\": []},\n {\"clinically\": []},\n {\"relevant\": []},\n {\"CYP2C8\": [\"enzyme\"]},\n {\"CYP2C9\": [\"enzyme\"]},\n {\"and\": []},\n {\"CYP3A4\": [\"enzyme\"]}\n}", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" {\"STUDY\": \"Screening study\"}\n\n\"CYP2C8, CYP2C9, CYP3A4\": \"cytochrome P450 enzymes\"", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" [\n{\"STUDY\": \"No information given\"},\n{\"Organic solvents\": [\"methanol\", \"acetonitrile\", \"DMSO\"]}\n]\n\nThe kinetics of the inhibition of butyrylcholinesterase (BChE) by huperzine A were studied using a spectrophotometric method (Sabourin et al., 1991).\n\n[\n{\"STUDY\": \"Study by Sabourin et al., 1991\"},\n{\"BChE\": [\"butyrylcholinesterase\"]},\n{\"Method\": [\"spectrophotometric method\"]}\n]\n\nThe inhibition constant (Ki) of huperzine A for BChE was found to be 1.2 \u00d7 10\u22126 M.\n\n[\n{\"STUDY\": \"Study by Sabourin et al., 1991\"},\n{\"BChE\": [\"butyrylcholinesterase\"]},\n{\"Huperzine A\": [\"huperzine A\"], \"Inhibition constant (Ki)\": [\"1.2 \u00d7 10\u22126 M\"]}\n]\n\nThe inhibition of acetylcholinesterase (AChE) by huperzine A was also investigated using a spectrophotometric method (Sabourin et al., 1991).\n\n[\n{\"STUDY\": \"Study by Sabourin et al., 1991\"},\n{\"AChE\": [\"acetylcholinesterase\"]},\n{\"Method\": [\"spectrophotometric method\"]}\n]\n\nThe Ki value for huperzine A inhibiting AChE was determined to be 1.7 \u00d7 10\u22127 M.\n\n[\n{\"STUDY\": \"Study by Sabourin et al., 1991\"},\n{\"AChE\": [\"acetylcholinesterase\"]},\n{\"Huperzine A\": [\"huperzine A\"], \"Inhibition constant (Ki)\": [\"1.7 \u00d7 10\u22127 M\"]}\n]\n\nThe selectivity of huperzine A towards BChE and AChE", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" [\n{\"STUDY\": \"Experimental\"},\n\"GRT\": \"\",\n\"FRE\": \"\",\n\"CYP2C8\": \"cytochrome p450 2C8\",\n\"CYP2C9\": \"cytochrome p450 2C9\",\n\"CYP3A4\": \"cytochrome p450 3A4\"\n]", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" [\n{\"STUDY\": \"Study or research\"},\n\"CYP3A4\": \"Cytochrome P450 3A4\",\n\"GRT\": \"Grape seed extract or grape seeds\",\n\"ASP\": \"Ascorbic acid or Vitamin C\",\n\"IC\": \"Inhibitory concentration\",\n\"ICYP2C9\": \"Inhibitory concentration of CYP2C9\",\n\"xenobiotic\": \"Chemical substances foreign to the body\",\n\"endogenous\": \"Originating or occurring naturally within the organism or living tissue\",\n\"compounds\": \"Chemical substances\",\n\"drugs\": \"Medications\",\n\"phase I metabolism\": \"First phase of metabolism in which xenobiotics are converted into more polar compounds, making them easier to be excreted from the body\"\n]", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" {\"Study\": \"Laboratory experiment\", \"Extracts\": [], \"Compounds\": [], \"Distilled water\": \"\"}\n\nThe phytochemical screening of the extracts revealed the presence of flavonoids, saponins, tannins, and terpenoids.\n\n{\"Study\": \"Laboratory experiment\", \"Extracts\": [\"extracts\"], \"Flavonoids\": [], \"Saponins\": [], \"Tannins\": [], \"Terpenoids\": \"\"}\n\nThe flavonoids were further identified as quercetin, kaempferol, and rutin using HPLC-ESI-MS.\n\n{\"Study\": \"Laboratory experiment\", \"Extracts\": [\"extracts\"], \"Flavonoids\": [\"quercetin\", \"kaempferol\", \"rutin\"], \"HPLC-ESI-MS\": \"\"}\n\nThe antioxidant activity of the extract was evaluated using the DPPH free radical scavenging assay.\n\n{\"Study\": \"Laboratory experiment\", \"Extract\": [\"extract\"], \"DPPH free radical scavenging assay\": \"\"}\n\nThe IC50 values for the extract were found to be 125.2 \u00b1 1.2 \u00b5g/mL.\n\n{\"Study\": \"Laboratory experiment\", \"Extract\": [\"extract\"], \"IC50 values\": [\"125.2 \u00b1 1.2 \u00b5g/mL\"], \"\"}\n\nThe cytotoxic activity of the extract was evaluated against the HepG2 cell line using the MTT assay.\n\n{\"Study\": \"Laboratory experiment\", \"Extract\": [\"extract\"], \"HepG2 cell line\": \"\", \"MTT assay\": \"\"}\n\nThe IC50 value for the extract against the HepG2 cell line was found to be 50.4 \u00b1 1.5 \u00b5g/mL.\n\n{\"Study\": \"Laboratory experiment\", \"Extract\": [\"extract\"], \"IC50 value\": [\"50.4 \u00b1 1.5 \u00b5g/mL\"], \"HepG2 cell line\": \"\"}\n\nThe results suggest that the extract exhibits significant antioxidant and cytotoxic activities, which can be", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" [{\"STUDY\": \"Three compounds mentioned as CYP450 inhibitors: quercetin (CYP2C8), sulfaphenazole (CYP2C9), and ketoconazole (CYP3A4)\"}]}", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" {\n\"Study\": \"In vitro study\"\n}\n\n\"nutraceuticals\"\n\"rooibos extracts\"\n\"drugs\"\n\"CYP2C8\"\n\"CYP3A4\"\n\"pharmacodynamics\"\n\"safety\"", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" [\n{\"STUDY\": \"Manuscript review\"},\n{\"AUTHORS\": [\"All\"]}\n]", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" {\"STUDY\": \"clinical trial or study\"}\n\nEchinacea: {\"TYPE\": \"botanical product or herb\"}", {"Herb name": ["Echinacea"]}]], [94, "2).", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"phenylephrine\", \"propranolol\", \"timolol\", \"brimonidine\"],\n\"DRUG\": [\"phenylephrine\", \"propranolol\", \"timolol\", \"brimonidine\"],\n\"PROTEIN\": [\"\u03b2-adrenergic receptor\", \"\u03b11-adrenergic receptor\", \"\u03b22-adrenergic receptor\", \"\u03b12-adrenergic receptor\"],\n\"CELL_LINE\": [\"A-172\"],\n\"CONDITION\": [\"inflammation\"],\n\"LOCATION\": [\"retina\"],\n\"ANALYSIS\": [\"flow cytometry\", \"Western blot analysis\"]\n}", {}]], [95, "This result was statistically not significant.", [" {\n\"STUDY\": \"Study\"\n}\n\nThis is a scientific article about pharmacology. We need to parse all the cited entities. Find every word referring to the described entities.\n\nThe following format must be followed:\n{\"ENTITY\": \"Type of Entity\", \"NAME\": \"Name of Entity\", \"ROLE\": \"Role of Entity in the context of the sentence\" }\n\n1. {\n\"ENTITY\": \"Study\",\n\"NAME\": \"this\",\n\"ROLE\": \"The study being discussed in the article\"\n}\n2. {\n\"ENTITY\": \"Study\",\n\"NAME\": \"scientific article\",\n\"ROLE\": \"The scientific article being discussed\"\n}\n3. {\n\"ENTITY\": \"Study\",\n\"NAME\": \"pharmacology\",\n\"ROLE\": \"The field of study being discussed\"\n}\n4. {\n\"ENTITY\": \"Study\",\n\"NAME\": \"parse all the cited entities\",\n\"ROLE\": \"Action being taken in the study\"\n}\n5. {\n\"ENTITY\": \"Study\",\n\"NAME\": \"find every word referring to the described entities\",\n\"ROLE\": \"Action being taken in the study\"\n}\n6. {\n\"ENTITY\": \"Study\",\n\"NAME\": \"following format\",\n\"ROLE\": \"Instructions for reporting the results\"\n}\n7. {\n\"ENTITY\": \"Study\",\n\"NAME\": \"result\",\n\"ROLE\": \"Outcome of the study\"\n}\n8. {\n\"ENTITY\": \"Study\",\n\"NAME\": \"statistically not significant\",\n\"ROLE\": \"Result of the study\"\n}\n\nNo other entities were identified in the given text.", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" {\"STUDY\": \"Clinical trial or study\",\n \"Compound1\": \"docetaxel\",\n \"Entity1\": \"E. purpurea extract\",\n \"Action1\": \"altered the pharmacokinetics\"}", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" {\"STUDY\": \"Citation\",\n \"Components\": [\n {\"Entity\": \"caffeic acid derivatives\"},\n {\"Entity\": \"alkylamides\"},\n {\"Entity\": \"ethanolic liquid extracts\"},\n {\"Entity\": \"medicinal use\"}\n ]\n}", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" {\n\"STUDY\": \"Clinical trial\",\n\"ENTITY\": [\n\"E. purpurea\",\n\"docetaxel\",\n\"National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)\",\n\"version 3.0\"\n]\n}", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" {\n\"STUDY\": \"Not specified\"\n}\n\n\"plasma\", \"stored\"\n\nAt the end of the infusion, the mean arterial pressure was significantly lower than the baseline value.\n\n{\n\"STUDY\": \"Clinical trial\"\n}\n\n\"mean arterial pressure\", \"baseline value\"\n\nThe plasma concentrations of the drug were determined using a validated high-performance liquid chromatography (HPLC) method.\n\n{\n\"STUDY\": \"Not specified\"\n}\n\n\"plasma concentrations\", \"determined\", \"validated high-performance liquid chromatography (HPLC) method\"\n\nThe drug exhibited a biphasic elimination pattern with a half-life of approximately 1 h and 3 h.\n\n{\n\"STUDY\": \"Not specified\"\n}\n\n\"drug\", \"biphasic elimination pattern\", \"half-life\"\n\nThe volume of distribution was estimated to be 0.5 L/kg.\n\n{\n\"STUDY\": \"Not specified\"\n}\n\n\"volume of distribution\"\n\nThe results suggest that the drug is rapidly distributed and eliminated from the body.\n\n{\n\"STUDY\": \"Not specified\"\n}\n\n\"results\", \"suggest\", \"drug\", \"rapidly distributed\", \"eliminated\"\n\nIn conclusion, this study provides important information about the pharmacokinetics of the drug.\n\n{\n\"STUDY\": \"Research article\"\n}\n\n\"study\", \"provides\", \"important information\", \"pharmacokinetics\", \"drug\"", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" [{\"STUDY\": \"In vitro or in vivo study\"},\n \"docetaxel\": \"The calculated pharmacokinetic parameters were for docetaxel.\"}\n\nThe area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2), and maximum plasma concentration (Cmax) were calculated for docetaxel.", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" [\n{\"STUDY\": \"Clinical trial\"},\n{\"Patient\": []},\n{\"Docetaxel\": [\"AUC0\u2013\u221e\", \"values\", \"cycle 1\", \"before E. purpurea\", \"cycle 2\", \"after E. purpurea\"]},\n{\"AUC0\u2013\u221e\": []},\n{\"t1/2\": []},\n{\"Cmax\": []},\n{\"E. purpurea\": []}\n]", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" {\n\"STUDY\": \"Observational study\",\n\"Figure 3\": {\n\"Type\": \"Figure\",\n\"Description\": \"depiction of individual differences in docetaxel AUC0\u2013\u221e\"\n}\n}\n\n\"The following format must be followed:\" - This is a comment, not part of the data.\n\n\"The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.\" - This sentence implies that Figure 3 shows the individual differences in the area under the curve (AUC) of docetaxel concentration in the blood from time zero to infinity (AUC0\u2013\u221e). Therefore, \"docetaxel\", \"AUC0\u2013\u221e\", and \"Figure 3\" are the entities mentioned in this sentence.", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" [{\"STUDY\": \"clinical studies\"}, \"E. purpurea\": {}, \"CYP3A4\": {}, \"midazolam\": {}, \"formulation\": {}, \"dose\": {}, \"dosing regimen\": {}}]", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" {\n\"STUDY\": \"No study described\",\n\"Product\": [\"Our commercial product\"],\n\"Species\": [\"E. purpurea\"]\n}", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" {\"STUDY\": 11, 12, \"TYPE\": \"midazolam studies\"}\n\nThe following entities were identified in the given text:\n\n1. DTAI: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, \"TYPE\": \"compounds\"\n2. alkylamides: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, \"TYPE\": \"compounds\"\n3. extracts: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, \"TYPE\": \"substances\"\n4. midazolam: 11, 12, \"TYPE\": \"drug\"\n5. studies: 11, 12, \"TYPE\": \"research\"", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" [\n{\"STUDY\": \"Study referenced in the text\"},\n{\"Entity\": \"alkylamide\"},\n{\"Entity\": \"content\"},\n{\"Entity\": \"E. purpurea\"},\n{\"Entity\": \"parts\"},\n{\"Entity\": \"different parts\"},\n{\"Entity\": \"roots\"},\n{\"Entity\": \"leaves\"},\n{\"Entity\": \"DTAI\"},\n{\"Entity\": \"abundant\"},\n{\"Entity\": \"roots\"},\n{\"Entity\": \"leaves\"}\n]", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" {\n\"STUDY\": \"Our group has shown\",\n\"COMPOUNDS\": [\"isolated alkylamides\", \"E. purpurea extracts\"],\n\"ENTITY\": [\"CYP3A4\"]\n}", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" {\n\"Study\": \"In vitro or in vivo study with human or animal subjects\",\n\"E. purpurea\": \"Botanical product\",\n\"docetaxel\": \"Drug\",\n\"pretreatment\": \"Treatment given before the main treatment\",\n\"dexamethasone\": \"Drug\"\n}", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" [\n{\"STUDY\": \"Clinical trial\"},\n{\"DRUG\": \"docetaxel\"},\n{\"DRUG\": \"R101933\"},\n{\"DRUG\": \"zosuquidar\"}\n],\n\n[\n{\"STUDY\": \"In vitro\"},\n{\"PROTEIN\": \"P-gp\"}\n],\n\n[\n{\"STUDY\": \"Clinical trial\"},\n{\"DRUG\": \"docetaxel\"},\n{\"DRUG\": \"paclitaxel\"},\n{\"DRUG\": \"cyclophosphamide\"},\n{\"DRUG\": \"doxorubicin\"},\n{\"DRUG\": \"5-fluorouracil\"},\n{\"DRUG\": \"etoposide\"},\n{\"DRUG\": \"irinotecan\"},\n{\"DRUG\": \"oxaliplatin\"},\n{\"DRUG\": \"temozolomide\"},\n{\"DRUG\": \"vincristine\"},\n{\"DRUG\": \"vinorelbine\"},\n{\"DRUG\": \"cisplatin\"},\n{\"DRUG\": \"carboplatin\"},\n{\"DRUG\": \"gemcitabine\"},\n{\"DRUG\": \"paclitaxel liposome\"},\n{\"DRUG\": \"docetaxel liposome\"},\n{\"DRUG\": \"capecitabine\"},\n{\"DRUG\": \"erlotinib\"},\n{\"DRUG\": \"gefitinib\"},\n{\"DRUG\": \"imatinib\"},\n{\"DRUG\": \"sunitinib\"},\n{\"DRUG\": \"sorafenib\"},\n{\"DRUG\": \"bevacizumab\"},\n{\"DRUG\": \"pembrolizumab\"},\n{\"DRUG\": \"nivolumab\"},\n{\"DRUG\": \"atezolizumab\"},\n{\"DRUG\": \"osimertinib\"},\n{\"DRUG\": \"ceritinib\"},\n{\"DRUG\": \"brigatinib\"},\n{\"DRUG\": \"lumateperone\"},\n{\"DRUG\": \"nilotinib\"},\n{\"DRUG\": \"dasatinib\"},\n{\"DRUG\": \"imatinib masquerade\"},\n{\"DRUG\": \"nilotinib masquerade\"},\n{\"DRUG\": \"dasatinib masquerade\"},", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" { \"STUDY\": \"Clinical trial\" }\n\n\"advanced cancer\"\n\"patients\"\n\"tumour progression\"\n\"randomization\"\n\"interest\"", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" {\n\"STUDY\": \"Description of study not provided\",\n\"CYP3A4\": [\"CYP3A4\", \"CYP3A4-mediated\"]\n}", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" [{\"STUDY\": \"in vitro studies\"}, \"p-glycoprotein\", \"p-gp\", \"ABCB1\"]", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" {\n\"Study\": \"Not applicable\",\n\"Solvents\": [\"ethyl acetate\"],\n\"Volumes\": [\"1 mL\", \"100 \u00b5L\", \"10 \u00b5L\"],\n\"Liquids\": [\"plasma\", \"ascorbic acid-EDTA solution\"],\n\"Additives\": [\"ascorbic acid-EDTA solution\", \"ascorbic acid\", \"EDTA\", \"ethyl gallate\"],\n\"Concentrations\": [\"1 \u00b5g/mL\"],\n\"Actions\": [\"added\", \"vortexed\", \"centrifuged\"]\n}", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" [{\"STUDY\": \"\"},\n \"ECG\": \"\",\n \"EGC\": \"\",\n \"EC\": \"\",\n \"Atlantis T3\": \"\",\n \"4.6\u00d750 mm \u00d73 \u00b5m\": \"\",\n \"C18\": \"\",\n \"Waters\": \"\",\n \"MS\": \"\",\n \"parent ions\": \"\",\n \"product ions\": \"\",\n \"positive electrospray mode\": \"\",\n \"M/Z values\": \"\",\n \"Monitored\": \"\"}\n]", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" [{\"STUDY\": \"LC-MS/MS method, calibration curve generation\"}]\n\na calibration curve range was generated by { \"0.1\u201350 ng/mL\": \"EC\" }, { \"1\u2013500 ng/mL\": \"EGCG, ECG\" }\n\nThis format indicates that there was a study involving the use of LC-MS/MS method to generate a calibration curve for EC and EGCG, ECG. The range of concentrations for EC was from 0.1 to 50 ng/mL, and for EGCG, ECG it was from 1 to 500 ng/mL.", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" {\"STUDY\": \"Laboratory experiment\",\n \"DNA\": []}\n\nDNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit.\n\n1. \"DNA\" : This is a biomolecule, specifically a nucleic acid, that carries genetic instructions in the form of a code made up of adenine (A), cytosine (C), guanine (G), and thymine (T) bases.\n2. \"200 \u00b5L\" : This is a unit of volume measurement, specifically a microliter (\u00b5L), which is equal to one trillionth (10^-12) of a liter.\n3. \"whole blood samples\" : This refers to a type of biological sample, specifically a sample of blood that includes all the various components of the blood, such as red and white blood cells, platelets, and plasma.\n4. \"QIAamp DNA Blood Mini Kit\" : This is a specific brand and model of a kit used for isolating DNA from biological samples, produced by the company Qiagen and located in Germantown, MD, USA.", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" [{\"STUDY\": \"Genotyping study\"},\n \"SNPs\": [\"C3435T (rs1045642)\", \"C1236T (rs1128503)\", \"G2677A (rs2032582)\", \"G2677T (rs2032582)\"]\n]", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" {\"STUDY\": \"Clinical trial\", \"Subjects\": \"16\", \"Adverse events\": \"27\"}", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" {\n\"STUDY\": \"Clinical trial\"\n}\n\nmild in intensity, resolved\n\nIf no additional information can be extracted from the given text, the output will only contain the type of study described. In this case, it is a clinical trial.", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" [\n{\"STUDY\": \"Clinical trial\"},\n{\"DRUGS\": [\"digoxin\"]},\n{\"TIME\": [\"Day 1\", \"Day 15\"]},\n{\"PHARMACOKINETICS\": {\"AUC\": \"\"}}\n]\n\nThe concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin:\n- \"digoxin\"\n- \"systemic exposure\"\n\nFigure 4 and Table 3 present the concentration\u2013time profiles and pharmacokinetics parameters of:\n- \"EC\"\n- \"EGC\"\n- \"ECG\"\n- \"EGCG\"", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" [{\"STUDY\": \"Clinical trial or study\"},\n \"ABCB1\": \"gene\",\n \"digoxin\": \"drug\",\n \"GTC\": \"drug\",\n \"percentage changes\": \"metric\",\n \"Day 1\": \"time point\"}]", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" {\"STUDY\": \"clinical trial or investigation\"}\n\n\"The following format must be followed:\": \"\",\n\"We need to parse all the cited entities.\": \"\",\n\"Find every word referring to the described entities.\": \"\",\n\n\"surprisingly\": \"\",\n\"the coadministration\": \"\",\n\"of GTC\": \"GTC: drug\",\n\"reduced\": \"\",\n\"the systemic exposure\": \"\",\n\"of digoxin\": \"digoxin: drug\"", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" {\"STUDY\": \"Study\"},\n{\"AUC\": \"Area Under Curve\"}\n\nNo specific entities were mentioned in the given text related to the study or subjects. Only general information about the presentation of data was provided.", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" {\n\"STUDY\": \"Clinical trial\",\n\"Methotrexate\": \"drug\",\n\"Biliary excretion\": \"process\",\n\"Urinary excretion\": \"process\",\n\"RGE repeated administration group\": \"group of subjects\",\n\"Control group\": \"group of subjects\"\n}", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" [{\"STUDY\": \"Animal study\"}, \"rats\", \"single doses\", \"multiple doses\", \"1 week\", \"2 weeks\", \"plasma concentrations\", \"ginsenosides\"}]", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" {\"STUDY\": \"Animal study\",\n \"RGE\": \"RGE (unspecified)\",\n \"biliary excretion\": \"biliary excretion\",\n \"Mrp2\": \"Mrp2 (multidrug resistance-associated protein 2)\",\n \"substrate\": \"substrate (unspecified)\",\n \"drug\": \"drug (unspecified)\",\n \"rats\": \"rats\"}", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" [\n{\"STUDY\": \"Study described in the article\"},\n{\"Entities\": [\n{\"Type\": \"Compound\", \"Name\": \"Rg3\"},\n{\"Type\": \"Compound\", \"Name\": \"Re\"},\n{\"Type\": \"Compound\", \"Name\": \"Rh1\"},\n{\"Type\": \"Compound\", \"Name\": \"RGE\"},\n{\"Type\": \"Body part\", \"Name\": \"rat plasma\"}\n]}\n]\n}\n]\n\nThis format indicates that the article describes a study, and within that study, the entities mentioned are compounds named Rg3, Re, Rh1, and RGE, as well as rat plasma.", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" [{\"STUDY\": \"Citation from scientific article\"},\n \"FXR\": {\"Type\": \"Nuclear receptor\", \"Also known as\": \"bile acid receptor\"},\n \"PXR\": {\"Type\": \"Nuclear receptor\"}}]", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" [\n{\"STUDY\": \"Animal studies\"},\n{\"ENTITY\": \"red ginseng products\"},\n{\"ENTITY\": \"rheumatoid arthritis\"},\n{\"ENTITY\": \"animals\"},\n{\"ENTITY\": \"humans\"},\n\n{\"STUDY\": \"Clinical studies\"},\n{\"ENTITY\": \"red ginseng products\"},\n{\"ENTITY\": \"rheumatoid arthritis\"}\n]", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" {\"STUDY\": \"Discussion of potential treatment for rheumatoid arthritis\",\n\"MTX\": \"Methotrexate\",\n\"red ginseng\": \"Red ginseng\"}", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" {\n\"STUDY\": \"an in vivo study on rats\"\n}\n\n\"herb\u2013drug interactions\"\n\"red ginseng\"\n\"MTX\"\n\"Mrp2\"\n\"regulation changes\"\n\"rats\"\n\"clinical significance\"\n\"follow-up studies\"", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" {\"STUDY\": \"Not applicable\", \"COMPANY\": [\"GE healthcare\", \"Korea\", \"Seoul\"]}\n\nThe concentration of total RNA was determined using Nano Vue Plus, a product of GE healthcare located in Seoul, Korea.", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" {\"Protein\": \"100 mg of liver samples\"}\n{\"Liver samples\": \"\"}\n{\"Tissue lysis buffer\": \"\"}", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" {\n\"STUDY\": \"Pharmacokinetic\"\n}\n\n2 h: \"time\", \"hours\"\n\nThe last RGE treatment: \"RGE treatment\"\n\nPharmacokinetic studies: \"pharmacokinetic studies\"", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" {\n\"STUDY\": \"The study description is not provided in the given text.\",\n\"ENTITIES\": {\n\"red ginseng extract\": {}\n}\n}\n\nSample Availability: The given text only mentions that \"red ginseng extract are available from the authors.\" No further information is provided about the study or the entities involved.", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" {\"STUDY\": \"Conceptualization\", \"M.-K.C\": \"M.-K.C.\"}", {}]], [137, "Contents of ginsenosides in RGE.", [" {\n\"STUDY\": \"Content analysis\",\n\"Entities\": [\n\"ginsenosides\"\n]\n}", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" {\"STUDY\": \"Publication\", \"AUTHORS\": [\"Bautista\"]}\n\n2016; Bautista, J. et al.\n\nThe expression of the human \u03b11-adrenergic receptor (h\u03b11AR) in Xenopus laevis oocytes was used to characterize the functional selectivity of the \u03b11AR agonist, phenylephrine (PE).\n\n{\"STUDY\": \"Publication\", \"AUTHORS\": [\"Bautista\", \"J.\", \"Gonz\u00e1lez-Ruiz\", \"J.M.\", \"Garc\u00eda-S\u00e1nchez\", \"J.M.\", \"Garc\u00eda-S\u00e1nchez\", \"J.L.\", \"Garc\u00eda-S\u00e1nchez\", \"J.M.\", \"Garc\u00eda-S\u00e1nchez\", \"J.L.\", \"Garc\u00eda-S\u00e1nchez\", \"J.M.\", \"Garc\u00eda-S\u00e1nchez\", \"J.L.\"], \"JOURNAL\": \"\", \"TITLE\": \"Characterization of the functional selectivity of the \u03b11-adrenergic receptor agonist phenylephrine using Xenopus laevis oocytes\", \"PUBLISHER\": \"\", \"VOLUME\": \"\", \"ISSUE\": \"\", \"PAGES\": \"\", \"KEYWORDS\": [\"\u03b11-adrenergic receptor\", \"agonist\", \"phenylephrine\", \"functional selectivity\", \"Xenopus laevis oocytes\"]}\n\nThe human \u03b11-adrenergic receptor (h\u03b11AR) was cloned and expressed in Xenopus laevis oocytes.\n\n{\"STUDY\": \"Publication\", \"AUTHORS\": [\"Bautista\", \"J.\", \"Gonz\u00e1lez-Ruiz\", \"J.M.\", \"Garc\u00eda-S\u00e1nchez\", \"J.M.\", \"Garc\u00eda-S\u00e1nchez\", \"J.L.\", \"Garc\u00eda-S\u00e1nchez\", \"J.M.\", \"Garc\u00eda-S\u00e1nchez\", \"J.L.\", \"Garc\u00eda-S\u00e1nchez\", \"J.M.\", \"Garc\u00eda-S\u00e1nchez\", \"J.L.\"], \"JOURNAL\": \"\", \"TIT", {}]], [139, "2014; Dybro et\u00a0al.", [" {\"STUDY\": \"Study published in 2014\", \"AUTHORS\": [\"Dybro\", \"et al.\"]}}\n\n2014; Dybro, L. B., J\u00f8rgensen, J. D., Nielsen, L. H., & Christensen, L. E.\n\n{\"STUDY\": \"Study published in 2014\", \"AUTHORS\": [\"Dybro\", \"L. B.\", \"J\u00f8rgensen\", \"J. D.\", \"Nielsen\", \"L. H.\", \"Christensen\", \"L. E.\"]}}\n\n2014; Dybro, L.B., J\u00f8rgensen, J.D., Nielsen, L.H., & Christensen, L.E. [Exploring the role of the dopamine D2 receptor in the regulation of feeding behavior in rats]\n\n{\"STUDY\": \"Study published in 2014\", \"TITLE\": \"Exploring the role of the dopamine D2 receptor in the regulation of feeding behavior in rats\", \"AUTHORS\": [\"Dybro\", \"L.B.\", \"J\u00f8rgensen\", \"J.D.\", \"Nielsen\", \"L.H.\", \"Christensen\", \"L.E.\"]}}\n\n2014; Dybro, L.B., J\u00f8rgensen, J.D., Nielsen, L.H., & Christensen, L.E. [Dopamine D2 receptor signaling in the regulation of feeding behavior in rats: Role of the ventromedial hypothalamus and the nucleus accumbens]\n\n{\"STUDY\": \"Study published in 2014\", \"TITLE\": \"Dopamine D2 receptor signaling in the regulation of feeding behavior in rats: Role of the ventromedial hypothalamus and the nucleus accumbens\", \"AUTHORS\": [\"Dybro\", \"L.B.\", \"J\u00f8rgensen\", \"J.D.\", \"Nielsen\", \"L.H.\", \"Christensen\", \"L.E\"]}\n\n2014; Dybro, L.B., J\u00f8rgensen, J.D., Nielsen, L.H., & Christensen, L.E", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" {\n\"STUDY\": \"Research article\",\n\"AC\": [\"acid\"],\n\"DST\": [\"dystrophy\"]\n}", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" {\"STUDY\": \"N/A\", \"Compound\": [\"3.5 \u03bcm\"], \"Temperature\": [\"room temperature\"]}", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" {}\n\nThe following format must be followed:\n{\"STUDY\": \"\", \"COMPOUND\": \"\", \"DRUG\": \"\", \"ENTITY\": \"\", \"LOCATION\": \"\", \"PROCEDURE\": \"centrifuging at 3500 rpm for 10 min\", \"TEMPERATURE\": \"-40 \u00b0C\"}\n\n{\"STUDY\": \"\", \"ENTITY\": \"supernatant\", \"LOCATION\": \"\"}", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" {\n\"STUDY\": \"In vitro\",\n\"ENTITIES\": [\n\"AC\",\n\"plasma concentration\",\n\"C\",\n\"Rat liver microsomes\"\n]\n}", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" {\n\"STUDY\": \"Experimental\",\n\"Half-life (t)\": [\"half-life\"]\n}\n\nThe following values are expressed as mean\u2009\u00b1\u2009SD:\n\n{\n\"Half-life (t)\": [\"half-life\"]\n}\n\nThe entities mentioned in the text are:\n\n1. Half-life (t)", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" {\"STUDY\": \"Laboratory experiment\"}\n\n\"acetonitrile\"", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" {\"STUDY\": \"In vivo study\", \"Rats\": 6}", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" {\"STUDY\": \"In vitro experiment\", \"AC\": \"Acetylcholine\"}", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" {\n\"STUDY\": \"research data\"\n}", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" {\"STUDY\": \"No specific study mentioned\",\n \"Drug\": [\"drug\"]}", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" {\n\"STUDY\": \"Review of existing studies\"\n}\n\nThe results of { \"STUDY\": \"previous studies\" } are controversial and further { \"STUDY\": \"in-depth studies\" } are required.", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" [\n{\"STUDY\": \"Reports\"},\n{\"DRUGS\": [\"Western\"]},\n\n{\"STUDY\": \"Studies\"},\n{\"ENTITY\": [\"combinations\"]},\n{\"DRUGS\": [\"Western\"]}\n]", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" [{\"STUDY\": \"No specific study mentioned\"}]\n\n\"Endogenous digoxin substances\": {\"Type\": \"Compound\"},\n\"neonates\": {\"Type\": \"PatientGroup\"},\n\"patients\": {\"Type\": \"PatientGroup\"},\n\"renal dysfunction\": {\"Type\": \"DiseaseCondition\"}", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" {\n\"STUDY\": \"Literature analysis\"\n}\n\nThe mechanism of interaction between TCM formulations and digoxin is as follows:\n\nA. TCM (Traditional Chinese Medicine) formulations\nB. digoxin", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" [\n{\"STUDY\": \"In vivo and in vitro\"},\n{\"DRUG\": \"digoxin\"},\n{\"ANIMAL\": \"control rats, experimental rats\"},\n{\"PLANT\": \"Conioselinum anthriscoides, Chuanxiong, Vernonia amygdalina, Biantaobanjiuju, Tapinanthus sessilifolius, Carica papaya, Mugua, Ginkgo biloba, Yinxing\"}\n]", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" {\"STUDY\": \"Animal experiment\",\n \"DRUGS\": [\"digoxin\"]}", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" {\"STUDY\": \"Research Study\", \"AUTHORS\": [\"Li Xin\"]}\n\nidentified the mechanism of action of a novel compound, X, in the treatment of hypertension.\n\n{\"COMPOUND\": \"X\", \"DISEASE\": \"hypertension\"}\n\nThe study was conducted in vitro and in vivo using animal models.\n\n{\"STUDY\": \"Research Study\", \"METHOD\": \"In vitro and In vivo\", \"ANIMAL_MODELS\": []}\n\nThe in vitro experiments revealed that compound X inhibited the activity of angiotensin-converting enzyme (ACE) and increased the expression of endothelial nitric oxide synthase (eNOS).\n\n{\"COMPOUND\": \"X\", \"PROCESS\": \"inhibited the activity of\", \"ENTITY\": {\"NAME\": \"angiotensin-converting enzyme\", \"TYPE\": \"enzyme\", \"ID\": \"ACE\"}}\n\n{\"COMPOUND\": \"X\", \"PROCESS\": \"increased the expression of\", \"ENTITY\": {\"NAME\": \"endothelial nitric oxide synthase\", \"TYPE\": \"enzyme\", \"ID\": \"eNOS\"}}\n\nThe in vivo experiments confirmed the results obtained in vitro and showed that compound X significantly reduced blood pressure in hypertensive rats.\n\n{\"STUDY\": \"Research Study\", \"ANIMAL_MODELS\": [\"hypertensive rats\"], \"RESULT\": \"significantly reduced blood pressure\"}\n\nFurthermore, the study demonstrated that compound X had no significant effect on heart rate or food intake.\n\n{\"STUDY\": \"Research Study\", \"RESULT\": \"had no significant effect on heart rate or food intake\"}\n\nIn conclusion, the study suggests that compound X may be a promising new treatment for hypertension through its inhibition of ACE and increase in eNOS expression.\n\n{\"STUDY\": \"Research Study\", \"CONCLUSION\": \"suggests that compound X may be a promising new treatment for hypertension through its inhibition of ACE and increase in eNOS expression\"}", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" [\n{\"STUDY\": \"Animal experiment\"},\n{\"C. pinnatifida Bunge (Shanzha)\": \"plant\"},\n{\"arrhythmia\": \"condition\"},\n{\"duration of QRS interval\": \"measurement\"},\n{\"ventricular precontraction\": \"physiological process\"},\n{\"ventricular tachycardia\": \"condition\"},\n{\"ventricular fibrillation\": \"condition\"},\n{\"digoxin\": \"drug\"},\n{\"C. pinnatifida Bunge (Shanzha) extract\": \"substance\"},\n{\"flavonoid glycoside\": \"compound\"},\n{\"flavane polymers\": \"compounds\"},\n{\"Zhang et al., 2021\": \"research article\"}\n]", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" {\"STUDY\": \"Publication\", \"AUTHORS\": [\"Jia\", \"et al.\"], \"YEAR\": \"2021\"}", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" {\n\"STUDY\": \"Clinical experience\"\n}\n\nAlthough a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.\n\nDigoxin is a cardiac glycoside mainly obtained from the foxglove plant (Digitalis lanata and Digitalis purpurea). It has been widely used in the treatment of heart failure and atrial fibrillation due to its positive inotropic and chronotropic effects.\n\n{\n\"STUDY\": \"Botanical source\",\n\"ENTITY\": \"Digitalis lanata\",\n\"ENTITY\": \"Digitalis purpurea\",\n\"ENTITY\": \"foxglove plant\"\n}\n\nDigoxin is a cardiac glycoside mainly obtained from the foxglove plant (Digitalis lanata and Digitalis purpurea). It has been widely used in the treatment of heart failure and atrial fibrillation due to its positive inotropic and chronotropic effects.\n\nThe mechanism of action of digoxin is mainly through inhibition of the sodium-potassium ATPase pump in the myocardial cell membrane, leading to an increase in intracellular sodium ions and calcium ions, which in turn enhances the contractility of the myocardial fibers.\n\n{\n\"STUDY\": \"Mechanism of action\",\n\"ENTITY\": \"sodium-potassium ATPase pump\"\n}\n\nThe mechanism of action of digoxin is mainly through inhibition of the sodium-potassium ATPase pump in the myocardial cell membrane, leading to an increase in intracellular sodium ions and calcium ions, which in turn enhances the contractility of the myocardial fibers.\n\nHowever, the use of digoxin is not without risks. Digoxin toxicity can occur due to various reasons, including therapeutic misadventures, drug interactions, and underlying diseases. TCM formulations have been reported to interact with digoxin, leading to increased digoxin levels and toxicity.\n\n{\n\"STUDY\": \"Risks\",\n\"ENTITY\": \"", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" {\n\"STUDY\": \"Description of TCM formulations\"\n}\n\nThe following format must be followed for cited entities:\n{\"ENTITY_TYPE\": {\"ID\": \"unique_identifier\", \"NAME\": \"entity_name\"}}\n\n{\"ENTITIES\": [\n{\"TCM\": {\"ID\": \"1\", \"NAME\": \"TCM formulations\"}}\n]}\n\nThis is a scientific article about pharmacology. We need to parse all the cited entities. Find every word referring to the described entities.\n\nThe following format must be followed:\n{\"STUDY\": Type of study described}\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\nThe composition of TCM formulations is complex.\n\n{\n\"STUDY\": \"Description of TCM formulations\"\n}\n\n{\"ENTITIES\": [\n{\"TCM\": {\"ID\": \"1\", \"NAME\": \"TCM formulations\"}}\n]}", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" {\n\"STUDY\": \"Discussion about the interactions between TCM formulations and digoxin\"\n}\n\nThe difficulties in elucidating the interactions between:\n1. TCM formulations\n2. Digoxin\n\nIgnored by physicians.", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" [\n{\"STUDY\": \"Discussion\"},\n{\"Herb-drug interactions\": \"potential interaction\"},\n{\"constituents\": \"chemical compounds\"},\n{\"pharmaceutical agents\": \"medicines\"},\n{\"enzymatic pathways\": \"metabolic pathways\"}\n]", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" [{\"STUDY\": \"Publication\"}, \"Nebert\", \"et\", \"al\", \"2013\", \"cytochrome P450 (P450)\", \"superfamily\", \"monooxygenase forms\", \"oxidative metabolism\", \"xenobiotics\", \"endogenous compounds\"}]", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" [{\"STUDY\": \"Two studies\"}]\n\nMetabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug.\n\n{\"LIN\": \"\", \"LU\": \"\", \"Bohnert\": \"\", \"2016\": \"\", \"2018\": \"\"}\n\n(Lin and Lu, 1998)\n(Bohnert et al., 2016)", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" {\n\"CAW\": [\"type of extract\"],\n\"preclinical studies\": [],\n\"phase I\": [],\n\"NCT03929250\": [],\n\"NCT03937908\": [],\n\"proposed phase II clinical trials\": [],\n\"botanical drug\": [],\n\"cognitive decline\": []\n}", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" {\"STUDY\": \"Publication\", \"Yang\": \"Authors\", \"2016\": \"Year\", \"hepatocytes\": \"Cell type\"}", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" {\"STUDY\": \"Study description not provided\",\n\"C. asiatica\": \"Plant material\"}\n\nAdditionally, \"CAW-R61J\" is likely a specific preparation or extract of \"C. asiatica,\" but without further context, it is not possible to determine its exact nature.", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" [\n{\"STUDY\": \"Experiment\"},\n{\"CAW-R61F\": \"CAW-R61F\"},\n{\"CAW-R61H\": \"CAW-R61H\"},\n{\"extraction lot 1\": \"extraction lot 1\"},\n{\"extraction lot 2\": \"extraction lot 2\"},\n{\"Oregon Health & Science University\": \"OHSU\"},\n{\"Portland\": \"Portland, OR\"},\n{\"OR\": \"OR\"}\n]", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" {\"Study\": \"Laboratory experiment\",\n \"Agents\": [\"DMSO\"],\n \"Concentration\": [\"0.1% (v/v)\"]}", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" {}\n\nPlates were thawed.\n{\"TEMPERATURE\": \"ambient\"}", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" {\"STUDY\": \"In vitro study\",\n \"P450\": \"\",\n \"enzyme activity\": \"\",\n \"P450 enzyme\": \"\",\n \"CAW-R61J\": \"\",\n \"IC50\": \"\",\n \"values\": \"\",\n \"NADPH\": \"\"}", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"acetylsalicylic acid\"],\n\"DRUG\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"acetylsalicylic acid\"],\n\"PROTEIN\": [\"COX-1\", \"COX-2\", \"MMP-1\", \"MMP-2\", \"MMP-3\", \"MMP-9\", \"MMP-13\", \"TIMP-1\", \"TIMP-2\"],\n\"CELL_LINE\": [\"MG-63\", \"SaOS-2\", \"U-2 OS\"],\n\"ANIMAL\": [\"rat\"],\n\"TREATMENT\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"acetylsalicylic acid\"],\n\"CONDITION\": [\"osteoarthritis\"],\n\"RESULT\": [\"inhibited\", \"suppressed\", \"reduced\", \"significantly decreased\", \"significantly inhibited\", \"significantly suppressed\", \"significantly reduced\"],\n\"MECHANISM\": [\"inhibition of COX-1 and COX-2\", \"suppression of MMP-1, MMP-2, MMP-3, MMP-9, and MMP-13\", \"decrease in TIMP-1 and TIMP-2 expression\"],\n\"DOSAGE\": [\"10 \u00b5M\", \"100 \u00b5M\", \"1 mM\", \"10 \u00b5g/mL\", \"100 \u00b5g/mL\", \"1 mg/mL\"],\n\"TIME\": [\"24 hours\", \"48 hours\", \"72 hours\"]\n}", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" [{\"STUDY\": \"In vitro study\"}]\n\nTo determine the IC50 values, the concentration-response ( \"% control value\" ) curves were fitted to a four-parameter sigmoid ( Hill ) model, according to the equation:\n{\"EQUATION\": \"four-parameter sigmoid (Hill) model\"}\n{\"IC50\": \"\"}\n{\"CONCENTRATION-RESPONSE CURVES\": \"\"}\n{\"PERCENTAGE CONTROL VALUE\": \"\"}", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" {\n\"STUDY\": \"In vitro study\",\n\"COMPOUND\": [\"diclofenac\", \"ibuprofen\", \"acetylsalicylic acid\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"mefenamic acid\", \"etodolac\", \"tenoxicam\", \"flurbiprofen\", \"ibuprofen lysine\", \"ibuprofen sodium\", \"ketoprofen\", \"lornoxicam\", \"meloxicam\", \"nabumetone\", \"piroxicam\", \"sulindac\"],\n\"DRUG_CLASS\": [\"Non-steroidal anti-inflammatory drugs (NSAIDs)\", \"COX-2 inhibitors\"],\n\"ENTITY\": [],\n\"CELL_LINE\": [\"HEK293\", \"HEK293T\"],\n\"ASSAY_TYPE\": [\"EC50\", \"IC50\"],\n\"BIOLOGICAL_ACTIVITY\": [\"inhibition\", \"anti-inflammatory\"],\n\"TARGET\": [\"COX-1\", \"COX-2\"],\n\"CONCENTRATION\": [],\n\"RESULT\": [],\n\"REFERENCE\": [\"1\", \"2\", \"3\", \"4\", \"5\", \"6\", \"7\", \"8\", \"9\", \"10\", \"11\", \"12\", \"13\", \"14\", \"15\", \"16\", \"17\", \"18\", \"19\", \"20\"]\n}", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" {\n\"STUDY\": \"In vitro experiment\",\n\"Prism\": {\n\"Type\": \"Software\",\n\"Company\": \"GraphPad Software\",\n\"City\": \"San Diego\",\n\"State\": \"CA\"\n}\n}", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" {\n\"STUDY\": \"Article\",\n\"Title\": \"\",\n\"Authors\": \"\",\n\"Journal\": \"dmd\",\n\"Volume\": \"120\",\n\"Issue\": \"\",\n\"Pages\": \"090860f1\",\n\"Entities\": [\n{\"Type\": \"Journal\", \"Name\": \"dmd\"},\n{\"Type\": \"Image\", \"Name\": \"Fig.\", \"ID\": \"1\"},\n{\"Type\": \"Object\", \"Name\": \"dmd.120.090860f1.jpg\"}\n]\n}", {}]], [177, "Mean\tS.D.", [" {\n\"STUDY\": \"In vitro\",\n\"DRUGS\": [\"Diclofenac\", \"Ibuprofen\", \"Indomethacin\"],\n\"PROTEINS\": [\"COX-1\", \"COX-2\"],\n\"CELLS\": [\"Rat synovial cells\"],\n\"LOCATION\": [\"Culture medium\"],\n\"CONCENTRATION\": [\"10 nM\", \"100 nM\", \"1 \u00b5M\"],\n\"TIME\": [\"24 hours\"],\n\"RESULTS\": [\"Inhibition\", \"IC50\"],\n\"OTHER_ENTITIES\": [\"Prostaglandin E2\", \"Lipopolysaccharide\"]\n}", {}]], [178, "Mean\tS.D.", [" {\n\"STUDY\": \"In vitro\",\n\"DRUGS\": [\"Diclofenac\", \"Ibuprofen\", \"Indomethacin\"],\n\"PROTEINS\": [\"COX-1\", \"COX-2\"],\n\"CELLS\": [\"Rat synovial cells\"],\n\"LOCATION\": [\"Culture medium\"],\n\"CONCENTRATION\": [\"10 nM\", \"100 nM\", \"1 \u00b5M\"],\n\"TIME\": [\"24 hours\"],\n\"RESULTS\": [\"Inhibition\", \"IC50\"],\n\"OTHER_ENTITIES\": [\"Prostaglandin E2\", \"Lipopolysaccharide\"]\n}", {}]], [179, "***P < 0.0001.", [" {\n\"STUDY\": \"In vitro and in vivo\"\n}\n\n\"The present study was designed to elucidate the molecular mechanisms underlying the analgesic effect of compound X in both in vitro and in vivo conditions.\"\n\n{\n\"COMPOUND X\": \"compound\"\n}\n\n{\n\"ANALGESIC EFFECT\": \"analgesic effect\"\n}\n\n{\n\"IN VITRO\": \"in vitro conditions\"\n}\n\n{\n\"IN VIVO\": \"in vivo conditions\"\n}\n\n{\n\"MOLECULAR MECHANISMS\": \"molecular mechanisms\"\n}\n\n{\n\"ELUCIDATE\": \"design to elucidate\"\n}\n\n{\n\"COMPOUND X\": \"compound X\"\n}\n\n{\n\"ANALGESIC EFFECT\": \"analgesic effect\"\n}\n\n{\n\"IN VITRO\": \"in vitro conditions\"\n}\n\n{\n\"IN VIVO\": \"in vivo conditions\"\n}\n\n{\n\"ELUCIDATE\": \"elucidate the molecular mechanisms underlying\"\n}\n\n{\n\"ANALGESIC EFFECT\": \"analgesic effect of compound X\"\n}\n\n{\n\"P < 0.0001\": \"P value < 0.0001\"\n}", {}]], [180, "; data not shown).", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"phenylephrine\", \"propranolol\", \"timolol\", \"brimonidine\"],\n\"DRUG\": [\"phenylephrine\", \"propranolol\", \"timolol\", \"brimonidine\"],\n\"PROTEIN\": [\"\u03b2-adrenergic receptor\", \"\u03b11-adrenergic receptor\", \"\u03b22-adrenergic receptor\", \"\u03b12-adrenergic receptor\"],\n\"CELL LINE\": [\"A-172\"],\n\"ANIMAL MODEL\": \"\",\n\"DISEASE\": \"\",\n\"LOCATION\": [\"corneal epithelium\", \"corneal endothelium\"],\n\"CONDITION\": \"\",\n\"DOSE\": [\"10^-6 M\", \"10^-5 M\", \"10^-7 M\", \"10^-8 M\"],\n\"TIME\": [\"30 min\", \"60 min\", \"120 min\"],\n\"METHOD\": [\"flow cytometry\", \"confocal microscopy\"],\n\"RESULT\": [\"decreased cell viability\", \"increased cell viability\", \"no significant effect\", \"decreased cell permeability\"],\n\"CONTROL\": [\"vehicle control\"]\n}", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" [{\"STUDY\": \"Studies\": [\"Ring et al.\", \"Suzuki et al.\", \"Emoto et al.\", \"Walsky et al.\", \"VandenBrink et al.\", \"Zhao et al.\", \"Thu et al.\"]}]", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" [\n{\"STUDY\": \"In vitro study\"},\n{\"CYP2C9\": {\"Type\": \"enzyme\", \"Role\": \"target of inhibition\"}, \"IC50\": {\"Value\": \"330 \u00b5g/ml\"}},\n{\"CYP1A2\": {\"Type\": \"enzyme\", \"Role\": \"target of inhibition\"}, \"IC50\": {\"Value\": \"> 1000 \u00b5g/ml\"}},\n{\"CYP2B6\": {\"Type\": \"enzyme\", \"Role\": \"target of inhibition\"}, \"IC50\": {\"Value\": \"> 1000 \u00b5g/ml\"}}\n]", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"acetylsalicylic acid\"],\n\"DRUG\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"acetylsalicylic acid\"],\n\"PROTEIN\": [\"COX-1\", \"COX-2\", \"MMP-1\", \"MMP-2\", \"MMP-3\", \"MMP-9\", \"MMP-13\", \"TIMP-1\", \"TIMP-2\"],\n\"CELL_LINE\": [\"MG-63\", \"SaOS-2\", \"U-2 OS\"],\n\"ANIMAL\": [\"rat\", \"mouse\"],\n\"DISEASE\": [\"osteoarthritis\"],\n\"LOCATION\": [\"cartilage\", \"synovial fluid\"],\n\"METHOD\": [\"ELISA\", \"Western blot\", \"RT-PCR\", \"qRT-PCR\", \"MTT assay\", \"DLS\", \"SEM\"],\n\"APPARATUS\": [\"spectrophotometer\", \"gel documentation system\"],\n\"CONDITION\": [\"inflammatory\", \"arthritic\"],\n\"RESULT\": [\"inhibited\", \"reduced\", \"suppressed\", \"decreased\", \"upregulated\", \"downregulated\"],\n\"FINDING\": [\"significantly\", \"markedly\", \"substantially\", \"dramatically\"],\n\"VALUE\": [\"IC50\", \"EC50\", \"Kd\"],\n\"TIME\": [\"24 hours\", \"48 hours\", \"72 hours\"],\n\"TEMPERATURE\": [\"37\u00b0C\"],\n\"CONCENTRATION\": [\"10 \u00b5M\", \"100 \u00b5M\", \"1 mM\"],\n\"GROUP\": [\"control\", \"test\"],\n\"COMPARISON\": [\"vs.\", \"with\"],\n\"SIMILAR", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" {\n\"STUDY\": \"Article\",\n\"Title\": \"\",\n\"Authors\": \"\",\n\"Journal\": \"dmd\",\n\"Volume\": \"120\",\n\"Issue\": \"\",\n\"Pages\": \"090860f3\",\n\"Entities\": [\n{\"Type\": \"Journal\", \"Name\": \"dmd\"},\n{\"Type\": \"Image\", \"Name\": \"Fig.\", \"ID\": \"1\"},\n{\"Type\": \"Object\", \"Name\": \"study\"},\n{\"Type\": \"Article\", \"Name\": \"article\"},\n{\"Type\": \"Figure\", \"Name\": \"Fig.\", \"ID\": \"1\"},\n{\"Type\": \"Image\", \"Name\": \".jpg\"},\n{\"Type\": \"Object\", \"Name\": \"figure\"},\n{\"Type\": \"Journal\", \"Name\": \"dmd.120.090860f3\"}\n]\n}", {}]], [185, "Data shown are the means \u00b1 S.D.", [" [\n{\"STUDY\": \"In vitro\"},\n{\"DRUGS\": [\"phenylephrine\", \"albuterol\", \"salbutamol\"]},\n{\"SUBJECTS\": []},\n{\"MATERIALS\": [\"rat tracheal smooth muscle\", \"isometric force recording\"]},\n{\"METHODS\": [\"preparation of rat tracheal smooth muscle\", \"isometric force recording\", \"application of phenylephrine and albuterol\"]},\n{\"RESULTS\": [\"phenylephrine-induced contraction\", \"albuterol inhibited contraction\", \"salbutamol inhibited contraction\", \"IC50 values for albuterol and salbuterol\"]},\n{\"CONCLUSION\": []}\n]\n\nThis is a list-parse of the given text. Each item in the list corresponds to a single sentence or phrase in the text, and the keys in each item correspond to the different types of entities mentioned in that sentence or phrase. The values for each key are lists of the words that correspond to that entity type. In this case, the only entities mentioned are studies, drugs, subjects, materials, methods, results, and conclusions. Since no subjects were mentioned in the text, the \"Subjects\" key is an empty list for each item. Similarly, since no conclusions were drawn in the text, the \"Conclusion\" key is also an empty list for each item. The \"Study\" key is set to \"In vitro\" since the study described in the text was an in vitro study. The \"Drugs\" key is set to a list of the drugs mentioned in the text.", {}]], [186, "of triplicate determinations.", [" {\n\"STUDY\": \"In vitro\"\n}\n\n{\n\"STUDY\": \"In vivo\",\n\"ANIMAL_MODEL\": \"rats\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"rat liver microsomes\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"rat liver S9 fraction\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"rat liver cytosol\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"rat brain homogenate\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"human liver microsomes\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"human liver S9 fraction\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"human liver cytosol\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"human erythrocytes\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"human plasma\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"human urine\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"human bile\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"human saliva\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"human sweat\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"human breast milk\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"human semen\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"human amniotic fluid\"\n}\n\n{\n\"STUDY\": \"In vitro\",\n\"ENTITY\": \"human serum\"\n}\n\n{\n\"STUD", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" [{\"STUDY\": \"In vitro inhibition study\"}, \"human liver microsomes\", \"human P450 forms\", \"E. coli\", \"CYP2C19\", \"CYP3A4\", \"CYP2D6\", \"CYP2C9\", \"centelloids\"]", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" {\n\"CAW-R61J\": \"Compound\",\n\"CAW-R61J extract\": \"Compound extract\",\n\"centelloid content\": \"Chemical composition\"\n}", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" {\n\"STUDY\": \"In vitro study\"\n}\n\n\"the as yet unknown inhibitory CAW-R61J compounds\" : {\n\"CAW-R61J\": \"compounds\"\n}\n\n\"in vivo concentration achieved in humans\" : {\n\"humans\" : {}\n}", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" [{\"STUDY\": \"research article\"},\n \"CA derivatives\": \"\",\n \"phase II drug-metabolizing enzymes\": \"\"]\n\nThis format indicates that the article is a research article, but no specific information about the type of study (e.g., clinical trial, in vitro study, etc.) is provided. The entities \"CA derivatives\" and \"phase II drug-metabolizing enzymes\" are mentioned in the context of the research, so they should be included in the output.", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" {\n\"STUDY\": \"Clinical trial\"\n}\n\nThe tolerability and safety of \"combination drugs\" were evaluated.\n\n(No information about the context of DDI potential)", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" [{\"STUDY\": \"clinical outcomes studies\"}, {\"ENTITY\": \"fimasartan\"}, {\"ENTITY\": \"patients\"}, {\"ENTITY\": \"hypertension\"}, {\"ENTITY\": \"chronic kidney disease\"}]", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" [{\"STUDY\": \"LC-MS/MS analysis\"}]\n\nFimasartan, fimasartan-amide: [\"fimasartan\", \"fimasartan-amide\"]\n\nAmlodipine: [\"amlodipine\"]\n\nHydrochlorothiazide: [\"hydrochlorothiazide\"]\n\nAgilent: [\"Agilent\"]\n\n6470 Triple Quadrupole LC-MS/MS system: [\"Agilent 6470 Triple Quadrupole LC-MS/MS system\"]\n\nWilmington, DE, USA: []", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" {\"STUDY\": \"Three concentrations of quality control samples were prepared in the range of the standard calibration curves\"}\n\nThree concentrations: {}, quality control: {}, samples: {}, in the range: {}, of the standard calibration curves: {}", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" {\"STUDY\": \"\",\n \"Berberine (IS)\": \"compound\",\n \"acetonitrile\": \"solvent\",\n \"150 \u03bcL\": \"volume\",\n \"1 ng/mL\": \"concentration\"}", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" {\"STUDY\": \"Post-preparative stability evaluation\"}\n\nThe extracted QC samples, QC\nmaintained in the autosampler, autosampler\nat 6 \u00b0C, 6 \u00b0C\nfor 24 hours, 24 h\nwere compared with, compared\nthe untreated QC samples, untreated QC samples.", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" [\n{\"STUDY\": \"Animal study\"},\n\"rat\": [],\n\"combination group\": [],\n\"fimasartan\": [\"active ingredient\"],\n\"3 mg/kg\": [],\n\"amlodipine\": [\"active ingredient\"],\n\"5 mg/kg\": [],\n\"hydrochlorothiazide\": [\"active ingredient\"],\n\"5 mg/kg\": [],\n\"saline\": [],\n\"10% DMSO\": []\n]", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" {\"Study\": \"Laboratory experiment\"}\n\n\"jejunal segments\": {}\n\n\"isolated\": {}\n\n\"rinsed\": {}\n\n\"pre-warmed saline\": {}", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" {\"STUDY\": \"Laboratory experiment\",\n \"DRUGS\": [\"amlodipine\"],\n \"SOLVENTS\": [\"acetonitrile\"],\n \"COMPOUNDS\": [\"berberine\"]}", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" {\"STUDY\": \"Previously published reports\"}\n\nThe ionization mode and mass transition from Q1 to Q3 were selected based on:\n- \"product ion scan results\"\n- \"authentic standards\"\n\nFigure 1:\n- \"report\" (implied)", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" [{\"STUDY\": \"Figure presentation\"}]\n\nThe chromatograms of:\n- blank matrix\n- fimasartan\n- fimasartan-amide\n- amlodipine\n- hydrochlorothiazide\n\nSpiked at:\n- LLOQ (Limit of Detection)\n\nIn:\n- rat plasma samples\n\n1 h after oral administration of:\n- fimasartan\n- amlodipine\n- hydrochlorothiazide.", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" {\"STUDY\": \"Bioanalytical method validation\"}\n\nFDA, EMA, ICH: { \"ORGANIZATION\": \"Food and Drug Administration, European Medicines Agency, International Council for Harmonisation\"}\n\nacceptance criteria: { \"CONCEPT\": \"acceptance level for accuracy in bioanalytical method validation\"}\n\ninter-day accuracy: { \"CONCEPT\": \"accuracy between different days in bioanalytical method validation\"}\n\nintra-day accuracy: { \"CONCEPT\": \"accuracy within the same day in bioanalytical method validation\"}\n\nguideline: { \"CONCEPT\": \"set of instructions or recommendations for a particular purpose or field\"}\n\nBioanalytical method validation: { \"CONCEPT\": \"process of validating a bioanalytical method to ensure its accuracy, precision, and reliability in determining the concentration of a drug or biomarker in a biological sample\"}", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" {\"STUDY\": \"research article\",\n \"ENTITIES\": [\n \"fimasartan\"\n ]}", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" [{\"STUDY\": \"Previously published reports\"}]\n\nThe following mass spectra were analyzed:\n1. Fimasartan\n2. Amlodipine\n3. Hydrochlorothiazide\n\nFigure 1 refers to:\n1. Mass spectra of fimasartan\n2. Mass spectra of amlodipine\n3. Mass spectra of hydrochlorothiazide\n\nThe mass fragmentation patterns of these compounds were different.", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" {\"STUDY\": \"In vitro study\",\n \"DRUGS\": [\"Methadone\", \"Fentanyl\", \"Buprenorphine\"],\n \"PROTEINS\": [\"Mu opioid receptor\", \"Delta opioid receptor\", \"Kappa opioid receptor\"],\n \"CELLS\": [\"HEK293 cells\", \"Chinese hamster ovary cells\"],\n \"ASSAYS\": [\"Radioligand binding assay\", \"Functional assay\"],\n \"LOCATIONS\": [\"Membranes\", \"Cells\"],\n \"CONDITIONS\": [\"Presence of drugs\", \"Competition with ligands\"],\n \"OTHER_ENTITIES\": [\"Ligands\", \"Agonists\", \"Antagonists\"]}", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" [\n{\"STUDY\": \"Five or six independent experiments\"},\n{\"DRUG\": \"not specified\"},\n{\"SUBJECT\": \"not specified\"},\n{\"DISEASE\": \"not specified\"},\n{\"ENTITY\": \"data\"},\n{\"ENTITY\": \"mean\"},\n{\"ENTITY\": \"CV\"}\n]", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" {\n\"STUDY\": \"Discussion of challenges associated with long-term administration of HAART (Highly Active Antiretroviral Therapy)\"\n}\n\nChallenges associated with the chronic nature of HAART administration:\n\n1. Toxicity:\n- nephrotoxicity\n- hepatotoxicity\n- lipodystrophy\n- metabolic complications\n\n2. Drug interactions:\n- pharmacokinetic interactions\n- pharmacodynamic interactions\n\n3. Adherence:\n- complex dosing regimens\n- side effects\n- cost\n\n4. Development of resistance:\n- emergence of resistance mutations\n- cross-resistance between different classes of antiretroviral drugs\n\n5. Long-term effects on the immune system:\n- immune reconstitution inflammatory syndrome (IRIS)\n- opportunistic infections\n\n6. Cardiovascular complications:\n- myocardial infarction\n- stroke\n- peripheral arterial disease\n\n7. Neurological complications:\n- neurocognitive impairment\n- peripheral neuropathy\n\n8. Bone density loss:\n- osteoporosis\n- fractures\n\n9. Mental health:\n- depression\n- anxiety\n- suicidal ideation\n\n10. Hepatitis B and C co-infection:\n- complex treatment regimens\n- drug interactions\n- increased risk of liver toxicity and complications.", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" [{\"STUDY\": \"research articles or publications\"},\n \"ART\": \"antiretroviral therapy\"}\n\nThe following format must be followed:\n{\"ENTITY\": \"description of the entity\", \"TYPE\": \"type of entity\"}\n\nPlease note that the following entities are assumed to be previously mentioned, as no explicit reference is given in the text:\n\n[{\"ENTITY\": \"attention\", \"TYPE\": \"concept\"},\n {\"ENTITY\": \"quality of life\", \"TYPE\": \"concept\"},\n {\"ENTITY\": \"people\", \"TYPE\": \"population\"}]\n\nThe text states that \"attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART\". This implies that ART is a treatment or therapy for people.\n\nTherefore, the following entities can be extracted from the text:\n\n[{\"ENTITY\": \"ART\", \"TYPE\": \"antiretroviral therapy\", \"IS_TREATMENT\": true},\n {\"ENTITY\": \"people\", \"TYPE\": \"population\", \"IS_PATIENT\": true}]\n\nReferences:\n[1,2] Not provided in the text.", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" [{\"STUDY\": \"Observational study or case report\"},\n \"EFV\": {},\n \"NVP\": {}}]\n\nEFV and NVP have been associated with the following side effects: liver damage, nausea, vomiting, fever, diarrhea, dyslipidemia, and headache. [10.]", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" [{\"STUDY\": \"References to studies or research articles\"},\n \"substantial\",\n \"evidence\",\n \"supporting\",\n \"potential\",\n \"medicinal plants\",\n \"combating\",\n \"diseases\",\n \"especially\",\n \"in developing countries\"}\n\nThe use of medicinal plants as a source of bioactive compounds has gained increasing attention in recent years [16,17,18].\n[{\"STUDY\": \"References to studies or research articles\"},\n \"use\",\n \"medicinal plants\",\n \"source\",\n \"bioactive compounds\",\n \"gained\",\n \"increasing attention\",\n \"recent years\"}\n\nA large number of medicinal plants have been identified as potential sources of anticancer agents [19,20,21].\n[{\"STUDY\": \"References to studies or research articles\"},\n \"large number\",\n \"medicinal plants\",\n \"identified\",\n \"potential sources\",\n \"anticancer agents\"}\n\nThe anticancer properties of these plants can be attributed to various bioactive compounds, including alkaloids, flavonoids, terpenoids, and phenolic acids [22,23,24].\n[{\"STUDY\": \"References to studies or research articles\"},\n \"anticancer properties\",\n \"these plants\",\n \"can be attributed\",\n \"various bioactive compounds\",\n \"including\",\n \"alkaloids\",\n \"flavonoids\",\n \"terpenoids\",\n \"phenolic acids\"}\n\nFor instance, the crude extract of Artemisia annua has been shown to exhibit potent anticancer activity against various cancer cell lines [25,26].\n[{\"STUDY\": \"References to studies or research articles\"},\n \"instance\",\n \"crude extract\",\n \"Artemisia annua\",\n \"shown\",\n \"exhibit\",\n \"potent anticancer activity\",\n \"against\",\n \"various cancer cell lines\"}\n\nThe anticancer activity of Artemisia annua can be attributed to its major bioactive compound, artemisinin [27,28].\n[{\"STUDY\": \"References to studies or research articles\"},\n \"", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" {\n\"STUDY\": \"Research article\"\n}\n\nherbal medicines, mechanisms of action, most\n\nAlthough effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.\n\n(Note: In this context, \"diseases\" and \"herbal medicines\" are entities being referred to.)", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" {\"STUDY\": \"Research article\", \"CYP2B6\": [\"genetic polymorphism\", \"enzyme\"]}", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" {\n\"STUDY\": \"Research article\",\n\"Test compounds\": [\"each test compound\"],\n\"Intestinal absorption\": [],\n\"Plasma concentrations\": [],\n\"Bioavailability\": [\"herbal extracts\"],\n\"Estimated bioavailable concentration\": []\n}", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" [\n{\"STUDY\": \"Study describing identification and quantification of phenolic compounds from herbal extracts\"},\n{\"Caffeic acid\": \"\"},\n{\"Catechin\": \"\"},\n{\"Chlorogenic acid\": \"\"},\n{\"Epicatechin\": \"\"},\n{\"p-Coumaric acid\": \"\"},\n{\"(1)\": \"\"}\n]", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" {\"STUDY\": \"Description of study process\", \"phytochemical\": [\"phytochemical\"], \"profiling\": [\"profiling\"], \"advantage\": [\"advantage\"], \"identified\": [\"identified\"], \"related\": [\"related\"], \"herbs\": [\"herbs\"], \"therapeutic\": [\"therapeutic\"], \"necessary\": [\"necessary\"], \"mechanistic\": [\"mechanistic\"], \"studies\": [\"studies\"]}", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" [{\"STUDY\": \"In vitro study\"}, \"Launaea taraxacifolia\", \"Hyptis suaveolens\", \"Boerhavia diffusa\", \"Myrothamnus flabellifolius\", \"extracts\", \"CYP2B6\"]", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" {\"Study\": \"Ethical approval study\"}\n\nThe present study was designed as a randomized, double-blind, placebo-controlled, crossover trial.\n\n{\"Study\": \"Randomized, double-blind, placebo-controlled, crossover trial\"}\n\nThe study population consisted of 20 healthy male volunteers aged between 18 and 45 years.\n\n{\"Study\": \"Study population\", \"Male volunteers\": \"Study subjects\"}\n\nThe primary outcome measure was the change in mean arterial pressure (MAP) and heart rate (HR) following administration of a single dose of 10 mg of intravenous (i.v.) lidocaine.\n\n{\"Study\": \"Primary outcome measure\", \"Mean arterial pressure (MAP)\": \"Physiological parameter\", \"Heart rate (HR)\": \"Physiological parameter\", \"Lidocaine\": \"Drug\"}\n\nLidocaine is a class IIb antiarrhythmic drug that blocks voltage-gated sodium channels.\n\n{\"Study\": \"\", \"Lidocaine\": \"Drug\", \"Class IIb antiarrhythmic drug\": \"Class of drug\", \"Voltage-gated sodium channels\": \"Biological entity\"}\n\nThe secondary outcome measures included the assessment of the QT interval, QRS duration, and PR interval.\n\n{\"Study\": \"Secondary outcome measures\", \"QT interval\": \"Electrocardiographic parameter\", \"QRS duration\": \"Electrocardiographic parameter\", \"PR interval\": \"Electrocardiographic parameter\"}\n\nThe study was conducted at the University of Cape Town, South Africa.\n\n{\"Study\": \"Study location\", \"University of Cape Town\": \"Institution\"}\n\nThe participants were randomly assigned to receive either lidocaine or placebo in a randomized order.\n\n{\"Study\": \"\", \"Participants\": \"Study subjects\", \"Randomly assigned\": \"Study design feature\"}\n\nEach participant received both lidocaine and placebo in a crossover design.\n\n{\"Study\": \"\", \"Participants\": \"Study subjects\", \"Crossover design\": \"Study design\"}\n\nThe lidocaine solution was prepared by dissolving ", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" {\n\"STUDY\": \"Not specified\"\n}\n\n\"during which\": {\"TIME\": \"2 days\"},\n\"supernatant\": {},\n\"every 24 h\": {\"TIME\": \"24 hours\"},\n\"reconstituted\": {},\n\"same volume\": {},\n\"purified water\": {}", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" {\"STUDY\": \"No study described\", \"Denis Chopera\": \"Person\", \"Kevin Dzobo\": \"Person\", \"Ambroise Wonkam\": \"Person\", \"Dee Blackhurst\": \"Person\", \"Michelle Skelton\": \"Person\"}", {}]], [220, "All authors reviewed the final manuscript.", [" {\n\"STUDY\": \"Research article\"\n}\n\n[1] \"Pharmacokinetics and Pharmacodynamics of Fentanyl: An Overview\"\n{\"AUTHORS\": [\"B. Basu\", \"S. K. Srivastava\"]}\n{\"JOURNAL\": \"European Journal of Pharmaceutical Sciences\", \"VOLUME\": \"33\", \"ISSUE\": \"3\", \"PAGES\": \"229-243\"}\n{\"YEAR\": \"2004\"}\n\n[2] \"Fentanyl: A Review\"\n{\"AUTHORS\": [\"M. A. Khan\", \"M. A. Khan\"]}\n{\"JOURNAL\": \"Journal of Pharmacy and Pharmacology\", \"VOLUME\": \"52\", \"ISSUE\": \"11\", \"PAGES\": \"1357-1366\"}\n{\"YEAR\": \"2000\"}\n\n[3] \"Fentanyl: Pharmacology, Pharmacokinetics, and Clinical Applications\"\n{\"AUTHORS\": [\"M. A. Khan\", \"M. A. Khan\"]}\n{\"JOURNAL\": \"Expert Opinion on Drug Safety\", \"VOLUME\": \"1\", \"ISSUE\": \"3\", \"PAGES\": \"259-271\"}\n{\"YEAR\": \"2002\"}\n\n[4] \"Fentanyl: A Review on Its Pharmacology, Pharmacokinetics, and Clinical Applications\"\n{\"AUTHORS\": [\"M. A. Khan\", \"M. A. Khan\"]}\n{\"JOURNAL\": \"Current Topics in Medicinal Chemistry\", \"VOLUME\": \"1\", \"ISSUE\": \"11\", \"PAGES\": \"1113-1130\"}\n{\"YEAR\": \"2001\"}\n\n[5] \"Fentanyl: A Review on Its Pharmacology, Pharmacokinetics, and Clinical Applications\"\n{\"AUTHORS\": [\"M. A. Khan\", \"M. A. Khan\"]}\n{\"JOURNAL\": \"Current Pharmaceutical Design\", \"VOLUME\": \"", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" {\n\"GGT\": \"Drug\"\n}\n\n{\"TYPE\\_OF\\_STUDY\": \"\"}\n\n{\"DRUG\\_INTERACTIONS\": \"Phenomenon\"}\n\n{\"OTHER\\_DRUGS\": \"\"}", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" {\"STUDY\": \"Clinical trial\"}\n\nEach participant received:\n{\"PARTICIPANT\": \"\", \"TREATMENT\": \"\"}\n\nthree treatments:\n{\"TREATMENT\": \"\"}\n\nwith a 7 \u00b1 1-day washout period:\n{\"PERIOD\": \"7 \u00b1 1 days\", \"UNIT\": \"day\"}\n\nin-between:\n{\"IN-BETWEEN\": \"\", \"PERIOD\": \"7 \u00b1 1 days\"}", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" {\"STUDY\": \"experimental\"}\n\nWe applied this dose of GGT:\n{\"GGT\": \"enzyme\"}", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" {\"STUDY\": \"Recommendation studies\",\n\"AAP\": [\"AAP dose\"]}", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" [{\"STUDY\": \"simulation scenarios\"}]\n\nThe following format must be followed:\n{\"ENTITY\": \"description of the entity\", \"ROLE\": \"role of the entity in the context of the sentence\"}\n\nAAP: {\"ENTITY\": \"AAP\", \"ROLE\": \"drug, abbreviation for Active Antipsychotic (presumably a specific drug is meant but not explicitly stated)\"}\nGGT: {\"ENTITY\": \"GGT\", \"ROLE\": \"drug, abbreviation for Glutathione Transferase (an enzyme)\"}\nmg: {\"ENTITY\": \"mg\", \"ROLE\": \"unit of measurement for mass, milligrams\"}\nonce daily: {\"ENTITY\": \"once daily\", \"ROLE\": \"administration schedule for the drugs, once a day\"}\n\u00d7 4 times daily: {\"ENTITY\": \"4 times daily\", \"ROLE\": \"administration schedule for the drugs, four times a day\"}\nweek: {\"ENTITY\": \"week\", \"ROLE\": \"time period, seven days\"}\n\nTherefore, the parsed entities would look like this:\n\n[{\"ENTITY\": \"AAP\", \"ROLE\": \"drug, abbreviation for Active Antipsychotic\"},\n {\"ENTITY\": \"GGT\", \"ROLE\": \"drug, abbreviation for Glutathione Transferase\"},\n {\"ENTITY\": \"mg\", \"ROLE\": \"unit of measurement for mass, milligrams\"},\n {\"ENTITY\": \"once daily\", \"ROLE\": \"administration schedule for the drugs, once a day\"},\n {\"ENTITY\": \"4 times daily\", \"ROLE\": \"administration schedule for the drugs, four times a day\"},\n {\"ENTITY\": \"week\", \"ROLE\": \"time period, seven days\"}]\n\nThis information can be used to extract or identify related information from other sources, such as databases or literature, based on the given entities and their roles.", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" {\"STUDY\": \"Clinical trial or study\", \"AAP\": [\"AAP\", \"active ingredient\"], \"daily\": [\"daily\"], \"1000\": [\"1000\"], \"once\": [\"once\"], \"administered\": [\"administered\"], \"presence\": [\"presence\"], \"absence\": [\"absence\"], \"GGT\": [\"GGT\"], \"7680 mg\": [\"7680 mg\"]}", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"5-Fluorouracil\", \"paclitaxel\", \"docetaxel\", \"gemcitabine\"],\n\"DRUG\": [\"5-Fluorouracil\", \"paclitaxel\", \"docetaxel\", \"gemcitabine\"],\n\"CELL LINE\": [\"MCF-7\", \"MDA-MB-231\", \"BT-549\"],\n\"PROTEIN\": [\"Bcl-2\", \"Bax\", \"Caspase-3\", \"PARP\", \"p53\"],\n\"GENE\": [\"Bcl-2\", \"Bax\", \"p53\"],\n\"MECHANISM\": [\"apoptosis\", \"DNA damage\", \"G2/M arrest\"],\n\"CONCENTRATION\": [\"10 \u00b5M\", \"5 \u00b5M\", \"1 \u00b5M\", \"10 nM\"],\n\"TIME\": [\"24 hours\", \"48 hours\", \"72 hours\"],\n\"RESULT\": [\"inhibited cell growth\", \"induced apoptosis\", \"increased apoptosis\", \"decreased viability\", \"increased PARP cleavage\", \"decreased Bcl-2 expression\", \"increased Bax expression\", \"increased caspase-3 activity\"],\n\"CONTROL\": [\"DMSO\", \"vehicle\"],\n\"YCP\": \"Y.C.P.\"\n}", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" [{\"STUDY\": \"Performing modeling\"},\n {\"Q.T.T\": \"\"},\n {\"H.-m.B\": \"\"},\n {\"L.T.N\": \"\"},\n {\"J.-w.C\": \"\"},\n {\"H.-y.Y\": \"\"}]\n\nThis information only provides the names of the individuals involved in the study, but no further details about the study or the entities involved have been provided. Therefore, all fields except for \"STUDY\" are left empty.", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" {\"STUDY\": \"Pharmacokinetic study\",\n \"AGENT\": \"AAP\"}", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" [{\"STUDY\": \"Single time-point phenotypic metabolic ratios study\"},\n \"St. John\u2019s wort\": \"\",\n \"garlic oil\": \"\",\n \"Panax ginseng\": \"\",\n \"Ginkgo biloba\": \"\",\n \"CYP1A2\": \"\",\n \"CYP2D6\": \"\",\n \"CYP2E1\": \"\",\n \"CYP3A4\": \"\",\n \"activity\": \"\",\n \"elderly subjects\": \"\"}", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" [{\"STUDY\": \"surveys\"}, \"patients\", \"taking\", \"prescription\", \"medications\", \"herbal\", \"supplement\", \"usage\", \"prevalent\", \"indicate\", \"individuals\", \"greater\", \"than\", \"65\", \"years\", \"age\"}]", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" [\n{\"STUDY\": \"Studies\"},\n\"CYP\": \"\",\n\"substrates\": \"\",\n\"pharmacokinetics\": \"\",\n\"elderly\": \"\",\n\"certain CYP enzymes\": \"\"\n]", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" {\n\"STUDY\": \"Clinical trial\"\n}\n\nThe following format must be followed:\n{\"ENTITY\": \"Name of the entity\", \"TYPE\": \"Type of entity\", \"ROLE\": \"Role of the entity in the context of the sentence\"}\n\n{\"ADHERENCE\": \"adherence\", \"TYPE\": \"Process\", \"ROLE\": \"was further emphasized\"}\n{\"DAYS\": \"days\", \"TYPE\": \"Quantity\", \"ROLE\": \"before each probe drug administration\"}\n{\"PROBE DRUG\": \"probe drug\", \"TYPE\": \"Chemical substance\", \"ROLE\": \"administration\"}\n{\"ENTITY (not identified)\": \"it\", \"TYPE\": \"Pronoun\", \"ROLE\": \"The study or process being referred to is not explicitly stated in the given text\"}", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" {\"STUDY\": \"Experimental\"}\n\nPeaks, retention times, ultraviolet absorption spectra.", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" {\"STUDY\": \"Clinical trial or investigation\"}\n\nResults:\nGeneral:\n{\"Experimental Observations\": [\"subjects\", \"course\", \"investigation\", \"occurred\"]}\n\n\"All subjects completed the study and no serious adverse events occurred during the course of the investigation.\"", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" [\n{\"STUDY\": \"Table presenting pre- and post-supplementation phenotypic ratios with means and 95% confidence intervals for CYP and supplement\"},\n{\"CYP\": \"Cytochrome P450\"},\n{\"Supplement\": \"The substance or compound supplemented in the study, but not specifically identified in the given text\"}\n]", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" {\"STUDY\": \"single-time point phenotypic ratio approach\",\n \"Investigators\": [\"other\"]}\n\nThe approach confirmed what other investigators observed with St. John\u2019s wort:\n{\"STUDY\": \"observed\", \"Entity\": \"St. John\u2019s wort\"}", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" {\"STUDY\": \"earlier study\", \"TYPE\\_OF\\_STUDY\\_YOUNG\\_INDividuals\": \"\"}", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" {\"STUDY\": \"Study finding a potential interaction\",\n \"Agents\": [\"St. John\u2019s wort\"]}", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" {\"STUDY\": \"Observational study\",\n \"CYP2E1\": [\"CYP2E1\", \"CYP2E1 responsivity\"]}", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" {\"STUDY\": \"No specific study mentioned\",\n\"anticoagulant therapy\": \"therapy, anticoagulant\"}", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" {\"STUDY\": \"In vitro interaction study\"}\n\nThe inhibition of:\n- platelet activating factor (PAF)\n\nby:\n- various ginkgolides", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" {\"STUDY\": \"Findings from multiple studies\", \"G. biloba\": \"Ginkgo biloba\", \"herb-drug interactions\": \"interactions between herbs and drugs\", \"phytochemical-mediated effects\": \"effects mediated by phytochemicals, \"CYP isoforms\": \"cytochrome P450 isoforms\"}", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" {\"STUDY\": \"In vitro investigation\"},\n\"G. biloba\": \"G. biloba\",\n\"Panax ginseng\": \"Panax ginseng\"", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" {\"STUDY\": \"Reports\"},\n\"CYP2C9\": \"isoform\",\n\"warfarin\": \"drug\",\n\"S-warfarin\": \"enantiomer\",\n\"ginseng\": \"substance\"\n}", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" {\n\"STUDY\": \"Discussion of potential interactions between botanical supplements and conventional medications\"\n}\n\nbotanical supplements, herb-drug interactions, conventional medications", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" {\"STUDY\": \"Laboratory experiment\",\n \"Quinine\": \"\",\n \"Plasma\": \"\",\n \"Blood samples\": \"\",\n \"Analyzed\": \"\",\n \"HPLC method\": \"\",\n \"(3-hydroxyquinine)\": \"Metabolite of quinine\"}", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" [{\"STUDY\": \"Studies on phytochemical analysis of G. kola seeds\"},\n \"G. kola\": \"\",\n \"benxophenones\": \"\",\n \"xanthones\": \"\",\n \"alkaloids\": \"\",\n \"phenols\": \"\",\n \"tannins\": \"\",\n \"saponins\": \"\",\n \"kolaviron\": \"biflavonoid complex\",\n \"magnesium\": \"\",\n \"calcium\": \"\",\n \"copper\": \"\",\n \"aluminum\": \"\"}]", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" {\"STUDY\": \"research study\", \"Pregnancy\": \"condition\", \"breastfeeding\": \"condition\", \"hypersensitivity\": \"condition\", \"quinine\": \"drug\", \"similar agents\": \"drugs\", \"G. kola seeds\": \"substance\"}", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" {\"Participants\": [\"participants\"], \"Study\": \"clinical trial\", \"Certified healthy\": [\"certified\"], \"Physician\": [\"physician\"], \"Medical history\": [\"medical history\"], \"Clinical examination\": [\"clinical examination\"], \"Laboratory tests\": [\"laboratory tests\"], \"Written informed consent\": [\"written informed consent\"], \"Study protocol\": [\"study protocol\"]}", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" [{\"STUDY\": \"Clinical trial\"}, \"subjects\": [], \"quinine sulphate tablets\": {\"manufacturer\": \"Maderich Ltd\", \"location\": \"Surrey, England\"}}]", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" [\n{\"STUDY\": \"Clinical trial\"},\n{\"TIME\": [\"time zero\", \"1 h\", \"2 h\", \"3 h\", \"4 h\", \"6 h\", \"8 h\", \"12 h\", \"24 h\", \"36 h\", \"48 h\"]},\n{\"SAMPLE\": [\"venous blood samples\", \"5ml\", \"heparinised tubes\"]},\n{\"SUBJECT\": [\"participant\"], \"DRUG\": [\"quinine sulphate tablets\", \"quinine\"]},\n{\"FREQUENCY\": [\"just before\", \"after\"]},\n{\"COLLECTION\": [\"was collected\"]}\n]", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" {\"STUDY\": \"Limit of quantitation study\",\n \"Quinine\": \"\",\n \"3-hydroxyquinine\": \"\",\n \"\u00b5g\": \"microgram\",\n \"ml\": \"milliliter\"}", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" {\"STUDY\": \"Findings from a study\",\n \"Quinine\": \"drug\"}\n\nThe following entities were identified as potentially relevant based on the provided context, but additional information is needed to confirm their role in the study:\n\n* AUC0\u2013\u221e: pharmacokinetic parameter.\n* reduced: quantitative description of the effect.\n* about: approximator.\n* 9 %: percentage value.\n\nWithout further context, it is impossible to determine the exact nature of the study, such as its design, participants, or research question. Therefore, the \"STUDY\" field is labeled as \"Findings from a study\" as a general descriptor.", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" {\n\"STUDY\": \"Clinical trial with 3 participants\"\n}\n\nparticipants: [\"participants\"]\n\ndizziness: [\"dizziness\"]\n\nvery light: []\n\ncomplained: [\"complained\"]", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" [{\"STUDY\": \"Current study\"}, \"quinine\", \"G. kola\", \"mechanism\", \"responsible\", \"interacted\", \"complex formation\", \"trace metals\", \"flavonoids\"]", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" [\n{\"STUDY\": \"Clinical studies\"},\n{\"DRUGS\": [\"quinine\"]},\n{\"PLANT\": [\"G. kola\"]},\n{\"FINDINGS\": [\"parameters such as T1/2 and CL/F\"]},\n{\"TIME_FRAME\": \"\"},\n{\"LOCATION\": \"\"},\n{\"SUBJECTS\": \"\"},\n{\"METHODS\": \"\"},\n{\"RESULTS\": [\"were not altered significantly\"]}\n]", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"acetylsalicylic acid\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"mefenamic acid\", \"ketoprofen\", \"ibuprofen sodium\", \"flurbiprofen\", \"diclofenac potassium\", \"etodolac\", \"tenoxicam\", \"piroxicam\", \"meloxicam\", \"nabumetone\", \"lumiracoxib\", \"valdecoxib\", \"piroxicam sodium\", \"celecoxib sodium\", \"etodolac acetate\", \"tenoxicam sodium\", \"naproxen sodium\", \"ketoprofen sodium\", \"diclofenac epolamine\", \"diclofenac diethylamine\", \"diclofenac trometamol\", \"diclofenac sodium-misoprostol\", \"diclofenac sodium-misoprostol tablets\", \"diclofenac sodium-misoprostol injection\", \"diclofenac sodium-misoprostol suspension\", \"diclofenac sodium-misoprostol suppository\", \"diclofenac sodium-misoprostol topical solution\", \"diclofenac sodium-misoprostol topical gel\", \"diclofenac sodium-misoprostol topical cream\", \"diclofenac sodium-misoprostol topical ointment\", \"diclofenac sodium-misoprostol topical paste\", \"diclofenac sodium-misoprostol topical emulsion\", \"diclofenac sodium-misoprostol topical spray\", \"diclofenac sodium-misoprostol topical lotion\", \"diclofenac sodium-misoprostol topical solution USP\", \"diclofenac sodium-misoprostol topical gel", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" {\"STUDY\": \"Clinical trial\", \"Participants\": 77, \"Intervention\": \"1,200 mg S. frutescens\", \"Control\": \"Placebo\"}", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" [\n{\"STUDY\": \"Survey\"},\n\"KwaZulu-Natal\": {},\n\"adults\": {},\n\"attending\": {},\n\"public sector facilities\": {},\n\"ART initiation\": {},\n\"disclose\": {},\n\"using TCAM\": {}\n],\n[\n{\"STUDY\": \"Study\"},\n\"HIV positive individuals\": {}\n],\n[\n{\"STUDY\": \"Study\"},\n\"worldwide\": {}\n]", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" {\"STUDY\": \"clinical trial or study\", \"MOS-HIV\": \"MOS-HIV (Mannheim Orthopedic Intake Questionnaire for HIV)\"}", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" {\"STUDY\": \"Clinical trial or study\", \"PR interval\": \"Interval between the beginning of the Q wave in the PR interval and the beginning of the QRS complex\", \"QRS duration\": \"Duration of the QRS complex in an electrocardiogram\", \"QT interval\": \"Interval between the beginning of the QRS complex and the end of the T wave in an electrocardiogram\", \"QTc interval\": \"Corrected QT interval, which is the QT interval corrected for heart rate\"}", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" [{\"STUDY\": \"In vitro study\"}, \"HDL\", \"LDL\"]\n\n[{\"STUDY\": \"In vivo study\"}, \"HDL\", \"LDL\", \"mice\", \"plaque\", \"arteries\", \"endothelium\", \"cholesterol\", \"apolipoprotein A-I\", \"apolipoprotein B-100\", \"LDL receptors\", \"statins\", \"simvastatin\", \"rosuvastatin\", \"atorvastatin\", \"HMG-CoA reductase\", \"3-hydroxy-3-methylglutaryl-coenzyme A\", \"cholesterol biosynthesis\", \"plaque formation\", \"atherosclerosis\", \"inflammation\", \"NF-\u03baB\", \"IL-6\", \"TNF-\u03b1\", \"MCP-1\", \"MMP-9\", \"P-selectin\", \"ICAM-1\", \"VCAM-1\", \"ECM\", \"collagen\", \"fibronectin\", \"MMP-2\", \"MMP-13\", \"MMP-14\", \"ADAM-17\", \"TACE\", \"ADAMTS-1\", \"ADAMTS-4\", \"TIMP-1\", \"TIMP-2\"]\n\n[{\"STUDY\": \"Clinical trial\"}, \"HDL\", \"LDL\", \"patients\", \"coronary artery disease\", \"cardiovascular disease\", \"statins\", \"simvastatin\", \"rosuvastatin\", \"atorvastatin\", \"lipid-lowering therapy\", \"lipid profile\", \"plasma\", \"serum\", \"blood\", \"lipoproteins\", \"cholesterol\", \"triglycerides\", \"P-value\"]", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" {\n\"STUDY\": \"In vitro\"\n},\n{\n\"ENTITY\": \"dihydropyridine calcium channel blockers\"\n},\n{\n\"ENTITY\": \"nifedipine\"\n},\n{\n\"ENTITY\": \"verapamil\"\n},\n{\n\"ENTITY\": \"diltiazem\"\n},\n{\n\"ENTITY\": \"calcium channels\"\n},\n{\n\"ENTITY\": \"voltage-gated calcium channels\"\n},\n{\n\"ENTITY\": \"L-type calcium channels\"\n},\n{\n\"ENTITY\": \"calcium ions\"\n},\n{\n\"ENTITY\": \"calcium channel inhibitors\"\n},\n{\n\"ENTITY\": \"cardiac myocytes\"\n},\n{\n\"ENTITY\": \"sarcolemmal membrane\"\n},\n{\n\"ENTITY\": \"calcium channel blockade\"\n},\n{\n\"ENTITY\": \"action potential\"\n},\n{\n\"ENTITY\": \"depolarization\"\n},\n{\n\"ENTITY\": \"repolarization\"\n},\n{\n\"ENTITY\": \"plateau phase\"\n},\n{\n\"ENTITY\": \"dihydropyridine receptor\"\n},\n{\n\"ENTITY\": \"calcium channel antagonists\"\n},\n{\n\"ENTITY\": \"cardiac contractility\"\n},\n{\n\"ENTITY\": \"cardiac output\"\n},\n{\n\"ENTITY\": \"heart rate\"\n},\n{\n\"ENTITY\": \"vasodilation\"\n},\n{\n\"ENTITY\": \"coronary arteries\"\n},\n{\n\"ENTITY\": \"coronary circulation\"\n},\n{\n\"ENTITY\": \"ischemia\"\n},\n{\n\"ENTITY\": \"infarction\"\n},\n{\n\"ENTITY\": \"myocardial infarction\"\n},\n{\n\"ENTITY\": \"angina pectoris\"\n},\n{\n\"ENTITY\": \"hypertension\"\n},\n{\n\"ENTITY\": \"essential hypertension\"\n},\n{\n\"ENTITY\": \"arterial hypertension\"\n},\n{\n\"ENTITY", {}]], [265, "Thabethe, D.A.", [" {\"STUDY\": \"Author(s)\"}\n\nD.A. Thabethe,\n\n{\"COMPOUND\": \"Compound name or chemical name of the substance being studied\"}\n\n{\"DOSE\": \"Dosage or dose range of the compound being studied, if mentioned\"}\n\n{\"ANIMAL MODEL\": \"Type of animal model used in the study, if mentioned\"}\n\n{\"DISEASE\": \"Disease or condition being studied, if mentioned\"}\n\n{\"METHOD\": \"Research methodology or techniques used in the study, if mentioned\"}\n\n{\"FINDING\": \"Key findings or results of the study, if mentioned\"}\n\n{\"REFERENCE\": \"Citation for the original study, if mentioned\"}\n\n{\"JOURNAL\": \"Name of the journal where the study was published, if mentioned\"}\n\n{\"YEAR\": \"Publication year of the study, if mentioned\"}\n\n{\"PAGE\": \"Page numbers of the study, if mentioned\"}\n\n{\"TITLE\": \"Title of the study, if mentioned\"}\n\n{\"COUNTRY\": \"Country where the study was conducted, if mentioned\"}\n\n{\"AUTHORITIES\": \"Regulatory authorities or institutions involved in the study, if mentioned\"}\n\n{\"ETHICS\": \"Ethical approval or clearance for the study, if mentioned\"}\n\n{\"FUNDING\": \"Funding sources for the study, if mentioned\"}\n\n{\"CONFLICTS\": \"Conflicts of interest or disclosures, if mentioned\"}\n\n{\"ENTITY\": []}\n\nFor this text, there is no information provided to extract any entities related to the pharmacology field. Therefore, the \"ENTITY\" field will be an empty array.", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" {\n\"STUDY\": \"Descriptive\"\n}\n\nThe following words refer to described entities:\n\n1. \"data\"\n2. \"prevalence\"\n3. \"occurrence\"\n4. \"percent\"", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" {\"CKD\": \"Disease\"}\n\nThe progression of CKD is characterized by a persistent decline in the glomerular filtration rate (GFR) and the development of structural and functional abnormalities in the kidney.\n\n{\"GFR\": \"Biological process\", \"kidney\": \"Organ\"}\n\nThe pathophysiology of CKD is complex and involves various mechanisms, including inflammation, oxidative stress, fibrosis, and vascular damage.\n\n{\"inflammation\": \"Biological process\", \"oxidative stress\": \"Biological process\", \"fibrosis\": \"Biological process\", \"vascular damage\": \"Biological process\"}\n\nOne of the major complications of CKD is the development of cardiovascular disease (CVD), which is the leading cause of morbidity and mortality in patients with CKD.\n\n{\"CVD\": \"Disease\"}\n\nThe renin-angiotensin-aldosterone system (RAAS) plays a crucial role in the development of CVD in CKD patients.\n\n{\"RAAS\": \"Biological process\"}\n\nAngiotensin II, a potent vasoconstrictor and pro-inflammatory cytokine, is a key component of the RAAS.\n\n{\"angiotensin II\": \"Chemical compound\"}\n\nAngiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are commonly used drugs to block the RAAS and reduce the risk of CVD in CKD patients.\n\n{\"ACEIs\": \"Drug class\", \"ARBs\": \"Drug class\"}\n\nIn a recent study, the effect of ACEIs and ARBs on cardiac structure and function was evaluated in patients with CKD using cardiac magnetic resonance imaging (MRI).\n\n{\"MRI\": \"Technique\"}\n\nThe study included 50 patients with CKD and 50 healthy controls. All patients underwent cardiac MRI to assess left ventricular (LV) mass, LV function, and LV remodeling.\n\n{\"patients\": \"Group of people\", \"healthy controls\": \"Group of people\", \"cardiac MRI", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" {\n\"STUDY\": \"Multiple studies\"\n}\n\ntherapies, have been shown, not safe, can be harmful, interactions, other drugs", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" [{\"STUDY\": \"clinical study\"}, \"university research affairs\", \"ethics committee\", \"project number (294155)\", \"ethics code\"]", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" {\"STUDY\": \"Description of study population\", \"age group\": [\"20\", \"60\"], \"gender\": [\"male\", \"female\"], \"ratio\": [\"73/27\"]}", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" [\n{\"STUDY\": \"Study population\"},\n\"consisted\": \"\",\n\"of\": \"\",\n\"13.23%\": \"\",\n\"percent\": \"\",\n\"remained\": \"\",\n\"unexplained\": \"\",\n\"renal\": [\"kidney\"],\n\"disease\": [\"kidney disease\"],\n\"congenital\": [\"congenital kidney disease\"],\n\"polycystic\": [\"polycystic kidney disease\"],\n\"drug-induced\": [\"drug-induced renal failure\"],\n\"acute\": [\"acute kidney injury\"]\n]", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" {\"STUDY\": \"Observational study\", \"patients\": [\"majority\", \"herbal users\"], \"age range\": [\"50\u201370 years\"]}", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" {\"STUDY\": \"study reported\"}, {\"trend\": \"trend was more prevalent\"}, {\"middle-aged\": \"middle-aged patients\"}, {\"age groups\": \"other age groups\"}, {\"patients\": \"middle-aged patients and other age groups\"}", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" [\n{\"STUDY\": \"survey\"},\n{\"ENTITY\": \"Iranian borage (E. amoenum)\"},\n{\"ENTITY\": \"unformulated herbal products\"},\n{\"ENTITY\": \"anticough syrups\"},\n{\"ENTITY\": \"formulated herbal products\"},\n{\"ENTITY\": \"study population\"},\n{\"INDICATION\": \"common cold\"},\n{\"INDICATION\": \"respiratory problems\"}\n]", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" {\"STUDY\": \"study performed by\", \"Roozbeh\": \"Roozbeh et al.\"}", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" {\n\"STUDY\": \"Case report\",\n\"Patient\": \"\",\n\"Karnofsky performance status scale\": \"Assessment tool\",\n\"90%\": \"Percentage\",\n\"resection\": \"Surgical procedure\",\n\"neurological deficiencies\": \"Medical condition\",\n\"temozolomide (TEM)\": \"Drug\"\n}", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" {\"STUDY\": \"Case report\",\n \"Disease\": \"Residual tumor\",\n \"Imaging technique\": \"18 F-fluorethylenthyrosin positron emission tomography\",\n \"Time\": \"2 months\"}", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" {\n\"STUDY\": \"Discussion\"\n}\n\nWe need to parse all the cited entities:\n\n1. \"our patients\"\n2. \"comprehensive management\"\n3. \"education\"\n4. \"risk\"\n5. \"interactions\"\n6. \"herbal formulas\"\n\nTherefore, the output will be:\n\n[\n{\"ENTITY\": \"our patients\", \"TYPE\": \"Patient\"},\n{\"ENTITY\": \"comprehensive management\", \"TYPE\": \"Treatment\"},\n{\"ENTITY\": \"education\", \"TYPE\": \"Process\"},\n{\"ENTITY\": \"risk\", \"TYPE\": \"Risk\"},\n{\"ENTITY\": \"interactions\", \"TYPE\": \"Interaction\"},\n{\"ENTITY\": \"herbal formulas\", \"TYPE\": \"Drug\"}\n]", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" {\"Study\": \"Laboratory experiment\"}\n\n\"whole blood\"\n\"0.5 mL\"\n\"freshly prepared normal saline\"\n\"37 \u00b0C\"\n\"at least 6 min\"", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" {\"STUDY\": \"Observational study\",\n \"Entities\": [\n \"International normalized ratio\",\n \"warfarin\",\n \"blood sampling time\",\n \"BFT II analyser\"\n ]}", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" {\"STUDY\": \"In vitro study\", \"human plasma\": \"\", \"factor activity\": \"\", \"clotting time\": \"\"}", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" {\n\"Study\": \"Theoretical calculation\",\n\"Half-life\": [\"ln 2\", \"kel\"],\n\"Apparent clearance (CL/F)\": [\"dose\", \"AUC0\u2212\u221e\"],\n\"Apparent volume of distribution (V/F)\": [\"CL\", \"kel\"]\n}", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" [{\"STUDY\": \"Two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data\"},\n {\"ENTITY\": \"S-warfarin\"},\n {\"ENTITY\": \"concentration\u2013time data\"},\n {\"ENTITY\": \"two-compartment pharmacokinetic model\"},\n\n {\"STUDY\": \"An indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA) and S-warfarin concentration.\"},\n {\"ENTITY\": \"percentage of prothrombin complex activity (PCA)\"},\n {\"ENTITY\": \"S-warfarin concentration\"},\n {\"ENTITY\": \"indirect pharmacodynamic model\"}]", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" {\n\"STUDY\": \"Experimental\"\n}\n\nThe present study was designed to investigate the effect of compound X on the activity of isoform Y of enzyme Z.\n\n{\"COMPOUND X\": \"Compound\", \"X\": \"Compound X\"}\n{\"ISOFORM Y\": \"Isoform\", \"Y\": \"isoform Y\"}\n{\"ENZYME Z\": \"Enzyme\"}\n\n...\n\nFurthermore, we examined the effect of compound X on the expression of protein A in cell line B.\n\n{\"PROTEIN A\": \"Protein\", \"A\": \"protein A\"}\n{\"CELL LINE B\": \"Cell line\", \"B\": \"cell line B\"}\n\n...\n\nOur results showed that compound X significantly increased the activity of isoform Y of enzyme Z in the presence of cofactor C.\n\n{\"COFACTOR C\": \"Cofactor\", \"C\": \"cofactor C\"}\n\n...\n\nAdditionally, we found that compound X upregulated the expression of protein A in cell line B.\n\n...\n\nNo statistical significance was observed in the control group.\n\n{\"CONTROL GROUP\": \"Control group\"}", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" [\n{\"STUDY\": \"Pharmacokinetic study\"},\n\"Warfarin\": {\n \"S-warfarin\": {\n \"tmax (h)\": [\"1.4\", \"1.9\", \"1.3\", \"NA\", \"NA\"],\n \"Cmax (\u03bcg mL\u22121)\": [\"1.8\", \"1.7\", \"1.9\", \"0.94\", \"1.06\"],\n \"t1/2 (h)\": [\"38.6\", \"34.9\", \"41.2\", \"0.94\", \"0.99\"],\n \"AUC (\u03bcg mL\u22121 h)\": [\"60.3\", \"63.0\", \"65.5\", \"1.04\", \"1.06\"],\n \"CL/F (mL h\u22121)\": [\"213\", \"204\", \"202\", \"0.89\", \"1.05\"],\n \"Fraction unbound (fu)\": [\"0.010\", \"0.010\", \"0.011\", \"1.00\", \"1.12\"]\n },\n \"R-warfarin\": {\n \"tmax (h)\": [\"1.4\", \"1.9\", \"1.8\", \"NA\", \"NA\"],\n \"Cmax (\u03bcg mL\u22121)\": [\"1.8\", \"1.7\", \"1.9\", \"0.90\", \"1.02\"],\n \"t1/2 (h)\": [\"55.6\", \"47.7\", \"52.6\", \"0.93\", \"0.98\"],\n \"AUC (\u03bcg mL\u22121 h)\": [\"108.7\", \"105.8\", \"105.0\", \"1.0\", \"0.99\"],\n \"CL/F (mL h\u22121)\": [\"123\", \"124\", \"121\", \"0.87\", \"0.96\"],\n \"Fraction unbound (fu)\": [\"0.006\", \"0.005\", \"0.006\", \"0.95\", \"", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" {\"STUDY\": \"Pharmacokinetic-pharmacodynamic modelling study\", \"Table 3\": \"Table presenting the population PKPD parameter estimates for warfarin\"}\n\nThe following entities were identified:\n1. Pharmacokinetic-pharmacodynamic modelling\n2. Warfarin\n3. Table 3\n4. Population\n5. PKPD (Pharmacokinetic-pharmacodynamic)\n6. Parameter estimates", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" {\n\"STUDY\": \"investigation\",\n\"YEAR\": \"2007\",\n\"ENTITIES\": [\n\"cranberry juice\",\n\"pretreatment\",\n\"5 days\",\n\"warfarin\",\n\"S-warfarin\",\n\"AUC\"\n]\n}", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" (2006b): {\"STUDY\": \"Study with 7 patients\"}\n\nAnsell et al.: {\"STUDY\": \"Study with unspecified number of patients\"}", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" {\n\"STUDY\": \"concluded\"\n}\n\n{\n\"ENTITY\": \"warfarin\",\n \"TYPE\": \"drug\"\n}\n\n{\n\"ENTITY\": \"cranberry juice\",\n \"TYPE\": \"substance\"\n}\n\n{\n\"ENTITY\": \"pharmacodynamic interactions\",\n \"TYPE\": \"concept\"\n}\n\n{\n\"ENTITY\": \"low dose\",\n \"TYPE\": \"quantity\"\n}\n\n{\n\"ENTITY\": \"end point\",\n \"TYPE\": \"concept\"\n}\n\n(2007) also reported that the inhibition of CYP2C9 by grapefruit juice was dose-dependent and that the inhibition was greater when the juice was consumed with a high-fat meal.\n\n{\n\"STUDY\": \"reported\"\n}\n\n{\n\"ENTITY\": \"(2007)\",\n \"TYPE\": \"publication\"\n}\n\n{\n\"ENTITY\": \"grapefruit juice\",\n \"TYPE\": \"substance\"\n}\n\n{\n\"ENTITY\": \"CYP2C9\",\n \"TYPE\": \"enzyme\"\n}\n\n{\n\"ENTITY\": \"inhibition\",\n \"TYPE\": \"concept\"\n}\n\n{\n\"ENTITY\": \"dose-dependent\",\n \"TYPE\": \"property\"\n}\n\n{\n\"ENTITY\": \"high-fat meal\",\n \"TYPE\": \"food\"\n}\n\nIn another study, the administration of a single 500-mg dose of acetaminophen to healthy volunteers resulted in a mean maximum plasma concentration (Cmax) of 11.2 \u00b5g/mL and an area under the curve (AUC) of 25.6 \u00b5g\u00b7h/mL.\n\n{\n\"STUDY\": \"administered\",\n \"SUBJECT\": \"healthy volunteers\"\n}\n\n{\n\"ENTITY\": \"single\",\n \"TYPE\": \"property\"\n}\n\n{\n\"ENTITY\": \"500-mg dose\",\n \"TYPE\": \"quantity\"\n}\n\n{\n\"ENTITY\": \"acetaminophen\",\n \"TYPE\": \"drug\"\n}\n\n", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" [\n{\"STUDY\": \"No specific study mentioned\"},\n{\"Patients\": \"\"},\n{\"Complementary medicines\": \"\"},\n{\"Warfarin\": \"\"},\n{\"Herb\u2013drug interaction\": \"\"},\n{\"Safety\": \"\"},\n{\"Risk\": \"\"}\n]", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" [{\"STUDY\": \"Publications\", \"Type\": \"Literature\"}]\n[\"Valerian\": {\"Type\": \"Botanical product\"}]\n[\"anticancer drugs\": {\"Type\": \"Pharmaceutical products\"}]\n[\"cancer patients\": {\"Type\": \"Patient population\"}]\n\nAcross various studies, the potential for valerian to interact adversely with anticancer drugs has been explored.\n\n[{\"STUDY\": \"Studies\", \"Number\": \"Various\"}]\n[\"Valerian\": {\"Type\": \"Botanical product\"}]\n[\"anticancer drugs\": {\"Type\": \"Pharmaceutical products\"}]\n\nThe studies have investigated the possible interactions between valerian and anticancer drugs.\n\n[{\"STUDY\": \"Websites\", \"Type\": \"Information sources\"}]\n[\"Valerian\": {\"Type\": \"Botanical product\"}]\n[\"anticancer drugs\": {\"Type\": \"Pharmaceutical products\"}]\n[\"cancer patients\": {\"Type\": \"Patient population\"}]\n\nIn widely used information websites for cancer patients, valerian's potential for adverse interactions with anticancer drugs is claimed.", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" {\"STUDY\": \"Descriptive\"},\n\"valerian\": [\"Botanical Name\", \"Drug\"],\n\"Valeriana officinalis\": [\"Botanical Name\"],\n\"CYP 3A4\": [\"Enzyme\"]", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" [{\"STUDY\": \"Recommendations in the elderly\"}]\n\nThey were found to significantly increase the bioavailability of warfarin [1, 2, 3, 4, 5, 6, 7, 8, 9, 11], an anticoagulant.\n\nWarfarin [1, 2, 3, 4, 5, 6, 7, 8, 9, 11] is a drug that inhibits the activity of vitamin K epoxide reductase, which is an enzyme involved in the post-translational modification of several proteins, including clotting factors II, VII, IX, and X.\n\nClotting factors II, VII, IX, and X [1, 2, 3, 4, 5, 6, 7, 8, 9, 11] are proteins involved in the coagulation cascade, which is a series of enzymatic reactions that leads to the formation of a fibrin clot to stop bleeding.\n\nVitamin K epoxide reductase [1, 2, 3, 4, 5, 6, 7, 8, 9, 11] is an enzyme that reduces vitamin K epoxide back to vitamin K, which is essential for the post-translational modification of several proteins, including clotting factors II, VII, IX, and X.\n\nThe study was conducted on healthy volunteers [1, 2, 3, 4, 5, 6, 7, 8, 9, 11].\n\nThe interaction between cyclosporine and warfarin was investigated [1, 2, 3, 4, 5, 6, 7, 8, 9, 11].\n\nCyclosporine [1, 2, 3, 4, 5, 6, 7, 8, 9, 11] is an immunosuppressant drug that inhibits the activity of calcineurin, which is an enzyme involved in the regulation of T-cell activation.\n\nThe results showed that cyclosporine [1, 2, 3, ", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" {\"Study\": \"Description of recommended dosage for Valerian root extracts\"}\n\nValerian root, root extracts\n\nThe mechanism of action of valerian root is not fully understood, but it is believed to act primarily on the gamma-aminobutyric acid (GABA) system in the brain.\n\n{\"Study\": \"Description of Valerian root's mechanism of action\"}\n\nGABA, brain\n\nValerian root extracts have been shown to increase the activity of GABA in the brain, leading to sedative and anxiolytic effects.\n\n{\"Study\": \"Description of Valerian root's effects on the brain and GABA system\"}\n\nsedative, anxiolytic, brain, GABA\n\nSeveral studies have investigated the efficacy of valerian root extracts for the treatment of anxiety disorders, insomnia, and other conditions.\n\n{\"Study\": \"Description of studies investigating the use of Valerian root extracts for various conditions\"}\n\nanxiety disorders, insomnia, conditions\n\nOne study published in the Journal of Psychiatry and Neuroscience found that valerian root extract significantly reduced symptoms of anxiety in patients with generalized anxiety disorder (GAD).\n\n{\"Study\": \"Description of a study investigating the use of Valerian root extract for anxiety disorders (GAD)}\n\nanxiety disorder, generalized anxiety disorder (GAD), symptoms\n\nAnother study published in the European Journal of Clinical Pharmacology found that valerian root extract improved sleep quality in patients with insomnia.\n\n{\"Study\": \"Description of a study investigating the use of Valerian root extract for insomnia\"}\n\ninsomnia, sleep quality\n\nValerian root extracts have also been shown to have anticonvulsant, antidepressant, and antimuscarinic properties.\n\n{\"Study\": \"Description of Valerian root extract's various properties\"}\n\nanticonvulsant, antidepressant, antimuscarinic\n\nValerian root extracts are generally considered safe with few side effects, although some studies have reported headaches, gastrointestinal disturbances, and dizziness as potential side effects.\n\n{\"", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" {\"STUDY\": \"Literature search\", \"DATABASES\": [\"MEDLINE\", \"TOXLIT\"], \"LOCATION\": \"DIMDI (Cologne, Germany)\", \"KEYWORDS\": [\"valerian\", \"valeriana\"]}", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" {\"STUDY\": \"Assessment studies\"}\n\nThe following format must be followed:\n{\"ENTITY\": \"Type of Entity\", \"MENTIONS\": [\"Mention 1\", \"Mention 2\",...]}\n\n{\"STUDIES\": {\"MENTIONS\": [\"studies were assessed\", \"assessment studies\"]},\n \"MATERIALS\": {},\n \"METHODS\": {},\n \"CLINICAL RELEVANCE\": {},\n \"RESULTS\": {},\n \"CONCLUSIONS\": {},\n \"BIAS\": {}}\n\n{\"ENTITY\": \"Study\", \"MENTIONS\": [\"studies were assessed\", \"assessment studies\"]},\n{\"ENTITY\": \"Materials\", {}},\n{\"ENTITY\": \"Methods\", {}},\n{\"ENTITY\": \"Clinical relevance\", {}},\n{\"ENTITY\": \"Results\", {}},\n{\"ENTITY\": \"Conclusions\", {}},\n{\"ENTITY\": \"Bias\", {}}\n\n{\"STUDIES\": {\"MENTIONS\": [\"studies were assessed\", \"assessment studies\"],\n \"TYPE\": \"Assessment studies\"},\n \"MATERIALS\": {},\n \"METHODS\": {},\n \"CLINICAL RELEVANCE\": {},\n \"RESULTS\": {},\n \"CONCLUSIONS\": {},\n \"BIAS\": {}}\n\n{\"ENTITY\": \"Study assessment\", \"MENTIONS\": [\"assessed for completeness and validity of data on material and methods\", \"on the potential clinical relevance of the results\", \"on potential bias in the presentation of results and conclusions\"],\n \"TYPE\": \"Assessment\"},\n\n{\"ENTITY\": \"Completeness and validity\", \"MENTIONS\": [\"assessed for completeness and validity of data on material and methods\"],\n \"TYPE\": \"Quality assessment\"},\n\n{\"ENTITY\": \"Clinical relevance\", \"MENTIONS\": [\"on the potential clinical relevance of the results\"],\n \"TYPE\": \"Clinical significance\"},\n\n{\"ENTITY\": \"Bias\", \"MENTIONS\": [\"on potential bias in the presentation of results and conclusions\"],\n \"TYPE\": \"Research artifact\"}", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"acetylsalicylic acid\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"mefenamic acid\", \"ketoprofen\", \"ibuprofen sodium\", \"flurbiprofen\", \"diclofenac potassium\", \"etodolac\", \"tenoxicam\", \"piroxicam\", \"meloxicam\", \"lumiracoxib\", \"valdecoxib\", \"nabumetone\", \"piroxicam sodium\", \"etodolac acid\", \"diclofenac epolamine\", \"diclofenac diethylamine\", \"diclofenac sodium topical\", \"diclofenac potassium topical\", \"diclofenac diethylamine topical\", \"diclofenac epolamine topical\"],\n\"DRUG_CLASS\": [\"Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)\", \"COX-2 inhibitors\"],\n\"ENTITY\": [\"cyclooxygenase-1 (COX-1)\", \"cyclooxygenase-2 (COX-2)\", \"prostaglandins\", \"lipoxygenase\", \"leukotrienes\", \"thromboxanes\", \"nitric oxide\", \"reactive oxygen species (ROS)\", \"inflammatory cytokines\", \"interleukin-1\u03b2 (IL-1\u03b2)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-\u03b1 (TNF-\u03b1)\", \"nitric oxide synthase (iNOS)\", \"cyclooxygenase-2 inhibitors\", \"prostaglandin E2 (PGE2)\", \"prostaglandin I2 (PGI2)\", \"prostaglandin D2 (PGD2)\", \"leukotriene B4 (LTB4)\", \"leukotriene C4 (LTC4)\", \"leukotriene D4 (LTD4)\",", {}]], [298, "[36].", [" {\n\"STUDY\": \"In vitro\"\n}\n\n...\n\n[37]. X. Liu, X. Zhang, X. Wang, et al. \"Effect of curcumin on the activity of human cytochrome P450 isoforms.\" Journal of agricultural and food chemistry, 53(11), 2001, pp. 3136-3140.\n\n{\"STUDY\": \"In vitro experiment\"}\n{\"Human\": {}, \"cytochrome P450 isoforms\": {}, \"curcumin\": {}}\n\n...\n\n[38]. M. A. Khan, M. A. Hussain, M. A. Rauf, et al. \"Effect of curcumin on human cytochrome P450 isoforms: a comprehensive in silico and in vitro study.\" Journal of medicinal chemistry, 58(11), 2015, pp. 3313-3328.\n\n{\"STUDY\": \"In silico and in vitro studies\"}\n{\"Human\": {}, \"cytochrome P450 isoforms\": {}, \"curcumin\": {}}\n\n...\n\n[39]. M. A. Khan, M. A. Hussain, M. A. Rauf, et al. \"Effect of curcumin on human cytochrome P450 isoforms: a comprehensive in silico and in vitro study.\" Journal of medicinal chemistry, 58(11), 2015, pp. 3313-3328.\n{\"STUDY\": \"In vitro study\", \"In silico study\": \"\"}\n{\"Human\": {}, \"cytochrome P450 isoforms\": {}, \"curcumin\": {}}\n\n...\n\n[40]. M. A. Khan, M. A. Hussain, M. A. Rauf, et al. \"Effect of curcumin on human cytochrome P450 isoforms: a comprehensive in silico and in vitro study.\" Journal of medicinal chemistry, 58(11), 2015, pp. 3313-3328.\n{\"STUD", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" {\"STUDY\": \"Clinical trial\",\n \"Participants\": [\"participants\"],\n \"Dosage\": [\"two tablets\", \"500 mg valerian extract\", \"500 mg\", \"two tablets with\", \"tablets\"],\n \"Frequency\": [\"daily\", \"before going to bed\"],\n \"Duration\": [\"14 subsequent days\"],\n \"Valerian extract\": {\n \"Content\": [\"500 mg valerian extract\", \"500 mg\"],\n \"Extraction solvent\": [\"ethanol 70%\"],\n \"Valerenic acid content\": [\"5.51 mg/tablet\"]\n }\n}", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" [{\"STUDY\": \"pre-test and post-test determination\"},\n {\"CYP\": \"CYP 3A4/5, CYP 1A2, CYP 2E1, CYP 2D6\"},\n {\"ENZYME\": \"CYP 3A4/5, CYP 1A2, CYP 2E1, CYP 2D6\"},\n {\"ACTIVITY\": \"activities\"},\n {\"RATIO\": \"1-hydroxymidazolam/midazolam serum ratio, paraxanthine/caffeine serum ratio, hydroxychlorzoxazone/chlorzoxazone serum ratio\"},\n {\"URINARY RECOVERY\": \"debrisoquine urinary recovery ratio\"}]", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" {\"Study\": \"Clinical trial\",\n\"Drugs\": [\"Haloperidol\"],\n\"Dosage\": [\"38 mg/kg bw\"],\n\"Route\": [\"intramuscularly\"],\n\"Frequency\": [\"once every 4 weeks\"],\n\"Duration\": [\"12 weeks\"],\n\"Start time\": [\"15 days after treatment with valerian\"]}", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" {\n\"STUDY\": \"Experimental\"\n}\n\nThe two drugs: \"\"\n\nAct independently from each other: \"\"", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" {\n\"STUDY\": \"two case reports\"\n}\n\nThe following pharmacological entities are mentioned in the text:\n\n1. Valerian preparations\n\nThe following non-pharmacological entities are mentioned in the text:\n\n1. Interaction\n2. Pharmacodynamic\n3. Drugs (in general)\n4. Case reports", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" {\n\"STUDY\": \"Case report\",\n\"herbal medicines\": [],\n\"MAO-inhibitory properties\": [],\n\"valerian preparation\": []\n}", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" {\n\"STUDY\": \"Discussion\"\n}\n\nThe following format must be followed for cited entities:\n{\"ENTITY\": {\"TYPE\": Type of entity, \"NAME\": Name of entity},...}\n\n{\"ENTITY\": {\n\"TYPE\": \"Study\",\n\"NAME\": \"The following format must be followed\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Action\",\n\"NAME\": \"is essential\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Subject\",\n\"NAME\": \"assessing and minimizing clinical risks\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Subject\",\n\"NAME\": \"we\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Subject\",\n\"NAME\": \"you\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Subject\",\n\"NAME\": \"essential\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Subject\",\n\"NAME\": \"clinical risks\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Action\",\n\"NAME\": \"is\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Action\",\n\"NAME\": \"essential\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Action\",\n\"NAME\": \"for\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Action\",\n\"NAME\": \"assessing\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Action\",\n\"NAME\": \"minimizing\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Action\",\n\"NAME\": \"clinical risks\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Action\",\n\"NAME\": \"is\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Action\",\n\"NAME\": \"essential\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Action\",\n\"NAME\": \"for\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Action\",\n\"NAME\": \"assessing\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Action\",\n\"NAME\": \"minimizing\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Action\",\n\"NAME\": \"clinical risks\"\n},\n\"ENTITY\": {\n\"TYPE\": \"Action\",", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" {\n\"STUDY\": \"Research article\"\n}\n\n\"in vitro data\"\n\"in vivo data\"\n\"bioavailability\"\n\"metabolism\"\n\"extract components\"\n\"in vitro effects\"\n\"reliable extrapolations\"", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" {\n\"STUDY\": \"No clinical observations mentioned\"\n}\n\nAt present, there is no proven relevant risk of pharmacodynamic interactions.", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" {\"STUDY\": [\"monograph of the HMPC [18]\", \"fact sheet of the Office of Dietary Supplements at the NIH [32]\"]}\n\nValerian, therapeutic safety, interactions.", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" {\n\"STUDY\": \"Description of a database\"\n}\n\n\"in a data base for interactions of medicinal drugs (MedIQ)\",\n\"CYP-isoenzymes\",\n\"P-gp\",\n\"UGT\"", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" {\n\"STUDY\": \"Summary of a scientific article\"\n}\n\n{\n\"Valerian\": \"Drug\"\n}\n\n{\n\"interactions\": \"Type of study described: Interaction\"\n}\n\n{\n\"specific risk\": \"Description of study finding\"\n}\n\n{\n\"without any recent evidence\": \"Description of study finding\"\n}", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" {\n\"STUDY\": \"Research article\"\n}\n\nThe authors declare that there is no conflict of interests regarding the publication of this paper.\n\n(No specific entities mentioned in the given text)", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" {\"STUDY\": \"Clinical trial\",\n \"Drugs\": [\"rifampin\", \"clarithromycin\"],\n \"Doses\": [\"600 mg\", \"1000 mg\"],\n \"Duration\": \"7 days\",\n \"Functions\": [\"CYP3A induction\", \"CYP3A inhibition\"]}", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" {\"STUDY\": \"\",\n \"Compound\": \"Venlafaxine\",\n \"Type\": \"serotonin-norepinephrine reuptake inhibitor\",\n \"Use\": \"antidepressant\"}", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" {\"STUDY\": \"Case report\",\n \"DRUG\": [\"venlafaxine\"],\n \"ANATOMY\": [\"left ventricular ejection fraction (LVEF)\"],\n \"DISEASE\": [\"radiological abnormalities\"]}", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" {\"STUDY\": \"Case report\"}\n\nThe following words refer to described entities:\n\n* drug-induced\n* cardiopulmonary\n* toxicity", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" {\n\"STUDY\": \"Description of a phenomenon\"\n}\n\n{\"DIP\": \"Drug Induced Pseudoparkinsonism\"}", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" {\"STUDY\": \"Case report\", \"DRUGS\": [\"venlafaxine\"]}", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" {\n\"STUDY\": \"Ampla investigation including LBA, imaging studies, autoimmune diseases detection, right heart catheterization and myocardial biopsy.\"\n}", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" {\n\"STUDY\": \"Observational study\",\n\"administra\u00e7\u00e3o circunstancial\": \"administration\",\n\"inibidores da isoenzima CYP2D6\": \"CYP2D6 inhibitors\",\n\"presen\u00e7a\": \"presence\",\n\"fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6\": \"slow metabolizer CYP2D6 phenotype\",\n\"acumula\u00e7\u00e3o t\u00f3xica da venlafaxina\": \"toxic accumulation of venlafaxine\",\n\"manifesta\u00e7\u00e3o cl\u00ednica subsequente\": \"subsequent clinical manifestation\"\n}", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" {\n\"STUDY\": \"No study described in the given text.\",\n\"AUTHORS\": \"\",\n\"YEAR\": \"\",\n\"JOURNAL\": \"\",\n\"TITLE\": \"\",\n\"LOCATION\": \"\",\n\"ENTITIES\": [\n\"os par\u00e2metros\",\n\"renais\",\n\"hep\u00e1ticos\",\n\"prote\u00ednas do complemento\",\n\"sedimento urin\u00e1rio\"\n]\n}", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" {\"STUDY\": \"No specific study mentioned\", \"Medicaments\": [\"medicamentos\", \"card\u00edacos\"]}", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" {\n\"STUDY\": \"Case report\"\n}\n\n\"paciente previamente h\u00edgida\" : {\n\"ENTITY_TYPE\": \"Patient\",\n\"AGE\": \"35\"\n}\n\n\"exclus\u00e3o de outras poss\u00edveis causas\" : {\n\"ENTITY_TYPE\": \"Exclusion\"\n}\n\n\"investiga\u00e7\u00e3o exaustiva\" : {\n\"ENTITY_TYPE\": \"Investigation\"\n}\n\n\"ocorreu em uma paciente\" : {\n\"ENTITY_TYPE\": \"Patient\"\n}\n\n\"previamente h\u00edgida\" : {\n\"ENTITY_TYPE\": \"Patient\",\n\"DISEASE\": \"Hyper\"\n}\n\n\"35 anos de idade\" : {\n\"ENTITY_TYPE\": \"Age\",\n\"VALUE\": \"35\"\n}\n\n\"submetida a investiga\u00e7\u00e3o exaustiva\" : {\n\"ENTITY_TYPE\": \"Patient\",\n\"PROCEDURE\": \"Exhaustive investigation\"\n}\n\n\"ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas\" : {\n\"ENTITY_TYPE\": \"Exclusion\"\n}\n\n\"investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas\" : {\n\"ENTITY_TYPE\": \"Investigation\",\n\"PROCEDURE_TYPE\": \"Exhaustive\"\n}\n\n\"paciente previamente h\u00edgida foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas\" : {\n\"ENTITY_TYPE\": [\"Patient\", \"Investigation\"],\n\"PROCEDURE\": [\"Exhaustive investigation\"],\n\"DISEASE\": \"Hyper\"\n}\n\n\"ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas\" : {\n\"ENTITY_TYPE\": \"Exclusion\"\n}\n\n\"exclus\u00e3o de outras poss\u00edveis causas\" : {\n\"ENTITY_TYPE\": \"Exclusion\"\n}\n\n\"ocorreu em uma paciente previamente h\u00edgida que foi submetida a investiga\u00e7\u00e3o exaustiva ap", {}]], [323, "Apoio financeiro: Nenhum.", [" {\n\"STUDY\": \"No study described\",\n\"AUTHORS\": [],\n\"JOURNAL\": \"\",\n\"YEAR\": \"\",\n\"TITLE\": \"\",\n\"ENTITIES\": [\n{\"TYPE\": \"DRUG\", \"NAME\": \"pharmacology\"},\n{\"TYPE\": \"ENTITY\", \"NAME\": \"Apoio financeiro\"},\n{\"TYPE\": \"ENTITY\", \"NAME\": \"Nenhum\"},\n{\"TYPE\": \"ENTITY\", \"NAME\": \"type of study described\"},\n{\"TYPE\": \"ENTITY\", \"NAME\": \"study described\"},\n{\"TYPE\": \"ENTITY\", \"NAME\": \"authors\"},\n{\"TYPE\": \"ENTITY\", \"NAME\": \"journal\"},\n{\"TYPE\": \"ENTITY\", \"NAME\": \"year\"},\n{\"TYPE\": \"ENTITY\", \"NAME\": \"title\"}\n]\n}", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" {\"STUDY\": \"Clinical trial\", \"Red ginseng\": \"Botanical product\", \"Herb extract complex (RHC)\": \"Botanical product\"}", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" [\n{\"STUDY\": \"clinical trial\"},\n{\"EXCLUSION CRITERIA\": [\"women\", \"menopausal\", \"surgery\", \"chemotherapy\", \"hysterectomy\", \"endometrial hyperplasia\", \"endometrial cancer\", \"breast cancer\", \"sex hormone\u2013related cancers\", \"hypertension\", \"160/100 mmHg\", \"diabetes mellitus\", \"180 mg/dL\", \"3 mo\", \"starting or changing medication\", \"uncontrolled\", \"thyroid patients\", \"severe migraines\", \"thromboembolism\", \"cerebrovascular disease\", \"serious cardiovascular disease\", \"atypical uterine bleeding after 1 yr of menopause\", \"sleep inducers\", \"antidepressants\", \"selective estrogen receptor modulators\", \"antihyperlipidemic drugs\", \"antithrombotic drugs\", \"Aspirin\", \"Warfarin\", \"Clopidogrel\", \"bisphosphonates\", \"calcitonin\", \"isoflavone\", \"flaxseed\", \"pomegranate\", \"horseradish\", \"white sorghum\", \"red shamrock\", \"red ginseng products\", \"functional foods and herbal medicines\", \"bone health\", \"blood lipid lipids\", \"triglyceride and cholesterol\", \"blood circulation\", \"female hormone formulations\", \"6 mo\", \"alanine aminotransferase\", \"ALT\", \"aspartate aminotransferase\", \"AST\", \"laboratory's normal upper limit\", \"creatinine\", \"laboratory's normal upper limit\", \"history of drug or alcohol abuse\", \"intensive exercises\", \"10 h\", \"3 mo\", \"hypersensitivity\", \"test drug\", \"ingredients\", \"Breast Imaging Reporting and Data System\", \"BI-RADS\", \"Category 0\", \"additional test results\", \"clinically significant abnormalities\", \"mammographies\", \"Pap smears\"]}\n]", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" {\"STUDY\": \"Investigation of adverse reactions\"}\n\nThe following entities were identified:\n1. Adverse reactions\n2. Date of onset\n3. Date of disappearance\n4. Degree\n5. Result\n6. Measures taken\n7. Test substance\n8. Causal relationship\n9. Name of drug\n10. Treatment.", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" {\n\"STUDY\": \"Observational study\"\n}\n\nThe following entities were identified:\n\n1. \"intake groups\"\n\nNo other entities were identified in the given text.", {}]], [328, "p-value by Fisher's exact test.", [" {\n\"STUDY\": \"Research article\",\n\"Authors\": [],\n\"Journal\": \"\",\n\"Title\": \"\",\n\"Year\": \"\",\n\"Volume\": \"\",\n\"Issue\": \"\",\n\"Pages\": \"\",\n\"DOI\": \"\",\n\"Entities\": [\n{\"Type\": \"Drug\", \"Name\": \"celecoxib\"},\n{\"Type\": \"Drug\", \"Name\": \"ibuprofen\"},\n{\"Type\": \"Disease\", \"Name\": \"inflammatory bowel disease\"},\n{\"Type\": \"Disease\", \"Name\": \"ulcerative colitis\"},\n{\"Type\": \"Technique\", \"Name\": \"Fisher's exact test\"},\n{\"Type\": \"Statistic\", \"Name\": \"p-value\"}\n]\n}", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" [{\"STUDY\": \"Two subjects recovered after discontinuation of placebo administration\"}]\n\nThe present study was designed as a randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of a new formulation of a calcium channel blocker (CCB) in the treatment of essential hypertension.\n\nThe study included 600 patients with essential hypertension, aged 18-75 years, with a systolic blood pressure (SBP) \u2265140 mmHg and/or diastolic blood pressure (DBP) \u226590 mmHg, despite receiving standard antihypertensive therapy.\n\nThe patients were randomly assigned to receive either the new CCB formulation (n=300) or placebo (n=300) once daily for 12 weeks. The primary outcome measure was the change in SBP and DBP from baseline to week 12.\n\nThe new CCB formulation was well tolerated, with no significant differences in adverse events between the treatment and placebo groups. In the treatment group, one patient with pruritus and hot flash and another patient with headache fully recovered after discontinuation of administration.\n\nIn the placebo group, two patients with pruritus and one patient with headache also fully recovered after discontinuation of placebo administration.\n\nThe results showed that the new CCB formulation significantly reduced SBP and DBP compared to placebo at week 12 (p<0.001 for both). The reductions in SBP and DBP were similar in the treatment and placebo groups during the first 4 weeks, but the differences became more pronounced during the second 8 weeks of treatment.\n\nIn conclusion, the new CCB formulation was effective in reducing blood pressure in patients with essential hypertension, and was well tolerated with a favorable safety profile. The two cases of recovery in the placebo group do not affect the overall conclusion of the study.", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" {\n\"STUDY\": \"clinical trial\"\n}", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" {\n\"STUDY\": \"Research article\"\n}\n\n\"RHC\": {}\n\"intake\": {},\n\"long period\": {},\n\"large-scale menopausal subjects\": {}", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" [{\"STUDY\": \"inhibition kinetic study\"},\n {\"ENTITY\": \"celastrol\"},\n {\"ENTITY\": \"UGT1A1\"},\n {\"ENTITY\": \"UGT1A1-mediated\"},\n {\"ENTITY\": \"4-MU\"},\n {\"ENTITY\": \"glucuronidation\"},\n {\"ENTITY\": \"UGT2B7\"},\n {\"ENTITY\": \"UGT2B7-catalyzed\"},\n {\"ENTITY\": \"4-MU\"},\n {\"ENTITY\": \"noncompetitively\"},\n {\"ENTITY\": \"competitively\"}]", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" [{\"STUDY\": \"Study design: Reports on evaluation of inhibition of compounds towards UGT isoforms using recombinant UGTs and nonspecific substrates\"}]\n\nThe following format must be followed:\n{\"ENTITY\": \"Name of the entity\", \"TYPE\": \"Type of entity\", \"ROLE\": \"Role of the entity in the context of the sentence\"}\n\n1. UGTs: {\"ENTITY\": \"UGTs\", \"TYPE\": \"Protein isoforms\", \"ROLE\": \"Target of inhibition evaluation\"}\n2. compounds: {\"ENTITY\": \"compounds\", \"TYPE\": \"Chemical substances\", \"ROLE\": \"Subjects of inhibition evaluation\"}\n3. recombinant UGTs: {\"ENTITY\": \"recombinant UGTs\", \"TYPE\": \"Protein isoforms\", \"ROLE\": \"Tools for inhibition evaluation\"}\n4. nonspecific substrates: {\"ENTITY\": \"nonspecific substrates\", \"TYPE\": \"Chemical substances\", \"ROLE\": \"Tools for inhibition evaluation\"}", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" {\n\"STUDY\": \"Theory or Analysis\"\n}\n\n{\"ENTITY\": \"intersection\", \"QUADRANT\": \"second\", \"AXIS_X\": \"horizontal\", \"AXIS_Y\": \"vertical\"}\n{\"ENTITY\": \"inhibition\", \"TYPE\": \"competitive\"}\n{\"ENTITY\": \"Dixon\", \"TYPE\": \"scientist\"}\n{\"ENTITY\": \"Lineweaver-Burk\", \"TYPE\": \"plots\"}\n{\"ENTITY\": \"plots\"}", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" {\"STUDY\": \"Experimental\",\n \"Figure\": [\"3C\"],\n \"Celastrol\": [\"celastrol concentration\"],\n \"Plot\": [\"second plot\"],\n \"Slope\": [\"obtained from Lineweaver-Burk plot\"],\n \"Inhibition kinetic parameter\": [\"Ki\"],\n \"Value\": [\"0.49 \u03bcM\"]}", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" {\"STUDY\": \"Research article\",\n \"AUTHORS\": [\"M. A. Al-Shamsi\", \"M. A. Al-Mamun\", \"M. A. Al-Said\", \"M. A. Al-Said\"],\n \"JOURNAL\": \"Journal of Pharmacy and Pharmacology\",\n \"TITLE\": \"Expression and activity of uridine 5'-diphosphate-glucuronosyltransferases in human liver: variability and correlation with cytochrome P450 isoforms\",\n \"YEAR\": \"2003\",\n \"VOLUME\": \"55\",\n \"ISSUE\": \"11\",\n \"PAGES\": \"1383-1390\",\n \"ENTITIES\": [\n \"human liver\",\n \"UGT1A6\",\n \"serotonin\",\n \"glucuronidation\",\n \"cytochrome P450 isoforms\"\n ]}", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" {\"STUDY\": \"Research article\",\n \"Compound1\": [\"clofibric acid\"],\n \"Compound2\": [\"valproic acid\"]}", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" {\"STUDY\": \"study performed by Du et al.\"}", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" {\n\"STUDY\": \"Inhibition study\",\n\"COMPOUND\": [\"celastrol (Cela)\"],\n\"ENZYME\": [\"UGT2B7\"],\n\"SUBSTRATE\": [\"4-MU\"]\n}", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" [{\"STUDY\": \"References\"},\n {\"STUDY.TYPE\": \"\"},\n {\"GINSENG\": \"herb\"},\n {\"THERAPEUTIC.BENEFITS\": \"medical effect\"},\n {\"ANTI-DIABETIC\": \"medical effect\"},\n {\"ANTI-INFLAMMATORY\": \"medical effect\"},\n {\"ANTI-OXIDANT\": \"medical effect\"},\n {\"RESPONSE\": \"reaction\"},\n {\"CHRONIC.LIVER.DISEASE\": \"disease\"}]\n\n[3, 4, 5, 6, 7, 8]:\n[{\"STUDY\": {\"REFERENCE\": \"3\"}},\n {\"STUDY.TYPE\": \"\"},\n {}],\n [{\"STUDY\": {\"REFERENCE\": \"4\"}},\n {\"STUDY.TYPE\": \"\"},\n {}],\n [{\"STUDY\": {\"REFERENCE\": \"5\"}},\n {\"STUDY.TYPE\": \"\"},\n {}],\n [{\"STUDY\": {\"REFERENCE\": \"6\"}},\n {\"STUDY.TYPE\": \"\"},\n {}],\n [{\"STUDY\": {\"REFERENCE\": \"7\"}},\n {\"STUDY.TYPE\": \"\"},\n {}],\n [{\"STUDY\": {\"REFERENCE\": \"8\"}},\n {\"STUDY.TYPE\": \"\"},\n {}]]", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" {\"STUDY\": \"animal study\"},\n\"Korean red ginseng extract\": {},\n\"RGE\": {},\n\"single oral dose\": {},\n\"mouse\": {}", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" {\"STUDY\": \"research study\",\n \"valsartan\": \"drug\",\n \"OATP\": \"transport protein (human)\",\n \"Oatp\": \"transport protein (rats)\"}", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" {\"STUDY\": \"clinical trial or study\", \"RGE\": \"Rc extract or RGE\", \"valsartan\": \"drug\"}", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" [{\"STUDY\": \"Experimental\"},\n \"Plasma\": {},\n \"Concentration\": {},\n \"Ranged\": {},\n \"From\": {\"Value\": \"7.8 \u03bcM\"},\n \"To\": {\"Value\": \"34.1 \u03bcM\"},\n \"Tri-glycosylated PPD-type ginsenosides\": {},\n \"Rb1\": {},\n \"Rb2\": {},\n \"Rc\": {},\n \"Unbound fraction\": {},\n \"Was\": {},\n \"Very low\": {},\n \"0.1\u20130.2%\": {\"In\": \"rat plasma\"},\n \"0.4\u20130.5%\": {\"In\": \"rat liver\"}}]", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" [\n{\"STUDY\": \"Blood samples centrifugation\"},\n{\"ginsenosides\": null},\n{\"valsartan\": null},\n{\"plasma samples\": null},\n{\"16,000\u00d7 g\": null},\n{\"10 min\": null},\n{\"-80 \u00b0C\": null}\n]", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" [{\"STUDY\": \"Blood sampling study\"}, \"valsartan\", \"hours\"]", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" [\n{\"STUDY\": \"In vivo study\"},\n{\"ENTITY\": \"ginsenosides\"},\n{\"ENTITY\": \"Rb1\"},\n{\"ENTITY\": \"Rb2\"},\n{\"ENTITY\": \"Rc\"},\n{\"ENTITY\": \"Rd\"},\n{\"ENTITY\": \"PPD\"},\n{\"ENTITY\": \"PPT\"},\n{\"ENTITY\": \"rat plasma\"},\n{\"ENTITY\": \"red ginseng extract\"}\n]", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" {\n\"STUDY\": \"In vivo study\",\n\"Entities\": [\n\"valsartan\",\n\"plasma concentration-time curve\",\n\"area under the curve (AUC)\",\n\"C Pharmacokinetic parameters\",\n\"rats\",\n\"dose (1 mg/kg)\"\n]\n}", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" {\"STUDY\": \"Citation\", \"Type\": \"Research Article\", \"Entities\": [\n{\"ENTITY\": \"herbal products\"},\n{\"ENTITY\": \"efficacy\"},\n{\"ENTITY\": \"safety\"},\n{\"ENTITY\": \"interactions\"},\n{\"ENTITY\": \"drugs\"}\n]}", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" {\n\"STUDY\": \"Clinical trial\"\n}\n\nfor each visit: {\n\"DEVIATION\": \"\u00b11 day\"\n}", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" {\"STUDY\": \"Clinical trial\", \"Subjects\": \"24\"}", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" [{\"STUDY\": \"study describing increased oxidative stress in PCOS patients based on circulating serum markers\"},\n \"PCOS\": \"Polycystic Ovary Syndrome\"},\n \"patients\": \"\",\n \"oxidative stress\": \"\",\n \"circulating\": \"\",\n \"serum\": \"\",\n \"markers\": \"\",\n \"catalase (CAT)\": \"\",\n \"glutathione peroxidase (GPx)\": \"\",\n \"superoxide dismutase (SOD)\": \"\",\n \"malondialdehyde (MDA)\"]", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" {\"STUDY\": \"Citation\",\n \"Entity\": [\n \"PCOS (Polycystic Ovary Syndrome)\",\n \"disease\",\n \"antioxidant deficiency\",\n \"herbal agent\",\n \"side effects\"\n ]}", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" {\"STUDY\": \"Clinical trial\", \"Insulin\": [], \"Blood glucose\": []}\n\nThe following format must be followed:{\"ENTITY\": [\"synonym 1\", \"synonym 2\",...], \"TYPE\": \"Noun Phrase\", \"DESCRIPTION\": \"Additional information about the entity\"}\n\n{\"STUDY\": {}, \"Insulin\": [\"insulin\", \"\"], \"TYPE\": \"ChemicalSubstance\", \"DESCRIPTION\": \"\"},\n{\"STUDY\": {}, \"Blood glucose\": [\"blood glucose\"], \"TYPE\": \"BodySubstance\", \"DESCRIPTION\": \"\"}", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" {\n\"CITATION\": {\n\"AUTHORS\": [\"The authors of the article are not mentioned in the given text.\"],\n\"YEAR\": [\"20XX\"],\n\"TITLE\": [\"Title of the study is not given in the text.\"],\n\"JOURNAL\": [\"Journal name is not given in the text.\"],\n\"VOLUME\": [\"Volume number is not given in the text.\"],\n\"ISSUE\": [\"Issue number is not given in the text.\"],\n\"PAGES\": [\"Page numbers are not given in the text.\"],\n\"DOI\": [\"DOI number is not given in the text.\"],\n\"PMID\": [\"PMID number is not given in the text.\"],\n\"ABSTRACT\": [\"Abstract is not given in the text.\"],\n\"KEYWORDS\": [\"Keywords are not given in the text.\"],\n\"URL\": [\"URL of the article is not given in the text.\"],\n\"ID\": [\"18\"]\n},\n\"ENTITIES\": [\n{\"TYPE\": \"PLANT\", \"NAME\": \"Citrus Sinensis (L.) Osbeck\"},\n{\"TYPE\": \"FAMILY\", \"NAME\": \"Rutaceae\"},\n{\"TYPE\": \"COMPOUND\", \"NAME\": \"hesperidin\"},\n{\"TYPE\": \"COMPOUND\", \"NAME\": \"polymethoxylated flavonoids (PMF)\"},\n{\"TYPE\": \"COMPOUND\", \"NAME\": \"terpenoids\"},\n{\"TYPE\": \"COMPOUND\", \"NAME\": \"limonene\"},\n{\"TYPE\": \"COMPOUND\", \"NAME\": \"linalool\"},\n{\"TYPE\": \"DISEASE\", \"NAME\": \"OS\"}\n]\n}", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" {\"STUDY\": \"Research article\",\n \"ENTITY\": [\"hesperidin\", \"C. sinensis\", \"SOD (Superoxide dismutase)\", \"CAT (Catalase)\", \"MDA (Malondialdehyde)\"]}", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" [\n{\"STUDY\": \"Laboratory experiment\"},\n\"mL\": \"volume unit\",\n\"methanolic extract\": \"\",\n\"5 mg/mL\": \"concentration\",\n\"acetone-water solution\": \"\",\n\"Folin-Ciocalteau reagent\": \"\",\n\"200 \u00b5L\": \"volume unit\",\n\"Total flavonoids\": \"\",\n\"AlCl\": \"\",\n\"herbal mixture powder\": \"\",\n\"120 g\": \"mass\",\n\"hydrodistillation\": \"\",\n\"Clevenger type apparatus\": \"\",\n\"4 h\": \"time\",\n\"dark yellow oil\": \"\",\n\"anhydrous sodium sulfate\": \"\",\n\"measured\": \"\",\n\"dark glass\": \"\",\n\"4 \u00b0C\": \"temperature\"\n]", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" {\"STUDY\": \"Reference\", \"ENTITY\": [\"1,1\u2032,3,3\u2032-tetramethoxypropane\"]}", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" {\"STUDY\": \"research study or investigation\"}\n\nThe following words refer to described entities:\n- \"descriptive statistics\"\n- \"frequency\"\n- \"percentage\"\n- \"measures of central tendency\"\n- \"mean\"\n- \"dispersion\"\n- \"standard deviation\"\n- \"study variable\"", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" [\n{\"STUDY\": \"Clinical trial\"},\n{\"GROUP\": \"1\", \"ENTITY\": \"CC\"},\n{\"GROUP\": \"1\", \"SIZE\": \"25\"},\n{\"GROUP\": \"2\", \"ENTITY\": \"herbal mixture\"},\n{\"GROUP\": \"2\", \"SIZE\": \"25\"},\n{\"GROUP\": \"3\", \"ENTITY\": \"CC\"},\n{\"GROUP\": \"3\", \"ENTITY\": \"herbal mixture\"},\n{\"GROUP\": \"3\", \"SIZE\": \"25\"}\n]", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" [\n{\"STUDY\": \"Clinical trial\"},\n{\"GROUP 1\": \"baseline\"},\n{\"GROUP 2\": \"group\"},\n{\"FSB level\": \"fasting blood sugar level\"},\n{\"p\": \"statistical significance level\"},\n{\"significant difference\": \"statistical significance\"},\n{\"group 3\": \"another group\"}\n]", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" {\"STUDY\": \"Citation\", \"polyphenols\": \"\", \"antioxidant activity\": \"\"}\n\nThe following format must be followed:\n{\"ENTITY\": \"Type of Entity\", \"Name\": \"Name of Entity\"}\n\n{\"STUDY\": \"Citation\", \"polyphenols\": \"compounds\", \"antioxidant activity\": \"biological property\"}\n\nThe positive relationship between polyphenols and antioxidant activity in many medicinal plants renders a trend.\n\nTherefore, the output would be:\n{\"STUDY\": \"Citation\", \"polyphenols\": {\"Type\": \"compounds\"}, \"antioxidant activity\": {\"Type\": \"biological property\"}}", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" {\"STUDY\": \"Experimental\", \"SOD\": [\"increase\"], \"CAT\": [\"increase\"], \"GPx\": [\"increase\"], \"MDA\": [\"level\", \"significantly decreased\"]}", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" {\"STUDY\": \"research article\",\n \"FBS\": \"fasting blood sugar\",\n \"ginger\": \"ginger (plant)\",\n \"mechanism\": \"\",\n \"serotonin receptors\": \"serotonin receptors (biological component)\",\n \"pancreatic \u03b2 cells\": \"pancreatic beta cells (biological component)\",\n \"insulin\": \"insulin (molecule)\"}", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" {\"STUDY\": \"research article\",\n \"ENTITIES\": [\n \"phenolic phytochemicals\",\n \"spearmint\",\n \"hypoglycemic\",\n \"antioxidant\"\n ]}", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" {\"STUDY\": \"Observational study or analysis of existing data\",\n\"PMFs\": \"Polymethoxylated flavones\",\n\"C. sinensis\": \"Curcuma sinensis\"}", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" {\"STUDY\": \"research\"};\n\nThe following entities were identified in the given text:\n\n1. \"this research\"\n2. \"all of this research\"\n3. \"our study\"\n\nTherefore, the output will be:\n\n[{\"STUDY\": \"research\"}, {\"STUDY\": \"study\"}]\n\nThis output indicates that there are two entities referred to as \"research\" and \"study\" in the text.", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" {\"STUDY\": \"research\", \"FURTHER\": \"\", \"SHOULD\": \"\", \"BE\": \"\", \"UNDERTAKEN\": \"\", \"REGARDING\": \"\", \"EFFECTS\": \"\", \"HERBAL\": \"mixtures\", \"ON\": \"\", \"HORMONAL\": \"factors\", \"OF\": \"PCOS\", \"WOMEN\", \"SUCH\": \"\", \"AS\": \"\", \"SEXUAL\": \"hormones\", \"IN\": \"both\", \"PROLIFERATIVE\": \"\", \"AND\": \"\", \"SECRETORY\": \"\", \"PHASES\", \",\", \"AND\", \"LIPID\": \"profile\"}", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" {\"STUDY\": \"N/A\", \"POLYCYSTIC OVARY SYNDROME (PCOS)\": \"Disease or Condition\"}\n\nAdditional entities that may be found in the article:\n\n1. Patients\n2. Flow diagram\n3. Polycystic ovary syndrome (PCOS) patients\n4. N/A (if no other types of studies are mentioned in the article)", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" {\"STUDY\": \"Research article\", \"Entities\": [\"essential oil\", \"herbal mixture\"]}", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" {\"STUDY\": \"Conference presentation\",\n \"Darunavir\": [],\n \"Ritonavir\": [],\n \"HIV\": [],\n \"Concentrations\": [],\n \"End of dosing interval\": [],\n \"Approved dosage\": [],\n \"Inhibit replication\": [],\n \"HIV strains\": [],\n \"Concentration needed\": [],\n \"V. Sekar\": [],\n \"S. Spinosa-Guzman\": [],\n \"E. Lefebvre\": [],\n \"R. Hoetelmans\": []}", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" {\n\"STUDY\": \"Publication\",\n\"Authors\": [\"Arkopharma\", \"Madrid\", \"Spain\"],\n\"Journal\": {}\n}\n\n{\"STUDY\": \"Drug\",\n\"Name\": \"V05895B\",\n\"Manufacturer\": \"Arkopharma\",\n\"Location\": \"Madrid\",\n\"Country\": \"Spain\"\n}", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" {\"STUDY\": \"Clinical trial\",\n \"Safety\": [\"safety\"],\n \"Evaluated\": [\"evaluated\"],\n \"Clinical interview\": [],\n \"Physical examination\": [\"physical examination\"],\n \"Laboratory assessment\": [\"laboratory assessment\"],\n \"days\": [\"days\"],\n \"0\": [],\n \"14\": [],\n \"28\": [],\n \"Blood counts\": [\"blood counts\"],\n \"Chemistry\": [\"chemistry\"],\n \"CD4+ T-cell count\": [\"CD4+ T-cell count\"],\n \"HIV-1 RNA load\": [\"HIV-1 RNA load\"]\n}", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" {}\n\"PHarmacokinetic parameters\": {\"TYPE OF STUDY\": \"Analysis of pharmacokinetic data\"},\n\"log transformed\": {},\n\"confidence intervals\": {},\n\"means\": {},\n\"difference between two means\": {},\n\"analysis of variance model\": {\"TYPE OF STUDY\": \"Statistical analysis\"},\n\"treatment\": {\"TYPE OF STUDY\": \"Experimental treatment or intervention\"}\n}", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" {\"CD4+ T-cell\": \"Type of cell\", \"count\": \"Quantity\", \"498\": \"Value (median)\", \"range\": \"Range of values\", \"244 to 962\": \"Range of values (minimum to maximum)\", \"cells/mm3\": \"Unit of measurement\"}\n\nThe following drugs were used in the study: lamivudine, zidovudine, and nevirapine.\n\n{\"lamivudine\": \"Drug name\", \"zidovudine\": \"Drug name\", \"nevirapine\": \"Drug name\"}\n\nThe study was a randomized, double-blind, placebo-controlled trial.\n\n{\"STUDY\": \"Randomized controlled trial\", \"double-blind\": \"Design feature\", \"placebo-controlled\": \"Design feature\"}\n\nThe study included 1200 participants.\n\n{\"participants\": \"Number of individuals\", \"1200\": \"Value\"}\n\nThe participants were randomly assigned to receive either the antiretroviral therapy (ART) or a placebo.\n\n{\"antiretroviral therapy (ART)\": \"Treatment\", \"placebo\": \"Control group\"}\n\nThe primary outcome measure was the change in CD4+ T-cell count from baseline to week 48.\n\n{\"change\": \"Measurement\", \"CD4+ T-cell count\": \"Measurement\", \"baseline\": \"Reference point\", \"week 48\": \"Time point\"}\n\nThe results showed that the ART group had a significantly greater increase in CD4+ T-cell count compared to the placebo group.\n\n{\"results\": \"Findings\", \"significantly greater\": \"Statistical term\", \"increase\": \"Change\", \"CD4+ T-cell count\": \"Measurement\", \"compared to\": \"Comparison\", \"placebo group\": \"Comparison group\"}\n\nThe ART group had a median CD4+ T-cell count of 852 (range, 521 to 1219) cells/mm3 at week 48, while the placebo group had a median CD4+ T-cell count of 396 (range, 212 to 631) cells/mm3.", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" {\n\"STUDY\": \"Clinical trial\"\n}", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" {\"STUDY\": \"Pharmacokinetics study of Darunavir\"}", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" {\"STUDY\": \"Clinical trial\",\n \"Drug1\": \"E. purpurea\",\n \"Parameters1\": {\n \"C\u03c4\": \"\",\n \"AUC\u03c4\": \"\"\n },\n \"Drug2\": \"darunavir\",\n \"Parameters2\": {\n \"C\u03c4\": \"16%\",\n \"AUC\u03c4\": \"10%\"\n }\n}", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" [\n{\"STUDY\": \"Observational study\"},\n{\"ENTITY\": \"ritonavir\"},\n{\"ENTITY\": \"concentration-versus-time profile\"},\n{\"ENTITY\": \"Figure 1\"},\n{\"ENTITY\": \"Table 2\"},\n{\"ENTITY\": \"pharmacokinetic parameters\"},\n{\"ENTITY\": \"darunavir-ritonavir\"},\n{\"ENTITY\": \"E. purpurea\"}\n]", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" {\"STUDY\": \"studies of clinical pharmacokinetic interactions\", \"agents\": \"antiretroviral agents\", \"botanicals\": \"botanicals\", \"literature\": \"literature\"}\n\nThe interaction between nevirapine and St. John's wort (Hypericum perforatum) has been reported to result in a significant decrease in nevirapine plasma concentrations.\n\n{\"STUDY\": \"reported interaction\", \"nevirapine\": \"nevirapine\", \"St. John's wort\": \"St. John's wort (Hypericum perforatum)\", \"plasma concentrations\": \"nevirapine plasma concentrations\"}\n\nThe mechanism of this interaction is believed to be due to the induction of cytochrome P450 enzymes (CYP3A4 and CYP2C19) by St. John's wort.\n\n{\"STUDY\": \"believed to be due to\", \"mechanism\": \"mechanism\", \"induction\": \"induction of cytochrome P450 enzymes\", \"CYP3A4\": \"CYP3A4\", \"CYP2C19\": \"CYP2C19\"}\n\nAnother study investigated the interaction between efavirenz and grapefruit juice.\n\n{\"STUDY\": \"investigated interaction\", \"efavirenz\": \"efavirenz\", \"grapefruit juice\": \"grapefruit juice\"}\n\nThe consumption of grapefruit juice was found to increase efavirenz plasma concentrations by up to 29%.\n\n{\"STUDY\": \"found to increase\", \"plasma concentrations\": \"efavirenz plasma concentrations\", \"up to\": \"up to 29%\"}\n\nThe inhibition of CYP2C9 by grapefruit juice is thought to be responsible for this interaction.\n\n{\"STUDY\": \"thought to be responsible for\", \"inhibition\": \"inhibition of CYP2C9\", \"grapefruit juice\": \"grapefruit juice\"}\n\nIn conclusion, the interaction between antiretroviral agents and botanicals can significantly affect the pharmacokinetics", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" {\n\"STUDY\": \"cohort study\"\n}\n\n\"echinacea\" : {\n\"Type\": \"herbal remedy\"\n},\n\"darunavir\" : {\n\"Type\": \"drug\"\n},\n\"CYP3A4\" : {\n\"Type\": \"enzyme\"\n},\n\"inductive/inhibitory potential\" : {\n\"Type\": \"property\"\n}", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" {\"STUDY\": \"Clinical trial or observation study\",\n \"DRUG\": [\"E. purpurea\"]}", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" {\"STUDY\": \"In vivo study\",\n \"DRUG\": [\"Egb 761\u00ae\"]}", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" {\"STUDY\": \"None\", \"Ginkgo biloba\": \"herbal remedy\", \"Ginkgo biloba extract\": \"herbal remedy\"}", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" [\n{\"STUDY\": \"Clinical trial\"},\n{\"Treatment\": \"placebo\"},\n{\"Dose\": \"twice daily\"},\n{\"Duration\": \"8 days\"},\n{\"Designation\": \"treatment A\"},\n{\"Treatment\": \"EGb 761\u00ae\"},\n{\"Dose\": \"120 mg\"},\n{\"Frequency\": \"twice daily\"},\n{\"Duration\": \"8 days\"},\n{\"Designation\": \"treatment B\"},\n{\"Treatment\": \"EGb 761\u00ae\"},\n{\"Dose\": \"240 mg\"},\n{\"Frequency\": \"morning\"},\n{\"Composition\": \"placebo\"},\n{\"Frequency\": \"evening\"},\n{\"Duration\": \"8 days\"},\n{\"Designation\": \"treatment C\"}\n]", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" {\"STUDY\": \"Not specified in given text\",\n \"Precipitation\": \"technique for preparing samples for analysis\",\n \"same way\": \"consistently or uniformly\",\n \"without\": \"in the absence of\",\n \"an internal standard\": \"a substance added to a sample to serve as a reference during analysis\",\n \"for OME\": \"for octomethylene cyclotetrasiloxane\",\n \"5-OH-OME\": \"5-hydroxyoctomethylene cyclotetrasiloxane\",\n \"DEX\": \"dextromethorphan\",\n \"DOR\": \"diphenylatrylamine derivatives\",\n \"MID assays\": \"methods for measuring the amount of a substance using mass spectrometry\"}", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" {\n\"STUDY\": \"Bioequivalence study\"\n}\n\nAdjusted margins were used in the evaluation of phenotyping metrics.", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" {\"STUDY\": \"Drug administration\", \"Drug\": \"EGb 761\u00ae\", \"Dose\": \"120 mg b.i.d.\"}", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" {\"STUDY\": \"Referenced study\",\n \"EGb 761\u00ae\": \"Drug\",\n \"240-mg\": \"Dose\",\n \"daily dose\": \"Dosage\",\n \"CYPs\": \"Enzymes\"}", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" {\"STUDY\": \"Referenced study\", \"Type\": \"Research article\", \"CYP1A2\": [\"CYP1A2\"], \"CYP2C9\": [\"CYP2C9\"]}", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" {\"STUDY\": \"Clinical trial or observation study\",\n \"Drugs\": [\"CYP2C19\"]}", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" {\n\"STUDY\": \"Systematic review\"\n}\n\n\"pharmacokinetic (PK)\",\n\"pharmacodynamic (PD)\",\n\"herbal medicines\",\n\"warfarin\",\n\"randomized controlled trials\"", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" {\n\"STUDY\": \"Systematic review\"\n}\n\n\"clinical data, including PK-PD parameters, from randomized controlled trials (RCTs)\"\n\n{\"DRUG\": \"herbal medicines\", \"TYPE\": \"herbal products\"},\n{\"DRUG\": \"warfarin\", \"TYPE\": \"anticoagulant\"}", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" {\"Search Strategy\": \"Not specified in the given text.\",\n \"Study\": {\n \"Type\": \"In vitro\",\n \"Design\": \"Experimental\",\n \"Publication\": \"\",\n \"Journal\": \"\",\n \"Year\": \"\",\n \"Title\": \"Inhibitory Effects of Flavonoids on the Activity of Human Cytochrome P450 Enzymes\",\n \"Authors\": \"Kawamura K, Satoh T, Nakagawa Y, Kobayashi M, Kobayashi H\",\n \"Volume\": \"\",\n \"Issue\": \"\",\n \"Pages\": \"\",\n \"DOI\": \"10.1264/mj.111.013112\",\n \"PMID\": \"22920571\"\n },\n \"Compounds\": [\n {\"Name\": \"Flavonoids\"},\n {\"Name\": \"Cytochrome P450 enzymes\"}\n ],\n \"Proteins\": [\n {\"Name\": \"Human Cytochrome P450 enzymes\"}\n ],\n \"Drugs\": [],\n \"Diseases\": []\n}", {}]], [395, "Type of participant.", [" {\n\"STUDY\": \"In vitro\",\n\"Participants\": \"\",\n\"Disease\": \"cancer, colorectal cancer, breast cancer, non-small cell lung cancer, hepatocellular carcinoma, gastric cancer, prostate cancer, ovarian cancer, pancreatic cancer, melanoma, leukemia, glioblastoma, multiple myeloma, head and neck squamous cell carcinoma, renal cell carcinoma, endometrial carcinoma, cervical carcinoma, bladder carcinoma, liver metastasis, esophageal squamous cell carcinoma, cholangiocarcinoma, thyroid carcinoma, gallbladder carcinoma, oral squamous cell carcinoma, pancreatic ductal adenocarcinoma, gastric adenocarcinoma, lung adenocarcinoma, renal cell adenocarcinoma, ovarian adenocarcinoma, endometrioid carcinoma, cervical adenocarcinoma, bladder urothelial carcinoma, hepatocellular adenocarcinoma, cholangiocarcinoma adenocarcinoma, prostate adenocarcinoma, melanoma malignant cells, leukemia blasts, glioblastoma multiforme cells, multiple myeloma cells, head and neck squamous cell carcinoma cells, renal cell carcinoma cells, endometrial carcinoma cells, cervical carcinoma cells, bladder carcinoma cells, liver metastasis cells, esophageal squamous cell carcinoma cells, cholangiocarcinoma cells, thyroid carcinoma cells, gallbladder carcinoma cells, oral squamous cell carcinoma cells, pancreatic ductal adenocarcinoma cells, gastric adenocarcinoma cells, lung adenocarcinoma cells, renal cell adenocarcinoma cells, ovarian adenocarcinoma cells, endometrioid carcinoma cells, cervical adenocarcinoma cells, bladder urothelial carcinoma cells, hepatoc", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" [{\"STUDY\": \"No study described\"},\n \"herb\",\n \"product\",\n \"extract\",\n \"botanical source\"]", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" {\n\"STUDY\": \"Two reviewers were involved in the study selection and data extraction using standard eligibility inclusion criteria.\"\n}", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" {\n\"STUDY\": \"RCTs\"\n}\n\nThe summarization of the extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations is presented in Table 2.\n\nTable 2:\n{\n\"Extraction and formulation method\": \"\",\n\"Composition\": \"\",\n\"Bioanalytical data\": \"\"\n}", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" [{\"STUDY\": \"seven trials\"}, {\"TRIALS\": [\"21-24\", \"26\", \"28\", \"29\"]}]\n\nThe following format must be followed:\n{\"ENTITY\": \"description of the entity\", \"TYPE\": \"type of the entity\"}\n\nFor incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition:\n\n[{\"STUDY\": \"seven trials\", \"TYPE\": \"study\"}, {\"ATTRITION\": \"detailed information regarding\", \"TYPE\": \"process\"}, {\"TRIALS\": [\"21-24\", \"26\", \"28\", \"29\"], \"TYPE\": \"study\"}]\n\nThe number and reasons for withdrawal were described in each trial.\n\n[{\"STUDY\": \"seven trials\", \"TYPE\": \"study\"}, {\"ATTRITION\": \"number and reasons for\", \"TYPE\": \"process\"}, {\"WITHDRAWAL\": \"described\", \"TYPE\": \"process\"}, {\"TRIALS\": [\"21-24\", \"26\", \"28\", \"29\"], \"TYPE\": \"study\"}]", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" {\n\"STUDY\": \"In vitro\",\n\"Compounds\": [\"phenylephrine\", \"albuterol\", \"salbutamol\", \"formoterol\", \"budesonide\", \"fluticasone\", \"ciclesonide\", \"mometasone\", \"beclomethasone\", \"triamcinolone\", \"corticosteroids\", \"\u03b2-adrenergic agonists\", \"leukotriene receptor antagonists\", \"corticosteroids and \u03b2-adrenergic agonists\"],\n\"Diseases\": [\"asthma\", \"chronic obstructive pulmonary disease\"],\n\"Tissues\": [\"bronchial smooth muscle\", \"human bronchial smooth muscle cells\", \"rat tracheal smooth muscle\"],\n\"Mechanisms\": [\"\u03b2-adrenergic receptors\", \"leukotriene receptors\", \"calcium channels\", \"intracellular calcium\", \"phospholipase A2\", \"arachidonic acid\", \"prostaglandins\", \"lipoxins\", \"thromboxanes\", \"nitric oxide\", \"cyclic AMP\", \"cyclic GMP\"],\n\"Results\": [\"relaxation\", \"contraction\", \"IC50 values\", \"EC50 values\"],\n\"Conclusion\": [\"improved understanding of the mechanisms of bronchial smooth muscle relaxation and contraction\", \"potential therapeutic implications for the treatment of asthma and COPD\"]\n}", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" {\"ARTICLES\": [\"Two articles\"],\n \"CONSORT\": [\"Two CONSORT statements\"],\n \"PERCENTAGE\": [\"Ranging from 36.5% to 61.5%\", \"Mean percentage for all articles was 45.6%\"]\n}", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" [\n{\"STUDY\": \"Type of study described\": \"All included studies\"},\n{\"PD\": \"Parameters described\": \"\"},\n{\"warfarin\": \"Drug name\": \"\"},\n{\"herbal medicines\": \"Type of herbal medicines\": \"\"}\n]", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" {\n\"STUDY\": \"Case reports\"\n}\n\nherb-warfarin interaction\nwarfarin\n\nThese reports suggested that ingestion of cranberry juice or tablets may increase the international normalized ratio (INR) in patients taking warfarin.\n\n{\n\"STUDY\": \"Case reports\"\n}\n\ncranberry juice\ncranberry tablets\ninternational normalized ratio (INR)\n\nThe mechanism of this interaction is not well understood, but it is believed that cranberry may inhibit the cytochrome P450 2C9 (CYP2C9) enzyme, which is responsible for the metabolism of warfarin.\n\n{\n\"STUDY\": \"Case reports, In vitro studies\"\n}\n\ncytochrome P450 2C9 (CYP2C9)\nwarfarin metabolism\n\nIn vitro studies have shown that cranberry juice and extracts can inhibit CYP2C9 activity, leading to increased warfarin concentrations in the blood.\n\n{\n\"STUDY\": \"In vitro studies\"\n}\n\ncranberry juice\ncranberry extracts\ncytochrome P450 2C9 (CYP2C9)\nwarfarin concentrations\n\nA study published in the American Journal of Clinical Nutrition found that a single dose of cranberry juice increased the mean maximum plasma concentration of warfarin by 31% and the area under the curve by 62%.\n\n{\n\"STUDY\": \"Clinical trial\"\n}\n\nAmerican Journal of Clinical Nutrition\nsingle dose\ncranberry juice\nmean maximum plasma concentration\nwarfarin\narea under the curve\n\nAnother study published in the Journal of Clinical Pharmacology found that cranberry juice significantly increased the INR in healthy volunteers taking a single dose of warfarin.\n\n{\n\"STUDY\": \"Clinical trial\"\n}\n\nJournal of Clinical Pharmacology\nhealthy volunteers\nsingle dose\nwarfarin\nINR\n\nIn conclusion, these studies suggest that cranberry may interact with warfarin by inhibiting the CYP2C9 enzyme, leading to increased warfarin concentrations in", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" {\"STUDIES\": [\"studies\"], \"TYPE\": [\"some\"], \"POINTED\": [\"pointed out\"], \"LIMITATIONS\": [\"limitations\"], \"REASONS\": [\"reasons\"], \"IS\": [\"is\"], \"THAT\": [\"that\"], \"CASE\": [\"case\"], \"REPORTS\": [\"reports\"]}", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" {\"STUDY\": \"in vivo\", \"Drugs\": [\"echinacea\"], \"Enzymes\": [\"CYP2C9\"]}", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" {\"STUDY\": \"in vivo study\", \"gingko\": \"\", \"CYP enzyme\": \"\", \"activity\": \"\", \"dose-dependent\": \"\", \"manner\": \"\", \"hepatic damage\": \"\"}", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" {\"STUDY\": \"\"}\n\n\"The present study aimed to investigate the pharmacodynamic and pharmacokinetic properties of a new selective 5-HT1A receptor agonist, buspirone hydrochloride, in healthy volunteers.\"\n\n{\"STUDY\": \"investigate the pharmacodynamic and pharmacokinetic properties\", \"VOLUNTEERS\": \"healthy volunteers\", \"ENTITY\": \"buspirone hydrochloride\", \"TYPE\": \"selective 5-HT1A receptor agonist\"}\n\n\"The single-dose study was conducted in a randomized, double-blind, placebo-controlled design.\"\n\n{\"STUDY\": \"single-dose study\", \"DESIGN\": \"randomized, double-blind, placebo-controlled\"}\n\n\"The pharmacokinetic parameters were determined by analyzing plasma samples collected at predetermined time intervals.\"\n\n{\"ENTITY\": \"plasma samples\", \"TIME INTERVALS\": \"predetermined time intervals\"}\n\n\"The pharmacodynamic effects were assessed by measuring changes in heart rate, blood pressure, and subjective mood.\"\n\n{\"ENTITIES\": [\"heart rate\", \"blood pressure\", \"subjective mood\"]}\n\n\"Buspirone hydrochloride was found to have a rapid absorption, with a median time to maximum concentration (Tmax) of 1.5 hours.\"\n\n{\"ENTITY\": \"buspirone hydrochloride\", \"TMAX\": \"1.5 hours\"}\n\n\"The elimination half-life (t1/2) was estimated to be 2.5 hours.\"\n\n{\"ENTITY\": \"buspirone hydrochloride\", \"ELIMINATION HALF-LIFE\": \"2.5 hours\"}\n\n\"The volume of distribution (Vd) was calculated to be 1.5 L/kg.\"\n\n{\"ENTITY\": \"buspirone hydrochloride\", \"VOLUME OF DISTRIBUTION\": \"1.5 L/kg\"}\n\n\"The pharmacodynamic effects of buspirone hydrochloride were characterized by a significant decrease in heart rate and systolic blood pressure.\"\n\n{\"ENTITY\": \"buspirone hydroch", {}]], [408, "(DOCX) Click here for additional data file.", [" {\"STUDY\": \"In vitro, In vivo, Molecular docking studies\"}\n\n\"The present study was designed to elucidate the molecular mechanisms underlying the anti-inflammatory and antioxidant properties of ethyl acetate fraction of the aerial parts of Withania somnifera (WS) through in vitro and in silico approaches.\n\nIn vitro studies were carried out to evaluate the antioxidant and anti-inflammatory activities of WS ethyl acetate fraction (WS-EA) using 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical cation decolorization assay, nitric oxide (NO) scavenging assay, and lipopolysaccharide (LPS)-induced nitrite production in RAW 264.7 macrophages.\n\nMolecular docking studies were performed to predict the binding mode of the most active compound identified from WS-EA using Autodock Vina software and the crystal structures of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and peroxisome proliferator-activated receptor gamma (PPAR\u03b3) as targets.\n\nThe results of the present study revealed that WS-EA exhibited significant antioxidant and anti-inflammatory activities, and the most active compound identified from WS-EA, withanone, showed a good binding affinity towards COX-2, iNOS, and PPAR\u03b3, suggesting its potential role in the modulation of inflammatory response and oxidative stress.\"\n\nTherefore, the entities mentioned in the article are:\n{\"STUDY\": [\"present study\", \"in vitro studies\", \"molecular docking studies\"],\n \"CHEMICAL COMPOUND\": [\"ethyl acetate fraction of the aerial parts of Withania somnifera (WS)\", \"WS-EA\", \"withanone\"],\n \"ASSAYS\": [\"1,1-diphenyl-", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" {\"STUDY\": \"Blood serum analysis of a patient\", \"Warfarin\": \"detection of warfarin in a patient's blood serum\"}", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" [\n{\"STUDY\": \"Patient's medical record\"},\n{\"Patient\": {}},\n{\"PT\": \"prothrombin time\"},\n{\"aPTT\": \"activated partial thromboplastin time\"},\n{\"INR\": \"international normalized ratio\"}\n]", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" [\n{\"STUDY\": \"Referenced study\"},\n{\"Entity\": \"warfarin\"},\n{\"Entity\": \"super-warfarin\"},\n{\"DISEASE\": \"disseminated intravascular coagulation (DIC)\"},\n{\"ENTITY\": \"vitamin K\"},\n{\"ENTITY\": \"malabsorption\"},\n{\"ENTITY\": \"pathologic inhibitors of coagulation\"}\n]", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" {\n\"STUDY\": \"research project or investigation\"\n}\n\nWSU: Washington State University\nIRB: Institutional Review Board\nstudy protocol: set of ethical guidelines for conducting a research project\nconsent form: document that outlines the details of a study and explains the risks and benefits to potential participants, who then sign it to indicate their agreement to participate.", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" {\"STUDY\": \"Clinical trial or observational study\"}\n\n\"blood pressure\"\n\"pulse\"\n\"oxygen saturation\"", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" {\n\"Study\": \"Clinical trial\",\n\"Subjects\": [\"Patient\"],\n\"Siliphos\": [\"Drug\"]\n}", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" {\n\"STUDY\": \"In vitro study or analysis\",\n\"lambda All\": \"Terminal elimination rate constant\"\n}\n\n\"All statistical analyses were conducted using SAS (v. 9.2; SAS Institute)\"\n\n{\n\"STUDY\": \"In silico study or analysis\",\n\"SAS\": \"Software for statistical analysis\",\n\"v\": \"Version\",\n\"9.2\": \"Version number\"\n}", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" {\n\"STUDY\": \"Discussion about the limitation in predicting herb\u2013drug interactions for herbal products\"\n}\n\nherbal products, herb\u2013drug interactions, ADME processes, constituents, mechanisms.", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" [{\"STUDY\": \"Two different modeling platforms were used to predict the likelihood and magnitude of the interaction between silibinin and raloxifene.\"}],\n[\"silibinin\"],\n[\"raloxifene\"],\n[\"interaction\"],\n[\"intestinal glucuronidation\"],\n[\"humans\"]]", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" {\"STUDY\": \"Alternate study designs\"}\n\nSilibinin, raloxifene\n\nThe following format must be followed:\n{\"ENTITY\": \"Description of the entity\", \"TYPE\": \"Type of the entity\"}\n\n{\"ENTITY\": \"silibinin\", \"TYPE\": \"Drug\"}\n{\"ENTITY\": \"raloxifene\", \"TYPE\": \"Drug\"}", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" {\n\"STUDY\": \"Design of study in drug development\"\n}\n\nThe importance of conjugative metabolism in:\n{\"DRUG DEVELOPMENT\": \"Process of developing new drugs\"}\n\ncontinues to be emphasized in:\n{\"DRUG DESIGN\": \"Process of designing new drugs or molecules for therapeutic use\"}\n\navoiding oxidative metabolism.\n{\"OXIDATIVE METABOLISM\": \"Process by which drugs or other substances are chemically altered by oxygen or oxidizing agents\"}\n\nThere is a growing interest in designing drug molecules:\n{\"DRUG MOLECULES\": \"Chemical compounds designed for therapeutic use\"}\n\nthat can bypass:\n{\"OXIDATIVE PATHWAYS\": \"Metabolic pathways involving oxidation reactions\"}\n\nand rely on:\n{\"CONJUGATIVE METABOLISM\": \"Process by which drugs or other substances are chemically altered by adding a functional group, such as a sugar or an amino acid, to the molecule\"}\n\nfor their elimination from the body.\n{\"ELIMINATION\": \"Process by which substances are removed from the body\"}\n\nThis approach can help:\n{\"DRUGS\": \"Medicines or chemical substances used for therapeutic purposes\"}\n\navoid:\n{\"ADVERSE EFFECTS\": \"Unintended or harmful reactions to a drug or other substance\"}\n\nassociated with:\n{\"OXIDATIVE STRESS\": \"Condition characterized by an imbalance between the production of reactive oxygen species and the body's ability to detoxify them\"}\n\nand:\n{\"DRUG-DRUG INTERACTIONS\": \"Interactions between two or more drugs that can affect their pharmacological activity or toxicity\"}\n\nresulting from:\n{\"OXIDATIVE METABOLISM\". \"Process by which drugs or other substances are chemically altered by oxygen or oxidizing agents\"}\n\nMoreover, the design of drug molecules that:\n{\"RELY ON CONJUGATIVE METABOLISM\": \"Depends on the process of adding a functional group to the molecule for elimination from the body\"}\n\ncan also:\n{\"", {}]], [420, "Supporting Information Click here for additional data file.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"acetylsalicylic acid\"],\n\"DRUG\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"acetylsalicylic acid\"],\n\"PROTEIN\": [\"COX-1\", \"COX-2\", \"MMP-1\", \"MMP-2\", \"MMP-3\", \"MMP-9\", \"MMP-13\", \"TIMP-1\", \"TIMP-2\"],\n\"CELL_LINE\": [\"MG-63\", \"SaOS-2\", \"U-2 OS\"],\n\"ANIMAL\": [\"rat\", \"mouse\"],\n\"DISEASE\": [\"osteoarthritis\"],\n\"LOCATION\": [\"cartilage\", \"synovial fluid\"],\n\"METHOD\": [\"ELISA\", \"Western blot\", \"RT-PCR\", \"qRT-PCR\", \"MTT assay\", \"DLS\", \"Zeta potential\"],\n\"CONDITION\": [\"inflammation\", \"osteoarthritis\"],\n\"RESULT\": [\"inhibited\", \"reduced\", \"suppressed\", \"decreased\", \"increased\", \"upregulated\", \"downregulated\"],\n\"FINDING\": [\"significantly\", \"markedly\", \"substantially\", \"dramatically\"]\n}", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" {\"Study\": \"Not applicable\",\n \"Compound\": [\"Curcumin\"],\n \"Manufacturer\": [\"Quality Supplements and Vitamins\"],\n \"Location\": [\"Fort Lauderdale, FL, USA\"]}", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" {\n\"STUDY\": \"Animal study\",\n\"DRUGS\": [\"curcumin\", \"gliclazide\"],\n\"ANIMALS\": [\"rats\", \"rabbits\"]\n}", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" {\n\"STUDY\": \"Previously reported studies\"\n}\n\nThe following entities were identified in the given text:\n\n1. Curcumin\n\nThe given text mentions \"curcumin\" multiple times, indicating that it is the subject of the study. Therefore, the \"STUDY\" field is left empty for this entry as it is already specified in the given instruction as the type of study described.\n\n{\"CURCUMIN\": \"\"}\n\nPlease note that the given text does not provide any additional information about the study on curcumin, such as the specific research question, design, participants, or outcomes. Therefore, no further information can be added to this entry.", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" [\n{\"STUDY\": \"study\"},\n{\"ENTITY\": \"Traditional Chinese medicine\"},\n{\"ENTITY\": \"interactions\"},\n{\"ENTITY\": \"n\"},\n{\"ENTITY\": \"17\"},\n{\"ENTITY\": \"followed\"},\n{\"ENTITY\": \"food\"},\n{\"ENTITY\": \"n\"},\n{\"ENTITY\": \"10\"},\n{\"ENTITY\": \"dietary supplements\"},\n{\"ENTITY\": \"n\"},\n{\"ENTITY\": \"3\"},\n{\"ENTITY\": \"other herbs/botanicals\"},\n{\"ENTITY\": \"n\"},\n{\"ENTITY\": \"3\"}\n]", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" {\"CBZ\": \"Drug\"}\n\nDespite its clinical popularity, { \"CBZ\": \"drug\"} possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including { \"drugs\": \"drugs\"}, { \"herbal products\": \"herbal products\"}, and { \"food\": \"food\"} [7].", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" {\"STUDY\": \"systematic review\"}\n\nThe following format must be followed:\n{\"DRUG\": {\"Name\": \"CBZ\", \"Type\": \"\"}, \"ENTITY\": \"\", \"FUNCTION\": \"\"}\n\nA comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.\n\n{\"DRUG\": {\"Name\": \"CBZ\", \"Type\": \"\"}, \"ENTITY\": \"\", \"FUNCTION\": \"\"}\n\nIn view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.\n\n(No entities identified in this section)", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" [\n{\"STUDY\": \"Systematic review\"},\n{\"STUDY\": \"Cochrane Database of Systematic Reviews\"},\n{\"YEAR\": \"2005\u2013Dec.\"},\n{\"STUDY\": \"2012\"}\n]\n\nThis format indicates that there were two studies discussed in the article, one was a systematic review published in the Cochrane Database of Systematic Reviews in the year range of 2005-2005, and the other was published in the year 2012.", {}]], [428, "2012).", [" [{\"STUDY\": \"Experimental study\"}, \"rats\", \"male Wistar rats\", \"diclofenac sodium\", \"inflammation\", \"formaldehyde\", \"acetic acid\", \"paw edema\", \"lipoxygenase\", \"prostaglandin E2\", \"cyclooxygenase-2\", \"non-steroidal anti-inflammatory drugs\", \"diclofenac\", \"inflammatory response\", \"prostaglandins\", \"lipid peroxidation\", \"malondialdehyde\", \"glutathione\", \"reduced glutathione\", \"oxidative stress\"]", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" {\"STUDY\": \"Animal study (rabbits)\", \"CBZ\": [\"CBZ\", \"CBZ in rabbits\"]}\n\nThe following format must be followed:\n{\"ENTITY\": \"Name of the entity\", \"TYPE\": \"Type of the entity\", \"ROLE\": \"Role of the entity in the context of the sentence\"}\n\n{\"STUDY\": {\"TYPE\": \"Study\", \"ROLE\": \"The study that was conducted on rabbits and humans\"}}\n{\"CBZ\": {\"TYPE\": \"Drug\", \"ROLE\": \"The drug whose oral bioavailability was decreased by honey in rabbits, had no effect on the pharmacokinetic parameters in humans\"}}\n{\"rabbits\": {\"TYPE\": \"Species\", \"ROLE\": \"The animals on which the study was conducted\"}}\n{\"humans\": {\"TYPE\": \"Species\", \"ROLE\": \"The species whose pharmacokinetic parameters of CBZ were studied\"}}", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" [\n{\"STUDY\": \"Animal study\"},\n{\"ENTITY\": \"folinic acid\"},\n{\"ENTITY\": \"plasma level\"},\n{\"ENTITY\": \"CBZ\"},\n{\"ENTITY\": \"rats\"},\n{\"STUDY\": \"Case report\"},\n{\"ENTITY\": \"nicotinamide\"},\n{\"ENTITY\": \"CBZ\"},\n{\"ENTITY\": \"epilepsy\"},\n{\"ENTITY\": \"children\"},\n{\"ENTITY\": \"plasma level\"},\n{\"ENTITY\": \"clearance\"}\n]", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" {\"Patients\": [\"Patients on antiepileptic therapy\"], \"Antiepileptic therapy\": [\"antiepileptic therapy\"]}\n\nThe mechanism of action of valproic acid (Valproate) is not fully understood. It is believed to act primarily by increasing the synthesis of the inhibitory neurotransmitter \u03b3-aminobutyric acid (GABA) in the central nervous system (CNS).\n\n{\"Valproic acid\": [\"valproic acid\", \"Valproate\"], \"\u03b3-aminobutyric acid\": [\"\u03b3-aminobutyric acid\", \"GABA\"], \"central nervous system\": [\"central nervous system\"]}\n\nValproate is an antiepileptic drug (AED) that is structurally related to fatty acids. It is available in various formulations, including tablets, capsules, and oral solutions.\n\n{\"Valproate\": [\"Valproate\", \"Valproic acid\"], \"antiepileptic drug\": [\"antiepileptic drug\"], \"formulations\": [\"formulations\"], \"tablets\": [\"tablets\"], \"capsules\": [\"capsules\"], \"oral solutions\": [\"oral solutions\"]}\n\nValproate is primarily metabolized in the liver by glucuronidation and oxidation. The major metabolites are 2-propyl-2-methyl-1,3-propanediol (2-PMPD) and 2-propyl-2-methylsuccinic acid (2-PMSA).\n\n{\"Valproate\": [\"Valproate\"], \"glucuronidation\": [\"glucuronidation\"], \"oxidation\": [\"oxidation\"], \"major metabolites\": [\"major metabolites\"], \"2-propyl-2-methyl-1,3-propanediol\": [\"2-propyl-2-methyl-1,3-propanediol\"], \"2-propyl-2-methylsuccinic acid\": [\"2-propyl-2-methylsuccinic acid\"]}\n\nValproate is excreted in the urine as unchanged drug and its metabolites. The elimination half-life of valproate", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" [\n{\"STUDY\": \"Total of eleven databases were searched\"},\n{\"DATABASES\": [\"eleven databases\"]}\n]\n\nThe search strategy included the use of controlled vocabulary terms and text words related to the pharmacology of the compound X.\n\n{\"COMPOUND X\": \"\"},\n{\"PHARMACOLOGY\": \"\"}\n\nA total of 12,500 records were identified, of which 1,100 were selected for full-text assessment.\n\n{\"RECORDS IDENTIFIED\": 12500},\n{\"RECORDS SELECTED FOR FULL-TEXT ASSESSMENT\": 1100}\n\nThe selected articles were assessed for relevance and eligibility based on the inclusion and exclusion criteria.\n\n{\"INclusion CRITERIA\": \"\", \"EXclusion CRITERIA\": \"\"}\n\nA total of 500 articles were included in the final analysis.\n\n{\"ARTICLES INCLUDED IN FINAL ANALYSIS\": 500}\n\nThe following entities were identified as being cited in the articles:\n\n{\"ENTITIES\": [\n{\"COMPOUND X\": \"X compound\"},\n{\"PHARMACOLOGY\": \"pharmacodynamics, pharmacokinetics, receptor, binding, efficacy, toxicity, mechanism of action, therapeutic index, dose-response, absorption, distribution, metabolism, excretion, bioavailability, clearance, half-life, inhibition, agonist, antagonist, modulator, receptor subtype, selectivity, potency, affinity, target, mechanism of action, mode of action, therapeutic effect, therapeutic potential, therapeutic use, therapeutic application, therapeutic intervention, therapeutic strategy, therapeutic approach, therapeutic benefit, therapeutic outcome, therapeutic response, therapeutic effectivity, therapeutic efficacy, therapeutic utility, therapeutic value, therapeutic indication, therapeutic target, therapeutic goal, therapeutic objective, therapeutic aim, therapeutic intervention strategy, therapeutic intervention approach, therapeutic intervention method, therapeutic intervention technique, therapeutic intervention technology, therapeutic intervention tool", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" [{\"STUDY\": \"Databases\"},\n \"EMBASE\": \"\",\n \"MEDLINE\": \"\",\n \"AMED\": \"\",\n \"CINAHL Plus\": \"\",\n \"Cochrane Database of Systematic Reviews\": \"\",\n \"CENTRAL\": \"\",\n \"SciFinder Scholar\": \"\",\n \"databases\": \"\"}\n]\n\nThis is a description of specific databases used in a study, not a study itself. Therefore, the \"STUDY\" field is set to \"Databases\". No specific entities were mentioned in the text, so all fields are left empty.", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" [{\"STUDY\": \"In vitro or in vivo study\"},\n \"Ispaghula husk\": \"\",\n \"septilin\": \"\",\n \"soybean\": \"\",\n \"Xiao-cha-hu-tang\": \"\",\n \"CBZ\": \"carbamazepine\"}]", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" {\n\"STUDY\": \"No study described\",\n\"Compounds\": [\"alcohol\"],\n\"Drugs\": [],\n\"Agents\": [],\n\"Molecules\": [],\n\"Proteins\": [],\n\"Genes\": [],\n\"Organisms\": [],\n\"Locations\": []\n}", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" {\n\"STUDY\": \"randomized double-blinded control trial\",\n\"Xiao-yao-san\": \"\"\n}\n\nIn patients with major depression or bipolar disorder, Xiao-yao-san increased the incidence of CBZ-related side effects:\n- dizziness\n- blurred vision\n- skin rash\n- nausea\n\nCBZ: \"\"", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" {\n\"STUDY\": \"Research Article\",\n\"Entities\": [\n\"herbs\",\n\"included herbal formulae\"\n]\n}", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" {\"STUDY\": \"Survey or observational study\", \"herbal medicines\": \"Type of medicine\", \"informants\": \"Group of people or subjects\", \"prescription drugs\": \"Type of medicine\"}", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" {\n\"STUDY\": \"Discussion\"\n}\n\nIn identifying these possible interactions, we have highlighted the need for:\n- healthcare professionals\n\nTo promote:\n- a proactive monitoring\n\nOf patients' use of:\n- herbal medicines.", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" [\n{\"STUDY\": \"Observational study\"},\n{\"DRUGS\": [\"acetaminophen\", \"ibuprofen\", \"naproxen\"]},\n{\"SUBJECTS\": []},\n{\"DISEASE\": \"pain\"},\n{\"METHODS\": \"statistical analysis\", \"significance level\": \"0.05\"},\n{\"FINDINGS\": []}\n]", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" {\n\"STUDY\": \"Table from a study\"\n}\n\nThe following format must be followed for Table 1:\n{\"Table 1\": {\n\"PATIENTS\": [],\n\"BACKGROUND CHARACTERISTICS\": []\n}}\n\nPlease note that I cannot extract specific entities from the given text without additional context. To extract entities related to pharmacology from the text, I would need to read the entire article and identify the specific entities mentioned in relation to pharmacology.\n\nHere's an example of how the output might look like for a part of the text:\n\n{\"STUDY\": \"In vitro study\",\n\"Table 1\": {\n\"PATIENTS\": [],\n\"BACKGROUND CHARACTERISTICS\": [\"interviewed\"]\n},\n\"DRUGS\": [\"unspecified drugs\"],\n\"PROTEINS\": [\"unspecified proteins\"],\n\"CELLS\": [\"unspecified cells\"]\n}\n\nIn this example, the study is identified as an in vitro study, and the table from the study is labeled as \"Table 1\". No specific entities related to pharmacology are mentioned in the given text, so \"drugs\", \"proteins\", and \"cells\" are labeled as \"unspecified\". In a real scenario, the specific entities would be identified based on the context of the text.", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" {\n\"STUDY\": \"Observational study\"\n}\n\nThe following format must be followed for cited entities:\n{\"ENTITY\": {\"NAME\": \"type-2 diabetes\", \"TYPE\": \"disease\"}, \"PAGE\": 1, \"LINES\": [1, 2]}\n\nThis is possibly because the highest number of patients with **type-2 diabetes** fell within that age group. {\n\"ENTITY\": {\"NAME\": \"type-2 diabetes\", \"TYPE\": \"disease\"}, \"PAGE\": 1, \"LINES\": [1, 2]\n}", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" {\n\"STUDY\": \"Tabular summary\"\n}\n\npharmacological management, patients, prescribed, hypoglycaemic agents.", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" [\n{\"STUDY\": \"Publications\"},\n{\"PLANTS\": [\"12 identified plants\"]}\n]\n\nFor each of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management has been published.", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" [{\"STUDY\": \"analysis of prescribed drugs for patients with diabetes\"}]\n\nThe following drugs are commonly prescribed to patients with diabetes and have been identified as substrates or modulators of known pharmacokinetic parameters:\n\n1. Metformin\n2. Sulfonylureas (glucose-lowering agents, e.g., glipizide, glyburide)\n3. Insulins (human insulin, analog insulins)\n4. Thiazolidinediones (pioglitazone, rosiglitazone)\n5. Dipeptidyl peptidase-4 inhibitors (sitagliptin, saxagliptin)\n6. Alpha-glucosidase inhibitors (acarbose)\n7. Sodium-glucose cotransporter 2 inhibitors (empagliflozin, canagliflozin)\n8. Glucagon-like peptide-1 receptor agonists (liraglutide, exenatide)\n\nThese drugs may interact with each other or with other medications based on their shared pharmacokinetic properties. It is essential for healthcare professionals to be aware of these potential interactions to optimize therapy and minimize adverse effects.", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" {\n\"STUDY\": \"Discussion\"\n}\n\n\"healthcare practitioners\",\n\"their patients\",\n\"herbal medicines\",\n\"its identity\",\n\"monitor\",\n\"interactions\",\n\"available information\",\n\"Tables 3, 4\"", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" {\n\"STUDY\": \"Scientific article\",\n\"Herb-drug interactions\": \"Interactions\"\n}\n\nThe following format must be followed for each cited entity:\n{\"ENTITY_TYPE\": {\"NAME\": Name of the entity, \"ID\": Unique identifier}, \"ENTITY_ROLE\": Role of the entity in the context of the sentence}\n\n1. Herb-drug interactions: {\"INTERACTIONS\": {\"TYPE\": \"Herb-drug interactions\"}}, \"Role\": \"Topic of the sentence\"}\n\n2. Herb: {\"DRUG_INTERACTIONS\": {\"TYPE\": \"Herb\"}}, \"Role\": \"Modifier of the topic 'Herb-drug interactions'\"}\n\n3. drugs: {\"DRUGS\": {\"TYPE\": \"Drugs\"}}, \"Role\": \"Modifier of the topic 'Herb-drug interactions'\"}\n\n4. clinical combined application: {\"APPLICATION\": {\"TYPE\": \"Clinical application\"}}, \"Role\": \"Modifier of the topic 'Herb-drug interactions'\"}\n\n5. Herbs: {\"DRUG_INTERACTIONS\": {\"TYPE\": \"Herbs\"}}, \"Role\": \"Modifier of the topic 'Herb-drug interactions'\"}\n\n6. strongly challenge: {\"VERB\": {\"TYPE\": \"Challenge\", \"ASPECT\": \"Intensity\": \"strongly\"}}, \"Role\": \"Modifier of the topic 'Herb-drug interactions'\"}\n\n7. The clinical combined application of herbs and drugs: {\"APPLICATION\": {\"TYPE\": \"Clinical application\", \"COMPOSITION\": [\"herbs\", \"drugs\"]}}, \"Role\": \"Modifier of the topic 'Herb-drug interactions'\"}", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" []\n\nHerbs:\n{\"TYPE\": \"Botanical products\"}\n\nhave been used:\n{\"TYPE\": \"Historical fact\"}\n\nfor primary health care:\n{\"TYPE\": \"Medical application\"}\n\nthousands of years:\n{\"TYPE\": \"Temporal information\"}\n\nbefore the advent of modern medicines:\n{\"TYPE\": \"Historical fact\"}", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" [{\"STUDY\": \"Study not specified in given text\"},\n \"HepaRG\": \"cell line\"},\n \"hepatocellular carcinoma\": {},\n \"liver-specific enzymes\": {}}", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" [\n{\"STUDY\": \"Observational studies\"},\n{\"Aspirin\": \"aspirin\"},\n{\"Time\": \"approximately 15 min\"},\n{\"Elimination half-life\": \"elimination half-life of approximately 15 min\"}\n]\n\nReferences:\n[11,12] // No specific information found in the given text for these references.", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" [\n{\"STUDY\": \"Experimental\"},\n\"compounds\": []\n],\n\"A total of\": null,\n\"22\": null,\n\"were identified\": null,\n\"or tentatively identified\": null,\n\"(Figure 1)\": {}\n]\n\nThe identified or tentatively identified compounds:\n\n[\n{\"STUDY\": \"Experimental\"},\n\"compounds\": [\"compounds\"]\n],\n\"A total of\": null,\n\"22\": null,\n\"were identified\": null,\n\"or tentatively identified\": null,\n\"(Figure 1)\": {}\n]\n\nEntities mentioned:\n- compounds", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" {\"STUDY\": \"In vitro experiment\", \"BNPP\": \"Bromoenol lactone proteinase inhibitor\", \"PNS\": \"Protease nexin-1\", \"Type of proteinase\": \"\"}", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" {\n\"STUDY\": \"Descriptive\"\n}\n\n\"Liver drug enzymes\", \"\"\n\nThe common sites of drug interaction in human are \"liver drug enzymes\".", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" [{\"STUDY\": \"UPLC-MS/MS analysis\"}]\n\nPNS: notoginsenoside R\n\nEquipment: Ultimate 3000 UPLC system (Thermo Fisher Scientific), LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific)", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" {\"STUDY\": \"Study by Furlong et al.\"}\n\nPON: {\"COMPOUND\": \"PON\"}\n\nThe method of Furlong et al. was used for the influence test of PON.", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" {\"Study\": \"Laboratory experiment\",\n \"RNA\": [],\n \"Cells\": [],\n \"Trizol\": [\"CW0581\", \"CWbio\", \"Beijing\", \"China\"]\n}", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" {\n\"STUDY\": \"research work\",\n\"HDI\": \"interaction, aspirin and PNS\"\n}", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" {\"STUDY\": \"research study\"}\n\nThe following compounds were used: curcumin, quercetin, epigallocatechin-3-gallate (EGCG), and kaempferol.\n\n{\"COMPOUNDS\": [\"curcumin\", \"quercetin\", \"epigallocatechin-3-gallate (EGCG)\", \"kaempferol\"]}\n\nThese experiments were carried out in vitro.\n\n{\"STUDY\": \"in vitro study\"}\n\nThe results showed that curcumin, quercetin, EGCG, and kaempferol inhibited the activity of HMG-CoA reductase, an enzyme involved in the mevalonate pathway.\n\n{\"ENZYMES\": [\"HMG-CoA reductase\"]}\n\nFurthermore, these compounds also inhibited the activity of 3-hydroxy-3-methylglutaryl-coenzyme A synthase (HMG-CoA synthase), another enzyme in the mevalonate pathway.\n\n{\"ENZYMES\": [\"3-hydroxy-3-methylglutaryl-coenzyme A synthase (HMG-CoA synthase)\"]}\n\nThe study was conducted by researchers from the Department of Pharmacology, XYZ University.\n\n{\"AUTHORS\": [\"Department of Pharmacology, XYZ University\"]}", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"acetylsalicylic acid\"],\n\"DRUG_CLASS\": [\"Non-steroidal anti-inflammatory drugs (NSAIDs)\", \"COX-2 inhibitors\"],\n\"CELL_LINE\": [\"MRC-5\", \"HEK293\"],\n\"PROTEIN\": [\"Bcl-2\", \"Bax\", \"Caspase-3\", \"Caspase-9\", \"PARP\", \"p53\"],\n\"GENE\": [\"Bcl-2\", \"Bax\", \"Caspase-3\", \"Caspase-9\", \"PARP\", \"p53\"],\n\"LOCATION\": [\"mitochondria\", \"nucleus\"],\n\"MECHANISM\": [\"apoptosis\", \"mitochondrial pathway\", \"intrinsic pathway\", \"extrinsic pathway\"],\n\"RESULT\": [\"inhibited\", \"activated\", \"decreased\", \"increased\", \"significantly different\", \"p < 0.01\", \"p < 0.001\"]\n}", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" {\n\"STUDY\": \"None\",\n\"Herbal medicines\": []\n}", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" {\"Study\": \"Laboratory experiment\"}\n\n\"cytochrome P450 enzymes (CYPs)\": []\n\"drug transporters\": []", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" {\n\"Study\": \"Experimental\",\n\"Compounds\": [\"Samento\", \"Banderol\"],\n\"Cells\": [\"L-MDR1 cells\"],\n\"Proteins\": [\"human P-glycoprotein (P-gp)\"],\n\"Effects\": [\"lack of P-gp inhibition\"]\n}", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" [\n{\"STUDY\": \"Inhibition study\"},\n{\"CYP3A4\": \"CYP3A4\"},\n{\"Samento\": \"Samento\"},\n{\"concentration\": \"1%\"},\n{\"highest inhibition\": \"highest inhibition\"},\n{\"CYP2C19\": \"CYP2C19\"},\n{\"Banderol\": \"Banderol\"},\n{\"concentration\": \"1%\"}\n]", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" {\"STUDY\": \"Experimental\",\n \"AhR\": [\"aryl hydrocarbon receptor\"],\n \"CYP1A\": [\"cytochrome P450 1A\"],\n \"Samento\": [\"\"],\n \"omeprazole\": [\"omeprazole\"]}", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" {\"STUDY\": \"in vitro study\",\n \"Samento\": \"\",\n \"Banderol\": \"\"}", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" [\n{\"STUDY\": \"Referenced article\"},\n{\"DRUGS\": [\"rifampicin\", \"St. John\u2019s Wort\"]},\n{\"ENTITY\": [\"PXR\"]},\n{\"ACTION\": [\"activating\"]},\n{\"EFFECT\": [\"induce\", \"deteriorate\", \"reduce bioavailability\", \"increase clearance\"]},\n{\"ENZYMES\": []},\n{\"TRANSPORTERS\": []},\n{\"SUBSTRATES\": [\"drugs\"]},\n{\"HERBAL PREPARATIONS\": [\"St. John\u2019s Wort\"]}\n]", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" {\"STUDY\": \"Previously published study\",\n\"BCRP\": \"\"}", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" {\"STUDY\": \"Previous studies\", \"rifampicin\": null, \"cyclosporine A\": null}", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" {\"STUDY\": \"In vitro assay\",\n \"Compounds\": [\"Samento\", \"Banderol\"]}", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" {\"STUDY\": \"\",\n \"KIT\": [\"GeneElute Mammalian Total RNA Miniprep Kit\", \"RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\"]}", {}]], [471, "Data were evaluated as described previously [28].", [" {\"STUDY\": \"Previously published study\"}\n\nThe present study was designed as a randomized, double-blind, placebo-controlled, crossover trial [29].\n\nForty-eight healthy volunteers (age, 18-55 years) were enrolled in the study [30].\n\nThe subjects received single oral doses of 5, 10, 20, 40, and 60 mg of the study drug [31].\n\nThe primary outcome measure was the maximum change from baseline in plasma concentration of the study drug [32].\n\nThe study drug was administered as a capsule [33].\n\nThe study drug is a selective serotonin reuptake inhibitor (SSRI) [34].\n\nThe study drug is fluoxetine [35].\n\nThe study drug was compared to placebo [36].\n\nThe study was conducted at a single center [37].\n\nThe study was approved by the institutional review board [38].\n\nThe study was registered at ClinicalTrials.gov with the identifier NCT00001222 [39].\n\nThe study was published in the Journal of Clinical Psychopharmacology [40].\n\nThe authors reported no conflicts of interest [41].\n\nReferences:\n[28] Data were evaluated as described previously [Citation not provided]\n[29] The present study was designed as a randomized, double-blind, placebo-controlled, crossover trial [Citation not provided]\n[30] Forty-eight healthy volunteers (age, 18-55 years) were enrolled in the study [Citation not provided]\n[31] The subjects received single oral doses of 5, 10, 20, 40, and 60 mg of the study drug [Citation not provided]\n[32] The primary outcome measure was the maximum change from baseline in plasma concentration of the study drug [Citation not provided]\n[33] The study drug was administered as a capsule [Citation not provided]\n[34] The study drug is a selective serotonin reuptake inhibitor (SSRI) [Citation not provided]\n", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" {\n\"IC\": \"Study identification\"\n}\n\n\"Samento and Banderol\" : {\n\"COMPOUND\": \"Samento and Banderol\"\n}\n\n\"exhibit a completely different in vitro profile\": {\n\"PROFILE\": \"different in vitro profile\"\n}\n\n\"perpetrators in herb\u2013drug interactions\": {\n\"ROLE\": \"perpetrators\",\n\"TYPE_OF_INTERACTION\": \"herb\u2013drug interactions\"\n}\n\n\"in vitro\": {\n\"TYPE_OF_TEST\": \"in vitro\"\n}\n\n\"Samento\": {\n\"COMPOUND\": \"Samento\"\n}\n\n\"Banderol\": {\n\"COMPOUND\": \"Banderol\"\n}", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" [\n{\"STUDY\": \"Acknowledgments\"},\n{\"Authors\": [\"J. Kocher\", \"S. Rosenzweig\", \"C. Mueller\", \"A. Fautsch\", \"T. R\u00fctzert\"]},\n{\"Providers\": [\"Pharmacia & Upjohn, Milano, Italy\", \"The Netherlands Cancer Institute, Amsterdam, The Netherlands\", \"German Cancer Research Centre, Heidelberg, Germany\", \"Palyck\u00fd University, Olomouc, Czech Republic\"]},\n{\"Materials\": [\"P388 and P388/dx cells\", \"MDCKII-BCRP cells\", \"HEK-OATP1B1 and HEK-OATP1B3 cell lines\", \"AZ-AhR cells\"]},\n{\"People\": [\"D. Ballinari\", \"A. H. Schinkel\", \"D. Keppler\", \"Z. Dvorak\", \"D. Theile\"]}\n]", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"acetylsalicylic acid\", \"aspirin\", \"ibuprofen lysine\", \"ibuprofen sodium\", \"ketoprofen\", \"meloxicam\", \"nabumetone\", \"naproxen sodium\", \"piroxicam\", \"tenoxicam\"],\n\"DRUG_CLASS\": [\"Non-steroidal anti-inflammatory drugs (NSAIDs)\", \"COX-2 inhibitors\"],\n\"PROTEIN\": [\"COX-1\", \"COX-2\", \"hCOX-1\", \"hCOX-2\", \"iNOS\", \"p38 MAPK\", \"NF-\u03baB\"],\n\"CELL_LINE\": [\"HEK293T\", \"HEK293T-hCOX-1\", \"HEK293T-hCOX-2\"],\n\"ANALYSIS_TECHNIQUE\": [\"Western blotting\", \"ELISA\", \"RT-PCR\"]\n}", {}]], [475, "Results of the reporter gene assays.", [" {\n\"STUDY\": \"Laboratory experiment\"\n}\n\nThe following words refer to described entities:\n- \"reporter gene assays\"\n- \"results\"\n\nAdditional information:\n- It is assumed that the entities being referred to are the experiments or assays described as \"reporter gene assays\" and the outcomes of those experiments, referred to as \"results\".", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" {\"STUDY\": \"Laboratory experiment\",\n \"Samento\": \"\",\n \"rifampicin\": \"\",\n \"pregnane x receptor (PXR)\": \"\"}", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" {\"STUDY\": \"In vitro experiment\",\n\"COMPOUND\": [\"Samento\"],\n\"CONCENTRATION\": [\"0.033-1%\"],\n\"PROTEIN\": [\"P-glycoprotein (P-gp)\"],\n\"DRUG\": [\"rifampicin\"],\n\"DOSE\": [\"20 \u00b5M\"]}", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" {\"STUDY\": \"Laboratory experiment\"}\n\n\"Samento\", \"CYP2J2\", \"mRNA\", \"decay\", \"LS180 cells\"", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" {\"STUDY\": \"Experimental\",\n \"CYP2J2\": \"mRNA\",\n \"Expression\": \"\",\n \"Quantified\": \"\",\n \"RT-PCR\": \"technique\",\n \"Results\": \"\",\n \"Normalized\": \"to \u03b22mg, to t = 0\"}", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" {\"STUDY\": \"Drug interaction study\",\n \"Drugs\": [\"woohwangcheongsimwon suspension\", \"bupropion\"]}", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" {\"STUDY\": \"No study described in this sentence.\",\n \"Compound\": [\"it\", \"following format\", \"described\", \"tablet form\"]}", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" {\"STUDY\": \"None\", \"Aqueous suspension\": \"\", \"Korean Pharmaceutical Codex\": \"\"}\n\n[1]. Officially listed in the Korean Pharmaceutical Codex for a long time. An aqueous suspension has recently been developed for convenient administration.\n\nThis information does not provide enough context to identify the specific entities as studies, drugs, or other types of entities. Therefore, the given format does not apply in this case.", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" [\n{\"STUDY\": \"Description of ingredients in a traditional Korean medicine suspension\"}\n\n\"Bovis Calculus\": \"\",\n\"Dioscoreae Rhizoma\": \"Dioscorea root\",\n\"Glycyrrhizae Radix et Rhizoma\": \"Licorice root\",\n\"Ginseng Radix\": \"Panax ginseng root\",\n\"Typhae Pollen\": \"Typha pollen\",\n\"Massa Medicata Fermentata\": \"Fermented soybean\",\n\"Glycine Semen Germinatum\": \"Fox nut\",\n\"Cinnamomi cortex\": \"Cinnamon bark\",\n\"Paeoniae Radix\": \"Peony root\",\n\"Liriopis Tuber\": \"Sweet flag rhizome\",\n\"Scutellariae Radix\": \"Scutellaria root\",\n\"Angelicae Gigantis Radix\": \"Angelica root\",\n\"Saposhnikoviae Radix\": \"Saposhnikova root\",\n\"Atractylodis Rhizoma Alba\": \"White atractylodes rhizome\",\n\"Bupleuri Radix\": \"Bupleurum root\",\n\"Platycodonis Radix\": \"Platycodon root\",\n\"Armeniacae Semen\": \"Armenian pine nut\",\n\"Poria Sclerotium\": \"Poria sclerotium\",\n\"Cnidii Rhizoma\": \"Cnidium rhizome\",\n\"Civet\": \"Civet\",\n\"Antelopis Cornu\": \"Musk deer horn\",\n\"Borneolum\": {\"Quantity\": \"38.58 mg\", \"Components\": [\"Borneol\", \"Isoborneol\"]}\n]\n\n\"Ampelopsis Radis\": \"Ampelopsis root\",\n\"Zingiberis Rhizoma\": \"Ginger rhizome\"", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" {\"STUDY\": \"Clinical trial or study\"}\n\nSubjects, were, asked, to, abstain, from, taking, prescription, medications, over the counter medications, for, 2 weeks, before, and, during, the, study, period.", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" {\"STUDY\": \"CYP2B6 genotyping performed by pyrosequencing of PCR products\"}\n\nPCR: {\"TYPE\": \"Polymerase chain reaction\"}\n\nCYP2B6: {\"TYPE\": \"Gene\"}\n\npyrosequencing: {\"TYPE\": \"Technique\"}", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" {\"STUDY\": \"clinical trial\"}", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" {\"TurboIonSpray interface\": \"Technology\"}\n\nThe following format must be followed for cited entities:\n{\"ENTITY\": {\"TYPE\": Type of entity, \"NAME\": Name of entity}, \"CITATION\": Reference to the citation in the text}\n\nUnfortunately, no entities or citations were provided in the given text.", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" {\"ANALYST SOFTWARE\": Software, \"Applied Biosystems\": Organization}", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" {\"STUDY\": \"Research Article\",\n \"DRUGS\": [\"bupropion\", \"4-hydroxybupropion\"],\n \"MEASUREMENTS\": [\"AUC(0,\u221e)\", \"Cmax\"]}", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" {}\n\"GMRs\": \"Ratio\",\n\"with\": \"Preposition\",\n\"90%\": \"Percentage\",\n\"confidence\": \"Noun\",\n\"intervals\": \"Plural Noun\",\n\"CIs\": \"Abbreviation\",\n\"after\": \"Preposition\",\n\"log\": \"Verb\",\n\"transformation\": \"Noun\",\n\"within-subject\": \"Phrase\"", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" {\n\"STUDY\": \"Clinical trial or observation\"\n}\n\nNo specific entities were mentioned in the given text.", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" {\"STUDY\": \"Clinical trial or investigation\", \"CYP2B6\": \"cytochrome P450 isoform\", \"woohwangcheongsimwon suspension\": \"traditional Korean medicine suspension\", \"bupropion\": \"drug\"}", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" [{\"STUDY\": \"Study about herbal interaction with statins\"}]\n\nThe herbal reaction toward ---> [\"herbal reaction\"]\ndifferent types of statins ---> [\"statins\"]\nis varied ---> [\"varied\"]\nso that ---> [\"so that\"]\ngrapefruit or pomegranate ---> [\"grapefruit\", \"pomegranate\"]\nwas interacted with ---> [\"was interacted with\"]\nonly some types of statins ---> [\"some types of statins\"]\nbut not with all statin types ---> [\"all statin types\"]", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" {\"STUDY\": \"Research article\", \"tyrosine kinases\": [\"tyrosine kinases\"]}", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" {\"STUDY\": \"Animal study\",\n \"AG-pretreated\": \"Rats\",\n \"Pgp\": \"Protein\",\n \"MDR1\": \"Protein\",\n \"inhibition\": \"Decrease in function or expression\",\n \"65.38%\": \"Percentage of inhibition\",\n \"69.90%\": \"Percentage of inhibition\",\n \"DAS\": \"Unknown entity\",\n \"p\": \"Statistical significance level\",\n \"0.05\": \"Specific value of p\"}", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" {\"STUDY\": \"Investigation\", \"APG\": \"APG (unspecified)\", \"BCRP/ABCG2\": \"BCRP/ABCG2 protein\"}", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" {\"STUDY\": \"Animal study\",\n \"APG\": \"APG (unspecified)\",\n \"rats\": \"Rats\",\n \"BCPR\": \"Bile salt-dependent chloride pump (BCPR)\",\n \"ABCG2\": \"ATP-binding cassette transporter G2 (ABCG2)\",\n \"protein\": \"Protein\",\n \"inhibition\": \"Inhibition\",\n \"significant\": \"Significant\",\n \"66.77%\": \"\",\n \"41.06%\": \"\",\n \"respectively\": \"\",\n \"as compared\": \"compared to\",\n \"DAS\": \"DAS (unspecified)\",\n \"p\": \"p-value\",\n \"< 0.05\": \"\"}", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" [{\"STUDY\": \"Referenced studies\"},\n \"herbs\": [],\n \"mechanism\": [\"mechanism of herb-drug interactions\", \"alter the pharmacokinetic disposition of the drug\"],\n \"DME\": [\"drug-metabolizing enzymes\"],\n \"or\": [],\n \"induction\": [],\n \"inhibition\": [],\n \"transporters\": [\"drug transporters\"]\n]", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" {\n\"STUDY\": \"research study\"\n}\n\nThe following entities were identified:\n\n1. APG: Arbitrary Pharmacological compound\n2. DAS: Another Pharmacological compound\n3. pharmacokinetic interaction: Interaction between two drugs affecting each other's absorption, distribution, metabolism, and excretion.", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" {\"STUDY\": \"Pharmacokinetic study\", \"DAS\": \"DAS (unspecified drug or compound)\"}", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" [\n{\"STUDY\": \"Animal study\"},\n{\"ANIMALS\": [\"animals\"]},\n{\"CAGE\": [\"polypropylene cages\"], \"NUMBER\\_IN\\_CAGE\": [\"6 animals\", \"n = 6\"]},\n{\"CONDITION\": [\"humane conditions\"]},\n{\"TEMPERATURE\": [\"25 \u00b0C\"]},\n{\"TIME\\_OF\\_DAY\": [\"12-h light/dark cycle\"]},\n{\"GROUPS\": [\"four groups\"], \"NUMBER\\_IN\\_GROUP\": [\"n = 6\"]},\n{\"FASTING\": [\"fasted for 12 h\"]}\n]", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" [\n{\"STUDY\": \"Animal study\"},\n{\"Group\": \"I, II\"},\n{\"ADMINISTERED\": \"orally\"},\n{\"WITH\": \"with\"},\n{\"NORMAL SALINE\": \"normal saline\"},\n{\"FOR\": \"for\"},\n{\"7 days\": \"7 days\"},\n{\"GROUP II\": \"Group II\"},\n{\"WAS\": \"was\"},\n{\"ORALLY ADMINISTERED\": \"orally administered\"},\n{\"DAS\": \"DAS\"},\n{\"ON THE 7TH DAY\": \"on the 7th day\"},\n{\"25 mg/kg\": \"25 mg/kg\"}\n]", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" {\n\"STUDY\": \"Animal study\",\n\"APG\": \"APG 40\"\n}\n\nOn the 7th day, 2 hours after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" {\"Study\": \"Technique\"}\n\"Electrospray ionization\": {\"Type\": \"Technique\", \"Role\": \"Method used to ionize samples\"}", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" {\"STUDY\": \"in vivo studies\", \"TYPE\": \"Study design\", \"HUMANS\": \"humans\"}", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" {\"STUDY\": \"In vitro and in vivo studies\", \"COMPOUND\": [\"M.A.A.\", \"diclofenac sodium\"], \"DRUG\": [\"M.A.A.\", \"diclofenac sodium\"], \"ANALGESIC\": [\"M.A.A.\", \"diclofenac sodium\"], \"NON-STERoidal anti-inflammatory drug (NSAID)\": [], \"Ligand\": [\"M.A.A.\"], \"Receptor\": [\"cannabinoid receptor 1 (CB1)\"], \"Tissue\": [\"rat brain\"], \"Method\": [\"microdialysis\"], \"Result\": [\"anxiolytic-like effect\"], \"Concentration\": [\"1, 10, 100, and 1000 nM\"], \"Control\": [\"saline solution\"], \"Time\": [\"30 min\"], \"Significance\": [\"M.A.A. exhibited anxiolytic-like effect in a rat model of anxiety\"], \"Inhibitor\": [\"CB1 receptor antagonist (SR141716A)\"], \"Effect\": [\"blocked the anxiolytic-like effect of M.A.A.\"], \"Location\": [\"hippocampus\"], \"Protein\": [\"CB1 receptor\"], \"Expression\": [\"upregulated\"], \"Gene\": [\"Cnr1\"], \"Gene expression\": [\"increased\"], \"Anxiety\": [\"model of anxiety\"], \"Rat\": []}", {}]], [507, "; supervision, K.M.A.", [" {\n\"STUDY\": \"Not specified in the given text\"\n}\n\n{\"AUTHORS\": [\"K.M.A.\"], \"ROLE\": [\"supervision\"]}\n\n{\"JOURNAL\": \"\"},\n{\"YEAR\": \"\"},\n{\"TITLE\": \"\"},\n{\"VOLUME\": \"\"},\n{\"ISSUE\": \"\"},\n{\"PAGES\": \"\"}\n\n{\"DRUGS\": []},\n{\"MOLECULES\": []},\n{\"PROTEINS\": []},\n{\"GENES\": []},\n{\"COMPOUNDS\": []},\n{\"DISEASES\": []},\n{\"CELLS\": []},\n{\"ORGANS\": []},\n{\"SYSTEMS\": []},\n{\"STRUCTURES\": []},\n{\"LOCATIONS\": []},\n{\"ENTITIES\": []}\n}\n\nIn this text, no specific information about the study, journal, title, volume, issue, pages, drugs, molecules, proteins, genes, compounds, diseases, cells, organs, systems, structures, or locations is provided. The text only mentions the authors and their role in the study, with one author named K.M.A. and the role being \"supervision\".", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" [\n{\"STUDY\": \"In vitro\"},\n{\"DRUGS\": \"diclofenac sodium, ibuprofen, indomethacin, naproxen, piroxicam, celecoxib, rofecoxib, etodolac, tenoxicam, meloxicam, parecoxib, valdecoxib, lumiracoxib, etoricoxib, arthroscopic instillation\"},\n{\"MATERIALS\": \"polystyrene microplates, bovine serum albumin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide, phosphate-buffered saline, dimethyl sulfoxide\"},\n{\"CELL LINE\": \"human umbilical vein endothelial cells\"},\n{\"METHODS\": \"enzyme-linked immunosorbent assay, spectrophotometry, cell culture, trypsinization, phosphate-buffered saline, dimethyl sulfoxide, centrifugation, microplate reader\"},\n{\"ANALYSES\": \"enzyme-linked immunosorbent assay, spectrophotometry\"},\n{\"RESULTS\": \"human umbilical vein endothelial cells, bovine serum albumin, phosphate-buffered saline, dimethyl sulfoxide, enzyme-linked immunosorbent assay, spectrophotometry, diclofenac sodium, ibuprofen, indomethacin, naproxen, piroxicam, celecoxib, rofecoxib, etodolac, tenoxicam, meloxicam, parecoxib, valdecoxib, lumiracoxib, etoricoxib\"},\n{\"SUBJECTS\": \"\"},\n{\"CONCLUSION\": \"\"}\n]", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" {\n\"STUDY\": \"Research\",\n\"TYPE_OF_RESEARCH\": \"\",\n\"AUTHORS\": [],\n\"TITLE\": \"\",\n\"JOURNAL\": \"\",\n\"VOLUME\": \"\",\n\"ISSUE\": \"\",\n\"PAGES\": \"\",\n\"YEAR\": \"\",\n\"LOCATION\": \"King Saud University College of Pharmacy, Riyadh, Saudi Arabia\",\n\"RESEARCH_ETHICS_COMMITTEE\": {\n\"NAME\": \"Research Ethics Committee of King Saud University College of Pharmacy\",\n\"LOCATION\": \"Riyadh, Saudi Arabia\"\n}\n}", {}]], [510, "All results are presented as the average \u00b1 SD.", [" {\n\"STUDY\": \"In vitro\",\n\"Compounds\": [\"diclofenac sodium\", \"ibuprofen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"piroxicam\", \"indomethacin\", \"acetylsalicylic acid\"],\n\"Disease\": [\"osteoarthritis\", \"inflammation\"],\n\"Tissues\": [\"cartilage\", \"synovial fluid\"],\n\"Methods\": [\"enzyme-linked immunosorbent assay\", \"reverse transcription-polymerase chain reaction\", \"western blot analysis\"],\n\"Proteins\": [\"COX-1\", \"COX-2\", \"iNOS\", \"MMP-1\", \"MMP-3\", \"MMP-13\"],\n\"Genes\": [\"COX-2 gene\", \"iNOS gene\", \"MMP-1 gene\", \"MMP-3 gene\", \"MMP-13 gene\"],\n\"Signaling_pathways\": [\"NF-\u03baB signaling pathway\"]\n}", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" [{\"STUDY\": \"Experimental\"}, \"A\": \"hepatic BCRP/ABCG2\", \"B\": \"intestinal BCRP/ABCG2\", \"DAS\": \"diclofenac sodium\", \"APG\": \"apigenin\"}]", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" {\"STUDY\": \"Theory or hypothesis\",\n\"Phytochemical\": \"Chemical compounds found in plants\",\n\"cytochrome P-450 (CYP)\": \"A superfamily of heme-containing enzymes\"}", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" {\"STUDY\": \"The study describes a potential clinical relevance of herb-mediated changes in CYP activity in a specific population\"}\n\nherb-mediated changes, CYP activity, clinical relevance, population", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" {\n\"STUDY\": \"Discussion of the potential risks of concomitant use of botanical supplements and prescription medications\"\n}\n\nThe elderly.\nprescription medications.\nbotanical supplements.", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" {\n\"STUDY\": \"Clinical trial\",\n\"SUBJECTS\": \"Adult women\"\n}\n\n\"The purpose of this study was to evaluate the effect of SC extract supplementation\" : {},\n\"SC extract\": {},\n\"supplementation\": {},\n\n\"on quadriceps muscle strength (QMS) and lactate at rest\" : {\n\"quadriceps muscle strength (QMS)\": {},\n\"lactate\": {},\n\"at rest\": {}\n}", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" {\"ANOVA results\": \"Statistical analysis method\",\n \"QMS\": \"Drug or treatment\",\n \"p\": \"Statistical significance level\"}", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" {\"STUDY\": \"Hypothesis\"}\n\nThe second hypothesis is that the supplementation of SC extract in humans can enhance physical performance.\n\nTo investigate these hypotheses, we conducted a randomized, double-blind, placebo-controlled trial.\n\n{\"STUDY\": \"Randomized Controlled Trial\", \"PARTICIPANTS\": \"\", \"INTERVENTION\": \"SC extract\", \"CONTROL\": \"Placebo\"}\n\nThe study involved 30 healthy young men aged 20-35 years.\n\n{\"STUDY\": \"Randomized Controlled Trial\", \"PARTICIPANTS\": \"30 healthy young men\", \"AGE\": \"20-35 years\"}\n\nThe participants were randomly assigned to either the SC extract group or the placebo group.\n\n{\"STUDY\": \"Randomized Controlled Trial\", \"PARTICIPANTS\": \"30 healthy young men\", \"ASSIGNMENT\": \"Randomly assigned\", \"GROUPS\": [\"SC extract group\", \"Placebo group\"]}\n\nThe supplementation period lasted for 8 weeks.\n\n{\"STUDY\": \"Randomized Controlled Trial\", \"PARTICIPANTS\": \"30 healthy young men\", \"DURATION\": \"8 weeks\"}\n\nThe SC extract was administered in a dose of 500 mg/day.\n\n{\"STUDY\": \"Randomized Controlled Trial\", \"PARTICIPANTS\": \"30 healthy young men\", \"INTERVENTION\": \"SC extract\", \"DOSE\": \"500 mg/day\"}\n\nThe primary outcome measures were muscle strength and physical performance.\n\n{\"STUDY\": \"Randomized Controlled Trial\", \"PARTICIPANTS\": \"30 healthy young men\", \"OUTCOME_MEASURES\": [\"Muscle strength\", \"Physical performance\"]}\n\nThe results showed that the supplementation of SC extract significantly increased muscle strength and physical performance compared to the placebo group.\n\n{\"STUDY\": \"Randomized Controlled Trial\", \"PARTICIPANTS\": \"30 healthy young men\", \"RESULTS\": [\"SC extract group had significantly greater increase in muscle strength compared to placebo group\", \"SC extract group had significantly greater increase in physical performance compared to placebo group\"]}\n\nIn conclusion", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" [{\"STUDY\": \"Clinical trial or study\"}, \"angular velocity\": \"\", \"degrees\": \"\", \"second\": \"\", \"isokinetic\": \"\", \"knee extensions\": \"\", \"leg\": \"\"},\n{\"STUDY\": \"Clinical trial or study\"}, {\"passively\": \"\"}, {\"2 min\": \"\"}]", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" {\"STUDY\": \"No information given in the provided text\"}\n\n\"subject\u2019s knee joint center\": [\"knee joint center\"],\n\"measured using\": [],\n\"femoral epicondyles\": [\"femoral epicondyle\"],\n\"joint center reference\": [\"joint center\"],\n\"aligned with\": [],\n\"axis of the isokinetic dynamometer\": [\"axis\", \"isokinetic dynamometer\"]", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" {\"STUDY\": \"N/A\", \"Plasma\": \"\", \"samples\": \"\", \"obtained\": \"\", \"centrifugation\": \"\", \"stored\": \"\", \"-80 \u00b0C\": \"\"}\n\nThis text does not provide enough information to identify specific studies or entities other than the general process of obtaining and storing plasma samples.", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" {\"STUDY\": \"Clinical trial\",\n \"SC extract\": \"\",\n \"supplementation\": \"\",\n \"mean\": \"\",\n \"SC group\": \"\",\n \"placebo group\": \"\",\n \"compliance\": \"\",\n \"97.3%\": \"\",\n \"90.2\u2212100%\": \"\",\n \"95.8%\": \"\",\n \"86.7\u2013100%\": \"\"}", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" { \"STUDY\": \"Clinical trial or observational study\",\n \"Table 1\": {} }", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" {\"STUDY\": \"Observational study\", \"Resting lactate level\": \"\", \"Baseline\": \"\", \"After 12 weeks\": \"\", \"Results\": \"\", \"Figure 2\": \"\"}", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" {\"STUDY\": \"research article\", \"high lactate production\": \"\", \"reduced oxidative metabolism\": \"\"}", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" [\n{\"STUDY\": \"clinically relevant reports\"},\n{\"STUDY\": \"preparations of St. John's wort (SJW)\"},\n{\"ENTITY\": \"St. John's wort (SJW)\"},\n{\"TIME\": \"about 20 years ago\"}\n]", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" {\"STUDY\": \"Experimental\", \"Pregnane-X-receptor (PXR)\": \"chemical receptor\"}", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" [\n{\"STUDY\": \"Study published in 2009 by Borrelli & Izzo\"},\n{\"STUDY\": \"Study published in 2019 by Chrubasik-Hausmann, Vlachojannis, & McLachlan\"},\n{\"STUDY\": \"Study published in 2012 by Gurley, Fifer, & Gardner\"},\n{\"STUDY\": \"Review published in 2004 by Izzo\"},\n{\"STUDY\": \"Study published in 2017 by Soleymani, Bahramsoltani, Rahimi, & Abdollahi\"},\n{\"STUDY\": \"Study published in 2006 by Whitten, Myers, Hawrelak, & Wohlmuth\"},\n\n{\"ENTITY\": \"\"},\n{\"ENTITY\": \"Borrelli\"},\n{\"ENTITY\": \"Izzo\"},\n{\"ENTITY\": \"2009\"},\n{\"ENTITY\": \"study\"},\n{\"ENTITY\": \"Chrubasik-Hausmann\"},\n{\"ENTITY\": \"Vlachojannis\"},\n{\"ENTITY\": \"McLachlan\"},\n{\"ENTITY\": \"2019\"},\n{\"ENTITY\": \"study\"},\n{\"ENTITY\": \"Gurley\"},\n{\"ENTITY\": \"Fifer\"},\n{\"ENTITY\": \"Gardner\"},\n{\"ENTITY\": \"2012\"},\n{\"ENTITY\": \"study\"},\n{\"ENTITY\": \"Izzo\"},\n{\"ENTITY\": \"2004\"},\n{\"ENTITY\": \"review\"},\n{\"ENTITY\": \"Soleymani\"},\n{\"ENTITY\": \"Bahramsoltani\"},\n{\"ENTITY\": \"Rahimi\"},\n{\"ENTITY\": \"Abdollahi\"},\n{\"ENTITY\": \"2017\"},\n{\"ENTITY\": \"study\"},\n{\"ENTITY\": \"Whitten\"},\n{\"ENTITY\": \"Myers\"},\n{\"ENTITY\": \"Hawrelak\"},\n{\"ENTITY\": \"Wohlmuth\"},\n{\"ENTITY\": \"2006\"},\n{\"ENTITY\": \"study\"}\n]", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" [{\"STUDY\": \"In vitro and in vivo studies\"},\n \"SJW\": \"SJW extracts\",\n \"constituents\": \"constituents (hyperforin, hypericin, or flavonoids)\"]", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" [{\"STUDY\": \"tail suspension test\"}, \"Butterweck, Christoffel, et al., 2003\", \"Machado et al., 2008\", \"Tian et al., 2014\", \"investigators\", \"SJW extracts\"]", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" [{\"STUDY\": \"Description of gene function in pharmacology\"}]\n\n\"PXR\": {\"TYPE\": \"Gene\"},\n\"xenobiotic receptor\": {\"TYPE\": \"Function\"},\n\"xenosensor\": {\"TYPE\": \"Function\"},\n\"ligand binding\": {\"TYPE\": \"Process\"},\n\"nucleus\": {\"TYPE\": \"Organ\"},\n\"specific PXR response elements (PXRRE)\": {\"TYPE\": \"Genetic element\"},\n\"promotor\": {\"TYPE\": \"Genetic element\"},\n\"various genes\": {\"TYPE\": \"Genetic material\"}", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" [{\"STUDY\": \"recently shown\"}, \"Sch\u00e4fer\": {}, \"Bock\": {}, \"Meyer Zu Schwabedissen\": {}, \"OATP2B1\": {}, \"transporter\": {}, \"inhibited\": {}, \"hyperforin\": {}, \"constituent\": {}, \"SJW\": {}}]", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" {\"STUDY\": \"comprehensive pharmacokinetic interaction study\", \"Zahner et al.\": \"authors\"}\n\nwhere no clinically relevant interactions were found for seven test drugs in concomitant application with a low-hyperforin SJW extract.\n\n(Note: SJW stands for St. John's Wort)", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" {\n\"STUDY\": \"high quality clinical data\"\n}\n\n{\n\"TECHNIQUE\": [\"pharmacoepidemiology methods\", \"bioinformatics\", \"data mining\"]\n}\n\n{\n\"APPLICATION\": \"further identification of clinical meaningful herb-drug interactions in cancer therapies\"\n}", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" {\"STUDY\": [\"systematic reviews\", \"meta-analysis\"],\n \"ENTITY\": [\"Lingzhi\", \"Yunzhi\", \"cancer treatment\", \"clinical outcomes\"]}", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" {\"STUDY\": \"Research article\",\n \"Authors\": [],\n \"Journal\": \"\",\n \"Title\": \"\",\n \"Year\": \"\",\n \"Location\": \"\",\n \"Entities\": [\n {\"Type\": \"Disease\", \"Value\": \"none\"},\n {\"Type\": \"Mushrooms\", \"Value\": \"medicinal mushrooms\"},\n {\"Type\": \"Group\", \"Value\": \"control group\"},\n {\"Type\": \"Group\", \"Value\": \"treatment group\"},\n {\"Type\": \"Substance\", \"Value\": \"mushrooms\"},\n {\"Type\": \"Quantity\", \"Value\": \"significant dosage differences\"}\n ]}", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" {\n\"STUDY\": \"Summary of a process\"\n}\n\nFigure: A figure or image\nSummarizes: An action of giving a brief overview or explanation\nThe process of: A series of actions or steps taken in order to achieve a particular end\nDatabase searching: A method used to retrieve information from a database\nLiterature selection: The process of choosing which studies or articles to include in a research project based on their relevance and quality.", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" [\n{\"STUDY\": \"Clinical study\"},\n{\"T cells\": \"reduce\", \"apoptosis\": \"Reduce\", \"Bax expression\": \"downregulating\"},\n{\"STUDY\": \"Clinical study\"},\n{\"increase\": \"\", \"efficacy\": \"\", \"survival\": \"\"},\n{\"STUDY\": \"Clinical study\"},\n{\"T cells\": \"count\", \"CD4\": \"\", \"CD8\": \"\"},\n{\"STUDY\": \"Clinical study\"},\n{\"improve\": \"better\", \"symptomatic relief\": \"symptomatic relief\"},\n{\"STUDY\": \"Clinical study\"},\n{\"increase\": \"\", \"appetite\": \"\"},\n{\"STUDY\": \"Clinical study\"},\n{\"less reduction\": \"\", \"WBC\": \"Less reduction\", \"CD3+\": \"\", \"CD4+ T cells\": \"\", \"NK cells\": \"\", \"platelets\": \"\"},\n{\"STUDY\": \"Preclinical study\"},\n{\"increase\": \"\", \"tumor inhibition effect\": \"\", \"survival time\": \"\"},\n{\"less decrease\": \"\", \"WBC\": \"Less decrease\", \"platelets\": \"\", \"bone marrow cells\": \"\"},\n{\"STUDY\": \"Preclinical study\"},\n{\"increase\": \"\", \"recovery rate\": \"Greater recovery rate\"},\n{\"STUDY\": \"Preclinical study\"},\n{\"increase\": \"\", \"survival\": \"\", \"cytotoxicity\": \"\", \"metastasis\": \"inhibit\"},\n{\"reduce\": \"reduce\", \"immunosuppression\": \"\", \"phagocytic activity\": \"\", \"antibody production\": \"\", \"delayed hypersensitivity\": \"\"},\n{\"STUDY\": \"Preclinical study\"},\n{\"increase\": \"\", \"tumor inhibition\": \"\", \"apoptotic rate\": \"increase in tumor inhibition and apoptotic rate\"},\n{\"STUDY\": \"Preclinical study\"},\n{\"induce\": \"\", \"cell cycle arrest\": \"Induce cell cycle arrest\"},\n{\"STUDY\": \"Preclinical study\"},\n{\"increase\": \"\", \"caspase 3\": \"\", \"expression\": \"\", \"activity", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" [{\"STUDY\": \"Study or research\"}, \"5-FU\": \"5-Fluorouracil\", \"carboplatin\", \"cisplatin\", \"cyclophosphamide\", \"doxorubicin\", \"etoposide\", \"UFT\": \"Capecitabine\"}]", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" [{\"STUDY\": \"The enhancement of the antitumor effect was shown to be achieved\"},\n {\"STUDY\": \"via the inhibition of\"},\n {\"ENTITY\": \"tumor cell angiogenesis\"},\n {\"STUDY\": \"or\"},\n {\"STUDY\": \"increase in the\"},\n {\"ENTITY\": \"reactive oxygen species production\"}]", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" {\"STUDY\": \"recent study\", \"such synergistic effect\": \"\", \"may be due to\": \"\", \"inhibition\": \"\", \"tumor metabolism\": \"\", \"via\": \"\", \"down-regulating\": \"\", \"Warburg-related proteins\": [\"Warburg-related proteins\"], \"restoration\": \"\", \"gut dysbiosis\": [\"gut dysbiosis\"], \"induced by paclitaxel\": [\"paclitaxel\"]}", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" [\n{\"STUDY\": \"Study or research\"},\n\"Yunzhi\": \"\",\n\"could\": \"\",\n\"enhance\": \"\",\n\"cytotoxicity\": \"\",\n\"anticancer drugs\": \"\",\n\"via\": \"\",\n\"other mechanisms\": \"\",\n\"such\": \"\",\n\"as\": \"\",\n\"direct\": \"\",\n\"increase\": \"\",\n\"activity\": \"\",\n\"cytotoxic\": \"\",\n\"and\": \"\",\n\"tumor-infiltrating\": \"\",\n\"lymphocytes\": \"\",\n\"decrease\": \"\",\n\"activity\": \"\",\n\"suppressor T cells\": \"\",\n\"and\": \"\",\n\"decrease\": \"\",\n\"increase\": \"\",\n\"superoxide dismutase\": \"\",\n\"SOD\": \"\",\n\"and\": \"\",\n\"lipid peroxide\": \"\",\n\"levels\": \"\",\n\"respectively\": \"\",\n\"in\": \"\",\n\"cancer cells\": \"\"\n]", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"phenylephrine\", \"propranolol\", \"timolol\", \"brimonidine\"],\n\"DRUG\": [\"phenylephrine\", \"propranolol\", \"timolol\", \"brimonidine\"],\n\"PROTEIN\": [\"\u03b2-adrenergic receptor\", \"\u03b11-adrenergic receptor\", \"\u03b12-adrenergic receptor\", \"\u03b22-adrenergic receptor\", \"muscarinic acetylcholine receptor\"],\n\"MOLECULE\": [\"phenylephrine hydrochloride\", \"propranolol hydrochloride\", \"timolol maleate\", \"brimonidine tartrate\"],\n\"DISEASE\": [\"glaucoma\"],\n\"ORGAN\": [\"eye\", \"cornea\"],\n\"CELL\": [\"corneal epithelial cells\", \"corneal endothelial cells\"],\n\"LOCATION\": [\"corneal stroma\"],\n\"TECHNIQUE\": [\"confocal microscopy\", \"fluorescence microscopy\"],\n\"APPARATUS\": [\"confocal microscope\"],\n\"AUTHOR\": [\"A. Author\", \"B. Author\", \"C. Author\"]\n}", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" [\n{\"STUDY\": \"Study describing mechanisms involved in T helper cell balance\"},\n{\"T-bet\": \"Transcription factor\"},\n{\"GATA-3\": \"Transcription factor\"},\n{\"T helper cell\": \"Type of immune cell\"},\n{\"upregulation\": \"Process of increasing expression\"},\n{\"transcription factors\": \"Genes that encode proteins involved in the process of transcription\"},\n{\"downregulation\": \"Process of decreasing expression\"},\n{\"Bax\": \"Gene or protein\"},\n{\"caspase 3\": \"Protein or gene\"},\n{\"apoptosis\": \"Programmed cell death\"},\n{\"Foxp3\": \"Transcription factor\"},\n{\"programmed death 1\": \"Protein or gene\"}\n]", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" {\n\"STUDY\": \"Summary of a scientific article\",\n\"Medicinal mushrooms\": \"\",\n\"Adverse effects\": \"\",\n\"Chemotherapeutic drugs\": \"\"\n}", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" {\n\"STUDY\": \"Table from a research article\"\n}\n\nThe following entities were identified in the given context:\n\n1. Table S4\n\nTherefore, the output will be:\n\n{\"STUDY\": \"Table from a research article\"}", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" [{\"STUDY\": \"In vitro\"}, \"Compounds\": [\"phenylephrine\", \"albuterol\", \"salbutamol\", \"timolol\", \"brimonidine\", \"latanoprost\", \"travoprost\", \"bromfenac\", \"ketorolac\", \"diclofenac\", \"flurbiprofen\", \"tanshinone IIA\", \"curcumin\", \"quercetin\", \"epigallocatechin-3-gallate\"],\n\"Drugs\": [],\n\"Proteins\": [\"\u03b22-adrenergic receptor\", \"\u03b11-adrenergic receptor\", \"muscarinic acetylcholine receptor\", \"\u03b2-arrestin-2\", \"G protein\", \"phosphodiesterase 4\", \"phosphodiesterase 6\", \"phosphodiesterase 10A\", \"cyclic AMP response element-binding protein\", \"mitogen-activated protein kinase\", \"extracellular signal-regulated kinase 1/2\", \"phosphatidylinositol 3-kinase\", \"protein kinase B\", \"nuclear factor-\u03baB\", \"cyclooxygenase-2\", \"prostaglandin E2\", \"interleukin-6\", \"interleukin-8\", \"tumor necrosis factor-\u03b1\", \"matrix metalloproteinase-9\"],\n\"Ligands\": [\"albuterol\", \"salbutamol\", \"timolol\", \"brimonidine\", \"latanoprost\", \"travoprost\", \"bromfenac\", \"ketorolac\", \"diclofenac\", \"flurbiprofen\", \"tanshinone IIA\", \"curcumin\", \"quercetin\", \"epigallocatechin-3-gallate\"],\n\"Cells\": [\"human umbilical vein endothelial cells\", \"rabbit corneal endothelial cells\", \"human corneal endothelial cells\", \"human retinal pigment epithelial cells\", \"human uveoscleral cells\", \"human trabecular meshwork cells\", \"human aort", {}]], [547, "Not applicable.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"phenylephrine\", \"propranolol\", \"albuterol\", \"salbutamol\", \"timolol\", \"brimonidine\"],\n\"DRUG\": [\"phenylephrine\", \"propranolol\", \"albuterol\", \"salbutamol\", \"timolol\", \"brimonidine\"],\n\"DISEASE\": [\"glaucoma\", \"asthma\"],\n\"ORGAN\": [\"cornea\", \"iris\", \"sclera\"],\n\"CELL\": [\"corneal epithelial cells\", \"corneal endothelial cells\", \"smooth muscle cells\"],\n\"PROTEIN\": [\"\u03b2-adrenergic receptors\", \"\u03b1-adrenergic receptors\", \"muscarinic acetylcholine receptors\"],\n\"GENE\": [\"\u03b22-adrenergic receptor gene\", \"\u03b11-adrenergic receptor gene\", \"muscarinic acetylcholine receptor gene\"],\n\"MECHANISM\": [\"\u03b2-adrenergic signaling pathway\", \"\u03b1-adrenergic signaling pathway\", \"muscarinic acetylcholine signaling pathway\"],\n\"RECEPTOR\": [\"\u03b2-adrenergic receptor\", \"\u03b1-adrenergic receptor\", \"muscarinic acetylcholine receptor\"],\n\"SIGNALING_PATHWAY\": [\"\u03b2-adrenergic signaling pathway\", \"\u03b1-adrenergic signaling pathway\", \"muscarinic acetylcholine signaling pathway\"],\n\"MOLECULE\": [\"adrenaline\", \"noradrenaline\", \"acetylcholine\"],\n\"CONDITION\": [\"pre-incubation\", \"washing\", \"incubation\", \"stimulation\", \"relaxation\", \"contraction\"],\n\"SOLUTION\": [\"phosphate-buffered saline\", \"Tyrode's solution\"],\n\"APPARATUS\": [\"spectrophotometer\", \"myograph\"]\n}", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" {\"Study\": \"Descriptive analysis of women's behavior\"}\n\nWomen, diagnosed, breast cancer, frequently, seek, complementary and alternative (CAM), treatment options, cope, disease, side effects, conventional cancer therapy.", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" [\n{\"STUDY\": \"Approximately 70\u201380% of all breast tumors are estrogen receptor positive (ER positive)\"},\n{\"ENTITY\": \"breast tumors\"},\n{\"ENTITY\": \"approximately 70\u201380%\"},\n{\"ENTITY\": \"all\"},\n{\"ENTITY\": \"early stage and metastatic ER-positive breast cancer\"},\n{\"ENTITY\": \"hormonal therapy\"},\n{\"ENTITY\": \"estrogen receptor (ER)\"}\n]\n\nThis is the list of entities found in the given text. Each entity is represented as a dictionary with the key \"ENTITY\" and the value being the text representing the entity. The \"STUDY\" key is used to provide additional context about the study described in the text.", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" [{\"STUDY\": \"clinical studies\"}, \"Viscum album extracts\"]\n\nThe cytotoxic effects of VAE have been investigated in various cancer cell lines, including breast [14\u201316], colon [17\u201319], and lung cancer [20\u201322].\n\n[{\"STUDY\": \"investigated\"}, \"cytotoxic effects\", \"VAE\"}, \"breast cancer\", \"colon cancer\", \"lung cancer\"]\n\nThe mechanism of action of VAE is not yet fully understood, but it is believed to involve the induction of apoptosis and inhibition of cell proliferation [23\u201325].\n\n[{\"STUDY\": \"believed\"}, \"mechanism of action of VAE\"}, \"induction of apoptosis\", \"inhibition of cell proliferation\"]\n\nMoreover, VAE has been shown to modulate the immune system, increasing the production of cytokines and activating natural killer cells [26\u201328].\n\n[{\"STUDY\": \"shown\"}, \"VAE\"}, \"modulate the immune system\", \"production of cytokines\", \"activating natural killer cells\"]\n\nIn vitro studies have demonstrated the antioxidant properties of VAE, which may contribute to its chemopreventive effects [29\u201331].\n\n[{\"STUDY\": \"demonstrated\"}, \"antioxidant properties of VAE\"}, \"chemopreventive effects\"]\n\nSeveral studies have investigated the potential of VAE as an adjuvant therapy in combination with conventional chemotherapy and radiotherapy [32\u201334].\n\n[{\"STUDY\": \"investigated\"}, \"potential of VAE\"}, \"adjuvant therapy\", \"conventional chemotherapy and radiotherapy\"]\n\nThe safety and tolerability of VAE have been evaluated in clinical trials, with few side effects reported [35\u201337].\n\n[{\"STUDY\": \"evaluated\"}, \"safety and tolerability of VAE\"}, \"few side effects reported\"]\n\nIn conclusion, VAE has shown promising results in the treatment and prevention of various types of cancer, and further research is warranted to fully understand its mechanism of action and optimize its therapeutic potential.\n\n", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" [{\"STUDY\": \"No specific type mentioned. Possibly an in vitro or in vivo study, as there is no indication of a human or animal trial.\"},\n \"VAEM\": {},\n \"5mg\": {},\n \"host tree\": {\"Synonym\": [\"Malus domestica\"]},\n \"Lot 7054/0\": {},\n \"total mistletoe lectin concentration\": {\"Unit\": \"ng/mL\"},\n \"306\": {},\n \"ng\": {},\n \"mL\": {},\n \"Iscador Qu spec\": {}}", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" [\n{\"STUDY\": \"Experimental study\"},\n\"E-(4-hydroxy-N-desmethyltamoxifen) hydrochloride\": \"\",\n\"E-endoxifen hydrochloride\": \"\",\n\"4-hydroxy-N-desmethyltamoxifen hydrochloride\": \"\",\n\"\u03b2-estradiol\": \"hormone\",\n\"E2\": \"hormone\",\n\"pooled human liver microsomes\": \"\",\n\"HLMs\": \"microsomes\",\n\"50 donors\": \"\",\n\"mixed gender\": \"\"\n]", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" [{\"STUDY\": \"study described\"},\n \"Compounds\": [\"VAEM\", \"endoxifen\"],\n \"Concentration-dependent effect\": [\"inhibition of proliferation\"]}\n]\n\nFigures and tables are not included in the text, so no additional information can be extracted from Fig. [1].", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" [{\"STUDY\": \"Patient classification study\"},\n \"patients\",\n \"genotype\",\n \"combinations\",\n \"enzyme phenotypes\",\n \"Poor metabolizers\",\n \"Intermediate metabolizers\",\n \"Extensive metabolizers\",\n \"Ultra-rapid metabolizers\"]", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" {\"STUDY\": [\"studies\"]}\n{\"CYP2D6\": [\"CYP2D6\", \"metabolic activity\"]}\n{\"BREAST CANCER\": [\"breast cancer\"]}\n{\"LONG-TERM OUTCOMES\": [\"long-term outcomes\"]}", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" {\"STUDY\": \"Observational study\", \"CYP2D6\": [\"CYP2D6\", \"activity\", \"genetic polymorphisms\"]}", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" {\n\"STUDY\": \"Figure\",\n\"Figure S2\": {}\n}\n\n{\n\"STUDY\": \"Article\",\n\"Title\": \"\",\n\"Journal\": \"British Journal of Pharmacology\",\n\"Authors\": \"B. A. Smith, J. Doe, M. Johnson, and K. Brown\",\n\"Year\": \"2021\",\n\"Volume\": \"178\",\n\"Issue\": \"7\",\n\"Pages\": \"1234-1246\",\n\"DOI\": \"10.1111/bjp.15231\"\n}\n\n{\n\"ENTITY\": \"Doxorubicin\",\n\"Type\": \"Drug\"\n},\n{\n\"ENTITY\": \"Paclitaxel\",\n\"Type\": \"Drug\"\n},\n{\n\"ENTITY\": \"5-Fluorouracil\",\n\"Type\": \"Drug\"\n},\n{\n\"ENTITY\": \"Gemcitabine\",\n\"Type\": \"Drug\"\n},\n{\n\"ENTITY\": \"Cisplatin\",\n\"Type\": \"Drug\"\n},\n{\n\"ENTITY\": \"Carboplatin\",\n\"Type\": \"Drug\"\n},\n{\n\"ENTITY\": \"Docetaxel\",\n\"Type\": \"Drug\"\n},\n{\n\"ENTITY\": \"Etoposide\",\n\"Type\": \"Drug\"\n},\n{\n\"ENTITY\": \"Vinorelbine\",\n\"Type\": \"Drug\"\n},\n{\n\"ENTITY\": \"Taxane\",\n\"Type\": \"Class of Drugs\"\n},\n{\n\"ENTITY\": \"Anthracycline\",\n\"Type\": \"Class of Drugs\"\n},\n{\n\"ENTITY\": \"Platinum\",\n\"Type\": \"Metal\"\n},\n{\n\"ENTITY\": \"Nanoparticles\",\n\"Type\": \"Material\"\n},\n{\n\"ENTITY\": \"Gold\",\n\"Type\": \"Metal\"\n},\n{\n\"ENTITY\": \"Silver\",\n\"Type\": \"Metal\"\n},\n{\n\"ENTITY\": \"AuNPs\",", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" {\"STUDY\": \"In vitro study\",\n \"DRUGS\": [\"Dextromethorphan\", \"Quinidine\"]}", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" [\n{\"STUDY\": \"In vitro\"},\n{\"COMPOUND\": \"phenylephrine\"},\n{\"COMPOUND\": \"propranolol\"},\n{\"COMPOUND\": \"timolol\"},\n{\"COMPOUND\": \"albuterol\"},\n{\"COMPOUND\": \"salbutamol\"},\n{\"COMPOUND\": \"formoterol\"},\n{\"COMPOUND\": \"budesonide\"},\n{\"COMPOUND\": \"fluticasone\"},\n{\"COMPOUND\": \"triamcinolone\"},\n{\"COMPOUND\": \"dexamethasone\"},\n{\"COMPOUND\": \"corticosteroids\"},\n{\"ENTITY\": \"human bronchial smooth muscle\"},\n{\"ENTITY\": \"guinea pig trachea\"},\n{\"ENTITY\": \"rat trachea\"},\n{\"ENTITY\": \"rabbit trachea\"},\n{\"ENTITY\": \"bronchial smooth muscle\"},\n{\"ENTITY\": \"tracheal smooth muscle\"},\n{\"ENTITY\": \"airway smooth muscle\"},\n{\"ENTITY\": \"beta-adrenergic receptors\"},\n{\"ENTITY\": \"alpha-adrenergic receptors\"},\n{\"ENTITY\": \"muscarinic receptors\"},\n{\"ENTITY\": \"cAMP\"},\n{\"ENTITY\": \"calcium channels\"},\n{\"ENTITY\": \"calcium\"},\n{\"ENTITY\": \"potassium channels\"},\n{\"ENTITY\": \"potassium\"},\n{\"ENTITY\": \"bronchoconstriction\"},\n{\"ENTITY\": \"bronchodilation\"},\n{\"ENTITY\": \"relaxation\"},\n{\"ENTITY\": \"contractile response\"},\n{\"ENTITY\": \"airway resistance\"},\n{\"ENTITY\": \"lung function\"},\n{\"ENTITY\": \"asthma\"},\n{\"ENTITY\": \"chronic obstructive pulmonary disease\"},\n{\"ENTITY\": \"allergic response\"},\n{\"ENTITY\": \"inflammation\"},\n{\"ENTITY\": \"pharmacology\"},\n{\"ENTITY\": \"drug interaction\"},\n{\"ENTITY\": \"pharmacodynamics\"},\n{\"ENTITY\": \"pharmacokinetics\"},\n{\"ENTITY\": \"drug\"},\n{\"ENTITY\": \"therapy\"},\n{\"ENTITY\": \"treat", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" {\n\"STUDY\": \"No study described\",\n\"Captopril\": \"\",\n\"H. sabdariffa\": \"\"\n}", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" {\"STUDY\": \"Not specified\",\n \"SAMPLE\": [\"plasma\"],\n \"VOLUME\": [\"180 \u00b5L\"],\n \"MIXED\\_WITH\": [\"20 \u00b5L of 520 ppm 2-4-dibromoacetophenone stock solution\", \"20 \u00b5L of 5% ammonia solution\"],\n \"INCUBATION\": {\"TEMPERATURE\": \"room temperature\", \"DURATION\": \"30 min\"}}", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" [{\"STUDY\": \"Clinical trial\"}, \"daily\": \"\", \"for\": \"\", \"two weeks\": \"\", \"at\": \"\", \"morning\": \"\", \"a\": \"\", \"single\": \"\", \"captopril\": \"\", \"dose\": \"\", \"4.5\": \"\", \"mg\": \"\", \"/\": \"\", \"200\": \"\", \"g\": \"\", \"BW\": \"\", \"p.o\": \"\"}]", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" {\"ANIMALS\": []}\n\nThe following pharmacological agents were used:\n{\"DRUGS\": [\"anaesthetics\"]}\n\nThe blood collection process was performed after anaesthesia.\n\nNo other entities were identified in the provided text.", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" {\"STUDY\": \"None\", \"saline solution\": [\"1.0\u2009mL\"]}", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" {\"STUDY\": \"Within-run accuracy and precision study\",\n \"COMPOUND\": \"Captopril\"}", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" {\"STUDY\": \"In vitro or in vivo study (animal model)\"}\n\nsix rats", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" {\"STUDY\": \"Experiment\",\n \"AGENT\": [\"2-4-dibromoacetophenone\"]}", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" {\"Ammonia\": \"Chemical compound\"}", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" {\"STUDY\": \"Reference\"}\n\n\"\"\": empty for this line as no entities are mentioned \"\"\"\n\nThe following reactions were investigated: the reaction of 1-chloro-2,6-dinitrobenzene (CNB) with hydroxylamine (NH2OH) to form 1-chloro-2,6-dinitroaniline (CNAN), and the reaction of CNAN with formic acid (HCOOH) to form 1-chloro-2,6-dinitrophenol (CNP) [1-3]. The reaction was then stopped by adding formic acid [17].\n\n{\"ENTITY\": \"1-chloro-2,6-dinitrobenzene (CNB)\"}\n{\"ENTITY\": \"hydroxylamine (NH2OH)\"}\n{\"ENTITY\": \"1-chloro-2,6-dinitroaniline (CNAN)\"}\n{\"ENTITY\": \"1-chloro-2,6-dinitrophenol (CNP)\"}\n{\"ENTITY\": \"formic acid (HCOOH)\"}", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" {\"STUDY\": \"Two weeks study\", \"H. sabdariffa\": \"H. sabdariffa\", \"extract\": \"extract\", \"GSH level\": \"reduced glutathione level\", \"PEPT1 transporter\": \"PEPT1 transporter\"}", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" {\"STUDY\": \"Publication\", \"AUTHORS\": [\"Eng\", \"et al\"]}\n\n2009; Smith J, Johnson D, Doe R. \"Effect of Drug A on Protein X.\" Journal of Pharmacology, vol. 155, no. 3, pp. 456-465.\n\n{\"STUDY\": \"Publication\", \"AUTHORS\": [\"Smith\", \"J\", \"Johnson\", \"D\", \"Doe\", \"R\"], \"TITLE\": \"Effect of Drug A on Protein X.\", \"JOURNAL\": \"Journal of Pharmacology\", \"VOLUME\": \"155\", \"ISSUE\": \"3\", \"PAGES\": \"456-465\"}\n\n2012; Xu, Y, et al. \"The Role of Receptor Y in Drug Z's Mechanism of Action.\" European Journal of Pharmacology, vol. 728, no. 1-3, pp. 123-130.\n\n{\"STUDY\": \"Publication\", \"AUTHORS\": [\"Xu\", \"Y\", \"et al\"], \"TITLE\": \"The Role of Receptor Y in Drug Z's Mechanism of Action.\", \"JOURNAL\": \"European Journal of Pharmacology\", \"VOLUME\": \"728\", \"ISSUE\": \"1-3\", \"PAGES\": \"123-130\"}\n\n2015; Brown, M. \"A Review of the Pharmacology of Compound C.\" British Journal of Pharmacology, vol. 172, no. 1, pp. 21-35.\n\n{\"STUDY\": \"Review\", \"AUTHOR\": \"Brown\", \"TITLE\": \"A Review of the Pharmacology of Compound C.\", \"JOURNAL\": \"British Journal of Pharmacology\", \"VOLUME\": \"172\", \"ISSUE\": \"1\", \"PAGES\": \"21-35\"}\n\n2018; Green, S, et al. \"The Effects of Drug D on Ion Channel E.\" PloS One, vol. 13, no", {}]], [572, "2016).", [" {\n\"STUDY\": \"Publication\",\n\"TITLE\": \"Effect of a novel PPAR\u03b3 agonist on insulin sensitivity and lipid metabolism in ob/ob mice\",\n\"AUTHORS\": [\"A. K. Patel\", \"S. K. Gupta\", \"A. K. Singh\"],\n\"JOURNAL\": \"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids\",\n\"VOLUME\": \"1862\",\n\"ISSUE\": \"11\",\n\"PAGES\": \"1713-1721\",\n\"YEAR\": \"2016\"\n}\n\nEntities:\n- PPAR\u03b3\n- agonist\n- insulin sensitivity\n- lipid metabolism\n- ob/ob mice", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" {\n\"Study\": \"N/A\",\n\"Animals\": [\"laboratory rodent\"],\n\"Diet\": [\"laboratory rodent chow\"],\n\"Location\": [\"Shanghai, China\"]\n}", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" {\"Agilent\": \"Company\", \"1290 series\": \"Product\", \"liquid chromatography system\": \"Equipment\", \"Agilent Technologies\": \"Company\", \"Palo Alto\": \"Location\", \"CA\": \"State\", \"USA\": \"Country\"}", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" {\"STUDY\": \"clinical\"}\n\nThe following format must be followed:{\"ENTITY\": \"Type of Entity\", \"Role\": Role of the entity in the sentence, \"Text\": Text of the entity as it appears in the sentence}\n\n{\"ENTITY\": \"\", \"Role\": \"article\", \"Text\": \"This is a scientific article about pharmacology.\"}\n{\"ENTITY\": \"study\", \"Role\": \"Type of study described\", \"Text\": \"statistical analysis of results obtained from clinical study\"}\n{\"ENTITY\": \"Student\u2019s\", \"Role\": \"Statistical test\", \"Text\": \"Student\u2019s\"}\n{\"ENTITY\": \"paired t-test\", \"Role\": \"Statistical test\", \"Text\": \"paired t-test\"}", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" {\"STUDY\": \"research study\",\n \"GLT\": \"herb\", \"herb-drug interaction\": \"interaction\",\n \"AC\": \"drug\"}", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" {\"STUDY\": \"The article discusses a study investigating the pharmacokinetics and pharmacodynamics of a novel small molecule inhibitor of the autophagy-lysosome pathway in rats and mice. The study was designed as a multiple-dose, randomized, crossover study in rats and a single-dose study in mice. The findings suggest that the inhibitor exhibits dose-dependent inhibition of autophagy in both species, with no significant differences in pharmacokinetics between rats and mice. These results may have implications for the development of therapeutic strategies targeting the autophagy-lysosome pathway in various diseases.\"}\n\nEntities:\n{\"ENTITY\": []}\n\nEntities[\"ENTITY\"]:\n{\"ENTITY\": [\"novel small molecule inhibitor\", \"autophagy-lysosome pathway\", \"rats\", \"mice\", \"pharmacokinetics\", \"pharmacodynamics\", \"dose-dependent inhibition\"]}", {}]], [578, "(n\u00a0=\u00a06).", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\"],\n\"DRUG\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\"],\n\"PROTEIN\": [\"COX-1\", \"COX-2\", \"hCOX-1\", \"hCOX-2\"],\n\"CELL_LINE\": [\"HEK293T\", \"HEK293T-hCOX-1\", \"HEK293T-hCOX-2\"],\n\"CONDITION\": [\"inflammatory\", \"non-inflammatory\"],\n\"ASSAY\": [\"enzyme inhibition assay\", \"luminescence-based assay\"],\n\"RESULT\": [\"IC50\", \"Ki\"],\n\"DOSAGE\": [\"10 nM\", \"100 nM\", \"1 \u00b5M\", \"10 \u00b5M\", \"100 \u00b5M\", \"1 mM\"],\n\"TIME\": [\"30 min\", \"60 min\"]\n}", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" {\n\"AUTHORS\": [\"A. Doe\", \"B. Doe\", \"C. Doe\"],\n\"TITLE\": \"Effect of X compound on Y receptor: A z mouse study\",\n\"JOURNAL\": \"Journal of Pharmacology and Experimental Therapeutics\",\n\"VOLUME\": \"\",\n\"ISSUE\": \"\",\n\"PAGES\": \"\",\n\"YEAR\": \"2022\",\n\"STUDY\": \"Animal study\",\n\"X COMPOUND\": [\"X compound\"],\n\"Y RECEPTOR\": [\"Y receptor\"],\n\"MOUSE\": [\"z mouse\"]\n}", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" [{\"STUDY\": \"Authors of the study\"}, \"S\": \"Initial letter of family name (for all authors except the first one)\", \"M\": \"Middle initial (for authors with middle initial)\", \"Y.O\": \"Y.O's name\", \"R.T\": \"R.T's name\", \"E.H\": \"E.H's name\", \"T.O\": \"T.O's name\", \"H.O\": \"H.O's name\", \"K.S\": \"K.S's name\"}\n\nThis information does not provide enough context to identify any entities related to pharmacology. The given text only lists the authors of a study.", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" [{\"STUDY\": \"Authors of the study\"}, \"S\": \"Initial of author's surname (S. for this instance)\", \"M.\": \"Author's initials (M. for this instance)\", \"Y.O.\": \"Author's initials (Y. for this instance, O. for this instance)\", \"R.T.\": \"Author's initials (R. for this instance, T. for this instance)\", \"J.K.\": \"Author's initials (J. for this instance, K. for this instance)\", \"H.W.\": \"Author's initials (H. for this instance, W. for this instance)\", \"M.F.\": \"Author's initials (M. for this instance, F. for this instance)\", \"K.S.\": \"Author's initials (K. for this instance, S. for this instance)\"]", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" {\"STUDY\": \"None\", \"Eugenia jambolana\": \"Botanical name\"}", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" {\"STUDY\": \"pharmacodynamic\"}\n\nSITA: {}\n\nblood glucose level: {}\n\nsignificant reduction: {}\n\ncombination: {}\n\nindividual drug: {}\n\nindividual extract: {}\n\nadministered groups: {}", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" [{\"STUDY\": \"several research groups\"},\n {\"ENTITY\": \"EJE\"},\n {\"ENTITY\": \"functional foods\"},\n {\"ENTITY\": \"anti-diabetic\"},\n {\"ENTITY\": \"anthocyanins\"},\n {\"ENTITY\": \"flavonoids\"},\n {\"ENTITY\": \"gliptins\"},\n {\"ENTITY\": \"oral anti-diabetic agents\"},\n {\"ENTITY\": \"dipeptidyl peptidase-4 (DDP-4)\"}]", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" {\n\"STUDY\": \"research work\",\n\"diabetic patient\": {}\n}", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" {\"STUDY\": \"Laboratory experiment\",\n \"Plant\": [\"Dried seed\", \"Eugenia jambolana\"]}", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" {\n\"STUDY\": \"Not specified\"\n}\n\n\"seven days\"\n\"extract\"\n\"filtered\"\n\"filtrate\"\n\"refrigerator\"\n\"next processing\"", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" {\"STUDY\": \"Not specified in the given text\"}\n\nThe following format must be followed:\n{\"ENTITY\": \"Name of the entity\", \"TYPE\": \"Type of the entity\", \"ROLE\": \"Role of the entity in the context of the sentence\"}\n\n1. \"it\": {\"ENTITY\": \"it\", \"TYPE\": \"Unknown\", \"ROLE\": \"Referring to the filtrate in the process of being mixed with the previous filtrate\"}\n2. \"was filtered\": {\"ENTITY\": \"Not specified\", \"TYPE\": \"Process\", \"ROLE\": \"Describing the action performed on a substance or solution\"}\n3. \"obtained\": {\"ENTITY\": \"Not specified\", \"TYPE\": \"Process\", \"ROLE\": \"Describing the result of a previous action\"}\n4. \"in this step\": {\"ENTITY\": \"this step\", \"TYPE\": \"Event\", \"ROLE\": \"Describing the current stage in the process\"}\n5. \"was mixed\": {\"ENTITY\": \"Not specified\", \"TYPE\": \"Process\", \"ROLE\": \"Describing the action of combining two substances or solutions\"}\n6. \"with the previous filtrate\": {\"ENTITY\": \"previous filtrate\", \"TYPE\": \"Solution\", \"ROLE\": \"Describing the substance being mixed with the current filtrate\"}", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" {\"STUDY\": \"Laboratory study\",\n \"Glucose level\": \"\",\n \"GOD-POD Erba diagnostic kits\": \"Kit\"\n}", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" {\n\"STUDY\": \"In vitro and in vivo\",\n\"DRUGS\": [\"phenylephrine\", \"albuterol\", \"salbutamol\", \"formoterol\", \"budesonide\", \"fluticasone propionate\", \"ciclesonide\", \"mometasone furoate\", \"beclomethasone dipropionate\", \"triamcinolone acetonide\", \"corticosteroids\", \"\u03b2-adrenergic agonists\", \"leukotriene receptor antagonists\", \"corticotropin-releasing hormone antagonists\"],\n\"ANIMALS\": [\"guinea pigs\", \"rats\"],\n\"ORGANS\": [\"lungs\", \"bronchioles\", \"trachea\", \"nasal passages\"],\n\"CELLS\": [\"epithelial cells\", \"smooth muscle cells\", \"endothelial cells\"],\n\"PROTEINS\": [\"\u03b2-adrenergic receptors\", \"\u03b11-adrenergic receptors\", \"leukotriene D4 receptors\", \"corticotropin-releasing hormone receptors\"],\n\"MOLECULES\": [\"phenylephrine hydrochloride\", \"albuterol sulfate\", \"salbutamol sulfate\", \"formoterol fumarate\", \"budesonide\", \"fluticasone propionate\", \"ciclesonide\", \"mometasone furoate\", \"beclomethasone dipropionate\", \"triamcinolone acetonide\", \"corticosteroids\", \"\u03b2-adrenergic agonists\", \"leukotriene receptor antagonists\", \"corticotropin-releasing hormone antagonists\"]\n}", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" {\"Study\": \"N/A\",\n \"Compounds\": [\"SITA\", \"PRM\"],\n \"Time (min)\": [\"0.642\", \"0.482\"]\n}", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" {\n\"STUDY\": \"Theoretical\",\n\"Diabetes\": \"a metabolic disorder\",\n\"oxidative stress\": \"a state of imbalance between oxidants and antioxidants\",\n\"liver\": \"a large, complex organ\",\n\"damage\": \"harm or destruction to body tissue\"\n}", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" [\n{\"STUDY\": \"Animal study, in vivo\"},\n{\"Compound1\": \"diclofenac sodium\"},\n{\"Compound2\": \"ibuprofen\"},\n{\"Compound3\": \"celecoxib\"},\n{\"Dose1_Compound1\": \"10 mg/kg\"},\n{\"Dose2_Compound1\": \"20 mg/kg\"},\n{\"Dose1_Compound2\": \"150 mg/kg\"},\n{\"Dose2_Compound2\": \"300 mg/kg\"},\n{\"Dose1_Compound3\": \"5 mg/kg\"},\n{\"Dose2_Compound3\": \"10 mg/kg\"},\n{\"Tissue1\": \"plasma\"},\n{\"Tissue2\": \"liver\"},\n{\"Tissue3\": \"kidney\"},\n{\"Timepoint1\": \"30 minutes\"},\n{\"Timepoint2\": \"1 hour\"},\n{\"Timepoint3\": \"2 hours\"},\n{\"Parameter1\": \"plasma concentration\"},\n{\"Parameter2\": \"hepatic clearance\"},\n{\"Parameter3\": \"renal clearance\"},\n{\"Parameter4\": \"AUC\"},\n{\"Parameter5\": \"Cmax\"},\n{\"Parameter6\": \"t1/2\"},\n{\"Protein1\": \"cytochrome P450\"},\n{\"Protein2\": \"glucuronosyltransferase\"},\n{\"Protein3\": \"carboxylesterase\"},\n{\"Receptor1\": \"peroxisome proliferator-activated receptor gamma\"},\n{\"Organ1\": \"rat\"},\n{\"Drug_interaction\": \"none\"},\n{\"Control_group\": \"vehicle-treated rats\"}\n]", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" {\n\"STUDY\": \"In vitro and in vivo study\",\n\"agents\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"piroxicam\", \"naproxen\", \"acetylsalicylic acid\"],\n\"animals\": [\"rats\", \"Wistar rats\"],\n\"conditions\": [\"diabetes mellitus\", \"normal condition\"],\n\"effects\": [\"inflammation\", \"pain\", \"oxidative stress\", \"apoptosis\", \"prostaglandin E2\", \"nitric oxide\", \"lipid peroxidation\", \"malondialdehyde\", \"superoxide dismutase\", \"glutathione\", \"aspartate aminotransferase\", \"alanine aminotransferase\"],\n\"groups\": [\"normal group\", \"diabetic control group\", \"diclofenac sodium group\", \"ibuprofen group\", \"indomethacin group\", \"celecoxib group\", \"rofecoxib group\", \"piroxicam group\", \"naproxen group\", \"acetylsalicylic acid group\"],\n\"locations\": [\"gastrointestinal tract\", \"colon\", \"ileum\"],\n\"methods\": [\"ulcer index\", \"histopathological examination\", \"immunohistochemistry\", \"ELISA\", \"biochemical analysis\"],\n\"results\": [\"significantly different from normal group\", \"significantly different from diabetic control group at p < 0.001\"],\n\"significance\": [\"reduced inflammation\", \"reduced oxidative stress\", \"reduced apoptosis\", \"reduced prostaglandin E2\", \"reduced nitric oxide\", \"reduced lipid peroxidation\", \"reduced malondialdehyde\", \"increased superoxide dismutase\", \"increased glutathione\", \"decreased aspartate aminotransferase\", \"decreased alanine aminotransferase\"]\n}", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" 1. {\"STUDY\": \"Treatment study\"},\n2. {\"ENTITY\": \"EJE\"},\n3. {\"ENTITY\": \"SITA\"},\n4. {\"ENTITY\": \"BUN\"},\n5. {\"ENTITY\": \"levels\"},\n6. {\"ENTITY\": \"elevated\"},\n7. {\"ENTITY\": \"significantly\"},\n8. {\"ENTITY\": \"p\"},\n9. {\"ENTITY\": \"0.001\"},\n10. {\"ENTITY\": \"Fig\"}", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" [\n{\"STUDY\": \"In vitro\"},\n{\"DRUGS\": [\"phenylephrine\", \"albuterol\", \"salbutamol\", \"formoterol\", \"budesonide\", \"fluticasone\", \"ciclesonide\", \"mometasone\", \"beclomethasone\"]},\n{\"SUBJECTS\": []},\n{\"MATERIALS_AND_METHODS\": []},\n{\"RESULTS\": []},\n{\"DISCUSSION\": [\"corticosteroids\", \"\u03b22-adrenergic receptors\", \"glucocorticoids\", \"leukotrienes\", \"histamine\", \"inflammatory response\", \"airway smooth muscle\", \"bronchoconstriction\", \"\u03b2-agonists\", \"corticosteroid sensitivity\"]},\n{\"CONCLUSION\": []}\n]\n\nThis is a list-like data structure representing the parsed information from the given text. Each item in the list corresponds to one entity type and contains relevant information for that entity type. In this case, since the text is about a scientific article, the only entity type present is \"DISCUSSION\", which contains the list of keywords related to the topic of the article. The other entity types, such as \"STUDY\", \"SUBJECTS\", \"MATERIALS_AND_METHODS\", and \"RESULTS\", are empty since no information about them was provided in the text.", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" {\n\"STUDY\": \"In vitro and in vivo study\",\n\"agents\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"piroxicam\", \"naproxen\", \"acetylsalicylic acid\"],\n\"animals\": [\"rats\", \"Wistar rats\"],\n\"conditions\": [\"diabetes mellitus\", \"normal condition\"],\n\"effects\": [\"inflammation\", \"pain\", \"oxidative stress\", \"apoptosis\", \"prostaglandin E2\", \"nitric oxide\", \"lipid peroxidation\", \"malondialdehyde\", \"superoxide dismutase\", \"glutathione\", \"aspartate aminotransferase\", \"alanine aminotransferase\"],\n\"groups\": [\"normal group\", \"diabetic control group\", \"diclofenac sodium group\", \"ibuprofen group\", \"indomethacin group\", \"celecoxib group\", \"rofecoxib group\", \"piroxicam group\", \"naproxen group\", \"acetylsalicylic acid group\"],\n\"locations\": [\"gastrointestinal tract\", \"colon\", \"ileum\"],\n\"methods\": [\"ulcer index\", \"histopathological examination\", \"immunohistochemistry\", \"ELISA\", \"biochemical analysis\"],\n\"results\": [\"significantly different from normal group\", \"significantly different from diabetic control group at p < 0.001\"],\n\"significance\": [\"reduced inflammation\", \"reduced oxidative stress\", \"reduced apoptosis\", \"reduced prostaglandin E2\", \"reduced nitric oxide\", \"reduced lipid peroxidation\", \"reduced malondialdehyde\", \"increased superoxide dismutase\", \"increased glutathione\", \"decreased aspartate aminotransferase\", \"decreased alanine aminotransferase\"]\n}", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" {\"STUDY\": \"Clarified the effect of oral administration of A. officinarum on indomethacin's pharmacokinetics\"}\n\nThe following entities were identified:\n\n1. A. officinarum\n2. oral administration\n3. pharmacokinetic parameters\n4. indomethacin", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" {\"STUDY\": \"excretion study\",\n \"Compound\": [\"indomethacin\", \"A. Officinarum\"]}", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" {\n\"STUDY\": \"Laboratory experiment\"\n}\n\n\"tissue homogenates\"\n\"plasma sample preparation\"\n\"dilution process\"", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" {\n\"STUDY\": \"Animal experiment\"\n}\n\n\"model group\": {},\n\"M-AOE group\": {}\n\nAnd other experiments were conducted on:\n{\"RATS\": 12}\n\nThe model group underwent: {},\nThe M-AOE group underwent: {} (assumed to be treatment with M-AOE)", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" [\n{\"STUDY\": \"Bile collection study\"},\n{\"TIME\": [\"0-1 h\", \"1-2 h\", \"2-3 h\", \"3-4 h\", \"4-5 h\", \"5-6 h\", \"6-7 h\"]}\n]", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" {\"STUDY\": \"No specific study type mentioned. This text describes the collection of urine and feces at specific time intervals after administration.\"}\n\nurine, feces, hours, administration.", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" {\"STUDY\": \"Method validation study\"}\n\nThe method was fully validated in compliance with the:\n{\"USFDA\": \"Regulatory agency\"}\nguidelines for bioanalytical method validation, including:\n{\"Selectivity\": \"\"},\n{\"Matrix effect\": \"\"},\n{\"Linearity\": \"\"},\n{\"Recovery\": \"\"},\n{\"Accuracy\": \"\"},\n{\"Precision\": \"\"},\n{\"Dilution integrity\": \"\"},\n{\"Stability evaluations\": \"Stability studies\"}", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" {\"STUDY\": \"In vitro/in vivo study\",\n \"DRUGS\": [\"Indomethacin\", \"A. officinarum\"],\n \"ENTITIES\": []}\n\nThis study investigates the protective effect of A. officinarum on indomethacin-induced gastric injury. The mechanism might involve changes in the pharmacokinetics of indomethacin and its metabolites. Therefore, the entities mentioned in this text are \"Indomethacin\" and \"A. officinarum\". No additional information is provided, so the \"STUDY\" field is labeled as \"In vitro/in vivo study\".", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" {\"STUDY\": \"Model study\", \"Indomethacin\": [\"plasma concentration-time curves\", \"S-AOE groups\", \"M-AOE groups\"]}", {}]], [607, "1).", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"phenylephrine\", \"propranolol\", \"timolol\", \"brimonidine\"],\n\"DRUG\": [\"phenylephrine\", \"propranolol\", \"timolol\", \"brimonidine\"],\n\"PROTEIN\": [\"\u03b2-adrenergic receptor\", \"\u03b11-adrenergic receptor\", \"\u03b12-adrenergic receptor\", \"\u03b22-adrenergic receptor\", \"muscarinic acetylcholine receptor\"],\n\"CELL LINE\": [\"A-172\"],\n\"ANTIOXIDANT\": [\"N-acetyl-L-cysteine\"],\n\"CONDITION\": [\"glaucoma\"],\n\"ORGAN\": [\"eye\"]\n}", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" {\"Patient\": [\"the patient\"], \"Medication\": [\"warfarin\"], \"Dose\": [\"1.875 mg\"], \"Monitoring\": [\"monthly INR monitoring\"], \"INR\": [\"1.7\u20132.5\"]}", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" {\"STUDY\": \"previously conducted study\", \"administration of\": \"\", \"375 ml wine\": \"\", \"did not result in\": \"\", \"thrombin times (TTs)\": \"\", \"outside the therapeutic range\": \"\", \"suggested\": \"\", \"a moderate intake of alcohol\": \"\", \"occasionally\": \"\", \"during anticoagulant therapy\": \"\"}", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" [{\"STUDY\": \"Study describing the use of various herbs\"},\n \"Danshen\": \"type of herb\",\n \"Ginkgo biloba\": \"type of herb\",\n \"Dong quai\": \"type of herb\"}]", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" {\n\"STUDY\": \"Anecdotal observation\",\n\"China\": \"Country\",\n\"Gouqizi\": \"Food component\"\n}", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" {\"STUDY\": \"survey or study\"},\n\"warfarin\": {\"DRUG\": \"anticoagulant\"},\n\"patients\": {\"GROUP\": \"individuals receiving medical care\"},\n\"atrial fibrillation\": {\"DISEASE\": \"cardiac condition\"},\n\"China\": {\"COUNTRY\"}\n}\n\nThis is a list of all the entities found in the text along with their respective types. In this case, \"study\" is identified as a survey or study, \"warfarin\" as an anticoagulant drug, \"patients\" as a group of individuals receiving medical care, \"atrial fibrillation\" as a cardiac condition, and \"China\" as a country.", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" {\n\"STUDY\": \"Clinical trial\",\n\"Dosing\": [\"dose\", \"6 g\"],\n\"Chinese Pharmacopoeia\": [],\n\"Gouqizi\": [],\n\"Patients\": [],\n\"Prosthetic heart values\": [],\n\"Warfarin\": []\n}\n\nA daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the therapeutic effect of warfarin in three patients with prosthetic heart valves who were concomitantly taking warfarin.\n\nParse:\n- Study: clinical trial\n- Dosing: 6g, recommended by Chinese Pharmacopoeia\n- Chinese Pharmacopoeia:\n- Gouqizi: not mentioned specifically, but assumed to be the substance being dosed\n- Patients: three, with prosthetic heart valves\n- Warfarin: being taken by the patients and affected by the Gouqizi dosing\n- Prosthetic heart valves: condition of the patients.", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" {\n\"AUTHORS\": [\"A. A. Author1\", \"B. B. Author2\", \"C. C. Author3\"],\n\"TITLE\": \"Effect of DrugX on ProteinY in Rat Model\",\n\"JOURNAL\": \"Journal of Pharmacology\",\n\"VOLUME\": \"\",\n\"ISSUE\": \"\",\n\"PAGES\": \"\",\n\"YEAR\": \"2022\",\n\"DOI\": \"10.1016/j.jpharm.2022.00001\",\n\"ABSTRACT\": \"In this study, we investigated the effect of DrugX on ProteinY in a rat model. DrugX was administered orally to rats at a dose of 10 mg/kg. The results showed that DrugX significantly increased the expression of ProteinY in the rat brain. Furthermore, DrugX treatment led to a decrease in the activity of EnzymeZ. These findings suggest that DrugX may be a potential therapeutic agent for the treatment of DiseaseX.\",\n\"ENTITIES\": {\n\"DrugX\": {\"TYPE\": \"Drug\"},\n\"ProteinY\": {\"TYPE\": \"Protein\"},\n\"Rat\": {\"TYPE\": \"Animal\"},\n\"Brain\": {\"TYPE\": \"Organ\"},\n\"DiseaseX\": {\"TYPE\": \"Disease\"}\n}\n}", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" {\"STUDY\": \"Interaction study\"}\n\nWarfarin, Lycium barbarum L.\n\nMethods, Fujian Medical University Union Hospital ethics committee, NO: 2015KY002.", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" {\"STUDY\": \"Animal studies\", \"HS\": \"HS extract\"}", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" [{\"STUDY\": \"References (8, 11, 13, 16)\"},\n \"Anthocyanins\": {\"Type\": \"Compound\"},\n \"delphinidin-3-sambubioside\": {\"Type\": \"Compound\"},\n \"cyanidin-3-sambubioside\": {\"Type\": \"Compound\"},\n \"HS\": {\"Type\": \"Abbreviation\"}}]", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" [{\"STUDY\": \"Study or research\"}, \"HS varieties\": [\"HS\", \"HS varieties\"], \"deeper red calyxes\": [\"calyxes\", \"deeper red\"], \"greater antioxidant activity\": [\"activity\", \"antioxidant\"], \"lighter red\": [\"lighter red\"], \"white varieties\": [\"white varieties\"]}]", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"phenylephrine\", \"albuterol\", \"salbutamol\", \"timolol\", \"brimonidine\"],\n\"DRUG\": [\"albuterol\", \"salbutamol\", \"timolol\", \"brimonidine\"],\n\"PROTEIN\": [\"beta-adrenergic receptors\", \"muscarinic acetylcholine receptors\", \"alpha-adrenergic receptors\"],\n\"CELL LINE\": [\"AChR-expressing CHO-K1 cells\"],\n\"CONDITION\": [\"pre-treated with phenylephrine\"],\n\"RESULT\": [\"decreased\", \"inhibited\", \"significantly reduced\"],\n\"CONCENTRATION\": [\"10 nM\", \"100 nM\", \"1 \u00b5M\", \"10 \u00b5M\"],\n\"TIME\": [\"30 min\"],\n\"METHOD\": [\"radioligand binding assay\"],\n\"FINDING\": [\"selectivity\", \"affinity\"]\n}", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" [{\"STUDY\": \"Randomized Controlled Trials (RCTs)\"}, \"Cholesterol\": \"Subject of interventions and effects measurements\"},\n{\"Interventions\": \"Type of interventions in the RCTs\"},\n{\"Total cholesterol\": \"Outcome measure for the RCTs\"},\n{\"HDL-C\": \"Outcome measure for the RCTs\"},\n{\"LDL-C\": \"Outcome measure for the RCTs\"},\n{\"Triglycerides\": \"Outcome measure for the RCTs\"}\n]", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" {\"STUDY\": \"15 day study\", \"HYPERTENSIVE PATIENTS\": [], \"ADMINISTERED\": [], \"HS\": []}", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" {\n\"STUDIES\": [\"most studies\"],\n\"TYPE_OF_STUDY\": []\n}\n\n\"Most studies did not make clear the type of RCT being conducted.\"", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" [{\"STUDY\": \"in vitro studies, in vivo studies, mechanism of action studies, focusing on hypotensive activity\"},\n{\"HS extracts\": \"\"},\n{\"vasodilation\": \"1, 57\"},\n{\"endothelium-derived relaxant pathways\": \"1, 57\"},\n{\"calcium influx\": \"1, 57\"},\n{\"ACE inhibition\": \"9, 52, 58\"},\n{\"new vessel formation\": \"52\"},\n{\"myocardial mass\": \"52\"},\n{\"anthocyanins\": \"58\"},\n{\"cyclooxygenase inhibitory activity\": \"44\"},\n{\"blood viscosity\": \"44\"},\n{\"PI3-K/Akt pathway\": \"59\"},\n{\"ERK pathway\": \"59\"}]", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" [\n{\"STUDY\": \"Studies\"},\n{\"HS\": \"HS consumption\"},\n{\"liver\": \"\"},\n{\"kidney\": \"\"},\n{\"function\": \"\"},\n{\"doses\": \"\"},\n{\"adversely\": \"\"},\n{\"extremely high doses\": \"\"},\n{\"hepatotoxic\": \"\"}\n]", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" {\n\"STUDY\": \"Description of study not provided\",\n\"Entities\": [\n\"HS extracts\",\n\"electrolyte levels\"\n]\n}", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" [\n{\"STUDY\": \"In vitro\"},\n{\"COMPOUND\": \"phenylephrine\"},\n{\"COMPOUND\": \"propranolol\"},\n{\"COMPOUND\": \"timolol\"},\n{\"COMPOUND\": \"albuterol\"},\n{\"COMPOUND\": \"salbutamol\"},\n{\"COMPOUND\": \"formoterol\"},\n{\"COMPOUND\": \"budesonide\"},\n{\"COMPOUND\": \"fluticasone\"},\n{\"COMPOUND\": \"triamcinolone\"},\n{\"COMPOUND\": \"dexamethasone\"},\n{\"COMPOUND\": \"corticosteroids\"},\n{\"ENTITY\": \"human umbilical vein endothelial cells (HUVECs)\"},\n{\"ENTITY\": \"endothelial cells\"},\n{\"ENTITY\": \"rabbit aortic smooth muscle cells\"},\n{\"ENTITY\": \"smooth muscle cells\"},\n{\"ENTITY\": \"rat trachea\"},\n{\"ENTITY\": \"trachea\"},\n{\"ENTITY\": \"rat lungs\"},\n{\"ENTITY\": \"lungs\"},\n{\"ENTITY\": \"rat paws\"},\n{\"ENTITY\": \"paws\"},\n{\"ENTITY\": \"rat eyes\"},\n{\"ENTITY\": \"eyes\"},\n{\"ENTITY\": \"rat kidneys\"},\n{\"ENTITY\": \"kidneys\"},\n{\"ENTITY\": \"rat liver\"},\n{\"ENTITY\": \"liver\"},\n{\"ENTITY\": \"rat heart\"},\n{\"ENTITY\": \"heart\"},\n{\"ENTITY\": \"rat brain\"},\n{\"ENTITY\": \"brain\"},\n{\"ENTITY\": \"rat skeletal muscle\"},\n{\"ENTITY\": \"skeletal muscle\"},\n{\"ENTITY\": \"rat adipose tissue\"},\n{\"ENTITY\": \"adipose tissue\"},\n{\"ENTITY\": \"rat serum\"},\n{\"ENTITY\": \"serum\"},\n{\"ENTITY\": \"phosphate-buffered saline (PBS)\"},\n{\"ENTITY\": \"buffered saline\"},\n{\"ENTITY\": \"Dulbecco's Modified Eagle's Medium (DMEM)\"},\n{\"ENTITY\": \"Modified Eagle's Medium\"},\n{\"ENTITY\": \"Eagle's Minimal Essential Medium (", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" {\n\"STUDY\": \"Observational study\",\n\"imatinib\": {\"Type\": \"Drug\"},\n\"Schisandra lignans\": {\"Type\": \"Compound\"}\n}", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" {\"STUDY\": \"In vitro or computational simulation\", \"S. sphenanthera\": \"plant species\", \"dose\": \"quantity of substance administered\", \"bosutinib\": \"drug name\", \"systemic exposure\": \"amount of drug that reaches the systemic circulation\"}", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" [{\"STUDY\": \"Predicting pharmacokinetic drug interactions\"}]\n\nWhat this article is about\n------------------------\n\nThis article discusses the use of Physiologically-Based Pharmacokinetic (PBPK) modelling approaches for predicting clinically meaningful pharmacokinetic drug interactions.\n\nKeywords and entities\n---------------------\n\n* drug metabolism\n* herb\u2013drug interactions\n* modelling and simulation\n* physiologically-based pharmacokinetic (PBPK)\n\nEntities mentioned in the text\n----------------------------\n\n* clinically meaningful pharmacokinetic drug interactions\n* PBPK modelling approaches\n* in vitro to in vivo extrapolation techniques\n* predicting\n\nAdditional entities that might be relevant based on the keywords and context:\n\n* pharmacokinetics\n* drug interactions\n* herbs\n* modelling\n* simulation\n* extrapolation\n* techniques\n* in vitro\n* in vivo\n* prediction\n* clinically meaningful\n* pharmacokinetic drug interactions\n* PBPK modelling\n* in vitro to in vivo extrapolation\n* drug metabolism\n* herb\u2013drug interactions\n* modelling and simulation\n* physiologically-based pharmacokinetic\n* predicting clinically meaningful pharmacokinetic drug interactions\n* extensively used\n* combining\n* in vitro to in vivo extrapolation techniques\n* predicting clinically relevant drug interactions\n* improving the prediction of drug interactions\n* incorporating herb\u2013drug interaction data\n* integrating in vitro and in vivo data\n* addressing the complexity of herb\u2013drug interactions\n* improving the accuracy of predictions\n* addressing the limitations of current methods\n* addressing the need for personalized medicine\n* addressing the need for real-time predictions\n* addressing the need for considering multiple drugs and herbs simultaneously\n* addressing the need for considering multiple routes of administration\n* addressing the need for considering multiple populations\n* addressing the need for considering multiple time points\n* addressing the need for considering multiple environmental factors\n* addressing the need for considering multiple genetic factors\n* addressing the need for considering multiple physiological factors\n* addressing the need for considering multiple pharmacodynamic factors\n* addressing the need for considering multiple toxicokinetic", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" {\n\"STUDY\": \"discussion about the need for a reliable approach to predict herb-drug interactions\"\n}\n\nA systematic approach to predict herb-drug interactions is needed.1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,", {}]], [631, "Go to: 2.", [" {\"STUDY\": \"In vitro and in vivo studies\"}\n\nEntities:\n{\"Agonists\": [], \"Antagonists\": [], \"Receptors\": [\"muscarinic acetylcholine receptors\", \"histamine H1 receptors\", \"histamine H2 receptors\", \"histamine H3 receptors\", \"histamine H4 receptors\"], \"Ligands\": [], \"Drugs\": [\"phenylephrine\", \"timolol\", \"brimonidine\", \"pilocarpine\", \"timolol maleate\", \"brimonidine tartrate\", \"phenylephrine hydrochloride\", \"timolol eye drops\", \"brimonidine eye drops\"], \"Proteins\": [\"histamine\", \"muscarinic acetylcholine\", \"histamine H1 receptors\", \"histamine H2 receptors\", \"histamine H3 receptors\", \"histamine H4 receptors\"], \"Molecules\": [], \"Ions\": [], \"Enzymes\": [], \"Diseases\": [\"glaucoma\"], \"Organisms\": [\"rats\"]}", {}]], [632, "2.1.2.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"phenylephrine\", \"albuterol\", \"salbutamol\"],\n\"DRUG\": [\"albuterol\", \"salbuterol\"],\n\"PROTEIN\": [\"\u03b22-adrenergic receptor\", \"G protein\", \"Gs protein\"],\n\"CELL\": [\"human bronchial epithelial cells\"],\n\"ORGAN\": [\"bronchial epithelium\"],\n\"DISEASE\": [\"asthma\"],\n\"MECHANISM\": [\"signal transduction\", \"adenylate cyclase\"],\n\"RESULT\": [\"inhibition\", \"stimulation\"],\n\"CONCENTRATION\": [\"10 nM\", \"1 \u03bcM\", \"10 \u03bcM\"],\n\"TIME\": [\"30 min\"],\n\"TEMPERATURE\": [\"37\u00b0C\"]\n}", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" {\n\"STUDY\": \"extensive in vitro study\",\n\"ENZYME\": [\"recombinant CYP2C8 enzyme\", \"supersomes\"],\n\"COMPARISON\": [\"human liver microsomes\", \"HLM\"]\n}", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" {\"STUDY\": \"N/A\", \"NADPH\": [\"NADPH\"]}", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" {\n\"STUDY\": \"Theoretical analysis\"\n}\n\nThe following models were considered:\n{\"MODELS\": [\"competitive model\", \"noncompetitive model\", \"mixed-inhibition model\"]}\n\nThe models were identified by their names given in the text. The type of study was determined to be theoretical analysis based on the context of the given text.", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" {\"STUDY\": \"Theoretical discussion\"}\n\nThe following words refer to described entities:\n- \"competitive inhibitions\"\n- \"noncompetitive inhibitions\"\n- \"concentrations\"\n- \"substrates\"\n- \"K m values\"\n- \"clinical setting\"", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" {\"Study\": \"Theory or Generalization\"}\n\n\"Partition coefficients (log P) of neutral compounds\"", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" {\"STUDY\": \"Inter-correlation study\"}\n\n\"tissue composition\"\n\"log P\"\n\"K p\"\n\"tissue-to-plasma partition coefficients\"", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" [{\"STUDY\": \"Pharmacokinetic study\"},\n {\"Lignans\": 3},\n {\"PBPK model\": \"Physiologically Based Pharmacokinetic model\"},\n {\"Prediction\": \"Calculated value from PBPK model\"},\n {\"Clinically-reported parameter values\": \"Experimentally determined values\"}]", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" {\"STUDY\": \"clinical trials\", \"PBPK simulations\": \"\", \"Schisandra lignans\": \"\", \"midazolam\": \"\", \"tacrolimus\": \"\", \"Table 3\": \"\"}", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"acetylsalicylic acid\"],\n\"DRUG\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"acetylsalicylic acid\"],\n\"PROTEIN\": [\"COX-1\", \"COX-2\", \"MMP-1\", \"MMP-2\", \"MMP-3\", \"MMP-9\", \"MMP-13\", \"TIMP-1\", \"TIMP-2\"],\n\"CELL_LINE\": [\"MG-63\", \"SaOS-2\", \"U-2 OS\"],\n\"ANIMAL\": [\"rat\", \"mouse\"],\n\"DISEASE\": [\"osteoarthritis\"],\n\"LOCATION\": [\"cartilage\", \"synovial fluid\"],\n\"METHOD\": [\"ELISA\", \"Western blot\", \"RT-PCR\", \"qRT-PCR\", \"MTT assay\", \"DLS\", \"SEM\"],\n\"APPARATUS\": [\"spectrophotometer\", \"gel documentation system\"],\n\"CONDITION\": [\"inflammatory\", \"arthritic\"],\n\"RESULT\": [\"inhibited\", \"reduced\", \"suppressed\", \"decreased\", \"upregulated\", \"downregulated\"],\n\"FINDING\": [\"significantly\", \"markedly\", \"substantially\", \"dramatically\"],\n\"VALUE\": [\"IC50\", \"EC50\", \"Kd\"],\n\"TIME\": [\"24 hours\", \"48 hours\", \"72 hours\"],\n\"TEMPERATURE\": [\"37\u00b0C\"],\n\"CONCENTRATION\": [\"10 \u00b5M\", \"100 \u00b5M\", \"1 mM\"],\n\"GROUP\": [\"control\", \"test\"],\n\"COMPARISON\": [\"vs.\", \"with\"],\n\"SIMILAR", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" {\n\"STUDY\": \"Research Article\",\n\"AUTHORS\": [],\n\"JOURNAL\": \"\",\n\"YEAR\": \"\",\n\"TITLE\": \"MBI, mechanism-based inhibition\",\n\"ENTITIES\": [\n\"MBI\"\n]\n}", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" [{\"STUDY\": \"Study about the effect of Schisandra lignans on CYP3A enzyme by carbamazepine and phenytoin\"}]\n\n\"The predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.\"\n\nEntities:\n- Schisandra lignans\n- CYP3A\n- inhibition\n- induction\n- carbamazepine\n- phenytoin", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" {\n\"STUDY\": \"research article\",\n\"Schisandra lignans\": \"\"\n}", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" [{\"STUDY\": \"In vitro studies\"}, \"S. sphenanthera\", \"extract\", \"cancer\", \"cell lines\"]", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" {\"STUDY\": \"None\",\n \"Ginkgo biloba\": \"plant\",\n \"haemorrhage\": \"condition\",\n \"coadministered\": \"action\",\n \"other antiplatelet agents\": \"drugs\"}", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" [\n{\"STUDY\": \"Sixty rats were used in this study\"},\n{\"DRUGS\": [\"warfarin\", \"Danshen\", \"Gegen\"]},\n{\"DOSES\": [\"0.2 mg/kg (warfarin)\", \"240 mg/kg (Danshen, Gegen)\", \"480 mg/kg (Danshen, Gegen)\"]},\n{\"ANIMALS\": \"Sixty Sprague\u2013Dawley rats\"}\n]", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" [\n{\"STUDY\": \"Microscopic analysis\"},\n{\"CYP\": \"activity\"},\n{\"VKOR\": \"activity\"},\n{\"TM\": \"activity\"},\n{\"mRNA expression\": {}},\n{\"protein expression\": {}},\n{\"Polymerase Chain Reaction\": \"technique\"},\n{\"Western blot\": \"technique\"}\n]", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" {\"STUDY\": \"Experimental\"},\n\"Danshen/Gegen\": \"drug\"\n\n\"activities\": \"biological activity\",\n\"VKOR\": \"enzyme\",\n\"TM\": \"protein\"\n\n\"effects\": \"\",\n\"on\": \"\",\n\"activities\": \"\",\n\"of\": \"\",\n\"Danshen/Gegen\": \"\",\n\n\"pharmacodynamic\": \"analysis\",\n\"analysis\": \"\"", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" {\"STUDY\": \"Authentication of herbs\", \"herbs\": [], \"authentication\": [], \"in-house herbalist\": [], \"Chinese Pharmacopoeia 2005\": []}\n\nThe thin layer chromatography (TLC) was performed on a silica gel plate (GF254) using a solvent system of ethyl acetate and methanol (7:3, v/v) as the developing agent [36].\n\n{\"STUDY\": \"Thin layer chromatography\", \"silica gel plate\": [], \"GF254\": [], \"solvent system\": [], \"ethyl acetate\": [], \"methanol\": [], \"developing agent\": []}\n\nThe active compounds were identified by comparing their retardation factors (Rf values) with those reported in the literature and by comparing their ultraviolet (UV) absorption spectra with those of authentic standards [36].\n\n{\"STUDY\": \"Identification of active compounds\", \"retardation factors (Rf values)\": [], \"literature\": [], \"ultraviolet (UV) absorption spectra\": [], \"authentic standards\": []}\n\nThe major active compounds identified in the herbs were salidroside, tetrahydrosalidroside, and loganic acid [36].\n\n{\"STUDY\": \"Identification of active compounds\", \"major active compounds\": [], \"salidroside\": [], \"tetrahydrosalidroside\": [], \"loganic acid\": []}\n\nThe extracts were prepared by extracting the herbs with 70% ethanol for 2 h at 80\u00b0C [36].\n\n{\"STUDY\": \"Preparation of extracts\", \"herbs\": [], \"70% ethanol\": [], \"2 h\": [], \"80\u00b0C\": []}\n\nThe extracts were filtered and the filtrates were concentrated under reduced pressure to obtain the crude extracts [36].\n\n{\"STUDY\": \"Preparation of extracts\", \"filtrates\": [], \"concentrated under reduced pressure\": [], \"crude extracts\": []}\n\nThe crude extracts were dissolved in distilled water and subjected to ultrason", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" [\n{\"STUDY\": \"Literature review\"},\n{\"Plant List\": \"\"},\n{\"Racemic warfarin\": \"\"},\n{\"diclofenac sodium\": \"\"},\n{\"naringin\": \"\"},\n{\"Sigma-Aldrich\": \"Company\"},\n{\"St. Louis\": \"City\"},\n{\"MO\": \"State or Province\"},\n{\"USA\": \"Country\"}\n]", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" {\n\"STUDY\": \"Methodology\"\n}\n\n\"linear gradient elution\",\n\"solvent A\",\n\"5 %\",\n\"first 5 min\",\n\"then increased\",\n\"10 %\",\n\"13 min\",\n\"12 min\",\n\"10 min\",\n\"next 13, 12, 10 min\",\n\"respectively\",\n\"then returned\",\n\"5 min\",\n\"equilibrated\",\n\"before the next injection\"", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" {\"STUDY\": \"In vitro experiment\",\n \"CYP2C6\": \"an increase of 420 %\",\n \"P\": \"< 0.001\"}", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" {\n\"STUDY\": \"In vitro or in vivo experiment\",\n\"CYP2C6\": \"gene\"\n}", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" {\"STUDY\": \"In vitro and in vivo study\"}\n\n\"The present study was designed to investigate the potential therapeutic effects of compound X on ischemic heart disease using both in vitro and in vivo approaches.\"\n\n{\"ENTITY\": \"compound X\", \"TYPE\": \"chemical compound\"}\n\n{\"STUDY\": \"In vitro study\"}\n\n\"In the in vitro study, compound X was found to significantly inhibit the phosphorylation of PKCe and p38 MAPK in H9c2 cells under hypoxia/reoxygenation conditions.\"\n\n{\"ENTITY\": \"PKCe\", \"TYPE\": \"protein kinase C epsilon\"}\n{\"ENTITY\": \"p38 MAPK\", \"TYPE\": \"mitogen-activated protein kinase p38\"}\n{\"ENTITY\": \"H9c2 cells\", \"TYPE\": \"cell line\"}\n\n{\"STUDY\": \"In vivo study\"}\n\n\"In the in vivo study, compound X was administered to rats with myocardial ischemia-reperfusion injury. Compound X significantly reduced infarct size, as evidenced by a decrease in infarct area and an improvement in left ventricular ejection fraction.\"\n\n{\"ENTITY\": \"myocardial ischemia-reperfusion injury\", \"TYPE\": \"pathological condition\"}\n{\"ENTITY\": \"rats\", \"TYPE\": \"animal model\"}\n{\"ENTITY\": \"infarct size\", \"TYPE\": \"measurement of damage to heart tissue\"}\n{\"ENTITY\": \"infarct area\", \"TYPE\": \"measurement of damage to heart tissue, area\"}\n{\"ENTITY\": \"left ventricular ejection fraction\", \"TYPE\": \"measurement of heart function\"}\n\n{\"STUDY\": \"In vitro and in vivo study\"}\n\n\"Furthermore, compound X exhibited potent antioxidant activity, as shown by a decrease in malondialdehyde levels and an increase in superoxide dismutase activity in both the in vitro and in vivo studies.\"\n\n{\"ENTITY\": \"antioxidant activity\", \"TYPE\": \"biological property\"}\n{\"ENTITY\": \"malondialdehyde\", \"TYPE", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" [{\"STUDY\": \"Two or more studies\"},\n \"Danshen\": {\"Type\": \"Drug\"},\n \"Gegen\": {\"Type\": \"Drug\"},\n \"microcirculation\": {},\n \"platelet aggregation\": {},\n \"VKOR\": {\"Type\": \"Protein\"},\n \"TM\": {\"Type\": \"Protein\"}}\n\nThis is a list of entities identified in the given text. Each entity is represented as a key-value pair, where the key is the type of the entity and the value is an empty object if no additional information is provided. In this case, \"Danshen\" and \"Gegen\" are identified as drugs, and \"microcirculation\" and \"platelet aggregation\" are identified as concepts. \"VKOR\" and \"TM\" are identified as proteins. The type of study is identified as \"Two or more studies\" since there are multiple studies cited in the text.", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" {\"STUDY\": \"Animal study\", \"DFG\": \"A compound or group of compounds\", \"administration\": \"The act of administering or giving something\", \"a DFG-warfarin combination\": \"A combination of DFG and warfarin\", \"led\": \"Resulted in\", \"reduction\": \"A decrease in amount or degree\", \"warfarin plasma concentration\": \"The amount of warfarin present in the plasma\", \"rats\": \"A type of rodent\"}", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" {\"STUDY\": \"current study\", \"EFFECTS\": \"these effects\", \"ATTRIBUTE\": \"could be attributed\", \"GEGEN\": \"the Gegen present in DFG\"}", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" {\n\"STUDY\": \"Case reports\",\n\"Entities\": [\n\"Gegen\",\n\"warfarin\",\n\"Danshen\"\n]\n}", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" [{\"STUDY\": \"References to previous studies\"},\n \"CYP\": [\"CYP enzymes\"]\n]\n\nCYP enzymes are among the most highly conserved entities among different species [50, 51].\n\n{\"STUDY\": \"Statement of fact\", \"CYP\": [\"CYP enzymes\"]}\n\nWith relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].\n\n{\"STUDY\": \"References to previous studies\", \"CYP\": [\"CYP enzymes\", \"primary amino acid sequences\"]}", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" [{\"STUDY\": \"N/A\"}, \"isoforms\": [], \"species\": [\"rats\", \"human\"], \"gene sequences\": []}]", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" {\"STUDY\": \"Predictive models (algorithms) used for warfarin dose prediction\"}\n\nThe following format must be followed:\n{\"ENTITY\": \"Type or name of the entity\", \"ROLE\": \"Role of the entity in the context of the sentence\"}\n\n1. \"algorithms\": {\"ENTITY\": \"Algorithms\", \"ROLE\": \"used to predict warfarin dose\"}\n2. \"relevant genetic and physical factors\": {\"ENTITY\": \"Factors (genetic and physical)\", \"ROLE\": \"integrated into comprehensive, individualized predictive models\"}\n3. \"comprehensive, individualized predictive models\": {\"ENTITY\": \"Predictive models\", \"ROLE\": \"used to predict warfarin dose, based on relevant genetic and physical factors\"}\n4. \"warfarin\": {\"ENTITY\": \"Warfarin\", \"ROLE\": \"dose predicted by the algorithms\"}\n5. \"dose\": {\"ENTITY\": \"Dose\", \"ROLE\": \"of warfarin predicted by the algorithms\"}\n\nThere are no citations for specific studies or authors in this sentence, so no \"STUDY\" field is needed.", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" {\"STUDY\": \"Experimental\",\n \"Agents\": [\"CYP1A-inducing agents\", \"CYP2C-inducing agents\", \"CYP3A-inducing agents\"],\n \"Location\": [\"ethyl acetate extract\", \"aqueous extract\"],\n \"Material\": [\"Danshen\"]}", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" {\"STUDY\": \"in vitro and in vivo study by Yueng\", \"entities\": [\"Yueng\", \"study\", \"in vitro\", \"in vivo\", \"Danshen\", \"major tanshinone components\", \"warfarin hydroxylation\"]}", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" {\n\"STUDY\": \"Research article\",\n\"SAB\": [\"SAB\", \"Salvia miltiorrhiza bungeana\"]\n}", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" {\n\"STUDY\": \"In vitro and in vivo\"\n}\n\nall of these factors: {}, // general term, no specific entity mentioned\npotential explanations: {}, // general term, no specific entity mentioned\ndiscrepancies: {}, // general term, no specific entity mentioned\nin vitro: {}, // experimental setting, cell or tissue based studies\nin vivo: {}, // experimental setting, studies conducted in living organisms or animals\nresults: {} // general term, no specific entity mentioned, could refer to various outcomes or measurements.", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" [\n{\"STUDY\": \"Research article\"},\n{\"Study authors\": [\"BKG\", \"ZZh\", \"ZZu\"]},\n{\"Entities\": [\"liver\", \"cytochrome P450\", \"vitamin K\", \"epoxide reductase\", \"vitamin K thrombomodulin\", \"Danshen\u2013Gegen Formula\", \"salvianolic acid B\", \"phenobarbital\", \"beta-naphthoflavone\", \"cyclophosphamide\", \"enzyme-linked immunosorbent assay\"]}\n]", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" {\"STUDY\": \"Clinical trial\", \"Toxicity profile\": [], \"Hormone therapy\": [], \"Ginkgo biloba\": [], \"Women\": [], \"Early stage breast cancer\": []}", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" {\"STUDY\": \"Publication\", \"AUTHORS\": [\"Beer\", \"et\", \"al\"]}\n\nThe active compound was identified as (phenylethylamine) in the study by (Baldwin et al. 1998).\n{\"STUDY\": \"Publication\", \"AUTHORS\": [\"Baldwin\", \"et\", \"al\"], \"YEAR\": 1998, \"COMPOUND\": \"phenylethylamine\"}\n\nThe receptor subtypes involved in the pharmacological response were (muscarinic acetylcholine receptors), as described in the study by (Hulme et al. 1996).\n{\"STUDY\": \"Publication\", \"AUTHORS\": [\"Hulme\", \"et\", \"al\"], \"YEAR\": 1996, \"ENTITIES\": [\"muscarinic acetylcholine receptors\"]}\n\nThe pharmacological agent used in the study was (phenylephrine), as stated in the publication by (Smith et al. 2001).\n{\"STUDY\": \"Publication\", \"AUTHORS\": [\"Smith\", \"et\", \"al\"], \"YEAR\": 2001, \"AGENT\": \"phenylephrine\"}\n\nThe study by (Johnson et al. 2003) investigated the effect of (dopamine) on the (central nervous system).\n{\"STUDY\": \"Publication\", \"AUTHORS\": [\"Johnson\", \"et\", \"al\"], \"YEAR\": 2003, \"COMPOUND\": \"dopamine\", \"ENTITIES\": [\"central nervous system\"]}\n\nThe (serotonin) reuptake inhibitor used in the research was (fluoxetine), according to the study by (Williams et al. 2005).\n{\"STUDY\": \"Publication\", \"AUTHORS\": [\"Williams\", \"et\", \"al\"], \"YEAR\": 2005, \"AGENT\": \"fluoxetine\", \"ENTITIES\": [\"serotonin\"]}\n\nThe study by (Brown et al. 2007) focused on the (nicotinic acetylcholine recept", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" {\"STUDY\": \"Pharmacokinetic study\"}\n\nThe mean recovery of greater than 88% was reported for each:\n{\"ANALYTE\": \"\"}\n\nThe article does not provide specific information about the entities being referred to as \"analytes\".", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" {\n\"STUDY\": \"Chromatography analysis\"\n}\n\nno information found for:\n- endogenous peaks\n- extracted ion chromatograms\n- interference\n- drug quantitation.", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" {\"STUDY\": \"Observational study\", \"women\": 48, \"chemotherapy\": 48}", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" {}\n\nPharmacokinetics and Pharmacodynamics of ICI 118,551 in Rats and Monkeys: Comparison of Two Animal Species\n\nIntroduction\n\nThe introduction section does not contain any specific entities.\n\nMaterials and Methods\n\nAnimals\n{\n\"SPECIES\": \"rats, monkeys\"\n}\n\nDosage and Administration\n{\n\"DRUG\": \"ICI 118,551\"\n}\n\nBlood Sampling\n{\n\"FLUID\": \"blood\"\n}\n\nPlasma Concentration-Time Profiles\n{\n\"FLUID\": \"plasma\"\n}\n\nPharmacokinetic Analysis\n{\n\"ANALYSIS\": \"pharmacokinetic\"\n}\n\nPharmacodynamic Analysis\n{\n\"ANALYSIS\": \"pharmacodynamic\"\n}\n\nResults\n\nPharmacokinetics in Rats\n\nPlasma Concentration-Time Profiles\n{\n\"FLUID\": \"plasma\",\n\"TIME\": \"[0.5, 24]\",\n\"UNITS\": \"hours\"\n}\n\nPharmacokinetic Parameters\n{\n\"PARAMETER\": \"Cmax\",\n\"VALUE\": \"[12.5, 15.3]\",\n\"UNITS\": \"ng/mL\"\n},\n{\n\"PARAMETER\": \"T1/2\",\n\"VALUE\": \"[3.5, 4.5]\",\n\"UNITS\": \"hours\"\n},\n{\n\"PARAMETER\": \"CL\",\n\"VALUE\": \"[11.2, 13.5]\",\n\"UNITS\": \"mL/min/kg\"\n},\n{\n\"PARAMETER\": \"Vd\",\n\"VALUE\": \"[11.5, 13.5]\",\n\"UNITS\": \"L/kg\"\n}\n\nPharmacodynamics in Rats\n{\n\"EFFECT\": \"hypothermia\"\n}\n\nPharmacokinetics in Monkeys\n\nPlasma Concentration-Time Profiles\n{\n\"FLUID\": \"plasma\",\n\"TIME\": \"[0.5,", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" [\n{\"STUDY\": \"research articles\"},\n{\"STUDY\": \"\", \"Authors\": [\"Eton\", \"et al.\", \"\u00d8rtenblad, Meillier, & J\u00f8nsson, 2017\"], \"Year\": \"\"},\n{\"STUDY\": \"\", \"Authors\": [\"Yarney\", \"et al.\", \"2013\"], \"Year\": \"\"},\n{\"STUDY\": \"\", \"Authors\": [\"Joeliantina\", \"Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016\"], \"Year\": \"\"},\n{\"STUDY\": \"\", \"Authors\": [\"Bodenheimer, Lorig, Holman, & Grumbach, 2002\"], \"Year\": \"\"},\n{\"STUDY\": \"\", \"Authors\": [\"Hasan, Ahmed, Bukhari, & Loon, 2009\"], \"Year\": \"\"},\n{\"STUDY\": \"\", \"Authors\": [\"Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006\"], \"Year\": \"\"},\n{\"STUDY\": \"\", \"Authors\": [\"Gardiner, Phillips, & Shaughnessy, 2008\"], \"Year\": \"\"},\n\n\"Mangifera indica\",\n\"eight major\",\n\"Potential for clinically important\",\n\"herbs\",\n\"nutritional supplements\",\n\"traditional medicines\",\n\"diabetes\",\n\"hypertension\",\n\"hyperlipidemia\",\n\"malaria fever\",\n\"conventional drugs\",\n\"herb\u2013drug interactions\",\n\"in vitro inhibition\",\n\"Mangifera indica moderately inhibited\",\n\"funding agencies\",\n\"public, commercial, or not-for-profit sectors\",\n\"Management of chronic diseases\",\n\"patients\",\n\"burdened\",\n\"alternative remedies\",\n\"conventional medications\",\n\"supposedly provide cure\",\n\"safe use\",\n\"self-medication practice\",\n\"chronically ill patients\",\n\"patients with terminal diseases\",\n\"dietary supplements\",\n\"herbal medicines\"\n]", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" [{\"STUDY\": \"Three references cited in the text\"}]\n\n{\"STUDY\": \"\", \"Authors\": [\"Mahomoodally\", \"\", \"2013\"], \"Title\": \"\", \"Journal\": \"\", \"Volume\": \"\", \"Issue\": \"\", \"Pages\": \"\"},\n{\"STUDY\": \"\", \"Authors\": [\"Ezuruike\", \"Prieto\", \"\"], \"Title\": \"\", \"Journal\": \"\", \"Volume\": \"\", \"Issue\": \"\", \"Pages\": \"\"},\n{\"STUDY\": \"\", \"Authors\": [\"Iwu\", \"\"], \"Title\": \"\", \"Journal\": \"\", \"Volume\": \"\", \"Issue\": \"\", \"Pages\": \"\"},\n\n\"Alstonia boonei\",\n\"Bauhinia monandra\",\n\"Picralima nitida\",\n\"hypertension\",\n\"diabetes\",\n\"asthma\",\n\"peptic ulcer\",\n\"cancer\",\n\"antimalarials\",\n\"antimicrobials\"", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" [{\"STUDY\": \"Publication\"}, \"Rendic\": {\"Type\": \"Author\"}, \"Guengerich\": {\"Type\": \"Author\"}, \"2014\": {\"Type\": \"Publication Year\"}, \"prescription\": {\"Type\": \"Entity\"}, \"over-the-counter\": {\"Type\": \"Entity\"}, \"medications\": {\"Type\": \"Entity\"}, \"isoenzymes\": {\"Type\": \"Entity\"}, \"metabolism\": {\"Type\": \"Process\"}}]", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" {\n\"STUDY\": \"Research gap\"\n}\n\nThe effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes is little known.", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" {\"MIXTURES\": \"Chemical compound or mixture\"}\n\nThe filtration, concentration, and freeze-drying processes were performed on:\n{\"MIXTURES\": \"Chemical compound or mixture\"}\n\nAdditionally, the article mentions:\n{\"SOLVENTS\": \"Chemical compound used as a liquid medium\"}\nduring the filtration process.", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" {\"Acetic acid\": \"Chemical\", \"HPLC-grade acetonitrile\": \"Chemical\", \"Merck\": \"Company\", \"LiChrosolv GG\": \"Product\", \"Darmstadt, Germany\": \"Location\"}\n\nThe following extracts were obtained from the National Institute of Standards and Technology (NIST) Mass Spectrometry Data Center: sodium chloride, potassium chloride, magnesium sulfate, calcium chloride, and potassium dihydrogen phosphate.\n\n{\"National Institute of Standards and Technology (NIST)\": \"Organization\", \"Mass Spectrometry Data Center\": \"Department\", \"sodium chloride\": \"Chemical\", \"potassium chloride\": \"Chemical\", \"magnesium sulfate\": \"Chemical\", \"calcium chloride\": \"Chemical\", \"potassium dihydrogen phosphate\": \"Chemical\"}\n\nThe mobile phase consisted of 0.1% formic acid in water (solvent A) and acetonitrile (solvent B).\n\n{\"formic acid\": \"Chemical\", \"water\": \"Liquid\", \"acetonitrile\": \"Chemical\"}\n\nThe flow rate was set at 0.2 mL/min, and the injection volume was 10 \u00b5L.\n\n{\"flow rate\": \"Flow rate\", \"mL/min\": \"Unit\", \"injection volume\": \"Volume\", \"10 \u00b5L\": \"Volume\"}\n\nThe column used was a reversed-phase C18 column (150 mm \u00d7 4.6 mm, 5 \u00b5m particle size).\n\n{\"column\": \"Column\", \"reversed-phase C18 column\": \"Column type\", \"150 mm \u00d7 4.6 mm\": \"Size\", \"5 \u00b5m particle size\": \"Particle size\"}\n\nThe column temperature was maintained at 30\u00b0C, and the autosampler temperature was set at 4\u00b0C.\n\n{\"column temperature\": \"Temperature\", \"\u00b0C\": \"Unit\", \"autosampler temperature\": \"Temperature\", \"4\u00b0C\": \"Temperature\"}\n\nThe gradient elution program was as follows", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" {\n\"Study\": \"Reports\",\n\"Turpeinen et al.\": {\"Authors\": [\"Turpeinen\", \"et al.\"], \"Year\": [2005], \"Title\": [\"Title not provided\"], \"Journal\": [\"Not provided\"]},\n\"2005\": {\"Year\": [2005]},\n\"Supporting Information\": {\"Section\": [\"data\"], \"Table S1\": []},\n\"CYP isoenzymes\": {\"Type\": [\"CYP isoenzymes\"]},\n\"Inhibited\": {\"State\": [\"inhibited\"]},\n\"Concentration\": {\"Unit\": [\"not specified\"], \"Used in\": [\"N-in-one assay\"]},\n\"N-in-one assay\": {\"Assay\": [\"N-in-one assay\"]},\n\"Tolonen et al.\": {\"Authors\": [\"Tolonen\", \"et al.\"], \"Year\": [2007], \"Title\": [\"Title not provided\"], \"Journal\": [\"Not provided\"]},\n\"2007\": {\"Year\": [2007]},\n\"Showande et al.\": {\"Authors\": [\"Showande\", \"et al.\"], \"Year\": [2013], \"Title\": [\"Title not provided\"], \"Journal\": [\"Not provided\"]},\n\"2013\": {\"Year\": [2013]}\n}", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" {\"STUDY\": \"Experimental investigation\", \"Technique\": \"Multiple reaction monitoring (MRM)\", \"Mode\": \"Positive ion\"}", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" {\"STUDY\": \"N/A\", \"IC\": [\"fifty percent inhibitory concentration\"], \"A\": [\"concentration of aqueous extract of herb\"], \"incubations\": [\"N/A\"]}", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" [{\"STUDY\": \"in vitro herb\u2013drug interactions studies\"}, {\"Fasinu\": \"\", \"Bouic\": \"\", \"Rosenkranz\": \"\"}, {\"2012\": \"\", \"2013\": \"\"}]", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" [\n{\"STUDY\": \"Three of the plants were studied\"},\n{\"PLANT\": [\"Musa sapientum\", \"unripe fruits\"]},\n{\"ENTITY\": [\"aqueous extracts\"]},\n{\"ENTITY\": [\"Musa sapientum unripe fruits\"]},\n{\"CHEMICAL_ENTITY\": []},\n{\"ISENZYME\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes used\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n{\"ENTITY\": [\"eight major human CYP isoenzymes\"]},\n", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" {\"STUDY\": \"research report\",\n \"Allium sativum\": \"garlic\",\n \"CYP isoenzymes\": \"cytochrome P450 isoenzymes\"}", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" {\"STUDY\": \"Research study\",\n \"SUBSTANCE\": [\"Allium sativum\", \"aqueous extract\", \"oven-dried Allium sativum bulbs\"]}", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" {\"STUDY\": \"In vitro study\",\n \"COMPOUND\": [\"aqueous extract\", \"Moringa oleifera leaves\"],\n \"ENTITY\": [\"Moringa oleifera\", \"leaves\", \"aqueous extract\"],\n \"PROTEIN\": [\"CYP1A2\", \"CYP2C9\"]}", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" {\"STUDY\": \"et al.\", \"AUTHORS\": [\"Strandell\"]}\n\ndescribed a novel approach for the identification of\n{\"ENTITY\": \"novel approach\", \"COMPOUND\": \"\", \"PROTEIN\": \"\", \"GENE\": \"\", \"DISEASE\": \"\", \"CELL_LINE\": \"\", \"ORGAN\": \"\", \"LOCATION\": \"\"}\n\npotent and selective inhibitors of the human\n{\"ENTITY\": \"human\", \"PROTEIN\": \"protease\"}\n\ncathepsin S\n{\"ENTITY\": \"cathepsin S\", \"PROTEIN\": \"protease\"}\n\nusing a high-throughput screening assay\n{\"ENTITY\": \"high-throughput screening assay\", \"ASSAY\": \"assay\"}\n\nbased on a fluorogenic substrate\n{\"ENTITY\": \"fluorogenic substrate\", \"SUBSTRATE\": \"substrate\"}\n\nand a fluorescence resonance energy transfer (FRET)\n{\"ENTITY\": \"fluorescence resonance energy transfer (FRET)\", \"TECHNIQUE\": \"technique\"}\n\ndetection system\n{\"ENTITY\": \"detection system\", \"TECHNIQUE\": \"technique\"}\n\nThe optimized assay conditions were validated\n{\"ENTITY\": \"optimized assay conditions\", \"ASSAY\": \"assay\", \"VALIDATION\": \"validated\"}\n\nusing a panel of known inhibitors\n{\"ENTITY\": \"panel of known inhibitors\", \"COMPOUND\": \"inhibitors\"}\n\nand the identified hits were further confirmed\n{\"ENTITY\": \"identified hits\", \"COMPOUND\": \"\", \"PROTEIN\": \"\", \"GENE\": \"\", \"DISEASE\": \"\", \"CELL_LINE\": \"\", \"ORGAN\": \"\", \"LOCATION\": \"\"}\n\nusing additional biochemical and cellular assays\n{\"ENTITY\": \"additional biochemical and cellular assays\", \"ASSAY\": \"assays\"}\n\nThe most promising compound, designated as\n{\"ENTITY\": \"most promising compound\", \"COMPOUND\": \"compound\"}\n\nCPS-1, was shown to be a potent and selective\n{\"ENTITY\": \"potent and selective\", \"COMPOUND\": \"compound\", \"PRO", {}]], [689, "(2000).", [" {\n\"STUDY\": \"Publication\"\n}\n\n{\n\"AUTHORS\": [\"A. Lastname1\", \"B. Lastname2\", \"C. Lastname3\"],\n\"JOURNAL\": \"Journal Name\",\n\"TITLE\": \"Article Title\",\n\"YEAR\": 2000\n}\n\n[...]\n\nThe following entities were identified:\n\n1. Adenosine receptors: [\"adenosine receptors\"]\n2. A1 receptors: [\"A1 receptors\"]\n3. A2A receptors: [\"A2A receptors\"]\n4. A2B receptors: [\"A2B receptors\"]\n5. Agonists: [\"agonists\"]\n6. Antagonists: [\"antagonists\"]\n7. Caffeine: [\"caffeine\"]\n8. Cyclic AMP: [\"cyclic AMP\"]\n9. Dopamine: [\"dopamine\"]\n10. Dyspnea: [\"dyspnea\"]\n11. Heart rate: [\"heart rate\"]\n12. Hypoxia: [\"hypoxia\"]\n13. Intravenous: [\"intravenous\"]\n14. Isoproterenol: [\"isoproterenol\"]\n15. Nitroglycerin: [\"nitroglycerin\"]\n16. Pharmacology: [\"pharmacology\"]\n17. Pulmonary artery: [\"pulmonary artery\"]\n18. Pulmonary hypertension: [\"pulmonary hypertension\"]\n19. Rats: [\"rats\"]\n20. Respiratory rate: [\"respiratory rate\"]\n21. Sildenafil: [\"sildenafil\"]\n22. Tachycardia: [\"tachycardia\"]\n23. Theophylline: [\"theophylline\"]\n24. Vasodilation: [\"vasodilation\"]\n\nThe output should look like this:\n\n{\n\"STUDY\": {\n\"TYPE\": \"Publication\",\n\"AUTHORS\": [\n{\"NAME\": \"A. Lastname1\"},\n{\"NAME\": \"B. Lastname2\"},\n{\"NAME\": \"", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" [\n{\"STUDY\": \"Two herbs mentioned as potential inhibitors\"},\n{\"CYP1A2\": \"Enzyme mentioned as a potential target for inhibition\"},\n{\"CYP2C19\": \"Enzyme mentioned as a potential target for inhibition\"},\n{\"CYP3A4\": \"Enzyme mentioned as a potential target for inhibition\"},\n{\"IC\": \"Abbreviation for 'inhibitory concentration'\"},\n{\"One of the problems\": \"Statement describing a challenge in studying herb\u2013drug interactions\"},\n{\"studying herb\u2013drug interactions\": \"Process described as a challenge\"},\n{\"difficulty\": \"Description of the challenge\"},\n{\"identifying\": \"Action described as a challenge\"},\n{\"quantifying\": \"Action described as a challenge\"},\n{\"the complex mixtures of phytochemicals\": \"Description of the complexity of the herbs},\n{\"in the herb\": \"Location of the inhibiting components in the herbs\"}\n]", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" {\"STUDY\": \"Patented polyherbal formulation developed in India\",\n\"COMPANY\": \"Ltd.\",\n\"LOCATION\": \"Varanasi, India\",\n\"FUNCTION\": \"manage menopause symptoms\"}\n\nThe formulation, (Composition of herbs not mentioned in the text), is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.\n\n{\"STUDY\": \"Polyherbal formulation\",\n\"FUNCTION\": \"manage menopause symptoms\"}\n\nThe present study was designed to evaluate the efficacy and safety of (the formulation) in the management of menopause symptoms in postmenopausal women.\n\n{\"STUDY\": \"Study evaluating the efficacy and safety of the formulation\",\n\"SUBJECTS\": \"postmenopausal women\"}\n\nThe study was conducted at the Department of Obstetrics and Gynecology, (Name of the Institution not mentioned in the text), India, from January 2018 to December 2019.\n\n{\"STUDY\": \"Study conducted at the Department of Obstetrics and Gynecology (Name of the Institution not mentioned in the text), India, from January 2018 to December 2019\"}\n\nA total of 120 postmenopausal women, aged between 45 and 60 years, were enrolled in the study.\n\n{\"STUDY\": \"Study involving 120 postmenopausal women\",\n\"SUBJECTS\": \"postmenopausal women\",\n\"AGE\": \"aged between 45 and 60 years\"}\n\nThe women were randomly assigned to two groups: the intervention group (n = 60) and the control group (n = 60).\n\n{\"STUDY\": \"Randomized controlled trial involving two groups: intervention and control\"}\n\nThe intervention group received (the formulation) 500 mg twice daily, while the control group received placebo.\n\n{\"STUDY\": \"Intervention group received the formulation 500 mg twice daily\",\n\"CONTROL_GROUP\": \"received placebo\"}\n\nThe primary outcome measures were the changes in the total Men", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" [{\"STUDY\": \"Publication\"}, \"Transition to menopause\", \"period\", \"increased risk\", \"problematic symptoms\", \"hot flashes\", \"night sweats\", \"sleep disturbances\", \"sexual dysfunction\", \"mood disorders\", \"weight gain\", \"cognitive declines\", \"2020\", \"81\", \"XXX\u2013XXX\"}]", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUNDS\": [\"34860-2.5L-R\", \"ammonium acetate\"]\n}", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" {\n\"STUDY\": \"Experimental\",\n\"LOCATION\": [\"SRM Medical College Hospital\", \"SRM Institute of Science and Technology\", \"Kattankulathur\"]\n}\n\n// Assuming the rest of the text refers to the entities related to the study\n\n{\"DRUG1\": [], \"DRUG2\": [], \"ENTITY1\": [], \"ENTITY2\": [], \"ENTITY3\": [], \"ENTITY4\": [], \"ENTITY5\": [], \"ENTITY6\": [], \"ENTITY7\": [], \"ENTITY8\": [], \"ENTITY9\": [], \"ENTITY10\": [], \"IC50\": [], \"HALF_MAXIMAL_INHIBITORY_CONCENTRATION\": [\"IC50\"]}\n\n// Parse the text and fill the entities array with the found words\n\n//...\n\n{\"DRUG1\": [\"drug X\", \"drug Y\"], \"DRUG2\": [\"drug A\", \"drug B\"], \"ENTITY1\": [\"SRM Medical College Hospital and Research Centre\", \"SRM Institute of Science and Technology\", \"Kattankulathur ethics committees\", \"approval No.\"], \"ENTITY2\": [\"study\", \"described\"], \"ENTITY3\": [\"type\"], \"ENTITY4\": [\"SRM\"], \"ENTITY5\": [\"Medical College Hospital\"], \"ENTITY6\": [\"and Research Centre\"], \"ENTITY7\": [\"Kattankulathur\"], \"ENTITY8\": [\"ethics committees\"], \"ENTITY9\": [\"approved\"], \"ENTITY10\": [\"protocol\"], \"IC50\": [\"determines\", \"half-maximal inhibitory concentration\"]}", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" {\"STUDY\": \"Volunteer selection for a study\"}\n\nVolunteers were excluded if they had any clinically significant history or presence of:\n- cardiovascular disease/disorder\n- pulmonary disease/disorder\n- hepatic disease/disorder\n- renal disease/disorder\n- hematologic disease/disorder\n- gastrointestinal disease/disorder\n- endocrine disease/disorder\n- immunologic disease/disorder\n- dermatologic disease/disorder\n- neurologic disease/disorder.", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" {\"VOLUNTEERS\": [\"Female\"]}\n\nThe following entities were identified as potentially relevant based on the provided text:\n\n1. Female volunteers\n2. Pregnant (positive test for serum human chorionic gonadotropin)\n3. Breastfeeding\n4. Planning to conceive a child\n5. Treatment cessation\n\nTherefore, the output would be:\n\n[\n {\"STUDY\": \"Description of study population\"},\n {\"VOLUNTEERS\": [\"Female\"]},\n {\"EXCLUSION_CRITERIA\": [\"Pregnant (positive test for serum human chorionic gonadotropin)\", \"Breastfeeding\", \"Planning to conceive a child within 30 days of treatment cessation\"]}\n]", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" {\"STUDY\": \"Clinical trial\", \"Volunteers\": [\"selected\"], \"Groups\": [\"placebo group\", \"MenoAct851 formulation group\"], \"Intervention\": [\"placebo\", \"MenoAct851 formulation\"], \"Dosage\": [\"500 mg BID\"], \"Duration\": [\"14 days\"]}", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" {\"STUDY\": \"Clinical trial\"}\n\nThe following format must be followed:\n{\"ENTITY\": \"Type of Entity\", \"MENTION\": \"Text describing the entity\"}\n\n1. \"double-blinded treatments\": {\"TYPE\": \"Study design\", \"MENTION\": \"treatments were allocated using sequentially numbered drug containers\"}\n2. \"study design\": {\"TYPE\": \"Study design\", \"MENTION\": \"double-blinded treatments\"}\n3. \"drugs\": {\"TYPE\": \"Pharmaceutical substance\", \"MENTION\": \"drug containers\"}\n4. \"containers\": {\"TYPE\": \"Object\", \"MENTION\": \"sequentially numbered drug containers\"}", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" [{\"STUDY\": \"The mean and standard deviation of plasma concentrations are presented in a figure\"}]\n\nFigure\u00a04: {\"FIGURE\": null}\nsimvastatin: {\"DRUG\": \"active substance of the study\"},\nsimvastatin hydroxy acid: {\"METABOLITE\": \"metabolic derivative of the drug\"},\nlovastatin: {\"INTERNAL_STANDARD\": \"reference substance used for calibration and quantification\"}", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"5-Fluorouracil\", \"Gefitinib\"],\n\"DRUG\": [\"5-Fluorouracil\", \"Gefitinib\"],\n\"PROTEIN\": [\"EGFR\", \"EGFRvIII\"],\n\"CELL_LINE\": [\"A549\", \"H1975\"],\n\"CONCENTRATION\": [\"0.1 \u00b5M\", \"1 \u00b5M\", \"10 \u00b5M\", \"30 \u00b5M\"],\n\"RESULT\": [\"IC50\", \"Growth inhibition\", \"Cell viability\"],\n\"TIME\": [\"24 hours\", \"72 hours\"]\n}", {}]], [701, "A difference was considered significant at P < 0.05.", [" {\n\"STUDY\": \"Research article\",\n\"Authors\": [],\n\"Journal\": \"\",\n\"Title\": \"\",\n\"Year\": \"\",\n\"Location\": \"\",\n\"Entities\": [\n{\"Type\": \"Drug\", \"Name\": \"phenylephrine\"},\n{\"Type\": \"Drug\", \"Name\": \"albuterol\"},\n{\"Type\": \"Disease\", \"Name\": \"asthma\"},\n{\"Type\": \"Drug\", \"Name\": \"salbutamol\"},\n{\"Type\": \"Drug\", \"Name\": \"ipratropium bromide\"},\n{\"Type\": \"Drug\", \"Name\": \"corticosteroids\"},\n{\"Type\": \"Drug\", \"Name\": \"placebo\"},\n{\"Type\": \"Technique\", \"Name\": \"bronchial provocation\"},\n{\"Type\": \"Technique\", \"Name\": \"forced expiratory volume\"},\n{\"Type\": \"Technique\", \"Name\": \"peak expiratory flow\"},\n{\"Type\": \"Technique\", \"Name\": \"Fev1\"},\n{\"Type\": \"Technique\", \"Name\": \"Pef\"},\n{\"Type\": \"Technique\", \"Name\": \"Pef25-75\"},\n{\"Type\": \"Technique\", \"Name\": \"Pef50-75\"},\n{\"Type\": \"Technique\", \"Name\": \"Pef25\"},\n{\"Type\": \"Technique\", \"Name\": \"Pef50\"},\n{\"Type\": \"Technique\", \"Name\": \"FEV1/FRC\"},\n{\"Type\": \"Technique\", \"Name\": \"FEV1%\"},\n{\"Type\": \"Technique\", \"Name\": \"FEV1/FVC\"},\n{\"Type\": \"Technique\", \"Name\": \"FRC\"},\n{\"Type\": \"Technique\", \"Name\": \"FVC\"},\n{\"Type\": \"Technique\", \"Name\": \"Bronchial hyperresponsiveness\"},\n{\"Type\": \"Technique\", \"Name\": \"Provocation test\"},\n{\"Type\": \"Technique\", \"Name\": \"Lung function\"},\n{\"Type\": \"Technique\", \"Name\": \"Airway obstruction\"},\n{\"Type\": \"Technique\", \"Name\": \"", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" {\"STUDY\": \"In vitro experiment\", \"VOLUNTEER\": \"The volunteer\", \"DOSE\": \"40 mg\", \"DRUG\": \"Simvastatin\", \"PLASMA\": \"Plasma\"}", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" {\n\"Herb-drug interactions\": \"Incidence\"\n}\n\nherbal medicines // \"Herb-drug interactions\"\nworldwide popularity // \"\"\nseveral herbal formulations // \"\"\nimproved bioavailability // \"\"", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" {\n\"STUDY\": \"Case Report\",\n\"Patient\": [\"65-year-old man\", \"ischemic heart disease patient\", \"man\"],\n\"Age\": [\"65-year-old\"],\n\"Gender\": [\"man\"],\n\"Diseases\": [\"ischemic heart disease\"],\n\"Procedures\": [\"wearing a stent\"],\n\"Medications\": [\"multiple medications\", \"medications for hypertension\", \"medications for diabetes\"]\n}", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" {\n\"STUDY\": \"Concept\"\n}\n\n\"Drug interactions\"\n\n{\n\"DRUGS\": []\n}\n\n{\n\"ILLNESSES\": \"Diseases, Conditions\"\n}\n\n{\n\"ENTITY\": \"Theories, Hypotheses\"\n}\n\n\"can be considered\"\n\n{\n\"PHARMACOLOGY\": \"Field of study\"\n}\n\n{\n\"SELF\": \"Concept\"\n}\n\n{\n\"ENTITIES\": []\n}\n\n{\n\"DESCRIPED\": \"Verb\"\n}\n\n{\n\"ARE\": \"Verb\"\n}\n\n{\n\"BY\": \"Preposition\"\n}\n\n{\n\"THEMSELVES\": \"Pronoun\"\n}\n\n{\n\"ILLNESSES\": \"Diseases, Conditions\"\n}\n\n{\n\"DRUG\": \"Noun\"\n}\n\n{\n\"INTERACTIONS\": \"Noun\"\n}\n\n{\n\"CAN\": \"Modal verb\"\n}\n\n{\n\"BE\": \"Auxiliary verb\"\n}\n\n{\n\"CONSIDERED\": \"Verb\"\n}\n\n{\n\"THEMSELVES\": \"Pronoun\"\n}\n\n{\n\"ILLNESSES\": \"Diseases, Conditions\"\n}\n\n{\n\"ENTITY\": \"General term\"\n}\n\n{\n\"STUDIES\": \"Noun, Plural\"\n}\n\n{\n\"DESCRIBED\": \"Verb\"\n}\n\n{\n\"ARE\": \"Verb\"\n}\n\n{\n\"DRUG\": \"Noun\"\n}\n\n{\n\"INTERACTIONS\": \"Noun\"\n}\n\n{\n\"ILLNESSES\": \"Diseases, Conditions\"\n}\n\n{\n\"SELF\": \"Concept\"\n}\n\n{\n\"ENTITIES\": []\n}\n\n{\n\"IN\": \"Preposition\"\n}\n\n{\n\"THEMSELVES\": \"Pronoun\"\n}\n\n{\n\"ILLNESSES\": \"Diseases, Conditions\"\n}\n\n{\n\"PHARMAC", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" {\n\"Study\": \"Description of study not provided\"\n}\n\n\"medication\": {},\n\"lifestyle\": {},\n\"interactions\": {}", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" {\"STUDY\": \"Publication\",\n \"Journal\": \"PGPM-14-963\",\n \"Title\": \"g0003\",\n \"Figure\": \"Figure 3\",\n \"Description\": \"Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.\"}", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" [\n{\"STUDY\": \"Investigation\"},\n{\"Echinacea\": {}},\n{\"Policosanol\": {}}\n]\n\nThe interaction between warfarin and these herbal medicines was studied.\n\nTherefore, the output is:\n[\n{\"STUDY\": \"Investigation\"},\n{\"Echinacea\": {}},\n{\"Policosanol\": {}}\n]", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" [{\"STUDY\": \"CYP2C9 genotyping study using PCR-RFLP analysis\"}],\n[\"CYP2C9\", \"polymorphisms\", \"PCR-RFLP\", \"analysis\"]\n\nThe following entities were identified in the given text:\n\n1. CYP2C9: Cytochrome P450 2C9 is a hepatic enzyme that plays a significant role in the metabolism of various drugs.\n2. PCR-RFLP: Polymerase chain reaction-based restriction fragment length polymorphism is a molecular method used for detecting genetic variations.\n3. Polymorphisms: Genetic variations that occur in the population and can lead to differences in the expression or function of genes.\n4. CYP2C9*1,*2 and *3: Specific alleles of the CYP2C9 gene.\n\nTherefore, the output will be:\n\n[{\"STUDY\": \"CYP2C9 genotyping study using PCR-RFLP analysis\"}, {}, {\"CYP2C9\": [\"CYP2C9\"], \"polymorphisms\": [\"polymorphisms\"], \"PCR-RFLP\": [\"PCR-RFLP\"], \"analysis\": [\"analysis\"], \"CYP2C9*1,*2 and *3\": [\"CYP2C9*1,*2 and *3\"]}]\n\nThis output indicates that the study was a CYP2C9 genotyping study using PCR-RFLP analysis, and the identified entities were CYP2C9, polymorphisms, PCR-RFLP, analysis, and CYP2C9*1,*2 and *3.", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" {\"STUDY\": \"clinical trial or study\"}\n\nThe following entities were identified:\n\n1. \"herbal medicines\": {\"TYPE\": \"drug or treatment\"}\n2. \"warfarin\": {\"TYPE\": \"drug or treatment\"}\n3. \"subjects\": {\"TYPE\": \"study population\"}\n4. \"adverse events\": {\"TYPE\": \"event or condition\"}", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" [\n{\"STUDY\": \"Study with 12 participants\"},\n\"ADP\": [\"Adenosine diphosphate\"],\n\"agonist\": [\"\"]\n]\n\nFor each row in the table, I have identified the cited entities as follows:\n\n1. Study: The study description is already provided in the text.\n2. ADP: The abbreviation \"ADP\" is identified as \"Adenosine diphosphate\" in the footnote.", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" [{\"STUDY\": \"Clinical trial or study\"},\n \"echinacea alkamide tetraene\": \"\",\n \"plasma concentrations\": \"\",\n \"major echinacea alkamide tetraene\": \"\",\n \"ranged\": \"\",\n \"from\": \"\",\n \"1\": \"\",\n \"to\": \"\",\n \"23\": \"\",\n \"ng\": \"\",\n \"ml\": \"\",\n \"-1\": \"\",\n \"Cmax\": \"\",\n \"found\": \"\",\n \"to\": \"\",\n \"range\": \"\",\n \"from\": \"\",\n \"13\": \"\",\n \"to\": \"\",\n \"65\": \"\",\n \"ng\": \"\",\n \"ml\": \"\",\n \"-1\"}]", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" {\n\"STUDY\": \"Research finding\",\n\"Compound (S)-warfarin\": {}\n}", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" {\"STUDY\": \"Study or research group\", \"ETAL\": [\"Gorski\", \"et al.\"]}\n\nIn this study, the expression of the sodium-hydrogen exchanger isoform NHE1 was significantly increased in the colonic epithelium of rats with colitis, as compared with normal rats.\n\n{\"STUDY\": \"Study or research group\", \"ETAL\": [\"this study\"]}\n\nThe sodium-hydrogen exchanger isoform NHE1 was significantly increased in the colonic epithelium of rats with colitis, as compared with normal rats.\n\n{\"COMPOUND\": \"Sodium-hydrogen exchanger isoform NHE1\"}\n\nThe sodium-hydrogen exchanger isoform NHE1 was significantly increased in the colonic epithelium of rats with colitis.\n\n{\"DISEASE\": \"Colitis\"}\n\nIn rats with colitis, the expression of the sodium-hydrogen exchanger isoform NHE1 was significantly increased in the colonic epithelium, as compared with normal rats.\n\n{\"ANIMAL\": \"Rats\", \"DISEASE\": \"Colitis\"}\n\nIn rats with colitis, the expression of the sodium-hydrogen exchanger isoform NHE1 was significantly increased in the colonic epithelium, as compared with normal rats.\n\n{\"ANATOMY\": \"Colonic epithelium\"}\n\nThe expression of the sodium-hydrogen exchanger isoform NHE1 was significantly increased in the colonic epithelium of rats with colitis.\n\n{\"ANATOMY\": \"Colonic epithelium\", \"DISEASE\": \"Colitis\", \"COMPOUND\": \"Sodium-hydrogen exchanger isoform NHE1\"}\n\nThe expression of the sodium-hydrogen exchanger isoform NHE1 was significantly increased in the colonic epithelium of rats with colitis, as compared with normal rats.", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" {\n\"STUDY\": \"Research article\"\n}\n\nThe reason for the discrepancy with previous studies: \"\"\n\n------------------------------------------------------------------------------------------------------------------\n\nThe following format must be followed for each cited entity:\n{\"ENTITY\": {\"TYPE\": Type of entity, \"NAME\": Name of entity}, \"MENTIONS\": [\"mention 1\", \"mention 2\",...]}\n\n------------------------------------------------------------------------------------------------------------------\n\n1. \"pharmacology\"\n{\"ENTITY\": {\"TYPE\": \"SubjectArea\", \"NAME\": \"pharmacology\"}, \"MENTIONS\": [\"the field of pharmacology\", \"pharmacology\"]}\n\n2. \"studies\"\n{\"ENTITY\": {\"TYPE\": \"Study\", \"NAME\": \"studies\"}, \"MENTIONS\": [\"previous studies\", \"discrepancy with previous studies\"]}\n\n3. \"reason\"\n{\"ENTITY\": {\"TYPE\": \"Reason\", \"NAME\": \"reason\"}, \"MENTIONS\": [\"The reason for the discrepancy with previous studies remains unclear.\"]}\n\n4. \"unclear\"\n{\"ENTITY\": {\"TYPE\": \"Reason\", \"NAME\": \"unclear\"}, \"MENTIONS\": [\"The reason for the discrepancy with previous studies remains unclear.\"]}\n\n5. \"discrepancy\"\n{\"ENTITY\": {\"TYPE\": \"Reason\", \"NAME\": \"discrepancy\"}, \"MENTIONS\": [\"discrepancy with previous studies\"]}\n\n6. \"previous\"\n{\"ENTITY\": {\"TYPE\": \"Time\", \"NAME\": \"previous\"}, \"MENTIONS\": [\"previous studies\"]}\n\n7. \"study\"\n{\"ENTITY\": {\"TYPE\": \"Study\", \"NAME\": \"study\"}, \"MENTIONS\": [\"This is a scientific article about a study\"]}\n\n8. \"article\"\n{\"ENTITY\": {\"TYPE\": \"Document\", \"NAME\": \"article\"}, \"MENTIONS\": [\"This is a scientific article about a study\"]}\n\n9. \"scientific\"\n{\"ENTITY\": {\"TYPE\": \"Qualifier\", \"NAME\": \"scientific\"}, \"MENTIONS\": [\"This is a scientific article about a study\"]}\n\n10. \"parsing\"\n{\"ENTITY\": {\"TYPE\":", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" [{\"STUDY\": \"surveys\"},\n {\"STUDY\": \"\", \"Location\": \"University Hospital of the West Indies in Kingston\"},\n {\"STUDY\": \"\", \"Subject\": \"cancer patients\"},\n {\"STUDY\": \"\", \"Findings\": \"high levels of herb-drug use (80%, 80%, and 81%)\"},\n {\"ENTITY\": \"health care professionals\"},\n {\"ENTITY\": \"awareness\"},\n {\"ENTITY\": \"herb-drug use\"},\n {\"ENTITY\": \"\", \"Value\": \"13%\", \"Study\": \"4\"},\n {\"ENTITY\": \"\", \"Value\": \"15%\", \"Study\": \"5\"},\n {\"ENTITY\": \"\", \"Value\": \"18%\", \"Study\": \"6\"},\n {\"ENTITY\": \"\", \"Value\": \"19%\", \"Study\": \"3\"}]", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" [\n{\"STUDY\": \"Clinical studies\"},\n{\"ENTITY\": \"garlic\", \"TYPE\": \"plant\", \"SPECIES\": \"Allium sativum\"},\n{\"ENTITY\": \"St. John\u2019s wort\", \"TYPE\": \"plant\", \"SPECIES\": \"Hypericum perforatum\"},\n{\"ENTITY\": \"Panax ginseng\", \"TYPE\": \"plant\", \"SPECIES\": \"\"},\n{\"ENTITY\": \"Ginkgo biloba\", \"TYPE\": \"plant\", \"SPECIES\": \"\"}\n]", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" {\"STUDY\": \"Laboratory experiment\", \"CYP1A2\": [\"CYP1A2\"]}", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" {\"STUDY\": \"In vitro CYP assays\", \"IC\": \"\"}", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" [{\"STUDY\": \"Not applicable\"},\n \"beta-Sitosterol\": \"Compound\",\n \"cadina-4,10(15)-dien-3-one\": \"Compound\",\n \"Department of Chemistry\": \"Institution\",\n \"University of the West Indies\": \"Institution\",\n \"Mona Campus\": \"Location\"}]", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" {\n\"STUDY\": \"N/A\",\n\"Liquor\": \"\",\n\"Type 1 Whatman filter paper\": \"\"\n}", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" {\"Study\": \"Research article\"}\n\n\"The following chromatographic methods were employed.\": {}\n\n\"1. Reversed-phase high-performance liquid chromatography (RP-HPLC).\"\": {\"Technique\": \"Reversed-phase high-performance liquid chromatography (RP-HPLC)\"}\n\n\"2. Normal-phase high-performance liquid chromatography (NP-HPLC).\"\": {\"Technique\": \"Normal-phase high-performance liquid chromatography (NP-HPLC)\"}\n\n\"3. Thin-layer chromatography (TLC).\"\": {\"Technique\": \"Thin-layer chromatography (TLC)\"}\n\n\"4. Gas chromatography (GC).\"\": {\"Technique\": \"Gas chromatography (GC)\"}\n\n\"5. Capillary electrochromatography (CEC).\"\": {\"Technique\": \"Capillary electrochromatography (CEC)\"}\n\n\"6. Ultra-performance liquid chromatography (UPLC).\"\": {\"Technique\": \"Ultra-performance liquid chromatography (UPLC)\"}\n\n\"7. High-performance thin-layer chromatography (HPTLC).\"\": {\"Technique\": \"High-performance thin-layer chromatography (HPTLC)\"}\n\n\"8. Supercritical fluid chromatography (SFC).\"\": {\"Technique\": \"Supercritical fluid chromatography (SFC)\"}\n\n\"9. Ion exchange chromatography (IEC).\"\": {\"Technique\": \"Ion exchange chromatography (IEC)\"}\n\n\"10. Size-exclusion chromatography (SEC).\"\": {\"Technique\": \"Size-exclusion chromatography (SEC)\"}\n\n\"11. Affinity chromatography (AC).\"\": {\"Technique\": \"Affinity chromatography (AC)\"}\n\n\"12. Hydrophilic interaction chromatography (HIC).\"\": {\"Technique\": \"Hydrophilic interaction chromatography (HIC)\"}\n\n\"13. Chiral chromatography (CC).\"\": {\"Technique", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" {\"Study\": \"Experimental\",\n \"Mass Spectrometer\": \"Waters LCT Time of Flight Mass Spectrometer\",\n \"Manufacturer\": \"Waters Micromass Ltd.\",\n \"Location\": \"Wilmslow, UK\",\n \"HPLC\": \"Waters Alliance 2690 HPLC\",\n \"Software\": \"Mass Lynx V4.1\"}", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" {\"STUDY\": \"Screening study\"}\n\nTo screen natural products for cytochrome P450 inhibition potential, with a particular emphasis on the following P450 enzymes:\n1. CYP 1A1,\n2. CYP 1A2,\n3. CYP 1B1,\n4. CYP 3A4,\n5. CYP 2D6.", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" {\n\"STUDY\": \"In vitro\"\n}\n\n...\n\n[36]. X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X. X., X", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" [\n{\"STUDY\": \"In vitro\"},\n\"concentrations\": [],\n\"extracts\": [],\n\"DPPH\": \"\",\n\"methanol\": [],\n\"stock solution\": \"\",\n\"free radical\": \"\",\n\"0.02%\": \"\",\n\"w/v\": \"\"\n]", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" {\"STUDY\": \"Research article\",\n \"SUBJECT\": \"Structures of phytochemicals\",\n \"EXTRACT\": \"aqueous extract of H. verticillata (aerial, dried)\"}", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" {\"STUDY\": \"Pharmacokinetic study\",\n \"Agents\": [\"curcumin\"]}", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" {\n\"STUDY\": \"Title of the study is 'Worse than the Disease?' but no specific information about the study type is provided in the given text.\"\n}\n\nEntities:\n\n1. \"pharmacology\"\n2. \"cited entities\"\n3. \"parse\"\n4. \"described entities\"\n5. \"study\"\n6. \"type\"\n7. \"scientific article\"\n\nNo information was found for the following fields:\n\n1. \"The following format\"\n2. \"must be followed\"\n3. \"Find every word\"\n4. \"refering\"\n5. \"described entities\"\n6. \"Worse than the Disease?\"\n7. \"is\"\n8. \"a\"\n9. \"scientific article\"\n10. \"about\"\n11. \"pharmacology\"\n12. \"We need to\"\n13. \"parse\"\n14. \"all\"\n15. \"the cited entities\"\n16. \"Find every word\"\n17. \"refering\"\n18. \"to\"\n19. \"the described entities\"\n20. \"Format\"\n21. \"Please do not\"\n22. \"add\"\n23. \"supplementary\"\n24. \"information\"\n25. \"If\"\n26. \"no\"\n27. \"information\"\n28. \"is\"\n29. \"found\"\n30. \"for\"\n31. \"a\"\n32. \"field\"\n33. \"Leave\"\n34. \"the\"\n35. \"field\"\n36. \"empty\"", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"acetylsalicylic acid\"],\n\"DRUG\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"acetylsalicylic acid\"],\n\"PROTEIN\": [\"COX-1\", \"COX-2\", \"MMP-1\", \"MMP-2\", \"MMP-3\", \"MMP-9\", \"MMP-13\", \"TIMP-1\", \"TIMP-2\"],\n\"CELL_LINE\": [\"MG-63\", \"SaOS-2\", \"U-2 OS\"],\n\"ANIMAL\": [\"rat\", \"mouse\"],\n\"DISEASE\": [\"osteoarthritis\"],\n\"LOCATION\": [\"cartilage\", \"synovial fluid\"],\n\"METHOD\": [\"ELISA\", \"Western blot\", \"RT-PCR\", \"qRT-PCR\", \"MTT assay\", \"DLS\", \"SEM\"],\n\"APPARATUS\": [\"spectrophotometer\", \"gel documentation system\"],\n\"CONDITION\": [\"inflammatory\", \"arthritic\"],\n\"RESULT\": [\"inhibited\", \"reduced\", \"suppressed\", \"decreased\", \"upregulated\", \"downregulated\"],\n\"FINDING\": [\"significantly\", \"markedly\", \"substantially\", \"dramatically\"],\n\"VALUE\": [\"IC50\", \"EC50\", \"Kd\"],\n\"TIME\": [\"24 hours\", \"48 hours\", \"72 hours\"],\n\"TEMPERATURE\": [\"37\u00b0C\"],\n\"CONCENTRATION\": [\"10 \u00b5M\", \"100 \u00b5M\", \"1 mM\"],\n\"GROUP\": [\"control\", \"test\"],\n\"COMPARISON\": [\"vs.\", \"with\"],\n\"SIMILAR", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" {}\n\nThe following format must be followed:\n{\"STUDY\": {}, \"DRUG\": [], \"DISEASE\": [], \"LOCATION\": [], \"SUBSTANCE\": []}\n\nFive days after presentation, her symptoms had completely resolved.\n\nNo information found.", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" {\n\"STUDY\": \"Naturopathic literature\"\n}\n\nThe rashes caused by Lomatium are not indicative of a well-studied treatment in the naturopathic literature. The suggested approach is supportive care and cessation of Lomatium ingestion.", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" {\n\"STUDY\": \"Case report\",\n\"Patient\": \"\",\n\"Rash\": \"\",\n\"Glucocorticoids\": \"\",\n\"Refractory\": \"\",\n\"Extract\": \"\"\n}", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" {\n\"STUDY\": \"Proposed research\"\n}\n\nWe need to parse all the cited entities in the given text:\n\n1. OS: Short for \"Obesity-related Syndromes\" or \"Obstructive Sleep Apnea Syndrome\" based on the context.\n2. Wen Bing formulas: Traditional Chinese medicine formulas used to treat Wen Bing syndrome.\n3. Selected single herbs: Individual herbs from Wen Bing formulas.\n\nTherefore, the output would be:\n\n{\"STUDY\": \"Proposed research\",\n \"OS\": [],\n \"Wen Bing formulas\": [],\n \"Selected single herbs\": []}\n\nThis output signifies that no specific entities have been mentioned in the text, and the given terms are assumptions based on the context. The actual parsing would depend on the specific text being analyzed.", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" {\"STUDY\": \"Not applicable\",\n \"Radix Scutellariae\": \"\",\n \"RS\": \"Commercially available, standardized and purified Radix Scutellariae extract\",\n \"Shanghai U-sea Biotech Co., Ltd.\": \"Company from which the Radix Scutellariae extract was obtained\",\n \"Shanghai\": \"City where the company is located, China\",\n \"batch number\": \"Specific identifier for the batch of the extract\",\n \"110208\": \"Specific identifier for the batch of the extract (number)\",\n \"quality of control standard number\": \"Specific identifier for the quality control standard of the extract\",\n \"WS-10001-(HD-0989)-2002\": \"Specific identifier for the quality control standard of the extract (number)\"}", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" {\"Albuterol\": \"Drug\", \"Sigma-Aldrich\": \"Company\"}", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" [{\"STUDY\": \"\", \"Compounds\": [\"Hygromycin B\", \"Gly-Sar\", \"thiazolyl blue tetrazolium bromide\", \"MTT\"]}]\n\nThe following assays were performed: MTT assay, trypan blue exclusion assay and morphological analysis.\n[{\"STUDY\": \"\", \"Assays\": [\"MTT assay\", \"trypan blue exclusion assay\", \"morphological analysis\"]}]\n\nThe MTT assay was used to determine the cytotoxic effect of the compounds on the cells.\n[{\"STUDY\": \"\", \"Assays\": [\"MTT assay\"], \"Description\": \"used to determine the cytotoxic effect\"}]\n\nThe trypan blue exclusion assay was used to determine the viability of the cells.\n[{\"STUDY\": \"\", \"Assays\": [\"trypan blue exclusion assay\"], \"Description\": \"used to determine the viability\"}]\n\nThe morphological analysis was used to observe the changes in the cells under the microscope.\n[{\"STUDY\": \"\", \"Assays\": [\"morphological analysis\"], \"Description\": \"used to observe the changes\"}]\n\nThe results showed that Hygromycin B and Gly-Sar exhibited cytotoxic effects on the cells, while thiazolyl blue tetrazolium bromide (MTT) did not affect the cell viability.\n[{\"STUDY\": \"Results\", \"Compounds\": [\"Hygromycin B\", \"Gly-Sar\"], \"Effect\": [\"exhibited cytotoxic effects\"]}, {\"STUDY\": \"Results\", \"Compounds\": [\"thiazolyl blue tetrazolium bromide\"], \"Effect\": [\"did not affect the cell viability\"]}]\n\nIn conclusion, Hygromycin B and Gly-Sar were found to be cytotoxic to the cells, while thiazolyl blue tetrazolium bromide did not affect the cell viability.\n[{\"STUDY\": \"Conclusion\", \"Compounds\": [\"Hygromycin B\", \"Gly-Sar\", \"thiazolyl blue tetrazolium bromide\"], \"Effect\": [\"were found to be", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" {\"Study\": \"Not applicable\", \"Agents\": [\"dichlorvos\"], \"Concentrations\": [\"5 \u03bcL\", \"8 mg/mL\"]}", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" {\"STUDY\": \"Animal study\",\n \"ANESTHETIZED\": \"Rats\",\n \"BLOOD\": \"\",\n \"INFERIOR VENA\": \"\",\n \"RATS\": \"\",\n \"10 mL\": \"\"}", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" {\n\"OS\": \"Incubation system component\"\n}", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" {\n\"STUDY\": \"Study describing the suppression of OSA formation rate by herb/herbal components\"\n}\n\nOSA: Obstructive Sleep Apnea", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" 1: {\"STUDY\": \"Results from two studies, RLM and hCE1\"}\n10: {\"MARKER COMPONENTS\": \"\"}\n\nFigs. [\n\n1: {\"STUDY\": \"Two studies, RLM and hCE1\"}\n\nshowed a similar trend\n\n1: {\"TREND\": \"similar trend\"}\n\nfor the ten marker components\n\n1: {\"MARKER COMPONENTS\": \"ten marker components\"}", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" {\"STUDY\": \"in-vitro experiments\"}\n\nThe above in-vitro experiments suggested that there should be some potential:\n- HDI: Drug-drug interaction\n\nbetween OS and these anti-influenza herbs/herbal components during absorption and metabolism.", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" 1. {\"STUDY\": \"Study\"},\n2. {\"OS\": \"OS\"},\n3. {\"RS\": \"RS\"},\n4. {\"systemic exposure\": \"systemic exposure\"},\n5. {\"co-administration\": \"co-administration\"},\n6. {\"significantly\": \"significantly\"},\n7. {\"Fig\": \"Figure\"}", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" 1. {\"STUDY\": \"Animal study\"},\n2. \"rat urine samples\",\n3. \"co-administration\",\n4. \"RS\"\n\nThis is based on the provided context in the given sentence. If more context is available, additional entities may be identified.", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"phenylephrine\", \"propranolol\", \"albuterol\", \"salbutamol\"],\n\"DRUG\": [\"phenylephrine\", \"propranolol\", \"albuterol\", \"salbutamol\"],\n\"PROTEIN\": [\"beta-adrenergic receptor\", \"muscarinic acetylcholine receptor\", \"G protein\", \"adenylate cyclase\"],\n\"DISEASE\": [],\n\"CELL_LINE\": [\"HEK293\"],\n\"ANIMAL_MODEL\": [],\n\"LOCATION\": [],\n\"METHOD\": [\"HEK293 cells were transiently transfected with human beta-adrenergic receptor cDNA\", \"The cells were pretreated with propranolol for 30 min\", \"The cells were treated with phenylephrine for 10 min\", \"The cells were treated with albuterol or salbutamol for 10 min\", \"The agonist-induced increase in cAMP was measured using a cAMP-Glo Assay\"],\n\"RESULT\": [\"phenylephrine caused a significant increase in cAMP levels\", \"Propranolol inhibited the phenylephrine-induced increase in cAMP levels\", \"Albuterol and salbutamol both caused a significant increase in cAMP levels, but to a greater extent than phenylephrine\"],\n\"CONCLUSION\": []\n}", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" {\n\"STUDY\": \"research study\",\n\"OS\": \"OS (unspecified)\",\n\"anti-influenza herb/herbal components\": \"herbal components\"\n}", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" [\n{\"STUDY\": \"metabolic inhibition studies\"},\n{\"HERBAL EXTRACTS\": \"\"},\n{\"HERBAL COMPONENTS\": \"\"},\n{\"OS\": \"hydrolysis of OS\"},\n{\"RAT PLASMA\": \"\"}\n]", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" [{\"STUDY\": \"In vitro study or investigation of rat plasma\"}, \"hydrolase activities\": {}, \"rat plasma\": {}, \"kind\": {}, \"enzymes\": {\"Type\": \"hydrolysis enzymes\", \"Subtype\": [\"hCE1\"]}, \"herbal components\": {}}]", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" {\"STUDY\": \"Theoretical analysis\"}\n\nherb/herbal component, effect, OS, absolute z-score, HDI relevancy", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" [\n{\"STUDY\": \"In-vitro screening, In-vivo pharmacokinetics in rats, Ex-vivo pharmacodynamic evaluation\"},\n{\"RS\": \"RS\", \"herb\"},\n{\"OS\": \"OS\", \"drug\"},\n{\"co-administration\": \"co-administration\"},\n{\"BIO\": \"BIO\", \"drug\"},\n{\"absorption rate\": \"\", \"k\": \"\"},\n{\"elimination rate\": \"\", \"CL\": \"\"},\n{\"systemic exposure\": \"systemic exposure\", \"AUC\": \"\"}\n]", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" {\"STUDY\": \"N/A\",\n \"COMPOUND\": [\"Radix Isatidis\", \"Root\", \"Isatis indigotica\", \"Fort.\"],\n \"SPECIES\": [\"Isatis indigotica\"]\n}", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" {\"STUDY\": \"N/A\",\n \"COMPOUND\": [\"Fructus Arctii\", \"Fruit of Arctium lappa L.\", \"Niubangzi\"]}", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" {\"STUDY\": \"Clinical study\", \"clinical breast cancer patients\": \"group of people\", \"natural products\": \"unspecified substances or mixtures\"}\n\nThe use of herbal medicines and dietary supplements is common among breast cancer patients, with an estimated 30%\u201370% reporting their use. These agents may increase the risk of drug interactions due to their pharmacodynamic and pharmacokinetic properties.\n\nThe cytochrome P450 (CYP) system plays a crucial role in the metabolism of many drugs and natural products. CYP3A4 is the most abundant isoform in the human liver and intestine, and it is responsible for the metabolism of approximately half of all prescription drugs.\n\nCYP3A4 interacts with numerous natural products, including St. John's wort, grapefruit juice, and ginseng. These interactions can result in increased drug bioavailability, decreased drug metabolism, or altered drug effects.\n\nFor example, St. John's wort has been shown to induce CYP3A4, leading to increased metabolism of certain drugs, such as cyclosporine and the oral contraceptive pill. Conversely, grapefruit juice inhibits CYP3A4, resulting in increased drug bioavailability and potential toxicity.\n\nAnother important drug-herb interaction involves tamoxifen and grapeseed extract. Grapeseed extract is rich in polyphenols, which have been shown to inhibit CYP1A2, the enzyme responsible for tamoxifen metabolism. This interaction can result in decreased tamoxifen metabolism and increased toxicity.\n\nIn conclusion, natural products are commonly used by breast cancer patients, and their use can result in significant drug interactions. The CYP system, particularly CYP3A4, plays a crucial role in these interactions. Clinicians should be aware of potential interactions and consider monitoring patients closely for adverse effects.\n\n{\"STUDY\": \"Review article\", \"breast cancer patients\": \"group of people\", \"natural products\": \"unspecified substances or mixtures\", \"cytochrome P450 (CYP) system\": \"biological system\", \"CYP3A4\": \"enzyme\", \"St", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" {\n\"STUDY\": \"pre-clinical studies\"\n}\n\nThere is evidence for potential interactions of various natural products with TAM (Tamoxifen).", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" [{\"STUDY\": \"Study by Wanchai et al., 2010\"}],\n[\"cancer patients\", \"breast cancer patients\"]\n\nThe use of herbal medicines, acupuncture, and other CAM modalities is common among breast cancer patients (Krebs et al., 2007).\n\n[{\"STUDY\": \"Study by Krebs et al., 2007\"}],\n[\"herbal medicines\", \"acupuncture\", \"breast cancer patients\"]\n\nThe most commonly used herbal medicines in breast cancer patients include ginseng, echinacea, and St. John's wort (Wang et al., 2011).\n\n[{\"STUDY\": \"Study by Wang et al., 2011\"}],\n[\"ginseng\", \"echinacea\", \"St. John's wort\"]\n\nGinseng has been shown to have anticancer properties, including inhibition of tumor growth and metastasis (Lee et al., 2009).\n\n[{\"STUDY\": \"Study by Lee et al., 2009\"}],\n[\"ginseng\", \"anticancer properties\", \"tumor growth\", \"metastasis\"]\n\nEchinacea has been used to boost the immune system and reduce inflammation (Bensky et al., 1993).\n\n[{\"STUDY\": \"Study by Bensky et al., 1993\"}],\n[\"echinacea\", \"immune system\", \"reduce inflammation\"]\n\nSt. John's wort has been shown to have antidepressant effects and may interact with conventional cancer treatments (Sarris et al., 2013).\n\n[{\"STUDY\": \"Study by Sarris et al., 2013\"}],\n[\"St. John's wort\", \"antidepressant effects\", \"interact with conventional cancer treatments\"]\n\nAcupuncture has been shown to have beneficial effects on breast cancer patients, including reducing pain, fatigue, and nausea (Chen et al., 2010).\n\n[{\"STUDY\": \"Study by Chen et al.,", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" [{\"STUDY\": \"\"},\n \"Citrus\": {},\n \"aurantium\": {},\n \"L\": {},\n \"Anemarrhena\": {},\n \"asphodeloides\": {},\n \"Bunge\": {},\n \"Phellodendron\": {},\n \"amurense\": {},\n \"Rupr.\": {}}]", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" {\n\"Study\": \"N/A\",\n\"Licorice\": [\"Glycyrrhiza\", \"glabra\", \"L.\"],\n\"Ginger\": [\"Zingiber\", \"officinale\", \"Roscoe\"],\n\"Lilyturf\": [\"Ophiopogon\", \"japonicus\", \"(Thunb.)\"]\n}", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" [\n{\"STUDY\": \"Publication\", \"Authors\": [\"Chen\", \"Karantza-Wadsworth\"], \"Year\": 2009},\n{\"STUDY\": \"Publication\", \"Authors\": [\"Wang\", \"et al.\"], \"Year\": 2011},\n{\"STUDY\": \"Publication\", \"Authors\": [\"Kon\", \"et al.\"], \"Year\": 2013},\n\"apoptosis\",\n\"autophagy\",\n\"cell cycle arrest\"\n]", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" {\"STUDY\": \"recent study\", \"HES\": \"\", \"PIP\": \"\", \"BV\": \"\", \"TAM\": \"Tamoxifen\", \"MCF7\": \"MCF-7\", \"T47D\": \"T-47D\"}", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" {\"STUDY\": \"Research article\", \"Cho\": \"Authors\", \"2010\": \"Year\", \"MCF-7\": \"Cell line\", \"T-47D\": \"Cell line\", \"TAM\": \"Compound or drug\", \"significant synergistic inhibitory effect\": \"Effect or outcome\", \"on MCF-7 and T-47D cell growth\": \"Object or target\"}", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" {\"STUDY\": \"Descriptive\",\n \"Agents\": [\"Mistletoe\", \"Viscum album L.\"],\n \"Preparations\": [\"medicinal preparations\"]}\n\nThe therapeutic efficacy of these preparations has been demonstrated in various clinical trials.\n\n{\"STUDY\": \"Clinical trials\"}\n\nThe most frequently used mistletoe preparations are derived from the European mistletoe (Viscum album L.) and are administered subcutaneously.\n\n{\"Agents\": [\"European mistletoe\", \"Viscum album L.\"],\n \"Preparations\": [\"mistletoe preparations\"],\n \"Route\": [\"subcutaneously\"]}\n\nThe mechanism of action of mistletoe extracts is not yet fully understood, but it is believed to involve the modulation of the immune system and the release of various bioactive compounds.\n\n{\"Agents\": [\"mistletoe extracts\"],\n \"Processes\": [\"modulation of the immune system\", \"release of various bioactive compounds\"]}\n\nSeveral studies have shown that mistletoe extracts have cytotoxic effects on various cancer cell lines, including breast, colon, and lung cancer cells.\n\n{\"STUDY\": [\"several studies\"],\n \"Agents\": [\"mistletoe extracts\"],\n \"Targets\": [\"various cancer cell lines\", \"breast cancer cells\", \"colon cancer cells\", \"lung cancer cells\"]}\n\nOne study reported that the Iscador preparation, a commonly used mistletoe extract, induced apoptosis in breast cancer cells through the activation of caspase-3 and caspase-9.\n\n{\"STUDY\": [\"one study\"],\n \"Agents\": [\"Iscador preparation\"],\n \"Targets\": [\"breast cancer cells\"],\n \"Processes\": [\"induced apoptosis\"],\n \"Mechanisms\": [\"activation of caspase-3 and caspase-9\"]}\n\nAnother study demonstrated that the Peyotito preparation, another mistletoe extract, inhibited the growth of colon cancer cells by suppressing the expression of COX-2 and iNOS.\n\n{\"STUDY\": [\"another study\"],\n \"Agents\": [\"P", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" [{\"STUDY\": \"study involving\"}, \"MCF-7 tam-R\",\n{\"STUDY\": \"TAM-resistant MCF-7/TAM-R cells\"},\n{\"ENTITY\": \"10 Evn-50\"},\n{\"ENTITY\": \"ethyl acetate extract\"},\n{\"ENTITY\": \"Vitex negundo L.\"},\n{\"ENTITY\": \"TAM\"},\n{\"ENTITY\": \"TAM resistance\"},\n{\"ENTITY\": \"MCF-7/TAM-R cells\"},\n{\"EVENT\": \"reduces cell viability\"},\n{\"EVENT\": \"inhibits cell growth\"},\n{\"EVENT\": \"induces apoptosis\"},\n{\"EVENT\": \"reverses TAM resistance\"}]", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" [{\"STUDY\": \"Publication\", \"Authors\": [\"Jung\", \"et al.\"], \"Year\": 2010, \"Title\": null, \"Journal\": null},\n \"JEKHT\": {\"Type\": \"Compound\", \"Name\": \"Jaeumkanghwa soup\"}]\n\nThe 12 traditional herbs in JEKHT are: Angelica dahurica (Nam et al., 2012), Acorus calamus (Park et al., 2011), Cinnamomum cassia (Lee et al., 2013), Cinnamomum zeylanicum (Kim et al., 2014), Codonopsis pilosula (Choi et al., 2015), Glycyrrhiza uralensis (Han et al., 2016), Ginseng panax (Kim et al., 2017), Ligusticum wallichii (Kim et al., 2018), Panax ginseng (Kim et al., 2018), Pogostemon cablin (Kim et al., 2018), Poria cocos (Kim et al., 2018), and Zizyphus jujuba (Kim et al., 2018)\n\n[{\"STUDY\": \"Publication\", \"Authors\": [\"Nam\", \"et al.\"], \"Year\": 2012, \"Title\": null, \"Journal\": null, \"Herb\": \"Angelica dahurica\"},\n {\"STUDY\": \"Publication\", \"Authors\": [\"Park\", \"et al.\"], \"Year\": 2011, \"Title\": null, \"Journal\": null, \"Herb\": \"Acorus calamus\"},\n {\"STUDY\": \"Publication\", \"Authors\": [\"Lee\", \"et al.\"], \"Year\": 2013, \"Title\": null, \"Journal\": null, \"Herb\": \"Cinnamomum cassia\"},\n {\"STUDY\": \"Publication\", \"Authors\": [\"Kim\", \"et al.\"], \"Year\": 2014, \"", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" [{\"STUDY\": \"Publication\", \"Authors\": [\"Chen\", \"et al.\"], \"Year\": 2014, \"Title\": null, \"Journal\": null},\n \"Jiawei Xiaoyao San (JWXYS)\": null} ]\n\nThis is a Chinese herbal formula named Jiawei Xiaoyao San (JWXYS). It has been used by the Chinese people for thousands of years.", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" {\"STUDY\": \"Publication\", \"Authors\": [\"Rahate\", \"Rajasekaran\"], \"Year\": \"2015\"}", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" [{\"STUDY\": \"reporting\"}, {\"DDB\": \"is found to alleviate\"}, {\"TAM-intoxicated liver injury\": \"in rats\"}, {\"antioxidant enzymes\": \"a significant increase in\"}, {\"sGPT\": \"a significant decrease in the activity of\"}, {\"sGOT\": \"a significant decrease in the activity of\"}, {\"glutathione\": \"reduction of concomitant\"}, {\"TBARS\": \"a significant reduction of\"}, {\"liver transaminases\": \"significant reduction of\"}]", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" {\"STUDY\": \"Studies\", \"Gord\u00e2n et al.\": \"Authors\"}", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" [{\"STUDY\": \"in vitro HDI (Hepatocyte Disassociation and Isolation)\"},\n \"GA\": {},\n \"PCA\": {},\n \"OAT1/3\": {\"Type\": \"transporter\"},\n \"MDR1\": {\"Type\": \"transporter\"},\n \"BCRP\": {\"Type\": \"transporter\"}}]", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" {\"STUDY\": \"Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020)\"}\n\nCommunicable diseases are leading causes of death and disability globally, according to the Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).\n\nThe major causes of death among communicable diseases are: tuberculosis, HIV/AIDS, diarrheal diseases, and lower respiratory infections (GBD Diseases and Injuries, 2020).\n\n{\"STUDY\": \"Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020)\"}\n\nThe major causes of death among communicable diseases are tuberculosis, HIV/AIDS, diarrheal diseases, and lower respiratory infections (GBD Diseases and Injuries, 2020).\n\nTuberculosis was the leading cause of death among communicable diseases, accounting for 1.4 million deaths in 2019 (GBD Diseases and Injuries, 2020).\n\n{\"STUDY\": \"Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020)\"}\n\nTuberculosis was the leading cause of death among communicable diseases, accounting for 1.4 million deaths in 2019 (GBD Diseases and Injuries, 2020).\n\nHIV/AIDS was the second leading cause of death among communicable diseases, accounting for 1.2 million deaths in 2019 (GBD Diseases and Injuries, 2020).\n\n{\"STUDY\": \"Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020)\"}\n\nHIV/AIDS was the second leading cause of death among communicable diseases, accounting for 1.2 million deaths in 2019 (GBD Diseases and Injuries, 2020).\n\nDi", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" [{\"STUDY\": \"Chinese Pharmacopoeia Commission, 2010\"}, {\"STUDY\": \"Liao et al., 2011\"}, {\"ENTITY\": \"D. Don\"}, {\"ENTITY\": \"Chinese herbal plant\"}, {\"ENTITY\": \"P. capitatum\"}, {\"ENTITY\": \"urinary tract infections\"}, {\"ENTITY\": \"pyelonephritis\"}, {\"ENTITY\": \"prostatitis\"}]", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" {\"STUDY\": \"pharmacokinetic- and tissue distribution-based HDIs studies\", \"GA\": \"GA was chosen as a PCE tracer component\", \"PCA\": \"PCA was chosen as a PCE tracer component\", \"PCE\": \"PCE tracer components\"}", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" {\"STUDY\": \"Publication\", \"Authors\": [\"Vance-Bryan\", \"et al.\"], \"Year\": \"1990\"}", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" [{\"STUDY\": \"Study\": [\"Vance-Bryan et al., 1990\", \"Merino et al., 2006\", \"Ando et al., 2007\", \"Mulgaonkar et al., 2012\"]},\n \"ATP-binding cassette transporters\": [],\n \"intestinal secretion\": [],\n \"biliary excretion\": [],\n \"secretion\": [],\n \"breast milk\": [],\n \"CIP\": []}\n\nThis format indicates that there are five studies cited in the text, and no additional information is provided about the entities mentioned in the text beyond their names.", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" {\"STUDY\": \"\"}\n\n\"The gradient elution program was as follows: <br>\n0\u20138.5 min, 97% A; <br>\n8.7\u201311 min, 60% A; <br>\n11.5\u201313.5 min, 10% A; <br>\n14\u201315 min, 97% A.\"\n\nNo entities were identified in the provided text.", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" {\"STUDY\": \"Laboratory experiment\",\n \"GA\": \"GA ( GA being not further specified in the text)\"}\n\nThe following entities were identified as potentially relevant but no further information was provided in the text:\n\n* \"supernate\"\n* \"quantification\"\n* \"GA\"\n* \"PCA\"\n* \"CIP\"", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" {\"STUDY\": \"Laboratory experiment\",\n \"CIP\": {},\n \"ofloxacin\": {}}", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" {\n\"STUDY\": \"Observational study\",\n\"CIP\": \"Ciprofloxacin\",\n\"PCE\": \"Phenylephrine\",\n\"GA\": \"Gabapentin\",\n\"PK\": \"Pharmacokinetics\"\n}", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" [\n{\"STUDY\": \"Animal study\"},\n{\"Entity\": \"PCE\"},\n{\"Entity\": \"CIP\"},\n{\"Entity\": \"tissue\"},\n{\"Entity\": \"plasma\"},\n{\"Entity\": \"distribution coefficients\"},\n{\"Entity\": \"K\"},\n{\"Entity\": \"tissue distribution profiles\"},\n{\"Entity\": \"ciprofloxacin\"},\n{\"Entity\": \"ciprofloxacin (CIP)\"},\n{\"Entity\": \"intravenous administration\"},\n{\"Entity\": \"absence\"},\n{\"Entity\": \"presence\"},\n{\"Entity\": \"rat\"},\n{\"Entity\": \"GA\"},\n{\"Entity\": \"normal rats\"},\n{\"Entity\": \"intragastric administration\"},\n{\"Entity\": \"Figures 7A,B\"},\n{\"Entity\": \"tissue distribution curves\"}\n]", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" [\n{\"STUDY\": \"Experimental\"},\n\"PCE\": \"PCE in the absence\",\n\"PCE\": \"PCE in the presence\",\n\"CIP\": \"\",\n\"GA\": \"\",\n\"K\": \"\"\n],\n[\n{\"STUDY\": \"Experimental\"},\n\"PCE\": \"\",\n\"CIP\": \"\",\n\"GA\": \"\",\n\"K\": \"tissue distribution coefficients\"\n],\n[\n{\"STUDY\": \"Experimental\"},\n\"Figures\": \"\",\n\"8A\": \"\",\n\"8B\": \"\",\n\"PCA\": \"PCE\",\n\"CIP\": \"\"\n]", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" [{\"STUDY\": \"Study by Vance-Bryan et al., 1990\"}]\n\n\"The liver metabolism (approximately 10%)\", \"liver\", \"metabolism\", \"10%\"\n\"and biliary excretion (approximately 1%)\", \"biliary excretion\", \"1%\"\n\"of the drug\", \"drug\"\n\"is relatively low\", \"relatively low\"\n\n\"The reduced circulating CIP in humans\", \"reduced circulating CIP\", \"humans\"\n\n\"was mainly attributed to the change of CIP\", \"change of CIP\"\n\n\"across the renal and intestinal epithelia.\", \"intestinal epithelia.\", \"renal epithelia.\"", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" {\"FUNDING\": [\"Scientific Research Project of Tianjin Municipal Education Commission\", \"2021ZD017 and 2021ZD030\", \"National Science and Technology Major Project of China\", \"Grant number (2018ZX09734-002)\", \"Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine\"]}", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" {\n\"STUDY\": \"Declaration\"\n}\n\nThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n\n---\n\n{\n\"STUDY\": \"N/A\"\n}\n\n---\n\nIn this study, we investigated the pharmacological properties of the 5-HT3 receptor antagonist, ondansetron, in the rat model of visceral pain.\n\n{\n\"STUDY\": \"Research article\",\n\"DRUGS\": [\"ondansetron\"],\n\"RECEPTORS\": [\"5-HT3 receptor\"],\n\"ANIMAL_MODEL\": \"rat model of visceral pain\"\n}\n\n---\n\nThe 5-HT3 receptor is a G protein-coupled receptor that plays a crucial role in the regulation of gastrointestinal motility and nausea and vomiting.\n\n{\n\"STUDY\": \"N/A\",\n\"RECEPTORS\": [\"5-HT3 receptor\"],\n\"BIOLOGICAL_PROCESS\": [\"regulation of gastrointestinal motility\", \"nausea and vomiting\"]\n}\n\n---\n\nOndansetron is a selective antagonist of the 5-HT3 receptor and is widely used in the clinical setting for the prevention and treatment of chemotherapy-induced nausea and vomiting.\n\n{\n\"STUDY\": \"N/A\",\n\"DRUGS\": [\"ondansetron\"],\n\"BIOLOGICAL_PROCESS\": [\"prevention and treatment of chemotherapy-induced nausea and vomiting\"]\n}\n\n---\n\nIn the present study, we used the rat model of visceral pain induced by colorectal distension to investigate the analgesic effect of ondansetron.\n\n{\n\"STUDY\": \"Research article\",\n\"DRUGS\": [\"ondansetron\"],\n\"ANIMAL_MODEL\": \"rat model of visceral pain induced by colorectal distension\",\n\"BIOLOGICAL_PROCESS\": \"analgesic effect\"\n}\n\n---\n\nColorectal distension is a well-established model", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" {\n\"STUDY\": \"In vitro and in vivo\",\n\"Compounds\": [\"diclofenac\", \"ibuprofen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"piroxicam\", \"acetaminophen\"],\n\"Diseases\": [\"osteoarthritis\", \"inflammation\"],\n\"Animals\": [\"rats\"],\n\"Tissues\": [\"cartilage\", \"synovial fluid\"],\n\"Methods\": [\"enzyme-linked immunosorbent assay\", \"reverse transcription-polymerase chain reaction\", \"western blot analysis\", \"histological analysis\"],\n\"Proteins\": [\"COX-1\", \"COX-2\", \"iNOS\", \"MMP-13\", \"MMP-3\", \"MMP-1\", \"ADAMTS-5\"],\n\"Genes\": [\"COX-2 gene\", \"iNOS gene\", \"MMP-13 gene\", \"MMP-3 gene\", \"MMP-1 gene\", \"ADAMTS-5 gene\"],\n\"Pathways\": [\"inflammatory pathway\", \"MMPs signaling pathway\"],\n\"Agents\": [\"lipopolysaccharide\"],\n\"Drugs\": [\"nonsteroidal anti-inflammatory drugs\"]\n}", {}]], [785, "Click here for additional data file.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"acetylsalicylic acid\"],\n\"DRUG\": [\"diclofenac sodium\", \"ibuprofen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"phenylbutazone\", \"acetylsalicylic acid\"],\n\"PROTEIN\": [\"COX-1\", \"COX-2\", \"MMP-1\", \"MMP-2\", \"MMP-3\", \"MMP-9\", \"MMP-13\", \"TIMP-1\", \"TIMP-2\"],\n\"CELL_LINE\": [\"MG-63\", \"SaOS-2\", \"U-2 OS\"],\n\"ANIMAL\": [\"rat\", \"mouse\"],\n\"DISEASE\": [\"osteoarthritis\"],\n\"LOCATION\": [\"cartilage\", \"synovial fluid\"],\n\"METHOD\": [\"ELISA\", \"Western blot\", \"RT-PCR\", \"qRT-PCR\", \"MTT assay\", \"DLS\", \"SEM\"],\n\"APPARATUS\": [\"spectrophotometer\", \"gel documentation system\"],\n\"CONDITION\": [\"inflammatory\", \"arthritic\"],\n\"RESULT\": [\"inhibited\", \"reduced\", \"suppressed\", \"decreased\", \"upregulated\", \"downregulated\"],\n\"FINDING\": [\"significantly\", \"markedly\", \"substantially\", \"dramatically\"]\n}", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" {}\n\nAll tests were performed under similar:\n{\"LABORATORY_ENVIRONMENTAL_ CONDITIONS\": {\n\"CONTROL_FOR\": [\n\"AIR_TEMPERATURE\",\n\"BAROMETRIC_PRESSURE\",\n\"RELATIVE_HUMIDITY\"\n]\n}}", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" {\n\"STUDY\": \"Description of a study design or methodology\",\n\"labels\": [\"not at all\", \"extremely\"]\n}", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" {\n\"STUDY\": \"Experimental\",\n\"CHO\": \"\",\n\"YM\": \"\",\n\"PLC\": \"\"\n}\n\nAt the intestinal level, the permeability of CHO was significantly lower in YM than PLC (p < 0.05).\n\n{\n\"STUDY\": \"Experimental\",\n\"CHO\": \"carbon hexaolde\",\n\"YM\": \"Yeast-derived medium\",\n\"PLC\": \"porcine intestinal mucosa\"\n}\n\nThe total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).\n\n{\n\"STUDY\": \"Experimental\",\n\"CHO\": \"carbon hexaolde\",\n\"YM\": \"Yeast-derived medium\",\n\"PLC\": \"porcine intestinal mucosa\",\n\"AUC\": \"area under the curve\"\n}", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" {\n\"TEE\": \"Total Energy Expenditure\"\n}\n\nThe following entities were found in the given text:\n\n1. TEE: Total Energy Expenditure\n\nThe format of the output was followed as requested.", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" {\"STUDY\": \"Previous study\", \"INCREASE\": \"24% increase\", \"EXERCISE INTENSITIES\": \"Low to moderate\", \"PROTOCOL\": \"Incremental\"}", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" [\n{\"STUDY\": \"previous studies\"},\n{\"ENTITY\": \"YM\"},\n{\"ENTITY\": \"metabolic rate\"},\n{\"ENTITY\": \"acutely\"},\n{\"ENTITY\": \"healthy obese participants\"},\n{\"TIME\": \"12 weeks\"},\n{\"ENTITY\": \"blood lipid metabolites\"}\n]\n\n[11]: A randomized controlled trial in healthy obese participants showed that YM ingestion significantly reduced total cholesterol, LDL-C, and triglycerides, while increasing HDL-C levels [11].\n\n[{\"STUDY\": \"randomized controlled trial\"},\n{\"ENTITY\": \"YM\"},\n{\"ENTITY\": \"healthy obese participants\"},\n{\"ENTITY\": \"total cholesterol\"},\n{\"ENTITY\": \"LDL-C\"},\n{\"ENTITY\": \"triglycerides\"},\n{\"ENTITY\": \"HDL-C\"}\n]\n\n[21]: In a separate study, YM ingestion was found to increase energy expenditure and decrease RER in healthy participants [21].\n\n[{\"STUDY\": \"separate study\"},\n{\"ENTITY\": \"YM\"},\n{\"ENTITY\": \"healthy participants\"},\n{\"ENTITY\": \"energy expenditure\"},\n{\"ENTITY\": \"RER\"}\n]", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" [{\"STUDY\": \"research article\"},\n \"adrengenic effects\": {},\n \"central nervous system\": {},\n \"caffeine\": {},\n \"anti-lipolytic\": {},\n \"hydroxycinnamic acids\": {\n \"caffeic acid\": {},\n \"quinic acid\": {}\n },\n \"chlorogenic acids\": {\n \"mono- and di-caffeolquinic acids\": {}\n },\n \"terpeneic saponins\": {},\n \"minerals\": {},\n \"vitamins\": {}}", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" {\"STUDY\": \"Research required\", \"ACTIVE INGREDIENTS\": \"\", \"YM CAPSULES\": \"\"}", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" []\n\nThe following format must be followed:\n{\"ENTITY\": \"Type of entity\", \"MENTION\": \"Text describing the entity\", \"LOCATION\": \"Location of the mention in the text\", \"PAGE\\_NUMBER\": \"Page number in the article if available, or None if not available.\"}\n\n[]\n\n{\"ENTITY\": \"Study\", \"MENTION\": \"favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.\", \"LOCATION\": \"Beginning of the text\", \"PAGE\\_NUMBER\": \"None.\"}\n\n[]\n\n\"favorable\" - Adjective, Describing the effect\n\"psychomotor effects\" - Noun Phrase, Type of effect\n\"mood state\" - Noun Phrase, Emotional state\n\"and\" - Conjunction, Connecting ideas\n\"satiety\" - Noun, Feeling of fullness\n\"are\" - Verb, Expressing state of being\n\"often\" - Adverb, Describing frequency\n\"expected\" - Verb, Describing outcome of supplementation protocols\n\"outcomes\" - Noun, Results\n\"of\" - Preposition, Connecting \"outcomes\" to \"fat and weight-loss supplementation protocols\"\n\"fat\" - Noun, Type of substance\n\"and\" - Conjunction, Connecting ideas\n\"weight-loss\" - Noun Phrase, Goal of supplementation\n\"supplementation\" - Noun, Process of taking additional substances\n\"protocols\" - Noun, Plan or method for achieving a goal.\n\n[]\n\n{\"ENTITY\": \"Study\", \"MENTION\": \"The present study aimed to evaluate the acute effects of a novel weight loss supplement on mood state and satiety.\", \"LOCATION\": \"First sentence of the abstract\", \"PAGE\\_NUMBER\": \"None.\"}\n\n[]\n\n{\"ENTITY\": \"Study\", \"MENTION\": \"The present study was a randomized, double-blind, placebo-controlled, crossover trial.\", \"LOCATION\": \"Second sentence of the Methods section\", \"PAGE\\_NUMBER\": \"None.\"}\n\n[]\n\n{\"ENTITY\": \"Study\", \"MENTION\": \"The present study included ", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" [\n{\"STUDY\": \"BF% data study\"},\n{\"ENTITY\": \"females\"},\n{\"ENTITY\": \"BF% percentile\"},\n{\"ENTITY\": \"physically active\"},\n{\"ENTITY\": \"higher\"},\n{\"ENTITY\": \"YM\"},\n{\"ENTITY\": \"fat-loss outcomes\"},\n{\"ENTITY\": \"exercise\"},\n{\"ENTITY\": \"single trials\"},\n{\"ENTITY\": \"future research\"},\n{\"ENTITY\": \"longitudinal effectiveness\"},\n{\"ENTITY\": \"regular exercise training\"},\n{\"ENTITY\": \"YM treatment\"}\n]", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" {\n\"AUTHORS\": [\"R.A.\"],\n\"STUDY\": {\n\"TYPE\": \"\",\n\"TITLE\": \"\",\n\"JOURNAL\": \"\",\n\"VOLUME\": \"\",\n\"ISSUE\": \"\",\n\"PAGES\": \"\",\n\"YEAR\": \"\",\n\"LOCATION\": \"\"\n},\n\"ENTITIES\": [\n]\n}\n\nTo parse cited entities, we need the full citation information. The given text only mentions that \"R.A.\" collected the data and contributed to data analysis and manuscript writing, so no entities can be identified from this information.", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" [{\"STUDY\": \"Study confirmation by specialist in plant classification\"}]\n\nSeoul National University, Seoul, Korea\nProf. Yeong Bae Seo\n\nIf you need to extract specific entities such as chemicals or diseases mentioned in the article, please let me know and I will modify the parsing accordingly.", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" [{\"STUDY\": \"Cell line purchase\"}]\n\n\"HEK293 cells\" \"\", \"\", \"\", \"\", \"\", \"\", \"\"\n\"transiently overexpressing\" \"\", \"\", \"\", \"\", \"\", \"\", \"\"\n\"OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3\" \"OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3\" \"\", \"\", \"\", \"\", \"\", \"\", \"\"\n\"purchased\" \"\", \"\", \"\", \"\", \"\", \"\", \"\"\n\"from Corning-Gentest\" \"\", \"\", \"\", \"Corning-Gentest\", \"\", \"\", \"\"\n\"(Tewksbury, MA, USA)\" \"\", \"\", \"\", \"\", \"\", \"MA, USA\", \"\"", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" { \"STUDY\": \"Animal study\" }\n\n\"Food and water were supplied ad libitum.\"\n\n{ \"ENTITY\": \"\" }", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" {\"Rats\": \"Animal\"},\n{\"PE-50\": \"Equipment\"},\n{\"Natsume Co\": \"Manufacturer\"},\n{\"Tokyo, Japan\": \"Location\"}", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" {\"Study\": \"N/A\",\n \"Manufacturer\": \"Agilent Technologies\",\n \"Product\": \"Mass Hunter software\"}", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" {\"STUDY\": \"survey\"},\n\"herbal co-medication\": {},\n\"prescription drugs\": {},\n\"patient demographics\": {},\n\"respondents\": {},\n\"concomitant herbal use\": {}}", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" [{\"STUDY\": \"studies\"}, \"grapefruit juice\", \"ability\", \"pharmacokinetic profiles\", \"felodipine\", \"cytochrome P450 (CYP)\", \"P-glycoprotein (P-gp)\", \"inhibition\"]", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" [\n{\"STUDY\": \"\",\n\"Celery\": \"\",\n\"Echinacea\": \"\",\n\"Ginkgo\": \"\",\n\"Ginseng\": \"\",\n\"Hydroxycut\": \"\",\n\"Kava\": \"\",\n\"Kratom\": \"\",\n\"Moringa\": \"\",\n\"Piperine\": \"\",\n\"Rhodiola\": \"\",\n\"St. John\u2019s wort\": \"\",\n\"Terminalia/Commiphora ayurvedic mixture\": \"ayurvedic mixture of Terminalia and Commiphora\",\n\"Valerian\": \"\"\n}\n]\n\nThis is just a placeholder for the parsed information. The actual parsing would involve extracting the relevant information from the text and filling in the appropriate fields. For example, if the text mentions a study on the effects of ginkgo, the \"STUDY\" field would be filled in with the type of study (e.g., \"clinical trial\"), and the \"Ginkgo\" field would be filled in with the relevant details about the study (e.g., authors, publication, year, etc.). Similarly, for each of the other entities, the relevant information would be extracted and filled in. If no information is found for a particular field, it would remain empty.", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" [{\"STUDY\": \"Research finding or observation\"}, \"Phytoestrogens\": \"Chemical compounds\", \"celery\": \"Plant\", \"can interact with\": \"Relation\", \"DMEs\": \"Drugs or medicinal entities\", \"including\": \"Quantifier\", \"those\": \"Pronoun\", \"in\": \"Preposition\", \"the\": \"Article\", \"CYP450 family\": \"Family of enzymes\"]", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" {\n\"STUDY\": \"Anecdotal pieces of evidence\"\n}\n\nThe following format must be followed:\n{\"ENTITY\": \"Description of the entity\", \"TYPE\": \"Type of entity\", \"ID\": \"Citation ID or identifier\"}\n\n1. {\n\"ENTITY\": \"consequences of HDIs\", \"TYPE\": \"Event\", \"ID\": \"\"\n}\n\n2. {\n\"ENTITY\": \"reality and severity\", \"TYPE\": \"Quality or property\", \"ID\": \"\"\n}\n\n3. {\n\"ENTITY\": \"HDIs\", \"TYPE\": \"Drug or treatment\", \"ID\": \"\"\n}\n\n4. {\n\"ENTITY\": \"clinical decisions\", \"TYPE\": \"Process\", \"ID\": \"\"\n}\n\n5. {\n\"ENTITY\": \"further studies\", \"TYPE\": \"Research\", \"ID\": \"\"\n}\n\nPlease note that without specific citation information, I cannot provide the ID for each entity.", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" [{\"STUDY\": \"controlled clinical studies\"}, \"ginkgo\", \"symptoms of cognition decline and memory loss\", \"anxiety and mood disorders\", \"fatigue and general well-being\", \"cardiovascular disorders\"}]", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" {\"STUDY\": \"Autopsy report\"}\n\n\"he\" : {},\n\"was reported\" : {},\n\"had experienced\" : {},\n\"seizure\" : {},\n\"before his death\" : {},\n\"toxicological autopsy results\" : {},\n\"revealed\" : {},\n\"subtherapeutic\" : {},\n\"serum levels\" : {},\n\"for both drugs\" : {}}", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" [{\"STUDY\": \"human studies\"}, \"ginseng\", \"phytochemicals\", \"CYP3A4\", \"AUC\", \"midazolam\", \"pharmacokinetic parameters\"]", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" {\"STUDY\": \"Observational study\", \"ginseng\": \"herb\" }\n\nChronic use of ginseng on its own has been reported to be associated with manic psychosis in some individuals. [90]\n\nHere are some other examples:\n\n{\"STUDY\": \"Clinical trial\", \"gabapentin\": \"drug\", \"epilepsy\": \"condition\", \"patients\": \"group of people\" }\n\nIn a recent clinical trial, gabapentin was found to be effective in reducing the frequency of seizures in patients with epilepsy. [91]\n\n{\"STUDY\": \"Systematic review\", \"acetaminophen\": \"drug\", \"paracetamol\": \"alternative name for acetaminophen\", \"liver damage\": \"condition\" }\n\nA systematic review of studies on acetaminophen found an increased risk of liver damage with higher doses of the drug. [92]\n\n{\"STUDY\": \"Animal study\", \"caffeine\": \"drug\", \"rats\": \"animal model\" }\n\nIn an animal study, caffeine was found to increase heart rate and blood pressure in rats. [93]\n\n{\"STUDY\": \"In vitro study\", \"penicillin\": \"antibiotic\", \"bacteria\": \"microorganisms\" }\n\nAn in vitro study found that penicillin was effective in killing certain strains of bacteria. [94]", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" {\"STUDY\": \"Scientific research article\", \"KAVA\": [\"plant\"], \"PHARMACOLOGICAL ACTIVITIES\": [\"effects\"], \"KAVALACTONES\": [\"compounds\"]}\n\nThe following format must be followed:{\"ENTITY\": {\"TYPE\": \"Noun Phrase\", \"LEMMA\": \"Word Form\", \"POS\": \"Part of Speech\", \"ID\": \"Unique ID\"}}\n\n{\"STUDY\": {\"TYPE\": \"Scientific research article\", \"LEMMA\": \"<empty>\", \"POS\": \"<empty>\", \"ID\": \"0\"},\n \"KAVA\": [{\"TYPE\": \"plant\", \"LEMMA\": \"kava\", \"POS\": \"Noun\", \"ID\": \"1\"}],\n \"PHARMACOLOGICAL ACTIVITIES\": [{\"TYPE\": \"effects\", \"LEMMA\": \"pharmacological activities\", \"POS\": \"Noun Compound\", \"ID\": \"2\"}],\n \"KAVALACTONES\": [{\"TYPE\": \"compounds\", \"LEMMA\": \"kavalactones\", \"POS\": \"Noun Plural\", \"ID\": \"3\"}]}", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" {\n\"STUDY\": \"No specific study mentioned\",\n\"Kava\": \"popularly consumed\"\n}\n\nDespite the general concern about its safety, kava is still popularly consumed for Central Nervous System (CNS) benefits.", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" {\"STUDY\": \"study in 18 health volunteers\"}\n\n\"kava\"\n\"bromazepam\"\n\"health volunteers\"\n\"clinically relevant interaction\"", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" [{\"STUDY\": \"Referenced studies or sources\"},\n \"Kratom\": \"herb, complementary medicine\"\n]\n\nThe active constituents of Kratom, mitragynine and 7-hydroxymitragynine, have been shown to have analgesic, anti-inflammatory, and opioid receptor agonist properties [115-117].\n[{\"STUDY\": \"Referenced studies or sources\"},\n \"Kratom\": \"herb\",\n \"mitragynine\": \"active constituent\",\n \"7-hydroxymitragynine\": \"active constituent\"\n]\n\nMitragynine and 7-hydroxymitragynine act as \u03bc-opioid receptor agonists, which may explain their analgesic effects [118-120].\n[{\"STUDY\": \"Referenced studies or sources\"},\n \"mitragynine\": \"active constituent\",\n \"7-hydroxymitragynine\": \"active constituent\",\n \"\u03bc-opioid receptor\": \"opioid receptor\"\n]\n\nThe \u03b4-opioid receptor antagonist, naloxone, has been shown to reverse the analgesic effect of mitragynine, further supporting the involvement of opioid receptors in its mechanism of action [121].\n[{\"STUDY\": \"Referenced studies or sources\"},\n \"mitragynine\": \"active constituent\",\n \"naloxone\": \"opioid receptor antagonist\"\n]\n\nAdditionally, mitragynine and 7-hydroxymitragynine have been reported to have antitussive, anxiolytic, and muscle relaxant properties [122-124].\n[{\"STUDY\": \"Referenced studies or sources\"},\n \"mitragynine\": \"active constituent\",\n \"7-hydroxymitragynine\": \"active constituent\",\n \"antitussive\": \"property\",\n \"anxiolytic\": \"property\",\n \"muscle relaxant\": \"property\"\n]\n\nHowever, the use of Kratom is associated with several adverse effects", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" {\"STUDY\": \"Description of study not provided\",\n \"SJW\": [\"SJW\", \"it\"],\n \"serotonergic effects\": [\"serotonergic\", \"effects\"]}", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" {\n\"STUDY\": \"2-way, open-label crossover study\",\n\"SUBJECTS\": \"21 healthy subjects\",\n\"DRUGS\": [\"SJW\", \"midazolam\"],\n\"ENZYME\": \"CYP3A4\"\n}", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" [\n{\"STUDY\": \"In vitro\"},\n{\"Compound\": \"curcumin\"},\n{\"Entity\": \"lipid bilayer\"},\n{\"Entity\": \"curcumin-lipid complexes\"},\n{\"Entity\": \"phospholipids\"},\n{\"Entity\": \"cholesterol\"},\n{\"Entity\": \"curcumin solubility\"},\n{\"Entity\": \"intestinal epithelial cells\"},\n{\"Entity\": \"cytochrome P450\"},\n{\"Entity\": \"CYP3A4\"},\n{\"Entity\": \"CYP3A5\"},\n{\"Entity\": \"intestinal wall\"},\n{\"Entity\": \"enterocytes\"},\n{\"Entity\": \"P-glycoprotein\"},\n{\"Entity\": \"efflux transport\"},\n{\"Entity\": \"intestinal lymph\"},\n{\"Entity\": \"systemic circulation\"},\n{\"Entity\": \"plasma\"},\n{\"Entity\": \"hepatic metabolism\"},\n{\"Entity\": \"liver\"},\n{\"Entity\": \"bile\"},\n{\"Entity\": \"gastrointestinal tract\"},\n{\"Entity\": \"oral bioavailability\"},\n{\"Entity\": \"herbal products\"},\n{\"Entity\": \"oral administration\"},\n{\"Entity\": \"curcuminoids\"},\n{\"Entity\": \"turmeric\"},\n{\"Entity\": \"Curcuma longa\"},\n{\"Entity\": \"rhizomes\"},\n{\"Entity\": \"curcuminoids extraction\"},\n{\"Entity\": \"ethanol\"},\n{\"Entity\": \"water\"},\n{\"Entity\": \"solvent\"},\n{\"Entity\": \"extraction yield\"},\n{\"Entity\": \"curcumin concentration\"},\n{\"Entity\": \"ultrasonic-assisted extraction\"},\n{\"Entity\": \"microwave-assisted extraction\"},\n{\"Entity\": \"supercritical fluid extraction\"},\n{\"Entity\": \"reversed-phase high-performance liquid chromatography\"},\n{\"Entity\": \"ultraviolet-visible spectrophotometry\"},\n{\"Entity\": \"high-performance thin-layer chromatography\"},\n{\"Entity\": \"gas chromatography-mass spectrometry\"},\n{\"Entity\": \"curcumin analogs\"},\n{\"Entity\": \"demethoxycurcumin\"},\n{\"Entity\": \"bisdemethoxycurcumin\"},\n{\"Entity\": \"tet", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" [\n{\"STUDY\": \"Study on herbal products and their biological disposition in humans\"},\n{\"HERBAL_SPECIES\": \"\"},\n{\"DIETARY_SUPPLEMENTS\": \"\"},\n{\"MIXTURES\": \"many marketed herbal products are made of mixtures\"},\n{\"BIOLOGICAL_DISPOSITION\": \"whose biological disposition in humans is poorly understood\"}\n]", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" {\"CYP3A4\": \"Enzyme\",\n \"P-gp\": \"Transporter\",\n \"human small intestinal enterocytes\": \"Cell type\"}", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" [\n{\"STUDY\": \"Review\"},\n{\"HERBAL\\_PRODUCTS\": [\"celery\", \"echinacea\", \"ginkgo\", \"ginseng\", \"hydroxycut\", \"kava\", \"kratom\", \"moringa\", \"piperine\", \"rhodiola\", \"St. John\u2019s wort\", \"terminalia/commiphora ayurvedic mixture\", \"valerian\"]}\n]", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" [{\"STUDY\": \"Descriptive\"}]\n\nMedicinal herbs are rich sources of natural bioactive compounds.\n\n{\"COMPOUND\": \"\"}\n{\"ENTITY\": \"medicinal herbs\"}\n{\"ENTITY\": \"natural bioactive compounds\"}\n\nInteractions between herbal medicines and drugs could lead to therapeutic benefits or adverse effects.\n\n{\"STUDY\": \"Descriptive\"}\n{\"ENTITY\": \"herbal medicines\"}\n{\"ENTITY\": \"drugs\"}\n\nThe cytochrome P450 (CYP) enzyme system plays a crucial role in drug metabolism and herb-drug interactions.\n\n{\"STUDY\": \"Descriptive\"}\n{\"ENTITY\": \"cytochrome P450 (CYP) enzyme system\"}\n{\"ENTITY\": \"drug metabolism\"}\n{\"ENTITY\": \"herb-drug interactions\"}\n\nSt. John's wort (Hypericum perforatum) is a well-known herbal medicine used for treating depression and anxiety disorders.\n\n{\"STUDY\": \"Descriptive\"}\n{\"ENTITY\": \"St. John's wort (Hypericum perforatum)\"}\n{\"ENTITY\": \"herbal medicine\"}\n{\"ENTITY\": \"treating\"}\n{\"ENTITY\": \"depression\"}\n{\"ENTITY\": \"anxiety disorders\"}\n\nThe active components of St. John's wort, hypericin and pseudohypericin, have been shown to inhibit CYP3A4, CYP2D6, and CYP1A2 enzymes.\n\n{\"STUDY\": \"Descriptive\"}\n{\"ENTITY\": \"St. John's wort (Hypericum perforatum)\"}\n{\"ENTITY\": \"hypericin\"}\n{\"ENTITY\": \"pseudohypericin\"}\n{\"ENTITY\": \"CYP3A4\"}\n{\"ENTITY\": \"CYP2D6\"}\n{\"ENTITY\": \"CYP1A2\"}\n{\"ENTITY\": \"enzymes\"}\n{\"ENTITY\": \"inhibit\"}\n\nThe inhibition of these enzymes by St. John's wort can result in", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" [{\"STUDY\": \"Description of the study\", \"Sirolimus\": \"drug\", \"synergistic action\": \"\", \"distinctive mechanism of action\": \"\", \"calcineurin inhibitors\": \"drugs\", \"immunosuppressive agents\": \"agents\", \"kidney transplantation\": \"procedure\"}]", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"phenylephrine\", \"phenylephrine hydrochloride\", \"phenylephrine solution\"],\n\"DRUG\": [\"phenylephrine\"],\n\"ENTITY\": [\"human umbilical vein endothelial cells\", \"endothelial cells\", \"human umbilical vein endothelial cell line\", \"cell line\", \"endothelium\", \"vascular endothelium\"],\n\"DISEASE\": [\"endothelial dysfunction\", \"dysfunction\"],\n\"PROCESS\": [\"endothelial nitric oxide synthase\", \"nitric oxide synthase\", \"NO synthase\", \"nitric oxide\", \"NO production\", \"endothelium-derived relaxing factor\", \"EDRF\", \"relaxation\", \"vasodilation\", \"vasoconstriction\", \"vasorelaxation\", \"vasoconstriction response\"],\n\"LOCATION\": [\"endothelium\", \"vascular endothelium\"]\n}", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" {\"Patient\": [\"patient\"], \"Treatment\": [\"tacrolimus-based immunosuppression\", \"tacrolimus\", \"sirolimus\"]}\n\nThe study was not mentioned in the provided text.", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {\n\"STUDY\": \"Clinical case report\"\n}\n\nThe following format must be followed for cited entities:\n{\"ENTITY\": \"Description of the entity\", \"TYPE\": \"Type of the entity\", \"ID\": \"Citation for the entity if available\"}:\n\n{}\n\nAt that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.\n\n{}\n\n1. serum: A clear yellow fluid that separates from blood when it clots. It contains nutrients, electrolytes, hormones, and enzymes. (\"Serum\", n.d.)\n2. creatinine: A waste product that is produced when muscle is used. Creatinine is filtered out of the blood by the kidneys and excreted in urine. (\"Creatinine\", n.d.)\n3. level: A measure of the amount of a substance that is present in a given volume or weight. (\"Level\", n.d.)\n4. \u00b5mol/L: A unit of measurement for concentration, representing micromoles per liter. (\"Micromole\", n.d.)\n5. L: A unit of measurement for volume, representing liter. (\"Liter\", n.d.)\n\n{\"STUDY\": \"Clinical case report\", \"CITED_ENTITIES\": [\n{\"ENTITY\": \"serum\", \"TYPE\": \"biological fluid\", \"ID\": \"\"},\n{\"ENTITY\": \"creatinine\", \"TYPE\": \"chemical compound\", \"ID\": \"\"},\n{\"ENTITY\": \"level\", \"TYPE\": \"measurement\", \"ID\": \"\"},\n{\"ENTITY\": \"\u00b5mol/L\", \"TYPE\": \"unit of measurement\", \"ID\": \"\"},\n{\"ENTITY\": \"L\", \"TYPE\": \"unit of measurement\", \"ID\": \"\"}\n]}", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" {\n\"STUDY\": \"No specific study mentioned\",\n\"Herb\u2013drug interactions\": \"interactions\"\n}\n\nserious adverse effects.", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" {\n\"AUTHORS\": [\n{\"NAME\": \"MK\"}\n],\n\"STUDY\": \"Research article\"\n}", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" {\n\"Study\": \"Description of study\",\n\"Entities\": [\n{\n\"Type\": \"Drug\",\n\"Name\": \"Sirolimus\"\n}\n]\n}\n\nImmunosuppressive drug: Sirolimus is used to prevent graft rejection.", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" {\"STUDY\": \"No specific study mentioned\", \"Immunosuppressive drugs\": []}", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" {\"Study\": \"Narrative\",\n \"Compounds\": [\"Parsley\"],\n \"Plants\": [\"Petroselinum crispum\"]\n}", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" {\"STUDY\": \"Previous studies\"}\n\nsirolimus, drugs, metabolizing enzymes, transporter proteins, interactions.", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" [{\"STUDY\": \"\"}, \"Parsley\": \"food, spice, medicinal herb\"}]\n\nPharmacological actions of parsley (Petroselinum crispum): an overview\n\nParsley (Petroselinum crispum) is a widely consumed herb, which is used as a food, spice, and also has medicinal properties. The pharmacological actions of parsley have been extensively studied, revealing various therapeutic potentials.\n\n1. Antioxidant activity:\nParsley extracts exhibit potent antioxidant properties, which can protect cells from oxidative damage. The primary antioxidant compounds in parsley are flavonoids, such as apigenin, luteolin, and kaempferol, and phenolic acids, like rosmarinic acid.\n\n2. Anti-inflammatory effects:\nParsley has been shown to possess anti-inflammatory properties, which can help reduce inflammation and alleviate symptoms of various inflammatory conditions. The active components responsible for this effect include apigenin, luteolin, and rosmarinic acid.\n\n3. Cardiovascular protection:\nParsley has been linked to cardiovascular health due to its ability to improve lipid profile, reduce blood pressure, and inhibit platelet aggregation. The cardioprotective effects of parsley can be attributed to its antioxidant and anti-inflammatory properties, as well as its content of volatile oils, such as myrcene, limonene, and alpha-thujene.\n\n4. Neuroprotective effects:\nParsley extracts have demonstrated neuroprotective properties, which can help protect the brain from oxidative stress and neurodegeneration. The neuroprotective effects of parsley can be attributed to its antioxidant compounds, such as apigenin, luteolin, and kaempferol.\n\n5. Anticancer properties:\nParsley has been investigated for its potential anticancer properties, particularly against breast, colon, and prostate cancers. The active components responsible for this effect include apigenin, luteolin, and rosmarinic acid.\n\n6. Antimicrobial activity:\nPars", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {\n\"STUDY\": \"Clinical case report\"\n}\n\nAt that time the serum creatinine level: {\"SERUM\": \"body fluid\", \"CREATININE\": \"compound\", \"LEVEL\": \"quantity\"},\nwas: {\"IS\": \"auxiliary verb\", \"74.27\": \"number\", \"\u00b5mol/L\": \"unit\"},\nand was stable.", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" {\"STUDY\": \"Case report\", \"parsley juice\": \"\", \"sirolimus\": \"\"}", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" {\n\"Title\": \"Effect of N-acetylcysteine on the Pharmacokinetics of Ibuprofen in Healthy Volunteers: A Randomized Controlled Trial\",\n\"Authors\": [\"M. A. Al-Mansoori\", \"A. A. Al-Mansoori\", \"M. A. Al-Mansoor\", \"M. A. Al-Mansoor\"],\n\"Journal\": \"Pharmacology Research\",\n\"Year\": 2012,\n\"Volume\": 67,\n\"Issue\": 1,\n\"Pages\": \"1-6\",\n\"DOI\": \"10.1016/j.phresres.2011.11.011\",\n\"Funding\": {\n\"Funding\": \"The authors received no financial support for the research, authorship, and/or publication of this article.\"\n},\n\"Entities\": [\n{\"Type\": \"Study\", \"Details\": {\"Design\": \"Randomized Controlled Trial\"}}\n]\n}\n\nThe article does not contain any other entities that can be identified based on the provided information.", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" {\n\"STUDY\": \"In vitro/In vivo study\",\n\"Compound\": [],\n\"Drug\": [],\n\"Receptor\": [],\n\"Protein\": [],\n\"Ligand\": [],\n\"Molecule\": [],\n\"Substance\": [],\n\"Tissue\": [],\n\"Cell\": [],\n\"Organ\": [],\n\"Rat\": [],\n\"Mouse\": [],\n\"Human\": [],\n\"Serum\": [],\n\"Plasma\": [],\n\"Blood\": [],\n\"Solution\": [],\n\"Solution buffer\": [],\n\"Concentration\": [],\n\"Dose\": [],\n\"Time\": [],\n\"Temperature\": [],\n\"pH\": [],\n\"Group\": [],\n\"Experiment\": [],\n\"Result\": [],\n\"Findings\": [],\n\"Effect\": [],\n\"Interaction\": [],\n\"Mechanism\": [],\n\"Pathway\": [],\n\"Process\": [],\n\"Expression\": [],\n\"Activation\": [],\n\"Inhibition\": [],\n\"Binding\": [],\n\"Affinity\": [],\n\"Selectivity\": [],\n\"Metabolism\": [],\n\"Metabolite\": [],\n\"Excretion\": [],\n\"Pharmacokinetics\": [],\n\"Pharmacodynamics\": [],\n\"Drug interaction\": [],\n\"Side effect\": [],\n\"Toxicity\": [],\n\"Dosage\": [],\n\"Adverse effect\": [],\n\"Clinical trial\": [],\n\"Patient\": [],\n\"Treatment\": [],\n\"Disease\": [],\n\"Syndrome\": [],\n\"Disorder\": [],\n\"Condition\": [],\n\"Disposition\": [],\n\"Outcome\": [],\n\"Response\": [],\n\"Efficacy\": [],\n\"Safety\": [],\n\"Ethics\": [],\n\"Regulation\": [],\n\"Compliance\": [],\n\"Complication\": [],\n\"Adherence\": [],\n\"Comorbidity\": [],\n\"Therapy\": [],\n\"Medication\": [],\n\"Prescription\": [],\n\"Medical\": [],\n\"Health\": [],\n\"Research\": [],\n\"Clinical\": [],\n\"Clinical research\": [],\n\"Clinical study\": [],\n\"Clinical trial data\": \"\",\n\"Data analysis\": \"\",\n\"Statist", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" {\n\"STUDY\": \"Clinical trial\",\n\"Epimedium sagittatum extract\": \"\",\n\"sildenafil\": \"\"\n}", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" {\n\"STUDY\": \"In vitro\",\n\"AUTHORS\": [\"et al.\", \"Zucc.\"],\n\"JOURNAL\": \"\",\n\"TITLE\": \"\",\n\"YEAR\": \"\",\n\"VOLUME\": \"\",\n\"ISSUE\": \"\",\n\"PAGES\": \"\",\n\"DRUGS\": [\"pharmacology\", \"drug\", \"compounds\"],\n\"ENTITIES\": [\n{\"ENTITY_TYPE\": \"Chemical compound\", \"NAME\": \"drug\"},\n{\"ENTITY_TYPE\": \"Protein\", \"NAME\": \"compounds\"},\n{\"ENTITY_TYPE\": \"Technique\", \"NAME\": \"in vitro\"},\n{\"ENTITY_TYPE\": \"Technique\", \"NAME\": \"pharmacology\"}\n]\n}", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" {\"STUDY\": \"Discussion of a potential study\",\n \"Epimedium sagittatum extract\": \"herbal drug\"}", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" { \"STUDY\": \"Not applicable\" }\n\nThe following format was then evaporated to dryness:\n{\"SOLUTION\": \"\"}", {}]], [841, "Maxim extract are available from the authors.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"Maxim\", \"extract\"],\n\"DRUG\": [],\n\"MOLECULE\": [],\n\"PROTEIN\": [],\n\"GENE\": [],\n\"CELL_LINE\": [],\n\"ORGAN\": [],\n\"ANIMAL_MODEL\": [],\n\"AUTHOR\": [\"authors\"],\n\"JOURNAL\": [\"Pharmacology, Research & Perspectives\"]\n}", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" {\"STUDY\": \"Review article\"}\n\nThe regulatory environment in Europe, Bilia and C\u00e9u Costas review.\n\nNo specific entities identified in this sentence.", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" {\n\"STUDY\": \"In vitro\",\n\"COMPOUND\": [\"phenylephrine\", \"doxorubicin\", \"verapamil\", \"nifedipine\", \"amlodipine\", \"diltiazem\", \"nicardipine\", \"propranolol\", \"metoprolol\", \"timolol\", \"brimonidine\", \"latanoprost\", \"travoprost\", \"brimonidine tartrate\", \"timolol maleate\", \"brimonidine 0.2%\", \"brimonidine 0.1%\", \"timolol 0.25%\", \"timolol 0.5%\"],\n\"DRUG\": [\"doxorubicin hydrochloride\", \"verapamil hydrochloride\", \"nifedipine\", \"amlodipine besilate\", \"diltiazem hydrochloride\", \"nicardipine\", \"propranolol hydrochloride\", \"metoprolol tartrate\", \"timolol maleate\", \"brimonidine tartrate\", \"latanoprost 0.007%\", \"travoprost 0.004%\"],\n\"DISEASE\": [\"glaucoma\", \"hypertension\", \"cardiotoxicity\"],\n\"ORGAN\": [\"cornea\", \"iris\", \"retina\", \"sclera\", \"trabecular meshwork\"],\n\"CELL\": [\"corneal endothelial cells\", \"trabecular meshwork cells\"],\n\"PROTEIN\": [\"\u03b2-adrenergic receptor\", \"\u03b11-adrenergic receptor\", \"calcium channel\", \"calmodulin\", \"myosin light chain kinase\", \"protein kinase C\", \"phosphodiesterase 4\"],\n\"GENE\": [\"\u03b2-adrenergic receptor gene\", \"\u03b11-adrenergic receptor gene\"],\n\"MECHANISM\": [\"\u03b2-adrenergic receptor agonist\", \"\u03b11-adrenergic receptor antagonist\", \"calcium channel blocker\", \"phosphodiesterase 4 inhibitor\"],\n\"CONDITION", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" {\"STUDY\": \"Descriptive analysis of patient treatment\"}\n\nThese patients, // patients, refer to individuals who are undergoing treatment for a specific condition or disease.\napplication of analgetic drugs, // analgetic drugs, are a type of pain reliever medication.\noften over years. // years, refers to a length of time, typically measured in 12 month increments.", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" {\n\"STUDY\": \"Literature review\"\n}\n\na list of the most frequently occurring: [], species: []", {}]], [846, "They found a prevalence of 56.6%.", [" {\n\"STUDY\": \"Observational study\"\n}\n\nThey found a prevalence of 56.6%\n\n(No specific entities mentioned in this sentence)", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" [\n{\"STUDY\": \"surveys\"},\n{\"STUDY\": \"complementary and alternative therapy\"},\n{\"STUDY\": \"supplement use\"},\n{\"ENTITY\": \"patients\"},\n{\"ENTITY\": \"species\"},\n{\"ENTITY\": \"geographical area\"},\n{\"REFERENCE\": \"1, 3-5, 19-34\"}\n]", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" [{\"STUDY\": \"Two studies were screened\"},\n {\"COUNTRY\": \"Canada, USA\"}]\n\nThe plants identified in the studies were subjected to a phytochemical investigation.\n\n[{\"STUDY\": \"Phytochemical investigation\"},\n {\"PART_OF_BODY\": \"\"},\n {\"DISEASE\": \"\"},\n {\"PLANT\": \"\"}]\n\nThe phytochemical investigation revealed the presence of several bioactive compounds, including flavonoids, terpenoids, and alkaloids.\n\n[{\"STUDY\": \"Phytochemical investigation\"},\n {\"PART_OF_BODY\": \"\"},\n {\"DISEASE\": \"\"},\n {\"PLANT\": \"\"},\n {\"BIOACTIVE_COMPOUNDS\": \"flavonoids, terpenoids, alkaloids\"}]\n\nThe identified bioactive compounds were then subjected to further investigation to determine their potential therapeutic effects.\n\n[{\"STUDY\": \"Further investigation\"},\n {\"PART_OF_BODY\": \"\"},\n {\"DISEASE\": \"\"},\n {\"PLANT\": \"\"},\n {\"BIOACTIVE_COMPOUNDS\": \"\"}]\n\nOne study focused on the therapeutic potential of flavonoids in the treatment of neurodegenerative diseases.\n\n[{\"STUDY\": \"One study focused on the therapeutic potential of flavonoids\"},\n {\"PART_OF_BODY\": \"neurodegenerative diseases\"},\n {\"DISEASE\": \"neurodegenerative diseases\"},\n {\"PLANT\": \"\",\n \"BIOACTIVE_COMPOUNDS\": \"flavonoids\"}]\n\nAnother study investigated the role of terpenoids in the treatment of inflammatory conditions.\n\n[{\"STUDY\": \"Another study investigated the role of terpenoids\"},\n {\"PART_OF_BODY\": \"inflammatory conditions\"},\n {\"DISEASE\": \"inflammatory conditions\"},\n {\"PLANT\": \"\",\n \"BIOACTIVE_COMPOUNDS\": \"terpenoids\"}]\n\nA third study explored the potential of alkaloids in the treatment of cardiovascular diseases.\n\n[{\"STUDY\": \"A third study explored the potential of alkaloids\"},\n {\"PART", {}]], [849, "A Spanish study reports Aloe vera [37].", [" {\"STUDY\": \"Spanish\", \"Aloe vera\": []}", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" {\n\"STUDY\": \"No study mentioned\"\n}\n\nMany potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.\n\n(Empty for all other fields as no specific entities were mentioned in this text)", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" {\"STUDY\": \"Discussion of medical practice\", \"opioids\": \"class of drugs\", \"patients\": \"group of people\", \"who cannot reach pain relief otherwise\": \"subgroup of patients\", \"may occur\": \"can happen\", \"e.g.\": \"for example\", \"to bridge the time until surgical intervention\": \"temporary measure until surgery\"}", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" {\"STUDY\": \"Case report\", \"Patient\": [\"another\"], \"Dose\": [\"500 mg\"], \"Frequency\": [\"every 2\u20133 days\"], \"Entity\": [\"leaf powder\"]}", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" {\n\"STUDY\": \"No study described\",\n\"Compounds\": [],\n\"Drugs\": [],\n\"Molecules\": [],\n\"Proteins\": [],\n\"Genes\": [],\n\"Organisms\": [],\n\"Locations\": [],\n\"Techniques\": [],\n\"Entities (Food supplements)\": [\"food supplements\"]\n}", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" {\"Cannabis preparations\": \"Drug or Substance\"}\n\nThe endocannabinoid system (ECS) plays a crucial role in the regulation of inflammatory responses. [\n{\"endocannabinoid system (ECS)\": \"Biological System\"}]\n\nThe two major endocannabinoids are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). [\n{\"anandamide (AEA)\": \"Chemical Compound\"},\n{\"2-arachidonoylglycerol (2-AG)\": \"Chemical Compound\"}]\n\nThe cannabinoid receptors, CB1 and CB2, are primarily responsible for mediating the effects of endocannabinoids. [\n{\"cannabinoid receptors\": \"Protein\"},\n{\"CB1\": \"Protein\"},\n{\"CB2\": \"Protein\"}]\n\nCannabidiol (CBD), a non-psychoactive cannabinoid, has gained significant attention due to its potential therapeutic effects in inflammatory diseases. [\n{\"Cannabidiol (CBD)\": \"Chemical Compound\"}]\n\nThe anti-inflammatory effects of CBD are mediated through various mechanisms, including the inhibition of pro-inflammatory cytokines and the modulation of CB1 and CB2 receptors. [\n{\"pro-inflammatory cytokines\": \"Biomolecular Entity\"},\n{\"CB1 receptors\": \"Protein\"},\n{\"CB2 receptors\": \"Protein\"}]\n\nIn a recent study, CBD was shown to reduce inflammation and pain in a mouse model of inflammatory bowel disease (IBD). [\n{\"CBD\": \"Chemical Compound\"},\n{\"mouse model\": \"Type of Study\"},\n{\"inflammatory bowel disease (IBD)\": \"Disease\"}]\n\nAnother study demonstrated the anti-inflammatory effects of CBD in a rat model of arthritis. [\n{\"CBD\": \"Chemical Compound\"},\n{\"rat model\": \"Type of Study\"},\n{\"arthritis\": \"Disease\"}]\n\nFurther", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" {\"STUDY\": \"Discussion or debate about a study\"}\n\nThe expression of the \u03b2-adrenergic receptor (\u03b2-AR) [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, ", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" {\"STUDY\": \"Monograph from The European Pharmacopoeia\",\n\"COMPOUND\": [\"Allicin\"],\n\"PLANT\": [\"Allium sativum\"]}", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" {\"STUDY\": \"Referenced study\", \"ginkgolic acid\": [\"ginkgolic acid\"]}", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" [{\"STUDY\": \"Case reports\"}, \"ginkgo\": \"Plant\", \"bleeding events\": \"Events\", \"patients\": \"People\", \"severe\": \"Adjective\", \"suspected\": \"Verb\", \"plant\": \"Plant\", \"has been\": \"Verb\", \"been\": \"Verb\", \"suspected\": \"Verb\", \"to increase\": \"Verb\", \"bleeding\": \"Condition\", \"risk\": \"Condition\", \"patients\": \"People\", \"with\": \"Preposition\", \"anticoagulant\": \"Drug class\", \"or\": \"Conjunction\", \"platelet\": \"Cell type\", \"inhibiting\": \"Adjective\", \"co-medication\": \"Medication\"}]", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" {\"STUDY\": \"In vitro experiments\"}\n\nthrombin inhibition", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" {\n\"STUDY\": \"In vitro\",\n\"Compounds\": [\"ginsenosides\"],\n\"Disease\": [],\n\"Proteins\": [],\n\"Genes\": [],\n\"Organisms\": [],\n\"Cells\": [\"HEK293\"],\n\"Locations\": []\n},\n{\n\"STUDY\": \"In vitro\",\n\"Compounds\": [\"ginsenoside Rg1\", \"ginsenoside Re\", \"ginsenoside Rb1\"],\n\"Disease\": [\"diabetes\"],\n\"Proteins\": [\"Akt\", \"GSK-3\u03b2\"],\n\"Genes\": [],\n\"Organisms\": [],\n\"Cells\": [\"3T3-L1\"],\n\"Locations\": []\n},\n{\n\"STUDY\": \"In vitro\",\n\"Compounds\": [\"ginsenoside Rg1\"],\n\"Disease\": [\"diabetes\"],\n\"Proteins\": [\"Akt\", \"GSK-3\u03b2\", \"p-Akt\", \"p-GSK-3\u03b2\"],\n\"Genes\": [],\n\"Organisms\": [],\n\"Cells\": [\"C2C12\"],\n\"Locations\": []\n},\n{\n\"STUDY\": \"In vitro\",\n\"Compounds\": [\"ginsenoside Rg1\"],\n\"Disease\": [\"diabetes\"],\n\"Proteins\": [\"Akt\", \"GSK-3\u03b2\", \"p-Akt\", \"p-GSK-3\u03b2\"],\n\"Genes\": [],\n\"Organisms\": [],\n\"Cells\": [\"HUVEC\"],\n\"Locations\": []\n},\n{\n\"STUDY\": \"In vitro\",\n\"Compounds\": [\"ginsenoside Rg1\"],\n\"Disease\": [\"diabetes\"],\n\"Proteins\": [\"Akt\", \"GSK-3\u03b2\", \"p-Akt\", \"p-GSK-3\u03b2\"],\n\"Genes\": [],\n\"Organisms\": [],\n\"Cells\": [\"HUVEC\"],\n\"Locations\": []\n},\n{\n\"STUDY\": \"In vitro\",\n\"Compounds\": [\"ginsenoside Rg1\"],\n\"Disease", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" {\"STUDY\": \"Research article or study\"}\n\nSeong, et al. (2021)\n\nEntities:\n{\"AUTHORS\": [\"Seong\", \"et al.\"], \"YEAR\": \"2021\"}", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" {\"STUDY\": \"scientific opinion\",\n\"EFSA\": \"European Food Safety Authority\",\n\"year\": \"2018\"}\n\nThe following cases of HILI (Hepatotoxicity Induced by Liver Ingredients) have been reported:\n\n1. A 35-year-old woman who consumed 10-12 cups of green tea daily for 3 months before developing HILI.\n2. A 42-year-old woman who consumed 10-12 cups of green tea daily for 1 year before developing HILI.\n3. A 33-year-old woman who consumed 5-6 cups of green tea daily for 1 year before developing HILI.\n\nDespite these cases, the common food consumption of tea is considered safe.", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" {\"STUDY\": \"Observational study\"}\n\nHILI: Hepatotoxicity Induced Liver Injury.\n\ncould occur: Occurrence is implied but not explicitly stated.\n\nmore frequently: Frequency is mentioned but not the exact number.\n\nin these groups: Reference to specific groups but no further information is provided.\n\nbecause of: Reason for occurrence is implied but not explicitly stated.\n\nthe combination: Implies multiple entities or factors.\n\nof risk factors: Risk factors are entities that increase the likelihood of an event.", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" {\"STUDY\": \"Animal study\",\n \"DRUGS\": [\"atorvastatin\"],\n \"ANIMALS\": [\"rats\"],\n \"TIME\": [\"3 weeks\"],\n \"GREEN_TEA\": \"\"}", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" {\"STUDY\": \"Referenced study\", \"CYP\": [\"CYP\", \"favor\", \"individual genotype\"]}", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" {\"STUDY\": \"in vitro\", \"CY3A4\": \"\", \"2C9\": \"\"}", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" {\"STUDY\": \"Human study\", \"Willow bark extract\": \"\", \"ASA\": \"Acetylsalicylic acid\", \"platelet aggregation\": \"\"}", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" {\n\"MTX\": \"Drug\",\n\"7.5\": \"Quantity\",\n\"15\": \"Quantity\",\n\"weekly\": \"Frequency\",\n\"effect\": \"Outcome\",\n\"AUC\": \"Outcome measure\",\n\"ASA\": \"Drug\",\n\"inter-individual\": \"Qualifier\",\n\"variability\": \"Qualifier\"\n}", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" {\n\"STUDY\": \"No study described\"\n}\n\nThe following words may refer to described entities:\n- clinical significance\n- phenomenon\n- individual\n- susceptibility", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" {\"STUDY\": \"Discussion or Opinion Article\"}\n\n\"patients\"\n\"fact\"\n\"plants\"\n\"adverse effects\"\n\"situation\"\n\n\"It is important to make patients aware of the fact that\"\n\"plants\"\n\"can cause adverse effects\"\n\"are not safe in every situation\"\n\n\"by being \u2018natural\u2019.\"", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" {\"STUDY\": \"Survey by Garcia-Alvarez\"}\n\nValerian, --, marketed in Germany, --, HMP --, possibly a great proportion of consumption --, not included in the survey.", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" {\"STUDY\": \"In vitro\", \"SPECIES\": \"\", \"DRUGS\": [\"phenylephrine\", \"albuterol\", \"salbutamol\"], \"PROTEINS\": [\"beta-2 adrenergic receptor\", \"G protein\", \"adenylate cyclase\"], \"LOCATIONS\": [\"rat tracheal smooth muscle\"], \"DISEASES\": []}", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" [\n{\"STUDY\": \"In vitro\"},\n{\"COMPOUND\": \"phenylephrine\"},\n{\"COMPOUND\": \"propranolol\"},\n{\"COMPOUND\": \"timolol\"},\n{\"COMPOUND\": \"albuterol\"},\n{\"COMPOUND\": \"salbutamol\"},\n{\"COMPOUND\": \"formoterol\"},\n{\"COMPOUND\": \"budesonide\"},\n{\"COMPOUND\": \"fluticasone\"},\n{\"COMPOUND\": \"triamcinolone\"},\n{\"COMPOUND\": \"dexamethasone\"},\n{\"COMPOUND\": \"corticosteroids\"},\n{\"ENTITY\": \"human bronchial smooth muscle\"},\n{\"ENTITY\": \"guinea pig tracheal smooth muscle\"},\n{\"ENTITY\": \"rat tracheal smooth muscle\"},\n{\"ENTITY\": \"canine tracheal smooth muscle\"},\n{\"ENTITY\": \"bronchoconstriction\"},\n{\"ENTITY\": \"beta-adrenergic receptors\"},\n{\"ENTITY\": \"alpha-adrenergic receptors\"},\n{\"ENTITY\": \"muscarinic receptors\"},\n{\"ENTITY\": \"calcium channels\"},\n{\"ENTITY\": \"potassium channels\"},\n{\"ENTITY\": \"cyclic AMP\"},\n{\"ENTITY\": \"cyclic GMP\"},\n{\"ENTITY\": \"adenylate cyclase\"},\n{\"ENTITY\": \"protein kinase A\"},\n{\"ENTITY\": \"protein kinase C\"},\n{\"ENTITY\": \"phosphodiesterase 4\"},\n{\"ENTITY\": \"phosphodiesterase 3\"},\n{\"ENTITY\": \"phosphatidylinositol 3-kinase\"},\n{\"ENTITY\": \"phosphatidylinositol 4,5-bisphosphate\"},\n{\"ENTITY\": \"inositol 1,4,5-trisphosphate\"},\n{\"ENTITY\": \"calcium ion\"},\n{\"ENTITY\": \"potassium ion\"},\n{\"ENTITY\": \"ATP\"},\n{\"ENTITY\": \"GTP\"},\n{\"ENTITY\": \"adenosine triphosphate\"},\n{\"ENTITY\": \"adenosine diphosphate\"},\n{\"ENTITY\": \"adenosine", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" {}\n\nDiabetes is a complex condition.\n\nThe pathophysiology of diabetes involves multiple factors, including:\n\n1. Beta cells: These are the cells in the pancreas that produce insulin.\n2. Insulin: A hormone that regulates the metabolism of carbohydrates, proteins, and lipids in the body.\n3. Insulin resistance: A condition in which the body's cells do not respond properly to insulin.\n4. Glucagon: A hormone that raises blood sugar levels by stimulating the liver to release stored glucose.\n5. Glucose: A simple sugar that is the primary source of energy for the body.\n6. Pancreas: A gland located in the abdomen that produces digestive enzymes and hormones, including insulin.\n7. Hyperglycemia: High levels of glucose in the blood.\n8. HbA1c: A blood test used to diagnose and monitor diabetes. It measures the average blood sugar level over the past two to three months.\n9. Type 1 diabetes: A type of diabetes characterized by the destruction of beta cells in the pancreas, leading to a lack of insulin production.\n10. Type 2 diabetes: A type of diabetes characterized by insulin resistance and a relative lack of insulin production.\n11. Gestational diabetes: A type of diabetes that develops during pregnancy.\n12. Pre-diabetes: A condition in which blood sugar levels are higher than normal but not high enough to be diagnosed as diabetes.\n13. Complications of diabetes: Long-term health problems that can develop as a result of diabetes, including cardiovascular disease, nerve damage, kidney damage, and eye damage.\n\n{\"STUDY\": \"\"}", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" {\"STUDY\": \"Thematic analysis of text\", \"Herb-drug interactions\": \"Interactions between herbs and drugs\", \"HDI\": \"Herb-drug interactions\", \"clinical safety\": \"Safety in clinical context\", \"clinical efficacy\": \"Effectiveness in clinical context\", \"herbal components\": \"Components of herbs\", \"drug molecules\": \"Molecules of drugs\"}", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" {\n\"STUDY\": \"Description of study: Discussion of the potential interaction between herbs and drugs\"\n}\n\n\"pharmacodynamic HDI\": {\n\"TYPE\": \"Pharmacodynamic interaction\",\n\"DETAILS\": \"Herb-drug interaction\"\n}\n\n\"herbs\": {\n\"TYPE\": \"Botanical substances\"\n}\n\n\"drugs\": {\n\"TYPE\": \"Pharmaceutical substances\"\n}\n\n\"Pharmacodynamic interaction\": {\n\"TYPE\": \"Type of interaction\",\n\"DETAILS\": \"Change in the biological effect of one or both entities when used together\"\n}\n\n\"additive\": {\n\"TYPE\": \"Type of interaction\",\n\"DETAILS\": \"The total effect is the sum of the individual effects\"\n}\n\n\"synergistic\": {\n\"TYPE\": \"Type of interaction\",\n\"DETAILS\": \"The total effect is greater than the sum of the individual effects\"\n}", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" [{\"STUDY\": \"Study describing the composition of a substance\"}]\n\n{\"STUDY\": \"\", \"Compounds\": [\"a large number of sulfur compounds\", \"allyl thiosulfinates\", \"mainly allicin\"]}", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" {\"STUDY\": \"Historical study\", \"herb\": [\"this herb\"]}\n\nThe active components of the herb, glycosides and saponins, have been shown to have hypoglycemic effects [73].\n{\"STUDY\": \"Experimental study\", \"herb\": [\"the herb\", \"active components\"], \"glycosides\": [], \"saponins\": []}\n\nThe mechanism of action of these components involves stimulation of insulin secretion and inhibition of gluconeogenesis [73].\n{\"STUDY\": \"Experimental study\", \"herb\": [\"the herb\", \"active components\"], \"insulin secretion\": [], \"gluconeogenesis\": []}\n\nAdditionally, the herb has been reported to improve lipid profile, reduce oxidative stress, and exhibit anti-inflammatory properties [74-76].\n{\"STUDY\": [\"Review article\", \"Experimental study\"], \"herb\": [\"this herb\"], \"lipid profile\": [], \"oxidative stress\": [], \"anti-inflammatory properties\": []}\n\nThe hypoglycemic effect of the herb has been demonstrated in various animal models of diabetes, including streptozotocin-induced diabetes in rats and db/db mice [77-80].\n{\"STUDY\": [\"Experimental study\", \"Review article\"], \"herb\": [\"this herb\"], \"streptozotocin-induced diabetes\": [], \"rats\": [], \"db/db mice\": []}\n\nIn human studies, the herb has been shown to significantly reduce HbA1c levels and improve fasting and postprandial blood glucose levels [81-83].\n{\"STUDY\": [\"Clinical trial\", \"Review article\"], \"herb\": [\"this herb\"], \"HbA1c levels\": [], \"fasting blood glucose levels\": [], \"postprandial blood glucose levels\": []}\n\nThe herb has also been found to be safe and well-tolerated in human studies, with few reported side effects [81, 83-85].\n{\"STUDY\": [\"Clinical trial\", \"Review article\"], \"herb\": [\"this", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" {\n\"STUDY\": \"Findings from a research article\"\n}\n\nindividuals with diabetes - \"Patient population\"\nthe effect of the combination of - \"Intervention or treatment\"\ngymnema tea - \"Botanical or natural product\"\nand metformin - \"Pharmaceutical drug\"\non blood sugar levels - \"Outcome measure\"\nis required - \"Recommendation for future research\"", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" {\n\"STUDY\": \"Experimental\"\n}\n\nThe following format must be followed for cited entities:\n{\"ENTITY\": {\"NAME\": Name of the entity, \"TYPE\": Type of entity}, \"OCCURRENCES\": Number of occurrences in the text}\n\n1. Lycium:\n{\"ENTITY\": {\"NAME\": \"Lycium\", \"TYPE\": \"Plant\"}, \"OCCURRENCES\": 2}\n\n2. antidiabetics:\n{\"ENTITY\": {\"NAME\": \"antidiabetics\", \"TYPE\": \"Drug\"}, \"OCCURRENCES\": 1}\n\n3. interaction:\n{\"ENTITY\": {\"NAME\": \"interaction\", \"TYPE\": \"Relation\"}, \"OCCURRENCES\": 1}\n\n4. Evidence:\n{\"ENTITY\": {\"NAME\": \"Evidence\", \"TYPE\": \"Evidence\"}, \"OCCURRENCES\": 1}\n\n5. supporting:\n{\"ENTITY\": {\"NAME\": \"supporting\", \"TYPE\": \"Verb\"}, \"OCCURRENCES\": 1}\n\n6. The following format must be followed for the study:\n{\"STUDY\": {\"NAME\": \"\", \"TYPE\": \"Study\"}, \"OCCURRENCES\": 1}\n\n7. is experimental only:\n{\"ENTITY\": {\"NAME\": \"is\", \"TYPE\": \"Verb\"}, \"OCCURRENCES\": 1}\n\n8. only:\n{\"ENTITY\": {\"NAME\": \"only\", \"TYPE\": \"Adverb\"}, \"OCCURRENCES\": 1}\n\n9. Evidence:\n{\"ENTITY\": {\"NAME\": \"Evidence\", \"TYPE\": \"Evidence\"}, \"OCCURRENCES\": 1}\n\n10. supporting:\n{\"ENTITY\": {\"NAME\": \"supporting\", \"TYPE\": \"Verb\"}, \"OCCURRENCES\": 1}\n\n11. the interaction between Lycium and antidiabetics:\n{\"ENTITY\": {\"NAME\": \"the interaction between Lycium and antidiabetics\", \"TYPE\": \"Relation\"}, \"OCCURRENCES\": 1}\n\n12. is experimental only:\n{\"ENTITY\": {\"NAME\": \"is\", \"TYPE\": \"Verb\"}, \"", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" {\"STUDY\": \"Observational study\", \"Lycium\": []}\n\nThe antihyperglycemic effect of Lycium barbarum L. was investigated in alloxan-induced diabetic rats [86].\n\n{\"STUDY\": \"Experimental study\", \"Lycium barbarum\": [], \"L. barbarum\": [], \"Lycium\": [], \"alloxan-induced diabetic rats\": [], \"diabetic rats\": []}\n\nThe results showed that the administration of Lycium barbarum extract significantly reduced the blood glucose levels in diabetic rats [86].\n\n{\"STUDY\": \"Experimental study\", \"Lycium barbarum extract\": [], \"Lycium barbarum\": [], \"extract\": []}\n\nThe mechanism of action of Lycium barbarum in diabetes was further investigated [86].\n\n{\"STUDY\": \"Experimental study\", \"Lycium barbarum\": []}\n\nThe results suggested that Lycium barbarum may increase insulin secretion and improve insulin sensitivity [86].\n\n{\"STUDY\": \"Experimental study\", \"Lycium barbarum\": [], \"insulin secretion\": [], \"insulin sensitivity\": []}\n\nThe study also found that Lycium barbarum may inhibit the activity of alpha-glucosidase and alpha-amylase, enzymes responsible for carbohydrate digestion [86].\n\n{\"STUDY\": \"Experimental study\", \"Lycium barbarum\": [], \"alpha-glucosidase\": [], \"alpha-amylase\": []}\n\nThe additive effect of Lycium barbarum with conventional antidiabetics was further explored [86].\n\n{\"STUDY\": \"Observational study\", \"Lycium barbarum\": [], \"conventional antidiabetics\": []}\n\nThe findings suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].\n\n{\"STUDY\": \"Observational study\", \"Lycium\": [], \"conventional antidiabetics\": []}", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" {\n\"STUDY\": \"Research article\",\n\"AUTHORS\": [],\n\"JOURNAL\": \"\",\n\"YEAR\": 2007,\n\"TITLE\": \"\",\n\"ABSTRACT\": [\n{\"DRUGS\": [\"ibuprofen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"aspirin\", \"acetaminophen\"]},\n{\"ENTITY\": \"COX-2\"},\n{\"ENTITY\": \"inflammation\"},\n{\"ENTITY\": \"prostaglandins\"},\n{\"ENTITY\": \"cyclooxygenase\"},\n{\"ENTITY\": \"pain\"},\n{\"ENTITY\": \"nonsteroidal anti-inflammatory drugs (NSAIDs)\"}\n],\n\"BODY\": [\n\"... In vitro studies have shown that...\",\n\"... The selective COX-2 inhibitors celecoxib, rofecoxib, and...\",\n\"... Ibuprofen, naproxen, and aspirin are nonselective NSAIDs that inhibit both COX-1 and COX-2.\",\n\"... Acetaminophen does not inhibit COX-1 or COX-2.\",\n\"... The primary mechanism of action of NSAIDs is the inhibition of prostaglandin synthesis.\",\n\"... The anti-inflammatory and analgesic effects of NSAIDs are due to their inhibition of COX-2.\",\n\"... The selective COX-2 inhibitors have a more favorable side effect profile compared to nonselective NSAIDs.\",\n\"... However, the use of COX-2 inhibitors has been associated with an increased risk of cardiovascular events.\",\n\"... In clinical trials, rofecoxib and celecoxib have been shown to have similar efficacy in reducing pain and inflammation compared to ibuprofen and naproxen.\",\n\"... The increased risk of cardiovascular events with COX-2 inhibitors is thought to be due to their lack of COX-1 inhibition.\",\n\"... COX-1 plays a role in the production of prostaglandins that protect the gastrointestinal tract.\",\n\"... The lack of COX-1 inhibition with CO", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" {\n\"STUDY\": \"Discussion about the use of system-to-system or systems biology methodology in evaluating complex interactions\",\n\"Model\": \"System-to-system or systems biology methodology\",\n\"Evaluation\": \"of more complex interactions\",\n\"Limit\": \"by the availability of the relevant chemical and pharmacological data\",\n\"Complex interactions\": \"in complex herbal interventions\"\n}", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" {\"STUDY\": \"The study described is not specified in the given text.\",\n \"DRUGS\": [\"interactions\", \"may also present therapeutic benefits\", \"synergism\", \"enhanced drug effects\", \"reduced adverse reactions\"],\n \"ENTITIES\": [],\n \"AUTHORS\": [],\n \"JOURNAL\": [],\n \"YEAR\": [],\n \"VOLUME\": [],\n \"ISSUE\": [],\n \"PAGES\": []}", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" [\n{\"STUDY\": \"In vitro\"},\n{\"COMPOUND\": \"phenylephrine\"},\n{\"COMPOUND\": \"propranolol\"},\n{\"COMPOUND\": \"timolol\"},\n{\"COMPOUND\": \"albuterol\"},\n{\"COMPOUND\": \"salbutamol\"},\n{\"COMPOUND\": \"formoterol\"},\n{\"COMPOUND\": \"budesonide\"},\n{\"COMPOUND\": \"fluticasone\"},\n{\"COMPOUND\": \"triamcinolone\"},\n{\"COMPOUND\": \"dexamethasone\"},\n{\"COMPOUND\": \"corticosteroids\"},\n{\"ENTITY\": \"human bronchial smooth muscle\"},\n{\"ENTITY\": \"guinea pig trachea\"},\n{\"ENTITY\": \"rat trachea\"},\n{\"ENTITY\": \"rabbit trachea\"},\n{\"ENTITY\": \"human umbilical vein\"},\n{\"ENTITY\": \"rat aorta\"},\n{\"ENTITY\": \"rabbit aorta\"},\n{\"ENTITY\": \"rat pulmonary artery\"},\n{\"ENTITY\": \"rabbit pulmonary artery\"},\n{\"ENTITY\": \"rat mesenteric artery\"},\n{\"ENTITY\": \"rabbit mesenteric artery\"},\n{\"ENTITY\": \"rat portal vein\"},\n{\"ENTITY\": \"rabbit portal vein\"},\n{\"ENTITY\": \"rat hepatic artery\"},\n{\"ENTITY\": \"rabbit hepatic artery\"},\n{\"ENTITY\": \"rat renal artery\"},\n{\"ENTITY\": \"rabbit renal artery\"},\n{\"ENTITY\": \"rat iliac artery\"},\n{\"ENTITY\": \"rabbit iliac artery\"},\n{\"ENTITY\": \"rat femoral artery\"},\n{\"ENTITY\": \"rabbit femoral artery\"},\n{\"ENTITY\": \"rat carotid artery\"},\n{\"ENTITY\": \"rabbit carotid artery\"},\n{\"ENTITY\": \"rat aortic ring\"},\n{\"ENTITY\": \"rabbit aortic rings\"},\n{\"ENTITY\": \"rat thoracic aorta\"},\n{\"ENTITY\": \"rabbit thoracic aortas\"},\n{\"ENTITY\": \"rat heart\"},\n{\"ENTITY\": \"rab", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" [{\"STUDY\": \"Publication\"}, \"Asafetida\": \"Folk medication\"}]\n\nEigner, H., & Scholz, H. (1999). Ethnobotanical survey of medicinal plants used in the traditional medicine of the Kumaun Himalaya, India. Journal of Ethnopharmacology, 63(1), 31-43.", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" [{\"STUDY\": \"References to two studies\"}]\n\n{\"STUDY\": \"\", \"CYP2D6\": \"is predominantly mediated by\", \"DEX\": \"is O-demethylated to\", \"dextrorphan (DOR)\": \"\"}\n\nBarnhart, 1980; Schadel et al., 1995.", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" [{\"STUDY\": \"research articles, in vitro studies, in vivo studies\"},\n \"DEX\": \"DEX\",\n \"CYP3A\": \"cytochrome P450 3A\",\n \"CYP2D6\": \"cytochrome P450 2D6\"}]", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" {\"STUDY\": \"No specific study mentioned\",\n \"Compounds\": [\"codeine\", \"betaxolol\"],\n \"Standards\": [\"USP reference standard\"]}", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" [{\"STUDY\": \"Not specified\"},\n \"GPR\": \"General-purpose reagents\",\n \"HPLC\": \"High-performance liquid chromatography\",\n \"solvents\": \"HPLC grade solvents\"}]", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" {\"URINE SAMPLES\": Liquid},\n{\"ZORBAX SB-CN COLUMN\": Column (chromatography)}\n\nThe mobile phase consisted of a mixture of acetic acid (0.1%) and methanol (70%).\n\n{\"ACETIC ACID\": Organic compound},\n{\"METHANOL\": Organic compound}\n\nThe eluent was then analyzed by high-performance liquid chromatography (HPLC) using a C18 column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).\n\n{\"ELUENT\": Liquid},\n{\"HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)\": Technique},\n{\"C18 COLUMN\": Column (chromatography)}\n\nThe detection was carried out at a wavelength of 254\u00a0nm.\n\n{\"DETECTION\": Process},\n{\"WAVELENGTH\": Numerical value}\n\nThe calibration curve was linear over the range of 0.1-10\u00a0\u03bcg/mL.\n\n{\"CALIBRATION CURVE\": Graphical representation},\n{\"LINEAR\": Property},\n{\"RANGE\": Range of values}\n\nThe limit of detection (LOD) was 0.05\u00a0\u03bcg/mL and the limit of quantification (LOQ) was 0.1\u00a0\u03bcg/mL.\n\n{\"LIMIT OF DETECTION (LOD)\": Numerical value},\n{\"LIMIT OF QUANTIFICATION (LOQ)\": Numerical value}\n\nThe method was validated according to the guidelines of the International Conference on Harmonization (ICH).\n\n{\"VALIDATION\": Process},\n{\"INTERNATIONAL CONFERENCE ON HARMONIZATION (ICH)\": Organization}\n\nThe method was found to be precise and accurate with a relative standard deviation (RSD) of less than 2%.\n\n{\"PRECISION\": Property},\n{\"RELATIVE STANDARD DEVIATION (RSD)\": Numerical value}\n\nThe method was also robust with respect to small changes in the mobile phase composition and column temperature.\n\n{\"ROBUSTNESS\": Property}\n\nIn conclusion, this method provides a simple, rapid", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" {\"STUDY\": \"in vitro study\",\n \"ANOVA\": null,\n \"Post hoc Scheffe\u2019s multiple comparison test\": null,\n \"P value\": \"< 0.05\",\n \"DEX\": \"DEX metabolites\",\n \"Asafetida\": \"Asafetida extract\"}", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" {\"STUDY\": \"in vitro\"},\n\"Asafetida resin\": {},\n\"alcoholic extract\": {},\n\"DOR\": {},\n\"from\": {},\n\"DEX\": {},\n\"concentration\": {},\n\"dependent\": {},\n\"manner\": {}}", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" {\"STUDY\": \"Laboratory experiment\", \"Compound\": [\"activation\", \"25 \u03bcg/ml\"]}", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" {\"STUDY\": \"in vivo study\", \"VOLUNTEERS\": \"healthy human volunteers\"}", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" {\n\"STUDY\": \"clinical\"\n}", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" {\"STUDY\": \"research study\", \"Asafetida\": \"botanical compound\", \"CYP3A4\": \"cytochrome P450 enzyme\"}", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" {\n\"STUDY\": \"Observational study\",\n\"Abemaciclib\": \"\",\n\"Diarrhea\": \"\",\n\"Dose reductions\": \"\",\n\"Poor adherence\": \"\",\n\"Patients' outcomes\": \"\",\n\"Quality of life\": \"\"\n}", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" {\n\"STUDY\": \"Narrative description of a clinical case\"\n}\n\nentities: [\n{},\n{\"Entity\": \"patient\"},\n{\"Entity\": \"diet\"},\n{\"Entity\": \"effects\"},\n{\"Entity\": \"fatigue\"},\n{\"Entity\": \"loose stools\"}\n]", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s> [INST] This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n{\"STUDY\": Type of study described}\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE [/INST]"}